As filed with the Securities and Exchange Commission on March 12, 201311, 2014

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 20-F

(Mark One)

¨REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

Or

þANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 20122013

Or

¨TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Or

¨SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 1-3334

Commission file number: 1-13688

 

REED ELSEVIER PLC REED ELSEVIER NV
(Exact name of Registrant as specified in its charter) (Exact name of Registrant as specified in its charter)
England The Netherlands
(Jurisdiction of incorporation or organisation) (Jurisdiction of incorporation or organisation)
1-3 Strand, London, WC2N 5JR, England Radarweg 29, 1043 NX, Amsterdam, The Netherlands
(Address of principal executive offices) (Address of principal executive offices)
Henry Udow Jans van der Woude
Company Secretary Company Secretary
Reed Elsevier PLC Reed Elsevier NV
1-3 Strand, London, WC2N 5JR, England Radarweg 29, 1043 NX, Amsterdam, The Netherlands
011 44 20 7166 5500 011 31 20 485 2222
henry.udow@reedelsevier.com j.vanderwoude@reedelsevier.com
(Name, telephone, e-mail and/or facsimile number and address of
Company Contact Person)
 (Name, telephone, e-mail and/or facsimile number and address of
Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class

  

Name of exchange on which
registered

Reed Elsevier PLC:

  

American Depositary Shares
(each representing four Reed Elsevier PLC ordinary shares)

  New York Stock Exchange

Ordinary shares of 14 51/116p each
(the “Reed Elsevier PLC ordinary shares”)

  New York Stock Exchange*

Reed Elsevier NV:

  

American Depositary Shares
(each representing two Reed Elsevier NV ordinary shares)

  New York Stock Exchange

Ordinary shares of €0.07 each
(the “Reed Elsevier NV ordinary shares”)

  New York Stock Exchange*

 

*Listed, not for trading, but only in connection with the listing of the applicable Registrant’s American Depositary Shares issued in respect thereof.

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

 

Indicate the number of outstanding shares of each of the issuers’ classes of capital or common stock as of December 31, 2012:2013:

 

Reed Elsevier PLC:

  Number of outstanding shares  

Ordinary shares of 14 51/116p each

   1,257,597,9771,267,036,696  

Reed Elsevier NV:

  

Ordinary shares of €0.07 each

   725,984,225734,149,956  

R shares of €0.70 each (held by a subsidiary of Reed Elsevier PLC)

   4,303,179  

 

Indicate by check mark if the registrants are well-known seasoned issuers, as defined in Rule 405 of the Securities Act.

Yes                þ                 No                ¨

If this report is an annual or transition report, indicate by check mark if the registrants are not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes                ¨                No                þ

Indicate by check mark whether the registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) have been subject to such filing requirements for the past 90 days:days.

Yes                þ                No                ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes                ¨                No                ¨

Indicate by check mark whether the registrants are large accelerated filers, accelerated filers, or non-accelerated filers. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  þ                            Accelerated filer  ¨                            Non-accelerated filer  ¨

Indicate by check mark which basis of accounting the registrants have used to prepare the financial statements included in this filing.

¨     US GAAP            þ    International Financial Reporting Standards as issued by the International Accounting Standards Board            ¨    Other

If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrants have elected to follow:

Item  17        ¨                     Item 18        ¨

If this is an annual report, indicate by check mark whether the registrants are shell companies (as defined in Rule 12b-2 of the Exchange Act):.

Yes                ¨                  No                þ

 

 

 


TABLE OF CONTENTS

 

      Page 

GENERAL

   1  

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

   2  

PART I

    

ITEM 1:

  IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS   N/A  

ITEM 2:

  OFFER STATISTICS AND EXPECTED TIMETABLE   N/A  

ITEM 3:

  KEY INFORMATION   3  
  

Selected Financial Data

   3  
  

Risk Factors

   78  

ITEM 4:

  INFORMATION ON REED ELSEVIER   1112  
  

History and Development

   1112  
  

Business Overview

   1314  
  

Government Regulation

   24  
  

Organisational Structure

   2425  
  

Property, Plants and Equipment

   2425  

ITEM 4A:

  UNRESOLVED STAFF COMMENTS   N/A  

ITEM 5:

  OPERATING AND FINANCIAL REVIEW AND PROSPECTS   2526  
  

Operating Results — Reed Elsevier

   2526  
  

Liquidity and Capital Resources — Reed Elsevier

   3439  
  

Contractual Obligations

   3540  
  

Off-Balance Sheet Arrangements

   3540  
  

Short Term Borrowings

   3742  
  

Operating Results — Reed Elsevier PLC and Reed Elsevier NV

   3843  
  

Trend Information

   3944  

ITEM 6:

  DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES   4045  
  

Directors

   40

Senior Management

4245  
  

Compensation

   4247  
  

Board Practices

   5668  
  

Employees

   5870  
  

Share Ownership

   5971  

ITEM 7:

  MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS   6677  
  

Major Shareholders

   6677  
  

Related Party Transactions

   6778  

ITEM 8:

  FINANCIAL INFORMATION   6879  

ITEM 9:

  THE OFFER AND LISTING   6980  
  

Trading Markets

   6980  

ITEM 10:

  ADDITIONAL INFORMATION   7182  
  

Memorandum and Articles of Association

   7182  
  

Material Contracts

   7687  
  

Exchange Controls

   7688  
  

Taxation

   7688  
  

Documents on Display

   7990  

ITEM 11:

  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK   8091  

ITEM 12:

  DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES   8293  


      Page 

PART II

    

ITEM 13:

  DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES   N/A  

ITEM 14:

  MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS   N/A  

ITEM 15:

  CONTROLS AND PROCEDURES   8394  

ITEM 16A:

  AUDIT COMMITTEE FINANCIAL EXPERT   89100  

ITEM 16B:

  CODES OF ETHICS   89100  

ITEM 16C:

  PRINCIPAL ACCOUNTANT FEES AND SERVICES   89100  

ITEM 16D:

  EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES   90101  

ITEM 16E:

  PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS   90101  

ITEM 16F:

  CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT   90101  

ITEM 16G:

  CORPORATE GOVERNANCE   90101

ITEM 16H:

MINE SAFETY DISCLOSURE

N/A  

PART III

    

ITEM 17:

  FINANCIAL STATEMENTS*   91102  

ITEM 18:

  FINANCIAL STATEMENTS   F-1  

ITEM 19:

  EXHIBITS   S-3  

 

*The registrants have responded to Item 18 in lieu of responding to this Item.


 

 

 

THIS PAGE INTENTIONALLY BLANK

 

 

 

 


GENERAL

Reed Elsevier PLC and Reed Elsevier NV conduct their business through two jointly owned companies, Reed Elsevier Group plc and Elsevier Reed Finance BV. Reed Elsevier PLC and Reed Elsevier NV have retained their separate legal and national identities. “Reed Elsevier” is not a legal entity but a collective reference to the separate legal entities of Reed Elsevier PLC, Reed Elsevier NV, Reed Elsevier Group plc and Elsevier Reed Finance BV and their respective subsidiaries, associates and joint ventures. The businesses of all of the entities comprising Reed Elsevier are collectively referred to in this annual report as “Reed Elsevier”, and the financial statements of the combined businesses are referred to as the “combined financial statements”. In this annual report, references to “we”, “our”, or “us” are to all of the entities comprising Reed Elsevier.

In this annual report, references to US dollars, $ and ¢ are to US currency; references to sterling, £, pence or p are to UK currency; references to euro and € are to the currency of the European Economic and Monetary Union.

Statements regarding our competitive position included herein were obtained from internal surveys, market research, publicly available information and industry publications. While we believe that the market research, publicly available information and industry publications we use are reliable, we have not independently verified market and industry data fromthird-party sources. Moreover, while we believe our internal surveys are reliable, they have not been verified by any independent source.

SPECIAL NOTE REGARDING FORWARD LOOKINGFORWARD-LOOKING STATEMENTS

This document contains or incorporates by reference a number of forward lookingforward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, with respect to:

 

  

financial condition;

 

  

results of operations;

 

  

competitive positions;

 

  

the features and functions of and markets for the products and services we offer; and

 

  

our business plans and strategies.

We consider any statements that are not historical facts to be “forward looking“forward-looking statements”. These statements are based on the current expectations of the management of our businesses and are subject to risks and uncertainties that could cause actual results or outcomes to differ from those expressed in any forward lookingforward-looking statement. These differences could be material; therefore, you should evaluate forward lookingforward-looking statements in light of various important factors, including those set forth or incorporated by reference in this document.

Important factors that could cause actual results to differ materially from estimates or forecasts contained in the forward looking statements include, among others:

 

  

competitive factors in the industries in which we operate;

 

  

demand for our products and services;

 

  

exchange rate fluctuations;

 

  

general economic, political and business conditions;

 

  

legislative, fiscal, tax and regulatory developments and political risks;

 

  

the availability of third party content and data;

 

  

breaches of our data security systems or other unauthorised access to our databases;

 

  

our ability to maintain high quality management;

 

  

changes in law and legal interpretation affecting our intellectual property rights and internet communications;

 

  

uncertainties as to whether our strategies, business plans and acquisitions will produce the expected returns;

 

  

significant failures or interruptions of our electronic platforms;

 

  

failure of third parties to whom we have outsourced business activities;

 

  

changes in the market values of defined benefit pension scheme assets and in the market related assumptions used to value scheme liabilities;

 

  

downgrades to the credit ratings of our debt;

 

  

breaches of generally accepted ethical business standards or applicable statutes;

 

  

our ability to manage our environmental impact; and

 

  

other risks referenced from time to time in the filings of Reed Elsevier PLC and Reed Elsevier NV with the Securities and Exchange Commission (the “SEC”).

The terms “estimate”, “project”, “plan”, “intend”, “expect”, “should be”, “will be”, “believe” and similar expressions identify forward lookingforward-looking statements. These forward lookingforward-looking statements are found at various places throughout this annual report and the other documents incorporated by reference in this annual report (see “Item 19: Exhibits” on pages S-3 and S-4 of this annual report).report.

You should not place undue reliance on these forward lookingforward-looking statements, which speak only as of the date of this annual report. We undertake no obligation to publicly update or release any revisions to these forward lookingforward-looking statements to reflect events or circumstances after the date of this annual report or to reflect the occurrence of unanticipated events.

PART I

ITEM 3: KEY INFORMATION

SELECTED FINANCIAL DATA

REED ELSEVIER

The selected combined financial data for Reed Elsevier should be read in conjunction with, and is qualified by, the combined financial statements included in this annual report. In addition, as separate legal entities, Reed Elsevier PLC and Reed Elsevier NV prepare separate consolidated financial statements which reflect their respective shareholders’ economic interests in Reed Elsevier accounted for on an equity basis.

All ofThe combined financial statements are prepared in accordance with accounting policies that are in conformity with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and as adopted by the European Union (“EU”). The selected financial data for Reed Elsevier (in £) as at and for the years ended December 31, 2013, 2012 and 2011 set out below has been extracted or derived from the audited combined financial statements.statements, included herein. The selected financial data for Reed Elsevier as at and for the years ended December 31, 2010 and 2009 set out below has been extracted or derived from our audited financial statements, which are not included herein, retrospectively restated for the adoption of International Accounting Standard (“IAS”) 19 Employee Benefits (revised).

Combined Income Statement Data(1)

 

  For the year ended December 31,   

For the year ended December 31,

   2012(2)    2012     2011     2010     2009     2008     

 2013(2) 

  

  2013  

  

  2012  
Restated

  

  2011  
Restated

  

  2010  
Restated

  

  2009  
Restated

  (in millions)   (in millions)

Amounts in accordance with IFRS:

                   

Revenue

  $9,908   £6,116   £6,002   £6,055   £6,071   £5,334    $10,018  £6,035  £6,116  £6,002  £6,055  £6,071

Operating profit(3)

   2,200    1,358    1,205    1,090    787    901    2,284  1,376  1,333  1,171  1,064  

781

Net finance costs

   (350  (216  (235  (276  (291  (192  (325)  (196)  (227)  (244)  (289)  

(310)

Disposals and other non operating items(4)

   73    45    (22  (46  (61  (92  26  16  45  (22)  (46)  (61)

Profit before tax

   1,923    1,187    948    768    435    617    1,985  1,196  1,151  905  729  

410

Taxation(5)

   (183  (113  (181  (120  (40  (155

Net profit

   1,740    1,074    767    648    395    462  

Net profit from discontinued operations(6)

                       18  

Non-controlling interests

   (8  (5  (7  (6  (4  (4

Profit attributable to parent companies’ shareholders

   1,732    1,069    760    642    391    476  

Tax expense(5)

  (134)  (81)  (102)  (167)  (132)  

(48)

Net profit for the year

  1,851  1,115  1,049  738  597  

362

Net profit for the year attributable tonon-controlling interests

  (8)  (5)  (5)  (7)  (6)  (4)

Net profit attributable to parent companies’ shareholders

  1,843  1,110  1,044  731  591  358

Combined Statement of Financial Position Data(1)

 

  As at December 31,   

As at December 31,

   2012(2)    2012     2011     2010     2009     2008     

 2013(2) 

  

  2013  

  

  2012  

  

  2011  

  

  2010  

  

  2009  

  (in millions)   (in millions)

Amounts in accordance with IFRS:

                   

Total assets

  $17,843   £11,014   £11,503   £11,158   £11,334   £12,866    $17,422  £10,495  £11,014  £11,503  £11,158  £11,334

Long term borrowings

   (5,122  (3,162  (3,300  (3,786  (4,028  (5,694  (4,371)  (2,633)  (3,162)  (3,300)  (3,786)  (4,028)

Net assets

   3,749    2,314    2,197    1,970    1,759    981    4,022  2,423  2,314  2,197  1,970  1,759

Non-controlling interests

   (55  (34  (25  (27  (27  (28  (55)  (33)  (34)  (25)  (27)  (27)

Combined shareholders’ equity

   3,694    2,280    2,172    1,943    1,732    953    3,967  2,390  2,280  2,172  1,943  1,732

 

(1)The combined financial statements are prepared in accordance with accounting policies that are in conformity with International Financial Reporting Standards (“IFRS”)IFRS as issued by the International Accounting Standards Board (“IASB”)IASB and as adopted by the European Union (“EU”).EU. The figures for 20092010 and 20082009 have been extracted or derived from the combined financial statements for the years ended December 31, 20092010 and 2008,2009, not included herein. Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 2 to the combined financial information on page F-16.

 

(2)Noon buying rates as at December 31, 20122013 have been used to provide a convenience translation into US dollars, see “— Exchange Rates” on page 6.7. At December 31, 20122013 the noon buying rate was $1.62$1.66 per £1.00. This compares to the average exchange rate for the year ended December 31, 20122013 of $1.59$1.56 to £1.00 applied in the translation of the combined income statement for the year.

 

(3)

Operating profit is stated after charging £329£318 million in respect of amortisation of acquired intangible assets (2011:(2012: £329 million; 2011: £359 million; 2010: £349 million; 2009: £368 million; 2008: £281 million); nil in respect of impairment of acquired intangible assets and goodwill (2011:(2012: nil;

2011: nil; 2010: nil; 2009: £177 million; 2008: £9 million); nil in respect of exceptional restructuring costs (2011:(2012: nil; 2011: nil; 2010: £57 million; 2009: £182 million; 2008: £152 million); £21£43 million in respect of acquisition related costs (2011:(2012: £21 million; 2011: £52 million; 2010: £50 million; 2009: £48 million; 2008: £27 million); nil in respect of the share of joint ventures’ profit on disposals (2011:(2012: nil; 2011: £1 million credit; 2010: nil; 2009: nil; 2008: nil) and £5£12 million in respect of taxation in joint ventures (2011:(2012: £5 million; 2011: £11 million; 2010: £9 million; 2009: £8 million; 2008: £9 million). Impairment charges in 2009 relate principally to Business Information. Exceptional restructuring costs in 2010 relate only to the restructuring of the Business Information business and in 2009 and 2008 relate to the exceptional restructuring programmes across Reed Elsevier.

(4)Disposals and other non operating items comprise an £86£11 million profitgain on disposal of businesses (2011:and assets held for sale (2012: £86 million gain; 2011: £12 million loss; 2010: £32 million loss; 2009: £49 million loss; 2008: £86 million loss), a £60 million charge of nil to property provisions on disposed businesses (2011:(2012: £60 million; 2011: £16 million; 2010: £22 million; 2009: £20 million; 2008: nil)million), and a £19£5 million gain relating to the revaluation of held for trading investments (2011:(2012: £19 million; 2011: £6 million gain;million; 2010: £8 million gain;million; 2009: £8 million gain; 2008: £6 million loss)million).

 

(5)TaxationTax expense in 20122013 includes a deferred tax credit of £221 million (2012: nil; 2011: nil; 2010: nil; 2009: nil) arising on the alignment of certain business assets with their global management structure and an exceptional prior year tax credit of nil (2012: £96 million (2011:million; 2011: nil; 2010: nil; 2009: nil; 2008: nil) relating to the resolution of a number of significant prior year tax matters.

(6)Net profit from discontinued operations in 2008 includes the gain of £67 million on disposal of the educational assessment business. Taxes on the completed disposals in 2008 were £49 million.

REED ELSEVIER PLC

The selected financial data for Reed Elsevier PLC should be read in conjunction with, and is qualified by, the consolidated financial statements of Reed Elsevier PLC included in this annual report. The results and financial position of Reed Elsevier PLC reflect the 52.9% economic interest of Reed Elsevier PLC’s shareholders in Reed Elsevier, after taking account of results arising in Reed Elsevier PLC and its subsidiaries. These interests have been accounted for on an equity basis.

All ofThe consolidated financial statements are prepared in accordance with accounting policies that are in conformity with IFRS as issued by the IASB and as adopted by the EU. The selected consolidated financial data for Reed Elsevier PLC (in £) as at and for the years ended December 31, 2013, 2012 and 2011 set out below has been extracted or derived from the audited consolidated financial statements, ofincluded herein. The selected financial data for Reed Elsevier PLC.PLC as at and for the years ended December 31, 2010 and 2009 set out below has been extracted or derived from our audited financial statements, which are not included herein, retrospectively restated for the adoption of IAS19 Employee Benefits (revised).

 

  For the year ended December 31,   For the year ended December 31, 
  2012(3) 2012 2011 2010 2009 2008   2013(3) 2013 2012
Restated
 2011
Restated
 2010
Restated
 2009
Restated
 
  (in millions, except per share amounts)   (in millions, except per share amounts) 

Amounts in accordance with IFRS:(1)

              

Profit before tax(2)

  $884   £546   £390   £328   £201   £247    $956   £576   ££532   £375   £301   £184  

Taxation

   10    6    (1  (1  (6  (6

Tax (expense)/credit

   (6  (4  6    (1  (1  (6

Profit attributable to ordinary shareholders

   894    552    389    327    195    241     950    572    538    374    300    178  

Earnings per Reed Elsevier PLC ordinary share from total operations of the combined businesses

   74.5¢   46.0  32.4  27.3  17.2  22.1   81.0¢   48.8  44.8  31.1  25.0  15.7

Earnings per Reed Elsevier PLC ordinary share from continuing operations of the combined businesses

   74.5¢   46.0  32.4  27.3  17.2  21.2

Diluted earnings per Reed Elsevier PLC ordinary share from total operations of the combined businesses

   73.5¢   45.4  32.1  27.1  17.1  21.9   80.0¢   48.2  44.3  30.9  24.9  15.6

Dividends per Reed Elsevier PLC ordinary share(4)

   35.5¢   21.9  20.65  20.4  20.4  100.9   39.3¢   23.65  21.9  20.65  20.4  20.4

Total assets

  $1,955   £1,207   £1,158   £1,037   £927   £515    $2,102   £1,266   £1,207   £1,158   £1,037   £927  

Total equity/Net assets

   1,954    1,206    1,149    1,028    916    504     2,098    1,264    1,206    1,149    1,028    916  

Weighted average number of shares(5)

   1,200.6    1,200.6    1,202.0    1,199.1    1,131.4    1,089.5     1,172.2    1,172.2    1,200.6    1,202.0    1,199.1    1,131.4  

 

(1)The consolidated financial statements of Reed Elsevier PLC are prepared in accordance with accounting policies that are in conformity with IFRS as issued by the IASB and as adopted by the EU. The figures for 20092010 and 20082009 have been extracted or derived from the consolidated financial statements for the years ended December 31, 20092010 and 2008,2009, not included herein. Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 2 to the combined financial information on page F-16.

 

(2)Profit before tax includes Reed Elsevier PLC’s share of the post-tax earnings of joint ventures, being both the continuing and discontinued operations of the Reed Elsevier combined businesses. Profit before tax in 2008 includes Reed Elsevier PLC’s £10 million share of joint ventures’ post-tax gain on disposal of the educational assessment business.

 

(3)Noon buying rates as at December 31, 20122013 have been used to provide a convenience translation into US dollars, see “��“— Exchange Rates” on page 6.7. At December 31, 20122013 the noon buying rate was $1.62$1.66 per £1.00. This compares to the average exchange rate for the year ended December 31, 20122013 of $1.59$1.56 to £1.00 applied in the translation of the combined income statement for the year.

 

(4)The amount of dividends per Reed Elsevier PLC ordinary share shown excludes the UK tax credit available to certain Reed Elsevier PLC shareholders; see “Item 10: Additional Information — Taxation”Taxation — UK Taxation — Dividends”.

  Dividends declaredpaid in the year, in amounts per ordinary share, comprise a 20112012 final dividend of 15.9p17.0p and 20122013 interim dividend of 6.00p6.65p giving a total of 21.9p.23.65p. The directors of Reed Elsevier PLC have proposed a 20122013 final dividend of 17.0p (2011:17.95p (2012: 17.0p; 2011: 15.9p; 2010: 15.0p; 2009: 15.0p; 2008: 15.0p), giving a total ordinary dividend in respect of the financial year of 23.0p (2011:24.60p (2012: 23.0p; 2011: 21.55p; 2010: 20.4p; 2009: 20.4p; 2008: 20.3p)20.4p). Dividends in 2008 included a special distribution of 82.0p per ordinary share paid from the net proceeds of the sale of the Education division.

 

  Dividends per Reed Elsevier PLC ordinary share in respect of the financial year ended December 31, 20122013 translated into cents at the noon buying rate on December 31, 20122013 were 37.340.8 cents. See “— Exchange Rates” on page 6.7.

(5)Weighted average number of shares excludes shares held in treasury and shares held by the Reed Elsevier Group plc Employee Benefit Trust. On January 7, 2008 the existing ordinary shares were consolidated into new ordinary shares on the basis of 58 new ordinary shares for every 67 existing ordinary shares. For the purposes of calculating earnings per share, the effective date of the share consolidation is deemed to be January 18, 2008, being the date on which the accompanying special distribution was paid. On July 30, 2009 Reed Elsevier PLC announced a share placing for 109,198,190 new ordinary shares, representing approximately 9.9% of the company’s share capital prior to the placing. The shares were fully subscribed at a price of 405p per share, raising £435 million, net of issue costs. This share placing was announced in conjunction with a similar share placing by Reed Elsevier NV.

 

  During 2012,2013, Reed Elsevier PLC repurchased 23,288,61641,961,920 Reed Elsevier PLC ordinary shares. These shares are held in treasury.

REED ELSEVIER NV

The selected financial data for Reed Elsevier NV should be read in conjunction with, and is qualified by, the consolidated financial statements of Reed Elsevier NV included in this annual report. The results and financial position of Reed Elsevier NV reflect the 50% economic interest of Reed Elsevier NV’s shareholders in Reed Elsevier. These interests are accounted for on an equity basis.

All ofThe consolidated financial statements are prepared in accordance with accounting policies that are in conformity with IFRS as issued by the IASB and as adopted by the EU. The selected financial data for Reed Elsevier NV (in €) as at and for the years ended December 31, 2013, 2012 and 2011 set out below has been extracted or derived from the audited consolidated financial statements, ofincluded herein. The selected financial data for Reed Elsevier NV.NV as at and for the years ended December 31, 2010 and 2009 set out below has been extracted or derived from our audited financial statements, which are not included herein, retrospectively restated for the adoption of IAS19 Employee Benefits (revised).

 

  For the year ended December 31,   For the year ended December 31, 
  2012(3) 2012 2011 2010 2009   2008   2013(3) 2013 2012
Restated
 2011
Restated
 2010
Restated
 2009
Restated
 
  (in millions, except per share amounts)   (in millions, except per share amounts) 

Amounts in accordance with IFRS:(1)

               

Profit before tax(2)

  $871   660   438   379   217    313    $909   659   644   421   349   199  

Taxation

   (3  (2  (1  (3  2     (19

Tax (expense)/credit

   (5  (4  (2  (1  (3  2  

Profit attributable to ordinary shareholders

   868    658    437    376    219     294     904    655    642    420    346    201  

Earnings per Reed Elsevier NV share from total operations of the combined businesses

  $1.19   0.90   0.59   0.51   0.32    0.44    $1.26   0.91   0.87   0.57   0.47   0.29  

Earnings per Reed Elsevier NV share from continuing operations of the combined businesses

  $1.19   0.90   0.59   0.51   0.32    0.43  

Diluted earnings per Reed Elsevier NV share from total operations of the combined businesses

  $1.17   0.89   0.59   0.51   0.31    0.44    $1.24   0.90   0.87   0.57   0.47   0.29  

Dividends per Reed Elsevier NV ordinary share(4)

  $0.60   0.456   0.413   0.402   0.397    2.192    $0.647   0.469   0.456   0.413   0.402   0.397  

Total assets

  $1,927   1,460   1,364   1,203   1,036    567    $ 2,062    1,494    1,460    1,364    1,203    1,036  

Total equity/Net assets

   1,851    1,402    1,303    1,137    970     491     1,979    1,434    1,402    1,303    1,137    970  

Weighted average number of shares(5)

   734.0    734.0    735.3    734.5    693.9     669.0     717.6    717.6    734.0    735.3    734.5    693.9  

 

(1)The consolidated financial statements of Reed Elsevier NV are prepared in accordance with accounting policies that are in conformity with IFRS as issued by the IASB and as adopted by the EU. The figures for 20092010 and 20082009 have been extracted or derived from the consolidated financial statements for the years ended December 31, 20092010 and 2008,2009, not included herein. Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 2 to the combined financial information on page F-16.

 

(2)Profit before tax includes Reed Elsevier NV’s share of post-tax earnings of joint ventures, being both the continuing and discontinued operations of the Reed Elsevier combined businesses. Profit before tax in 2008 includes Reed Elsevier NV’s €11 million share of joint ventures’ post-tax gain on disposal of the educational assessment business.

 

(3)Noon buying rates as at December 31, 20122013 have been used to provide a convenience translation into US dollars, see “— Exchange Rates” on page 6.7. At December 31, 20122013 the Noon Buying Rate was $1.32$1.38 per €1.00. This compares to the average exchange rate for the year ended December 31, 20122013 of $1.29$1.32 to €1.00 applied in the translation of the combined income statement for the year.

(4)Dividends declaredpaid in the year, in amounts per ordinary share, comprise a 20112012 final dividend of €0.326€0.337 and 20122013 interim dividend of €0.130€0.132 giving a total of €0.456.€0.469. The directors of Reed Elsevier NV have proposed a 20122013 final dividend of €0.337 (2011:€0.374 (2012: €0.337; 2011: €0.326; 2010: €0.303; 2009: €0.293; 2008: €0.290)€0.293), giving a total ordinary dividend in respect of the financial year of €0.467 (2011:€0.506 (2012: €0.467; 2011: €0.436; 2010: €0.412; 2009: €0.400; 2008: €0.404)€0.400). Dividends in 2008 included a special distribution of €1.767 per ordinary share paid from the net proceeds of the sale of the Education division.

 

  Dividends per Reed Elsevier NV ordinary share in respect of the financial year ended December 31, 20122013 translated into dollars at the noon buying rate on December 31, 20122013 were $0.62.$0.70. See “— Exchange Rates” on page 6.7.

 

(5)Weighted average number of shares excludes shares held in treasury and shares held by the Reed Elsevier Group plc Employee Benefit Trust and takes into account the R shares in the company held by a subsidiary of Reed Elsevier PLC, which represent a 5.8% interest in Reed Elsevier NV. On January 7, 2008 the existing ordinary shares were consolidated into new ordinary shares on the basis of 58 new ordinary shares for every 67 existing ordinary shares. For the purposes of calculating earnings per share, the effective date of the share consolidation is deemed to be January 18, 2008, being the date on which the accompanying special distribution was paid. On July 30, 2009 Reed Elsevier NV announced a share placing for 63,030,989 ordinary shares, representing approximately 9.9% of the company’s share capital prior to the placing. The shares were fully subscribed at a price of €7.08 per share, raising €441 million, net of issue costs. Correspondingly Reed Elsevier NV also issued 252,459 new R shares and transferred 135,179 existing R shares held in treasury to a subsidiary of Reed Elsevier PLC at a price of €73.00 per share for total proceeds of €29 million. This share placing was announced in conjunction with a similar share placing by Reed Elsevier PLC.

 

  During 20122013 Reed Elsevier NV repurchased 12,660,29624,282,106 Reed Elsevier NV ordinary shares and 62,34194,053 R shares.shares (equivalent to 940,530 Reed Elsevier NV ordinary shares). These shares are held in treasury.

EXCHANGE RATES

For a discussion of the impact of currency fluctuations on Reed Elsevier’s combined results of operations and combined financial position, see “Item 5: Operating and Financial Review and Prospects”.

The following tables illustrate, for the periods and dates indicated, certain information concerning the Noon Buying Rate for pounds sterling expressed in US dollars per £1.00 and for the euro expressed in US dollars per €1.00. The exchange rate on February 27, 201228, 2014 was £1.00 = $1.51$1.68 and €1.00 = $1.31.$1.38.

US dollars per £1.00 — Noon Buying Rates

 

   Period 

Year ended December 31,

  End   Average(1)   High   Low 

2012

   1.62     1.59     1.63     1.53  

2011

   1.55     1.60     1.67     1.54  

2010

   1.56     1.55     1.64     1.43  

2009

   1.62     1.57     1.70     1.37  

2008

   1.45     1.85     2.03     1.44  

Month

   High   Low 

February 2013 (through February 27, 2013)

  

   1.58     1.51  

January 2013

  

   1.63     1.57  

December 2012

  

   1.63     1.60  

November 2012

  

   1.61     1.58  

October 2012

  

   1.62     1.59  

September 2012

  

   1.63     1.59  

August 2012

  

   1.59     1.55  
   Period 

Year ended December 31,

  End   Average(1)   High   Low 

2013

   1.66     1.56     1.66     1.48  

2012

   1.62     1.59     1.63     1.53  

2011

   1.55     1.60     1.67     1.54  

2010

   1.56     1.55     1.64     1.43  

2009

   1.62     1.57     1.70     1.37  

Month

   High   Low 

February 2014

  

   1.68     1.63  

January 2014

  

   1.66     1.63  

December 2013

  

   1.66     1.63  

November 2013

  

   1.64     1.59  

October 2013

  

   1.62     1.59  

September 2013

  

   1.62     1.55  

US dollars per €1.00 — Noon Buying Rates

 

   Period 

Year ended December 31,

  End   Average(1)   High   Low 

2012

   1.32     1.29     1.35     1.21  

2011

   1.29     1.39     1.49     1.29  

2010

   1.33     1.32     1.45     1.20  

2009

   1.44     1.40     1.51     1.25  

2008

   1.41     1.47     1.60     1.24  

Month

   High   Low 

February 2013 (through February 27, 2013)

  

   1.37     1.31  

January 2013

  

   1.36     1.30  

December 2012

  

   1.33     1.29  

November 2012

  

   1.30     1.27  

October 2012

  

   1.31     1.29  

September 2012

  

   1.31     1.26  

August 2012

  

   1.26     1.21  
   Period 

Year ended December 31,

  End   Average(1)   High   Low 

2013

   1.38     1.32     1.38     1.28  

2012

   1.32     1.29     1.35     1.21  

2011

   1.29     1.39     1.49     1.29  

2010

   1.33     1.32     1.45     1.20  

2009

   1.44     1.40     1.51     1.25  

Month

   High   Low 

February 2014

  

   1.38     1.35  

January 2014

  

   1.38     1.35  

December 2013

  

   1.38     1.36  

November 2013

  

   1.36     1.34  

October 2013

  

   1.38     1.35  

September 2013

  

   1.35     1.31  

 

(1)The average of the Noon Buying Rates on the last day of each month during the relevant period.

Noon Buying Rates have not been used in the preparation of the Reed Elsevier combined financial statements, the Reed Elsevier PLC consolidated financial statements or the Reed Elsevier NV consolidated financial statements but have been used for certain convenience translations where indicated.

RISK FACTORS

The key material risks to our business are included below. Additional risks not presently known to us or that we currently deem immaterial may also impair our business.

We operate in a highly competitive environment that is subject to rapid change.

Our businesses operate in highly competitive markets. These markets continue to change in response to technological innovations, changing legislation, regulatory changes, the entrance of new competitors, and other factors. We cannot predict with certainty the changes that may occur and the effect of those changes on the competitiveness of our businesses. In particular, the means of delivering our products and services, and the products and services themselves, may be subject to rapid technological and other changes. We cannot predict whether technological innovations, changing legislation or other factors will, in the future, make some of our products wholly or partially obsolete or less profitable. Failure to anticipate market trends could impact the competitiveness of our products and services and consequently adversely affect our revenue and profit.

We cannot assure you that there will be continued demand for our products and services.

Our businesses are dependent on the continued acceptance by our customers of our products and services and the value placed on them. We cannot predict whether there will be changes in the future, either in the market demand or from the actions of competitors, which will affect the acceptability of products, services and prices to our customers. Failure to meet evolving customer needs could impact demand for our products and services and consequently adversely affect our revenue.

Fluctuations in exchange rates may affect our reported results.

Our financial statements are expressed in pounds sterling and euros and are, therefore, subject to movements in exchange rates on the translation of the financial information of businesses whose operational currencies are other than our reporting currencies. The United States is our most important market and, accordingly, significant fluctuations in US dollar exchange rates can significantly affect our reported results and financial position from year to year. In addition, in some of our businesses we incur costs in currencies other than those in which revenues are earned. The relative movements between the exchange rates in the currencies in which costs are incurred and the currencies in which revenues are earned can significantly affect the results of those businesses.

Current and future economic, political and market forces, and dislocations beyond our control may adversely affect demand for our products and services.

The demand for our products and services may be impacted by factors that are beyond our control, including macro economic, political and market conditions, the availability of short term and long term funding and capital and the level of volatility of interest rates, currency exchange rates and inflation. The United States, Europe and other major economies have recently undergone a period of severe economic turbulence, and the global economic environment has recently been less favourable than in prior years and this may continue into the future. Any one or more of these factors may contribute to reduced activity by our customers, may result in a reduction of demand for our products and services, and may adversely affect suppliers and third parties to whom we have outsourced business activities. Further disruption to global credit markets, which has significantly contributed to the recent economic turbulence described above, could have further disruptive consequences for global economic growth and customer demand.

Changes in tax laws or uncertainty over their application and interpretation may adversely affect our reported results.

Our businesses operate worldwideglobally and our earnings are subject to taxation in many differing jurisdictions and at differing rates. We seek to organise our affairs in a tax efficient manner, taking account of the jurisdictions in which we operate. However, tax laws that apply to our businesses may be amended or interpreted differently by the relevant authorities, which could adversely affect our reported results.

Changes in regulation of information collection and use could adversely affect our revenues and our costs.business.

Legal regulation relating to internet communications, data protection, e-commerce, direct marketing, credit scoring and digital advertising, privacy, information governance and use of public records is becoming more prevalent. Existing and proposed legislation and regulations, including changes in the manner in which such legislation and regulations are interpreted by courts in the United States, the European Union and other jurisdictions may impose limits on our collection and use of certain kinds of information about individuals and our ability to communicate such information effectively with our customers. For example, many of the products offered by Risk Solutions are governed by the US Fair Credit Reporting Act (“FCRA”), Graham Leach Bliley Act (“GLBA”), Drivers Privacy Protection Act (“DPPA”) and related state laws. Certain of these laws further provide for statutory penalties and attorneys fees for non-compliance. We are unable to predict in what form laws and regulations will be adopted or modified or how they will be construed by the courts, or the extent to which any such laws or interpretation changes might adversely affect our business.

Changes in provision of third party information to us could adversely affect our businesses.

A number of our businesses rely extensively upon content and data from external sources to maintain our databases.sources. Data is obtained from public records, governmental authorities, customers and other information companies, including competitors. In the case of public records, including social security number data which are obtained from public authorities, our access is governed by law. We also obtain the credit header data in our databases from consumer credit reporting agencies. The disruption or loss of data sources, in the future,either because of changes in the law or because data suppliers decide not to supply them, could adversely affect our businesses if we were unable to arrange for substitute sources in a timely manner or at all.products and services.

Our business, operations and reputation could be adversely affected by a failure to comply with FTC Settlement Orders.

Through our Risk Solutions business, we are party to two consent orders and two subsequent related supplemental orders (the “FTC Settlement Orders”) embodying settlements with the US Federal Trade Commission (“FTC”) that resolved FTC investigations into our compliance with federal laws governing consumer information security and related issues, including certain fraudulent data access incidents. We also entered into an Assurance of Voluntary Compliance and Discontinuance (“AVC”(the “AVC”) with the Attorneys General of 43 states and the District of Columbia in connection with one such FTC investigation. The FTC Settlement Orders and the AVC require us to institute and maintain information security, verification, credentialing, audit and compliance, and reporting and record retention programmes and to obtain an assessment from a qualified, independent third party every two years for twenty years (with the FTC having the right to extend such twenty-year period by up to two additional biennial assessment periods) to ensure that our performance under these information security programmes complies with the FTC Settlement Orders. Failure to comply with the FTC Settlement Orders and the AVC could result in civil penalties and adversely affect our business, operations and reputation.

Breaches of our data security systems or other unauthorised access to our databases could adversely affect our business and operations.

Our businesses provide customers with access to database information such as case law, treatises, journals, and publications as well as other data. Our Risk Solutions business also provides authorised customers with access to public records and other information on US individuals made available in accordance with applicable privacy laws and regulations. There are persons who try to breach our data security systems or gain other unauthorised access to our databases in order to misappropriate such information for potentially fraudulent purposes and we have previously disclosed incidents of such unauthorised access. Because the techniques used by such persons change frequently, we may be unable to anticipate or protect against the threat of breaches of data security or other unauthorised access. Breaches of our data security systems or other unauthorised access to our databases could damage our reputation and expose us to a risk of loss or litigation and possible liability, as well as increase the likelihood of more extensive governmental regulation of these activities in a way that could adversely affect this aspect of our business.

Changes in government funding of, or spending by, academic institutions may adversely affect demand for the products and services of our sciencescientific, technical and medical (“STM”) businesses.

The principal customers for the information products and services offered by our science and medicalSTM publishing businesses are academic institutions, which fund purchases of these products and services from limited budgets that may be sensitive to changes in private and governmental sources of funding. Accordingly, any decreases in budgets of academic institutions or changes in the spending patterns of academic institutions could negatively impact our businesses.business and revenues.

Our intellectual property rights may not be adequately protected under current laws in some jurisdictions, which may adversely affect our results and our ability to grow.

Our products and services are largely comprised of intellectual property content delivered through a variety of media, including journals, books, compact discs, and online, including the internet. We rely on trademark, copyright, patent, trade secret and other intellectual property laws to establish and protect our proprietary rights in these products and services. However, we cannot assure you that our proprietary rights will not be challenged, limited, invalidated or circumvented. Despite trademark and copyright protection and similar intellectual property protection laws, third parties may be able to copy, infringe or otherwise profit from our proprietary rights without our authorisation. These unauthorised activities may be facilitated by the internet.

In addition, whilst there is now certain internet-specific copyright legislation in the United States and in the European Union, there remains significant uncertainty as to the date from which such legislation will be enforced and the form copyright law regulating digital content may ultimately take. In several jurisdictions, including the United States, Australia and the European Union, copyright laws are increasingly coming under legal review. These factors create additional challenges for us in protecting our proprietary rights in content delivered through the internet and electronic platforms. Moreover, whilst non-copyrightable databases are protected in many circumstances by law in the European Union, there is no equivalent legal protection in the United States.

We may be unable to implement and execute our strategic and business plans if we cannot maintain high qualityhigh-quality management.

The implementation and execution of our strategic and business plans depend on our ability to recruit, motivate and retain high qualityhigh-quality people. We compete globally and across business sectors for talented management and skilled individuals, particularly those with technology and data analytics capabilities,capabilities. An inability to recruit, motivate or retain such people could adversely affect our business performance.

We may not realizerealise all of the future anticipated benefits of acquisitions.

From time to time, we acquire businessesWe regularly make small business acquisitions to strengthen our portfolio. Whilst our acquisitions are made within the framework of our overall strategy, which emphasizesemphasises organic development, we cannot assure you we will be able to generate the anticipated benefits such as revenue growth, synergies and/or cost savings associated with these acquisitions. Failure to realize the anticipated benefits of acquisitions could adversely affect our return on invested capital and financial condition.

We cannot assure you whether our substantial investment in electronic product and platform initiatives will produce satisfactory, long term returns.

We are investing significant amounts to develop and promote electronic products and platforms. The provision of electronic products and services is very competitive and we may experience difficulties developing this aspect of our business due to a variety of factors, many of which are beyond our control. These factors may include competition from comparable and new technologies and changes in regulation.

Our businesses may be adversely affected if their electronic delivery platforms, networks or distribution systems experience a significant failure or interruption.

Our businesses are dependent on electronic platforms and distribution systems, primarily the internet, for delivery of their products and services. From time to time we have experienced verifiable attacks on our platforms and systems by unauthorised parties. To date such attacks have not resulted in any material damage to us, however, our businesses could be adversely affected if their electronic delivery platforms and networks experience a significant failure, interruption or security breach.

Our businesses may be adversely affected by the failure of third parties to whom we have outsourced business activities.

Our organisational and operational structures have increased dependencyare dependent on outsourced and offshored functions. Poor performance or the failure of third parties to whom we have outsourced business functions could adversely affect our business performance, reputation and financial condition.

Our scientific, technical and medical primary publications could be adversely affected by changes in the market.

Our scientific, technical and medical (“STM”)STM primary publications, like those of most of our competitors, are published on a paid subscription basis. There is debate in government, academic and library communities, which are the principal customers for our STM publications, regarding whether such publications should be free and funded instead through fees charged to authors and from governmental and other subsidies or authors’ funders and/or made freely available after a period following publication. If these methods of STM publishing are widely adopted or mandated, it could adversely affect our revenue from our paid subscription publications.

Spending by companies on advertising and other marketing activities, which comprises a significant portion of our revenue, has historically been cyclical.

In 2012 6%2013 4% of our revenue was derived from advertising and 14% from exhibitions.advertising. In Business Information, 30%21% of revenue was derived from advertising in 20122013 compared with 37%30% in 2011.2012. Total advertising revenues for our businesses in 20122013 were £350£240 million compared with £437£350 million in 2011.

2012. Traditionally, spending by companies on advertising and other marketing activities has been cyclical, with companies spending significantly less on advertising in times of economic slowdown or turbulence. In addition, there has been a structural shift of advertising and lead generation to Google and other search engines.

The exhibitions businessExhibitions is similarly affected by cyclical pressures on spending by companies. Additionally, participation and attendance at exhibitions is affected by the availability of exhibition venues and the propensity of exhibitors and attendees to travel. Our results could be adversely affected if the availability of venues or the demand from exhibitors and attendees were reduced, for example due to international security or public health concerns or acts of terrorism or war.

Changes in the market values of defined benefit pension scheme assets and in the assumptions used to value defined benefit pension scheme obligations may adversely affect our businesses.

We operate a number of pension schemes around the world. Historically, the largest schemes have been of the defined benefit type in the United Kingdom, the United States and the Netherlands. The assets and obligations associated with defined benefit pension schemes are particularly sensitive to changes in the market values of assets and the market related assumptions used to value scheme liabilities. In particular, adverse changes to asset values, discount rates or inflation could increase future pension costs and funding requirements.

Our impairment analysis of goodwill and indefinite lived intangible assets incorporates various assumptions which are highly judgemental. If these assumptions are not realised, we may be required to recognise a charge in the future for impairment.

As at December 31, 2012,2013, goodwill on the combined statement of financial position amounted to £4,545£4,576 million and intangible assets with an indefinite life amounted to £354£347 million. We conduct an impairment test at least annually, which involves a comparison of the carrying value of goodwill and indefinite lived intangible assets by cash generating unit with estimated values in use based on latest management cash flow projections. The assumptions used in the estimation of value in use are, by their very nature, highly judgemental, and include profit growth of the business over a five year forecast period, the long term growth rate of the business thereafter, and related discount rates. There is no guarantee that our businesses will be able to achieve the forecasted results which have been included in the impairment tests and impairment charges may be required in future periods if we are unable to meet these assumptions.

Our borrowing costs and access to capital may be adversely affected if the credit ratings assigned to our debt are downgraded.

Our outstanding debt instruments are, and any of our future debt instruments may be, publicly rated by independent rating agencies such as Moody’s Investors Service Inc., Standard & Poor’s Rating Services and Fitch Ratings. A rating is based upon information furnished by us or obtained by the relevant rating agency from its own sources and from publicly available information and is subject to revision, suspension or withdrawal by the rating agency at any time. Rating agencies may review the assigned ratings due to developments that are beyond our control. Factors cited as a basis for a ratings downgrade or an assignment of a negative outlook could include the macro economic environment and the level of our indebtedness as a consequence of an acquisition. If the ratings of our debt are downgraded in the future, our borrowing costs and access to capital may be adversely affected.

Breaches of generally accepted ethical business standards or applicable statutes concerning bribery could adversely affect our reputation and financial condition.

As a world leading global provider of professional information solutions to the science, technical and medical, risk, legal and business sectors, we are expected to adhere to high standards of independence and ethical conduct. Whilst our employees are expected to abide by the Reed Elsevier Code of Ethics and Business Conduct, employees may still fail to abide by its guidelines relating to anti-bribery and principled business conduct. Similarly, whilst our major suppliers are expected to abide by our Supplier Code of Conduct, suppliers may still fail to abide by its guidelineguidelines relating to anti-bribery and principled business conduct. A breach of generally accepted principledethical business standards or applicable statues concerning bribery by our employees or our suppliers could adversely affect our business performance, reputation and financial condition.

Failure to manage our environmental impact could adversely affect our businesses.

Our businesses have an impact on the environment, principally through the use of energy and water, waste generation and, in our supply chain, through our paper use and print and production technologies. Whilst we are committed to reducing these impacts by limiting resource use and by efficiently employing sustainable materials and technologies, we cannot assure you that these efforts and expenditures incurred by us in order to comply with either new environmental legislation and regulations, new interpretations or existing laws and regulations or more rigorous enforcement of such laws and regulations will not adversely impact on our businesses or reputation.

ITEM 4: INFORMATION ON REED ELSEVIER

HISTORY AND DEVELOPMENT

Corporate structure

Reed Elsevier came into existence in January 1993, when Reed Elsevier PLC and Reed Elsevier NV contributed their respective businesses to two jointly-owned companies, Reed Elsevier Group plc, a UK registered company which owns the publishing and information businesses, and Elsevier Reed Finance BV, a Dutch registered company which owns the financing activities. Reed Elsevier PLC and Reed Elsevier NV have retained their separate legal and national identities and are publicly held companies. Reed Elsevier PLC’s securities are listed in London and New York, and Reed Elsevier NV’s securities are listed in Amsterdam and New York.

Equalisation arrangements

Reed Elsevier PLC and Reed Elsevier NV each hold a 50% interest in Reed Elsevier Group plc. Reed Elsevier PLC holds a 39% interest in Elsevier Reed Finance BV, with Reed Elsevier NV holding a 61% interest. Reed Elsevier PLC additionally holds a 5.8% indirect equity interest in Reed Elsevier NV, reflecting the arrangements entered into between the two companies at the time of the merger, which determined the equalisation ratio whereby one Reed Elsevier NV ordinary share is, in broad terms, intended to confer equivalent economic interests to 1.538 Reed Elsevier PLC ordinary shares. The equalisation ratio is subject to change to reflect share splits and similar events that affect the number of outstanding ordinary shares of either Reed Elsevier PLC or Reed Elsevier NV.

Under the equalisation arrangements, Reed Elsevier PLC shareholders have a 52.9% economic interest in Reed Elsevier, and Reed Elsevier NV shareholders (other than Reed Elsevier PLC) have a 47.1% economic interest in Reed Elsevier. Holders of ordinary shares in Reed Elsevier PLC and Reed Elsevier NV enjoy substantially equivalent dividend and capital rights with respect to their ordinary shares.

The Boards of both Reed Elsevier PLC and Reed Elsevier NV have agreed, other than in special circumstances, to recommend equivalent gross dividends (including, with respect to the dividend on Reed Elsevier PLC ordinary shares, the associated UK tax credit), based on the equalisation ratio. A Reed Elsevier PLC ordinary share pays dividends in sterling and is subject to UK tax law with respect to dividend and capital rights. A Reed Elsevier NV ordinary share pays dividends in euros and is subject to Dutch tax law with respect to dividend and capital rights.

The principal assets of Reed Elsevier PLC comprise its 50% interest in Reed Elsevier Group plc, its 39% interest in Elsevier Reed Finance BV, its indirect equity interest in Reed Elsevier NV and certain amounts receivable from subsidiaries of Reed Elsevier Group plc. The principal assets of Reed Elsevier NV comprise its 50% interest in Reed Elsevier Group plc, its 61% interest in Elsevier Reed Finance BV and certain amounts receivable from subsidiaries of Reed Elsevier Group plc. Reed Elsevier NV also owns shares, carrying special dividend rights, in Reed Elsevier Overseas BV, a Dutch registered subsidiary of Reed Elsevier Group plc.

Material acquisitions and disposals

Total acquisition expenditure in the three years ended December 31, 2012,2013, including the buy out of non-controlling interests, was £924£1,120 million, net of cash acquired.acquired of £50 million. During 2013, a number of acquisitions were made for total consideration of £239 million, net of cash acquired of £14 million. During 2012, a number of acquisitions, including the buy out of non-controlling interests, were made for a total consideration of £341 million, net of cash acquired of £12 million. During 2011, a number of acquisitions including the buy out of non-controlling interests, were made for a total consideration of £540 million, net of cash acquired. During 2010, a numberacquired of small acquisitions were made for a total£24 million.

Total consideration from disposal transactions closed in 2013 was £331 million, including £6 million in respect of £43 million.

Grossfreehold properties. The net cash proceedsreceived in the calendar year from business disposals, amounted to £242 million (2011: £101 million; 2010: £66 million), including £7 million from the sale of non-controlling interests. Net cash proceeds, before tax, amounted to £160 million (2011: £80 million; 2010: £6 million), after relatedtiming differences and separation and transaction costs, additional pension scheme contributions, and working capital and other adjustments in respect of prior year transactions.was £195 million (2012: £160 million; 2011: £80 million).

Capital expenditure

Capital expenditure on property, plant, equipment and internally developed intangible assets principally relates to investment in systems infrastructure to support electronic publishing activities, computer equipment and office facilities. Total such capital expenditure, which was financed from operatingusing cash flows generated from operations, amounted to £333£308 million in 2012 (2011:2013 (2012: £333 million; 2011: £350 million; 2010: £311 million). In 2012,2013, there was continued investment in new product and related infrastructure, particularly in Legal.the Legal segment. Further information on capital expenditure is given in notes 1615 and 1817 to the combined financial statements.

Principal Executive Offices

The principal executive offices of Reed Elsevier PLC are located at 1-3 Strand, London WC2N 5JR, England. Tel: +44 20 7166 5500. The principal executive offices of Reed Elsevier NV are located at Radarweg 29, 1043 NX Amsterdam, the Netherlands. Tel: +31 20 485 2222. The principal executive office located in the United States is at 125 Park Avenue, 23rd Floor, New York, New York, 10017. Tel: +1 212 309 5498.8100. Our internet address is www.reedelsevier.com. The information on our website is not incorporated by reference into this report.

Our agent in the United States is Kenneth Thompson II, General Counsel Intellectual Property, Privacy and Governance, Reed Elsevier, kenneth.thompson@reedelsevier.com, 9443 Springboro Pike, B4/F5/514, Miamisburg, Ohio, 45342.

BUSINESS OVERVIEW

Reed Elsevier is a world leading provider of professional information solutions operating across several market segments: Scientific, Technical & Medical, providing information and tools to help its customers improve scientific and healthcare outcomes; Risk Solutions, providing tools that combine proprietary, public and third-party information, with advanced technology and analytics; Business Information, providing data services, information and marketing solutions to business professionals; Legal, providing legal, tax, regulatory news and business information to legal, corporate, government, and academic markets; and Exhibitions, organising exhibitions and conferences.

Our principal operations are in North America and Europe. For the year ended December 31, 20122013 we had total revenue of approximately £6.1£6.0 billion and an average of approximately 30,50029,000 employees. As at December 31, 20122013 we had approximately 30,40028,000 employees. In 2012,2013, North America represented our largest single geographic market, contributing 52%51% of our total revenue.

Revenue is derived principally from subscriptions, circulation and transactional sales, exhibition fees and advertising sales. In 2012, 49%2013, 52% of Reed Elsevier’s revenue was derived from subscriptions; 26%subscriptions, 44% from circulationtransactional sales and transactional sales; 14% from exhibition fees; 6%4% from advertising sales; and 5% from other sources.sales. An increasing proportion of revenue is derived from electronic information products, principally internet based. In 2012, 64%2013, 66% of our revenue was derived from such sources, including 96% of Risk Solutions revenue, 76% of Legal revenue, 68%72% of Scientific, Technical & Medical revenue, 54%60% of Business Information revenue, and 2% of Exhibitions revenue.

Subscription sales are defined as revenue derived from the periodic distribution or update of a product or from the provision of access to online services, which is often prepaid. Circulation and transactionalTransactional sales include all other revenue from the distribution of a product and transactional salestransactions of online services, usually on cash or credit terms. The level of publishing related advertising sales and exhibition fees has historically been tied closely to the economic and business investment cycle with changes in the profit performance of advertisers, business confidence and other economic factors having a high correlation with changes in the size of the market. Subscription sales and circulation and transactional sales have tended to be more stable than advertising sales through economic cycles.

Revenue is recognised for the various categories as follows: subscriptions — on periodic despatch of subscribed product or rateably over the period of the subscription where performance is not measurable by despatch; circulation and transactional — on despatch or occurrence of the transaction; exhibitions — on occurrence of thetransaction or exhibition and advertising — on publication or period of online display. Where sales consist of two or more independent components whose value can be reliably measured, revenue is recognised on each component as it is completed by performance, based on the attribution of relative value.

Our businesses compete for subscription, circulationtransactional, and transaction, and marketingadvertising expenditures in scientific and medical, risk, legal and business sectors. The bases of competition include, for readers and users of the information, the quality and variety of the editorial content and data, the quality of the software to derive added value from the information, the timeliness and the price of the products and, for exhibitors and advertisers, the quality and the size of the audiences targeted.

For additional information regarding revenue from our business activities and geographic markets, see note 3 to the combined financial statements contained herein.

   Revenue
Year ended December 31,
 
   2012  2011  2010 
   (in millions, except percentages) 

Scientific, Technical & Medical

  £2,063     34 £2,058     34 £2,026     34

Risk Solutions

   926     15    908     15    927     15  

Business Information

   663     11    695     12    718     12  

Legal

   1,610     26    1,634     27    1,691     28  

Exhibitions

   854     14    707     12    693     11  
  

 

 

   

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

Total

  £6,116     100 £6,002     100 £6,055     100
  

 

 

   

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

   Revenue
Year ended December 31,
 
   2013  2012  2011 
   (in millions, except percentages) 

Scientific, Technical & Medical

  £2,126     35 £2,063     34 £2,058     34

Risk Solutions

   933     16    926     15    908     15  

Business Information

   547     9    663     11    695     12  

Legal

   1,567     26    1,610     26    1,634     27  

Exhibitions

   862     14    854     14    707     12  
  

 

 

   

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

Total

  £6,035     100 £6,116     100 £6,002     100
  

 

 

   

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

SCIENTIFIC, TECHNICAL & MEDICAL

 

   Year ended December 31, 
   2012   2011   2010 
   (in millions) 

Revenue

  £2,063    £2,058    £2,026  
  

 

 

   

 

 

   

 

 

 
   Year ended December 31, 
   2013   2012   2011 
   (in millions) 

Revenue

  £2,126    £2,063    £2,058  
  

 

 

   

 

 

   

 

 

 

In Scientific, Technical & Medical markets, we provide information and tools to help customers improve scientific and healthcare outcomes.

Elsevier is a leading provider of scientific, technical and& medical information and servesserving scientists, health professionals and students worldwide. Its objective is to help its customers advance science and improve healthcare by providing world class informationworld-class content and innovative information solutions that enable them to make critical decisions, enhance productivity and improve outcomes.

Elsevier is a global business with principal operations in Amsterdam, Beijing, Boston, Chennai, Delhi, London, Madrid, Munich, New York, Oxford, Paris, Philadelphia, Rio de Janeiro, St. Louis, San Diego, Singapore and Tokyo. It has 7,0006,700 employees.

In 2013, approximately 67% of revenue came from subscription sales, 30% from transactional sales, and 3% from advertising. Approximately 38% of revenue by destination in 2013 was derived from North America, 30% from Europe and the remaining 32% from the rest of the world. 72% of revenue was delivered electronically.

Elsevier serves the needs of the science, technology and health& medical markets by publishing primary research, reference, and education content, as well as by providing a range of database and workflow solutions. Elsevier’s customers are scientists, academic institutions “educators”, research leaders and administrators, medical researchers, doctors, nurses, allied health professionals and students, as well as hospitals, research institutions, health insurers, managed healthcare organisations, research-intensive corporations, and governments. All of these customers rely on Elsevier to provide high qualityhigh-quality content and critical information for making scientific and medical decisions; to review, publish, disseminate and preserve research findings; to create innovative tools to help focus research strategies, increase research effectiveness, improve medical outcomes, and enhance the efficiency of healthcare and healthcare education.

In 2012, approximately 65% of revenue came from subscription sales, 27% from circulation and transactional sales, 3% from advertising, and the remaining 5% from other sources. Approximately 40% of revenue by destination in 2012 was derived from North America, 31% from Europe and the remaining 29% from the rest of the world. 68% of revenues were delivered electronically.

In the primary research market during 2012,2013, over 1 million research papers were submitted to Elsevier, a double digit increase on the prior year.Elsevier. Over 10,000 editors managed the peer review and selection of these papers, resulting in the publication of more than 330,000350,000 articles in almost 2000over 2,000 journals, many of which are the foremost publications in their field and a primary point of reference for new research. This content was accessed by around 11 million people, with nearlymore than 700 million full text article downloads last year.in 2013. Content is provided free or at very low cost in most of the world’s poorest countries. Elsevier’s journals are primarily published and delivered through theScienceDirectplatform, the world’s largest database of scientific and medical research, hosting over 1112 million articles,pieces of content, and over 11,00026,000 full-text e-books. Flagship journals includeCellandThe Lancetfamilies of titles.

In 2013 Elsevier continuously innovatesacquired Mendeley, an innovative research management and social collaboration platform. Researchers use Mendeley’s desktop and cloud-based tools to improve the utilitymanage and effectiveness of its journals. For example, its “Article of the Future” enhances the traditional scientific paperannotate documents, create citations and bibliographies, collaborate on research projects and network with new and broader types of content, such as links to experimental data, related content, and enhanced media to supplement the article’s text.fellow academics.

Elsevier is also a global leader in the scientific, technical and& medical reference market, providing authoritative and current professional reference content. While reference has traditionally been a print industry, Elsevier has been a leader in driving the shift from print to electronic. Elsevier publishes over 20,000 reference titles, with 1,400 new titles published annually along with supporting bibliographic data, indices and abstracts. Approximately 85% of these titles are available electronically. Flagship titles include works such asGray’s Anatomy,Nelson’s PediatricsandNetter’s Atlas of Human Anatomy.

Elsevier launchedClinicalKeyin 2012, a product that allowsproviding physicians with access to access the leading Elsevier and third-party reference and evidence-based medicinemedical content in a single, fully-integrated site.fully integrated site.Since launchClinicalKeyincludes a full taxonomy has grown rapidly, and improved smart content search to help clinicians look up detailed information on highly specific topics as they seek to answer clinical questions. The platform covers Elsevier’s as well as relevant third-party health content.ClinicalKeyhas already been deployed at leading teaching hospitals, such as Oxford University’s John Radcliffe, the Cleveland Clinic, and the US Department of Veterans Affairs.currently serves over 1,000 institutions.

In medical education, Elsevier serves students of medicine, nursing and allied health professions through print and electronic books, as well as electronic solutions. For example, itsEvolveportal provides a rich resource, an online suite of solutions designed to support facultyhelp students of nursing and students and now hasallied health professionals, had over 3.54 million registered users;Evolve Reachprovides online review and testing tools for nursing and the allied health professions;Evolve Teach provides online resources and solutions to support faculty.users in 2013.

Elsevier’s database and workflow products provide a range of tools and solutions for professionals in the science, technical, and medical fields. Customers include academic and corporate researchers, research administrators and healthcare professionals.

For academic and corporate researchers, significant products includeScopus,GeofacetsReaxys, andReaxysKnovel.Scopusis the largest abstract and citation database of research literature in the world, with abstractsover 50 million abstract and bibliographic information on almost 50 million scientific research articles

records from 19,500 peer reviewedmore than 20,000 peer-reviewed journals and 5,000 international publishers.Geofacetsis an oil and gas exploration tool which packages research-relevant Elsevier and third-party geological content and tags that content to enable rich search functionality.Reaxysis a leading solution for synthetic chemists, integrating chemical reaction and compound data searching with synthesis planning.

In December 2012, Elsevier acquiredKnovel,provides a range of web-based provider of productivity tools for the engineering community, integrating technical information with analytics and search to deliver trusted answers and drive innovation.

Elsevier serves academic and government research administrators through itsSciValsuite of products that help them evaluate their institutions’ research performance, determine research strategies and increase institutional efficiencies. Leveraging bibliometric data, such as citations fromScopus,SciVal Spotlighthelps institutions and governments to identify their distinctive research strengths, evaluate performance and increase the focus of their research and development investments.SciVal Fundingassists researchers and institutions in identifying grants that are most relevant in their research areas.

In August 2012, Elsevier bolstered its research management portfolio by acquiringAtira, a provider of software and tools that complement theSciValplatform and help academic institutions and researchers improve their research outcomes.

For healthcare professionals, Elsevier develops products to deliver patient-specific solutions at the point of care to improve patient outcomes. Its clinical solutions includeGold Standard, which provides critical information on drug interactions to assist effective treatment andCPM Resource Center, which provides a data-driven framework to support nurses in undertaking procedures.

Elsevier further bolstered its clinical solutions portfolio with the acquisition in September 2012 ofExitCare, a provider of patient education and discharge instructions.ExitCare’sproducts, incorporated into Elsevier’s clinical decision support content and tools, will help healthcare providers improve the delivery of healthcare information and services across all care environments.

Market Opportunitiesopportunities

Scientific, Technicaltechnical & Medicalmedical information markets have good long-term demand growth characteristics. The importance of research and development to economic performance and competitive positioning is well understood by governments, academic institutions and corporations. This is reflected in the long-term growth in research and development spend and in the number of researchers worldwide.

Growth in health markets is driven by ageing populations in developed markets, rising prosperity in developing markets and the increasing focus on improving medical outcomes and efficiency. Given that a significant proportion of scientific research and healthcare is funded directly or indirectly by governments, spending is influenced by governmental budgetary considerations. The commitment to research and health provision does, however, remain high, even in more difficult budgetary environments.

Strategic Prioritiespriorities

Elsevier’s strategic goal is to providelead the way in providing information solutions that advance science, technology and improve health. To achieve this, Elsevier creates solutions that reflect deep insight into the way its users work and the outcomes they are seeking to achieve; drivesstrives for excellence in content, service and technology;execution; constantly adapts and revitalises its products, solutionsbusiness models and business models;technology; and leverages its sharedinstitutional skills, assets and resources and knowledge to promote innovation efficiency and excellence in execution.efficiency.

For academic and corporate researchers,Elsevier’s strategic priorities are to continue to strengthen journal brandsincrease content volume and the quality of published articles,quality; to expand content coverage, building out integrated solutions combining Elsevier, third-party and customer data; to increase content utility, using “Smart Content” to enable new e-solutions; to combine content with analytics and technology, focused on measurably improving productivity and outcomes for customers; and to further improve scientific communicationcontinue to drive operational efficiency and user experience witheffectiveness.

In the primary research market, Elsevier aims to grow volume through new journal launches, expansion of author-pays journals and growth from emerging markets; to enhance quality by building on our journal content. Elsevier is focusedpremium brands; and to add value to core platforms by implementing new capabilities such as advanced recommendations on delivering journal content quickly, making it availableScienceDirectand social collaboration through different access channels, and exploring a range of innovative new business models. Elsevier will also build new services, and add greater functionality and utility to existing solutions to improve researcher productivity.Mendeley.

For science and health professionals,In clinical reference markets, priorities are to continue enhancing the quality and relevance of ourexpand content and our workflow tools, while actively managing the ongoing format shift from printcoverage, including licensing high-quality third-party content forClinicalKey, as well as ensuring consistent tagging to electronic information.

For students, priorities are to continue to provide the highest quality educationallink content and tools and to develop an even better customer experience. In addition, Elsevier will develop tools to track student performance, train new faculty members, and improve the effectiveness of existing faculty staff.assets across products.

Business Model, Distribution Channelsmodel, distribution channels and Competitioncompetition

Science and medical research is principally disseminated on a paid subscription basis to the research facilities of academic institutions, government and corporations, and, in the case of medical and healthcare journals, also to individual practitioners and medical society members. For a number of journals, advertising and promotional income represents a small proportion of revenues predominantly from pharmaceutical companies in healthcare titles.

Over the past 15 years alternative payment models for the dissemination of research such as so-called “author-pays open access” or “author’s-funder-pays” have emerged. While it is expected that paid subscription will remain the primary distribution model, Elsevier has long invested in alternate business models to address the needs of customers and researchers. Over 1,5001,600 of Elsevier’s journals now offer the option of funding research publishing and distribution via a sponsored article fee. In addition, Elsevier now publishes around 30 “author-pays”more than 50 open access journals.

Electronic products, such asScienceDirect,ScopusandClinicalKey, are generally sold direct to customers through a dedicated sales force that has offices around the world. Subscription agents facilitate the sales and administrative process for print journals. Books are sold through traditional and online book stores, wholesalers and, particularly in medical and healthcare markets, directly to end users.

Competition within science and medical publishing is generally on a title-by-title and product-by-product basis. Competing journals, books and databases are typically published by learned societies and other professional publishers. Workflow tools face similar competition as well as from software companies and internal solutions developed by customers.

Major Brandsbrands

Elsevier is the master brand used for the business.

Elsevier’s major brands include:Cell, a life sciences journal in biochemistry and molecular biology; andThe Lancet, one of the world’s leading medical journals since 1823. Many other products and journals are major brands in their fields, including:ScopusMendeley, a scientific abstractan innovative research management and citation database;social collaboration platform;SciVal, research performance tools for academic institutions and funding intelligence;pharmapendiumReaxys,, an online drugs safety database that supports drug development researchers;a leading web-based chemical reaction workflow solution for industrial chemists;ClinicalKey,combines reference and evidence-based medical content into its fully-integrated clinical insight engine;Geofacets,an extensive database of georeferenced geological maps;ScienceDirect,the world’s largest database of scientific and medical research articles; andCPM CarePoints,a leading comprehensive care planning and clinical documentation system.

RISK SOLUTIONS & BUSINESS INFORMATION

In Risk Solutions & Business Information, we provide data, analytics and insight that enable customers to evaluate and manage risks,risk, and develop market intelligence, supporting more confident decisions, improved economic outcomes, and enhanced operational efficiency.

RISK SOLUTIONS

 

   Year ended December 31, 
   2012   2011   2010 
   (in millions) 

Revenue

  £926    £908    £927  
  

 

 

   

 

 

   

 

 

 
   Year ended December 31, 
   2013   2012   2011 
   (in millions) 

Revenue

  £933    £926    £908  
  

 

 

   

 

 

   

 

 

 

LexisNexis Risk Solutions is a leading provider of solutions that combine proprietary, public and third-party information, with advanced technology and analytics.analytics, and are powered by High Performance Computing Cluster (HPCC) Systems. These solutions assist customers in evaluating, predicting and managing risk and improving operational effectiveness, predominantly in the US.

LexisNexis Risk Solutions, is headquartered in Alpharetta, Georgia, has principal operations in Georgia, Florida, and Ohio, and has 4,1003,300 employees.

In 2012,2013, approximately 86%84% of Risk Solutions’ revenue came from circulation and transactional sales 11%and 16% from subscription sales, and the remaining 3% from other sources.sales. 96% of Risk Solutions’ revenue is delivered electronically.

LexisNexis Risk Solutions is organised around market facingmarket-facing industry/sector groups: insurance, business services (including the financial services, receivables management and corporate groups), government and government.healthcare. The most significantlargest of these is insurance. These groups are supported by a shared infrastructure for technology operations, data management, and other support functions including compliance and marketing. A number of transactional support activities, including some financial processes, are provided from a shared services organisation managed by the LexisNexis Legal & Professional business. The Legal & Professional business also distributes Risk Solutions products into legal markets in the US and internationally.

Insurance Solutions provides a comprehensive combination of data and analytics to property and casualty, (P&C) personal and commercial lines insurance carriers and life insurance carriers in the US to improve critical aspects of their business, from customer acquisition and underwriting to claims handling. Information solutions, including the US’s most comprehensive US personal loss history database,C.L.U.E.®, help insurers assess risks and provide important inputs to pricing and underwriting insurance policies. Additional key products includeLexisNexis®Data Prefill, which provides critical information on customers, potential customers and their auto, ownershipproperty and life policy information directly into the insurance workflow, andLexisNexis®Current Carrier, which identifies current or previous insurance as well as any lapses in coverage.

Business Services provides financial institutions with risk management, identity management, fraud detection, credit risk management, and compliance solutions. These include “know your customer” and anti-money laundering (“AML”) products. The business also provides risk and identity management solutions for corporate customers in retail, telecommunications and utilities sectors. Receivables management solutions help debt recovery professionals in the segmentation, management and collection of consumer and business debt.

Government Solutions provides data and analytics to US federal, state and local law enforcement and government agencies to help solve criminal and intelligence cases and to identify fraud, waste and abuse in government programmes.

Health Care Solutions provides identity, fraud and clinical analytics solutions across key stages of thehealthcareworkflow to enable intelligent decision making for payers and providers.

The LexisNexis Risk Solutions business also provides risk-related information to the legal industry through LexisNexis Legal & Professional.

LexisNexis Risk Solutions continues to focus on developing a pipeline of new solutions to drive growth in existing business segments and selected adjacent markets and geographies. For example, inIn 2013,this strategy was reinforced with a number of focused acquisitions.

In the UK,Insurance business, LexisNexis Risk Solutions has launchedacquired Mapflow, an industry-leading geographic risk assessment technology company based in Dublin, Ireland. Mapflow’s technology combined with Risk Solutions’ comprehensive data, advanced analytics, supercomputing platform (HPCC Systems) and linking capabilities help commercial and home insurers better understand property-level geographic peril risk to make more informed underwriting decisions.

In Business Services, LexisNexis Risk Solutions acquired the remaining stake in WorldCompliance, a new product that uses public informationleading provider of customer and vendor screening content, to help insurers assesscomplement our existing AML and segment risk more effectively among motor insurance customerscompliance solutions. LexisNexis Risk Solutions also acquired RSA Security’s consumer Knowledge Based Authentication technology to drive further innovation and is planning to launch additional innovative products to facilitate sharingstrengthen its leadership position in identity management. In Health Care, the acquisition of data across motor insurers, improving insurers’ ability to understand underwriting risks. InEnclarity supplements the government segment, customers are adoptingexisting identity and fraud, detection, waste, and abuse solutions which enable government agencieswith the most comprehensive provider information available. The transition of MEDai from Elsevier to identify incidencesRisk Solutions’ Health Care business was announced, enabling the combination of taxMEDai’s clinical expertise with Risk Solutions’ analytics, data, and benefits fraud, and boost revenue collections. Risk Solutions has also continuedHPCC technology to broaden its portfolio of identity management solutions, including one-time-password and biometric solutions, and has made existing identity products more configurable to address the specific needs of customers across our market segments.create leading clinical analytics solutions.

The identity verificationmanagement and risk evaluation solutions provided by Risk Solutions utilise a comprehensive database platforms of public records and proprietary information with more than 2,000 terabytes2 petabytes of unique data, which makes it the largest database of its kind in the US market today.LexisNexis Accurintis a flagship product, powered by the High Performance Cluster Computing (HPCC)HPCC technology. Thismarket-leading technology enables LexisNexis Risk Solutions to provide its customers with highly relevant search results swiftly and to create new, low-cost solutions quickly and efficiently. It is also increasingly used across other Reed Elsevier markets such as Legal and Scientific, Technical & Medical.

In JanuaryFebruary 2013, Risk Solutions announcedcompleted the sale of its Screening business. This will allowallows it to increase its focus onhigher-growth segments leveraging its core data, technology and analytical capabilities. The Screening business presented limited opportunities to apply these capabilities to generate unique customer value, sustained growth, and superior margins.

Market Opportunitiesopportunities

Risk Solutions operates in markets with strong long-term underlying growth drivers including: insurance underwriting transactions; insurance, healthcare, tax and entitlement fraud; credit defaults and financial fraud; regulatory compliance and due diligence requirements surrounding customer enrolment; and security and privacy considerations.

In the insurance segment, growth is supported by increasing transactional activity in the auto, property and life insurance markets and the increasing adoption by insurance carriers of more sophisticated data and analytics in the prospecting, underwriting and claims evaluation processes, to assess underwriting risk, increase competitiveness and improve operating cost efficiency. Transactional activity is driven by product extensions across insurance carriers’ workflow and growth in insurance quoting and policy switching, as consumers seek better policy terms. This activity is stimulated by increasing competition between insurance companies, high levels of carrier advertising, and rising levels of internet quoting and policy binding.

A number of factors support growth for risk solutions in the financial services market, including new credit originations, continued high fraud losses, stringent regulatory compliance requirements and increasing anti-money laundering fines. In receivables management, demand is driven mainly by levels of consumer debt and the prospect of recovering that debt, which is impacted by employment conditions in the US. In corporate markets, demand is supported by growth in online retail sales and continued high levels of credit card fraud. Growth in government markets is driven by the increasing use of data and analytics to combat criminal activity, fraud, and tax evasion and to address security issues. The level and timing of demand in this market is influenced by government funding and revenue considerations. In Health Care, there are numerous growth drivers for fraud and analytics solutions including the expansion of insurance coverage under the Affordable Care Act and the focus on cost containment and better patient outcomes.

Strategic Prioritiespriorities

Risk Solutions’ strategic goal is to make businesses and government more effective, through a better understanding of the risks associated with individuals, other businesses and transactions and by providing the highest quality tools to help

manage those risks efficiently and cost effectively. To achieve this, Risk Solutions is focused on: delivering innovative new products across customer workflows; expanding the range of risk management solutions across adjacent markets; addressing international opportunities in selected markets to meet local risk management needs; and continuing to strengthen its content, technology and analytical capabilities.

Business Model, Distribution Channelsmodel, distribution channels and Competitioncompetition

LexisNexis Risk Solutions’ products are predominantly sold directly, with pricing mostly on a transactional basis for insurance carriers and corporations, and primarily on a subscription basis for government entities.

LexisNexis Risk Solutions and Verisk, a competitor, each sell data and analytics solutions to insurance carriers but largely address different activities. LexisNexis Risk Solutions’ principal competitors in commercial and government sectors include Thomson Reuters and major credit bureaus, which in many cases addressingaddress different activities in these sectorssegments as well.

Major Brandsbrands

LexisNexis is the master brand used by LexisNexis Risk Solutions.

LexisNexis Risk Solutions’ major brands include:C.L.U.E.®, a comprehensive US personal insurance claims database;LexisNexis®Data Prefill, tools to automate the insurance application process providing critical information insurers need to quote and underwrite a policy;Accurint® for Collections, a leading online US solution to help locate debtors quickly and accurately;LexisNexis® Identity Management, a range of solutions to help clients verify that an identity exists and authenticate individuals;LexisNexis® Anti-Money Laundering Solutions, content and information for anti-money laundering compliance, risk mitigation and enhanced due diligence;LexisNexis® Current Carrier,database that identifies the existence of current or previous insurance, and whether or not the applicant has had a possible lapse in coverage;LexisNexis® RiskView,comprehensive suite of credit risk management tools to help assess consumer creditworthiness and risk potential; andLexisNexis® Revenue Recovery and Discovery,a suite of tools to enable governments to leverage public records and analytics to identify instances of fraud and to more efficiently collect on outstanding debts.

BUSINESS INFORMATION

 

   Year ended December 31, 
   2012   2011   2010 
   (in millions) 

Revenue

  £663    £695    £718  
  

 

 

   

 

 

   

 

 

 
   Year ended December 31, 
   2013   2012   2011 
   (in millions) 

Revenue

  £547    £663    £695  
  

 

 

   

 

 

   

 

 

 

Reed Business Information (“RBI”) provides information and online data services to business professionals worldwide. RBI provides its customers with high-value industry critical data services, information and marketing solutions to business professionals across industries globally. It produces industry critical data services and lead generation tools online community sites as well as producing conferences, websites and business magazinesmagazines. It has many strong global brands with market leadingmarket-leading positions in manyacross a wide range of industry sectors.

RBI is a global business with principal operations in London, Amsterdam, Chicago, Atlanta and Shanghai. RBI has 3,900 employees worldwide. Approximately 27%28% of Business Information revenue in 20122013 came from North America, 19%20% from the United Kingdom, 39% from Continental Europe and 15%13% from the rest of the world.

RBI is a global business headquartered in Sutton in the UK and in addition has principal operations in London, Amsterdam, Skokie (Illinois), Norcross (Georgia) and Boston (Massachusetts) in the US, as well as Paris, Milan and Shanghai. RBI has 4,800 employees worldwide.

RBI’s customers use its data and online services to help make key strategic decisions, and reduce risk, to improve productivity and performance, andto identify new business opportunities.opportunities and to reduce risk. RBI’s magazines and websites deliver high valuehigh-value news, information and opinion to business professionals across many industry sectors while also providing an effective marketing channel for customers. RBI’s online marketing solutions bring buyers and sellers together through a range of innovative digital channels.

RBI’s market leadingmarket-leading data services include:ICIS, an information and pricingdata service in chemicals, fertilisers and energy;BankersAccuityAccuity, a provider of payment routing data, anti-money laundering (AML) services and compliance informationsolutions to the banking and corporate sectors;sectors focused on payment efficiency, “know your customer”, anti-money laundering (“AML”) and compliance;XpertHR, an online service providing regulatory guidance, best practices and tools for HR professionals; andReed Construction Data, a provider of online construction data and information to the construction industry.

RBI’s other leading brands includeFlightGlobal,New Scientist,Farmers Weekly,Estates Gazette,Elseviermagazine andBoerderij. Online marketing solutions includeemedia, an email bulletin based lead generation service andBuyerZone, a web-based request for quotation (RFQ) service.

In 2012,2013, RBI continued to reshape its portfolio, significantly, addressing continued growth opportunities in data services while exiting areas not core to its paid content strategy. In addition, the business continued to focus on cost efficiency across the traditional publishing businesses.

As part of this strategy RBI sold Totaljobs Group, comprising seven recruitment job boards, created organically by RBI. RBIhas continued to create value from its existing magazine brands, while exiting a number of titles includingVariety, the entertainment market title in the US, and those in the electronics and catering markets in the UK. In January 2013, RBI announced that it had completed the sale of RBI Australia. RBI is in a process to exit its operationsMarketing Solutions businesses. Approved Index was sold in Spain.2013,BuyerZone has been sold since year end and the sale process of emedia is ongoing. In addition, RBI completed its exit of its publishing businesses in Australia, France, Spain and Italy.ICIS made a small acquisition in the carbon trading information space,Tschach Solutions.

Market Opportunitiesopportunities

The growing need for high qualityhigh-quality industry data and information and insight is driving demand for online subscription data services and providing new opportunities. Business-to-business marketing spend has historically been driven by levels of corporate profitability, which itself has followed GDP growth, and business investment.

Strategic Prioritiespriorities

RBI’s strategic goal is to help business professionals achieve better outcomes with information and decision support in its individual markets. Its areas of strategic focus are: further growing the data services businesses; restructuring the business magazinesadvertising-driven portfolio and advertising-driven portfolio; developingfocusing other products on paid content services in key markets and supporting print franchises through brand extensions and redesign;content; and driving further organisational effectiveness.

Business Model, Distribution Channelsmodel, distribution channels and Competitioncompetition

Across the RBI portfolio, user and subscription revenues now account for 69%78% of the total business with the remaining 31%22% derived from print and online advertising and lead generation. RBI electronic revenue streams now account for 54%60% of total revenue.

Data services are typically sold directly on a subscription or transactional basis. Business magazines are mainly distributed on a paid basis. Advertising and lead generation revenues are sold directly or through agents.

RBI’s data services and titlesproducts compete with a number of publishersinformation providers on a service and title-by-title basis including: UBM,IHS, McGraw Hill and Wolters Kluwer as well as many niche and privately-ownedprivately owned competitors. RBI competes for online advertising with other business-to-business websites, as well as Googlesearch engines and other search engines.social media.

Major Brandsbrands

RBI’s major brands include:ICIS,a global provider of news, price benchmarks, data, analytics and research to the energy, chemical and fertiliser industries;Reed Construction Data,a provider of actionable insight for the construction industry through cost data, project leads, market intelligence and marketing solutions;NewScientist,a science and technology media brand;Flightglobal,data, news and advisory services for professionals working in the global aviation industry;XpertHR,online services with reference data, compliance information and good practice guides for HR professionals;Elsevier,newsa leadingnews and opinion servicemagazine in the Netherlands;BankersAccuity,Accuity,payment routing data, AML services and compliance tools for the banking and corporate sectors worldwide;estatesgazette,news, data and research services for the UK commercial property industry; andemedia,Farmers Weeklydigital lead generation services in the US, UK, news, insight and Europe.software solutions for farmers and agricultural businesses.

LEGAL

 

   Year ended December 31, 
   2012   2011   2010 
   (in millions) 

Revenue

  £1,610    £1,634    £1,691  
  

 

 

   

 

 

   

 

 

 
   Year ended December 31, 
   2013   2012   2011 
   (in millions) 

Revenue

  £1,567    £1,610    £1,634  
  

 

 

   

 

 

   

 

 

 

In Legal markets, we are a world leading provider of legal, regulatory and news & business information and analysis to legal,law firm, corporate, government and academic customers.

Serving customers in more than 175 countries, LexisNexis Legal & Professional provides resources and services that inform decisions, increase productivity and drive new business.

LexisNexis Legal & Professional is headquartered in New York and has principal operations in the New York area, Ohio and North Carolina in the United States,US, Toronto in Canada, London and Paris in Europe, and cities in several other countries in Africa and Asia Pacific. It has 10,40010,000 employees worldwide.

In 2012,2013, approximately 74%77% of Legal’s revenue came from subscription sales, 13%19% from circulation and transactional sales 5%and 4% from advertising, including directory listings, and the remaining 8% from other sources.advertising. Approximately 68% of Legal’s revenue by destination in 20122013 was derived from North America, 21% from Europe and the remaining 11% from the rest of the world. 76% of Legal’s revenues wererevenue was delivered electronically.

LexisNexis Legal & Professional is organised in market facingmarket-facing groups. The most significant are Research & Litigation Solutions and Business of Law Software Solutions in the US and LexisNexis International and LexisNexis Asia outside the US. These are supported by global shared services organisations providing platform and product development, operational and distribution services, and other support functions.

In the US, in Research & Litigation Solutions, electronic information solutions and innovative workflow tools, developed through close collaboration with customers, help legal and business professionals make better informed decisions in the practice of law and in managing their businesses. Flagship products for legal research areLexis.comandLexis Advance, which provide federal and state statutes and case law, together with analysis and expert commentaries from sources such asMatthew BenderandMichieand the leading citation serviceShepard’s, which advises on the continuing relevance of case law precedents. Research solutions also include news and business information, ranging from daily news to company filings, as

well as public records information and analytics. Through its litigation solutions, LexisNexis provides lawyers with a suite of tools covering case preparation to processing and review to trial preparation. LexisNexis partners with law schools to provide services to students as part of their training.

In 2012,2013, LexisNexis introduced in the US twocontinued to release new releasesversions ofLexis Advance, an innovative web application designed to transform how legal professionals conduct research. Built on an advanced technology platform,Lexis Advanceallows primary researchers within legal and professional organisations to find highly relevant information more easily and efficiently, helping them to drive better outcomes. Future releases will continue to expand content and outreach and add new innovative tools. LexisNexis employs lawyers and trained editors with professional legal backgrounds who review, annotate and update the legal content to help ensure each document in the collection is current and comprehensive. This domain expertise combined with the application of Reed Elsevier’s “big data” HPCC technology means LexisNexis is able to update its entire legal collection faster and more efficiently, while also identifying and linking content, enabling customers to uncover previously undiscovered relationships between documents.

New workflow and analytical tools and content sets are regularly introduced onLexis Advance. For example, in 2013 LexisNexis launchedMedMal Navigator, a workflow tool that integrates medical and legal research with case facts, assisting attorneys in determining their course of action. Also, LexisNexis launched new modules forLexis Practice Advisorin the US in 2012,, a web-based practical guidance product tailored for attorneys who handle transactional matters. Additionally, LexisNexis introduced a legal news solutionstrengthened its core content offering through the acquisitionacquisitions ofLaw360 Sheshunoff and A.S. Pratt and analytical titles from Oxford University Press — providing attorneys with breaking newsenhanced information in online and analysis by practice area to supplement the legal research process.ebooks formats.

In litigation solutions, LexisNexis launched its web-enabled Early Data Analyzer which enables users to determine the nature and amount of relevant data in a lawsuit at its source location. Additionally, LexisNexis released a new version ofHosted Concordance Evolutionwhich is a fully hosted service that delivers supporting the direct import of files fromLAW PreDiscovery — reducing time, costs and storage needs by streamlining electronic discovery review capabilities on an “on-demand” basis.Sanction Solutionswas also acquired, adding trial presentation software to the LexisNexis suite of litigation offerings.

The web-based marketing services group assists law firms in their client development throughlawyers.com and providing them with website development, search engine optimisation and other web marketing services.workflow.

LexisNexis Business of Law Software Solutions provides law firms with practice management solutions, including time and billing systems, case management, cost recovery and document management services.

In August 2013, LexisNexis Martindale-Hubbell and Internet Brands announced the set-up of a joint venture, bringing togetherMartindale-Hubbell lawyer directory, includingLawyers.com, with Internet Brands’ online marketing services for lawyers.

In International markets outside the United States,US, LexisNexis serves legal, corporate, government, accounting and academic markets in Europe, Canada, Africa and Asia Pacific with local and international legal, regulatory and business information. The most significant businesses are in the UK, France, Australia, Canada and South Africa.

LexisNexis focuses on providing customers with leading collections of content and innovative online solutions to help legal and business professionals make better decisions more efficiently. Penetration of online information services has grown strongly and electronic solutions now account for 58%60% of revenue outside the US.

In the UK, LexisNexis is a leading legal information provider offering an unrivalled collection of primary and secondary legislation, case law, expert commentary, and forms and precedents. Its extensive portfolio includes a number of heritage brands:Halsbury’s,Tolleys, andButterworths. The content is delivered through multiple formats — from print to online to mobile apps and embedded in customers’ workflow.

In 2012,2013, LexisNexis launched additional modules offor the UKLexisPSLproduct suite which provides lawyers a single destination for their practical legal information needs with direct links to the relevant cases, legislation, precedents, forms, practical guidance and expert commentary. The ability to drive measurable customer value was recognised by the British Legal Awards which has named LexisNexis UK ‘2012 Supplier of the Year’ for its innovation, authoritySimilar practical guidance services were launched in Canada, South Africa and understanding of law firms’ needs. A similar service is being launched across other markets — Australia already has 13 practice area modules and by the end of next year it will have more.Australia.

In France, LexisNexis is a leading online provider of information to lawyers, notaries and courts. A heritage brandJurisClasseurand leading authoritative content is provided through multiple formats — lexisnexis.fr, mobile and in print. These content sources are, as in the UK, being combined with new content and innovative workflow tools to develop practical guidance and practice management solutions. In 2012,2013, LexisNexis France launchedcontinued to enhanceLexis 360, the first semantic search online tool combining legal information, practical content and results from the web.web by providing tailored solutions for the notary market.

Following the success ofLexis for Microsoft Office(LMO) in the US and Canadian markets, a Canadianan Australian version was launched in 2012.2013. LMO enables customers to access LexisNexis content and services via add-ins/toolbars within Microsoft Word and Outlook.

In 2012,2013, LexisNexis Legal & Professional strengthened its positions in Asia through acquisitions and enhanced products

created specifically for legal professionals and practitioners, corporate counsels, legal researchers and government institutions in markets including India, China and Japan. In Japan,China, LexisNexis launchedacquiredLexis AS ONELegalStudio, a product created specifically for corporate complianceleading provider of model contracts and legal professionals to help navigate the complex regulatory environment.practical guidance, strengthening its position in high-growing Corporate and Intellectual Property practice areas.

Market Opportunitiesopportunities

Longer termLonger-term growth in legal and regulatory markets worldwide is driven by increasing levels of legislation, regulation, regulatory complexity and litigation, and an increasing number of lawyers. Additional market opportunities are presented by the increasing demand for online information solutions and practice management tools that improve the quality and productivity of research, deliver better legal outcomes, and improve business performance. Notwithstanding this, legal activity and legal information markets are also influenced by economic conditions and corporate activity, as has been seen with the dampening impact on demand of the recent global recession and the somewhat subdued environment that followed in North America and in Europe.

Strategic Prioritiespriorities

LexisNexis Legal & Professional’s strategic goal is to enable better legal outcomes and be the leading provider of productivity enhancingproductivity-enhancing information and information-based workflow solutions in its markets. To achieve this LexisNexis is focused on introducing next generation products and solutions on the global New Lexis platform and infrastructure; leveraging New Lexis globally to continue to drive print to electronic migration and long-term international growth; and upgrading operational infrastructure, improving process efficiency and gradually improving margins.

In the US, LexisNexis’ focus is on the continuing development of next generation legal research and practice solutions. It is also conducting a major upgrade in operations infrastructure and customer service and support platforms. This will provide customers with an integrated and superior experience across US legal research, litigation services, practice managementmultiple products and client development.solutions. Over the next few years progressive product introductions, often based on the New Lexis platform, leveraging big data HPCC technology, will combine advanced technology with enriched content, sophisticated analytics and applications to enable LexisNexis’ customers to make better legal decisions and drive better outcomes for their organisations and clients.

Outside the US, LexisNexis is focused on growing online services and developing further high qualityhigh-quality actionable content and workflow tools, including the development of practical guidance and practice management applications. In 2013,2014, LexisNexis will begincontinue to introduceNewintroduce New Lexis globally. Additionally, LexisNexis is focusing on the expansion of its activities in emerging markets.

Business Model, Distribution Channelsmodel, distribution channels and Competitioncompetition

LexisNexis Legal & Professional products and services are generally sold directly to law firms and to corporate, government, accounting and academic customers on a paid subscription basis, with subscriptions with law firms often under multi-year contracts.

Principal competitors for LexisNexis in US legal markets are West (Thomson Reuters), and CCH (Wolters Kluwer),. In news and business information they are Bloomberg and Factiva (News Corporation) in news and business information.. Competitors in litigation solutions also include software companies. Significant international competitors include Thomson Reuters, Wolters Kluwer and Factiva.

Major Brandsbrands

LexisNexis is the master brand used by LexisNexis Legal & Professional.

LexisNexis Legal & Professional’s major brands include:Lexis®, legal, news and public records content for legal professionals;Matthew Bender®, critical analysis, checklists, forms, and practice guides authored by industry experts covering over 50 major practice areas;Lexis®Library, LexisNexis® for Microsoft® Office, an integration of LexisNexis content, open Web search and Microsoft Office;Lexis®Library, LexisNexis UK flagship legal online product;Lexis®PSL, LexisNexis® UK legal practical guidance

service;JurisClasseur, an authoritative online legal resource in France;Shepard’s®, a citation service;Lexis Advance, a new online legal research tool that transforms the way legal professionals conduct research; andLexis® Practice Advisor, a new resource that offers guidance to help attorneys handle transactional matters more efficiently and effectively.

EXHIBITIONS

 

   Year ended December 31, 
   2012   2011   2010 
   (in millions) 

Revenue

  £854    £707    £693  
  

 

 

   

 

 

   

 

 

 
   Year ended December 31, 
   2013   2012   2011 
   (in millions) 

Revenue

  £862    £854    £707  
  

 

 

   

 

 

   

 

 

 

InReed Exhibitions we areis a leading eventsexhibitions business, with almost 500 events in over 30 countries.

Reed Exhibitions’ portfolio of exhibitions and conferences serves 4443 industry sectors across the Americas, Europe, the Middle East, Africa and Asia Pacific.globe. In 2012,2013, Reed Exhibitions brought together over 6 million event participants from around the world, generating billions of dollars inof business and facilitating entry into new markets for its customers and boosting the local economies where the events are hosted.

Reed Exhibitions is a global business headquartered in London and has principal offices in Paris, Vienna, Norwalk (Connecticut), São Paulo, Abu Dhabi, Beijing, Moscow, Tokyo and Sydney. Reed Exhibitions has 3,2003,400 employees worldwide.

Over 70% of Exhibitions’ revenue is derived from exhibitor participation fees, with the balance primarily comprising of conference fees, online and offline advertising, sponsorship fees and admission charges. In 2012,2013, approximately 15%16% of Exhibitions’ revenue came from North America, 50%43% from Europe and the remaining 35%41% from the rest of the world on an event location basis.

Reed Exhibitions organises events which are relevant to industry needs, where participants from around the world meet face to faceface-to-face to do business, to network and to learn. Its exhibitions and conferences encompass a wide range of sectors. They include construction, electronics, energy and alternative energy, engineering, entertainment, gifts and jewellery, healthcare, hospitality, interior design, logistics, manufacturing, pharmaceuticals, real estate, recreation, security and safety, transport and travel.

Market Opportunitiesopportunities

Growth in the exhibitions market is influenced by both business-to-business marketing spend and business investment. Historically, these have been driven by levels of corporate profitability, which in turn has followed overall growth in GDP. Emerging markets and higher growth industriessectors provide additional opportunities.opportunities for Reed Exhibitions. As some events are held other than annually, growth in any one year is affected by the cycle of non-annual exhibitions.

Strategic Prioritiespriorities

Reed Exhibitions’ strategic goal is to provideunderstand and respond to its customers’ evolving needs and objectives better than its competition through deep knowledge of its customers and the markets they serve.

Reed Exhibitions delivers a platform for industry communities to conduct business, to network and to learn through a range of market-leading events in growth sectors, especially in higher growth geographies, enabling exhibitors to target and reach new customers quickly and cost-effectively and providing a platform for industry participantscost effectively.

Organic growth will be achieved by continuing to do business, to network and to learn. To achieve this, Reed Exhibitions is focused on driving organic growth by leveraging its global sector expertise,generate greater customer value through the intelligent application of customer knowledge, by developing new events, and by building out its technology platforms. Itplatforms to ensure the rapid deployment of innovation and best practices across the organisation. Reed Exhibitions is also shaping theits portfolio through a combination of strategic partnerships and selective acquisitions in high growthhigh-growth sectors and geographies as well as withdrawalby withdrawing from markets and industries with lower long-term growth prospects.

Reed Exhibitions is committed to continually improving customer solutions and experience by implementing best practice initiatives across geographies and sectors. Itsexperience. By providing a variety of services, including its integrated web event platform, is used by more than 70 per cent of events and is driving boththe company continues to drive customer satisfaction and insight.satisfaction. Using customer insights, Reed Exhibitions has developed an innovative product offering which enhances the value proposition for exhibitors by broadening their options in terms of the type and location of stand they take and the timing of their commitment to the event.

In 20122013 Reed Exhibitions launched 3037 new events. These included events which extended the geographical footprint of the luxury travel brand, ILTM, to MexicoAfrica and the high end Privé jewelleryart brand, Paris Photo, to Panama.Los Angeles. Reed Exhibitions Japan responded again to customer demand by introducing several new events, some of which werereplicating its Tokyo-based World Smart Energy Week in Osaka. The UK-based event, Oceanology International, was successfully launched in China through a collaborative effort between the fast moving sectors of cosmeticsChinese and high-technology plastics. In China, the Nepcon brand was used to launch an electronics manufacturing event in the western city of Chengdu. AUK teams. Regional strategies remain a key element of building business in China and Brazil, is a regional strategy, taking more events to China’s second tier cities and cloning events from São Paulo to Recife in Brazil’s fast developing north east. Reed Exhibitions now organises over 150nearly 200 events in emerging markets.

A number of targeted acquisitions were completed during 2012. In Brazil, Reed Exhibitions took full ownership2013. These included the Capsule portfolio of its joint venture, Reed Exhibitions Alcantara Machado,contemporary fashion events, located mainly in North America; Travelweek São Paolo, a high-end travel event servicing premium buyers across Latin America, and expanded into hospitality (Equipotel) and logistics (Movimat), cementing Reed Exhibitions’ position asExpo Ferretera, the leading exhibition organizerhardware event in Brazil.Mexico. Elsewhere, acquisitions were made to extendexpand Reed Exhibitions’ reachfootprint in China and its global position in the alternative energyadvanced materials sector. During the year, Reed Exhibitions also established positionsentered into a partnership with Thebe Exhibitions, one of the leading events companies in new markets with attractive growth prospects, including Indonesia, Saudi ArabiaSouth Africa, to form Thebe Reed Exhibitions, which will run a number of events, primarily in the travel and Turkey, where a joint venture has been created with Tüyap, the country’s leading event organiser.interior design sectors.

Business Model, Distribution Channelsmodel, distribution channels and Competitioncompetition

The substantial majority of Reed Exhibitions’ revenues are from sales of exhibition space. The balance includes conference fees, online and offline advertising, sponsorship fees and, for some shows, admission charges. Exhibition space is sold directly or through local agents where applicable. Reed Exhibitions often works in collaboration with trade associations, which use the events to promote access for members to domestic and export markets, and with governments, for whom events can provide important support to stimulate foreign investment and promote regional and national enterprise. Increasingly, Reed Exhibitions is offering visitors and exhibitors the opportunity to interact before and after the show through the use of online tools such as directories and matchmaking.

Reed Exhibitions is the global market leader in a fragmented industry, holding less than a 10 per cent10% global market share. Other international exhibition organisers include UBM, Informa IIR and some of the larger German Messe, including Messe Frankfurt, Messe Düsseldorf and Messe Munich. Competition also comes from industry trade associations and convention centre and exhibition hall owners.

Major Brandsbrands

Reed Exhibitions’ major brands include:MipcomPollutec,®, an international exhibition of environmental equipment, technologies and services;Gifts and Home,one of the largest business gifts and home fairs in China;Feicon Batimat,the international construction trade fair;Mipim,the world’s property market;World Smart Energy Week,a leading entertainment content market;event for smart and renewable energy;Intercharm,an international perfumery and cosmetics exhibition;World Travel Market,®, a globalpremier event for the travel industry; andMipim®,National Hardware Show,a global event for the property industry;Automec,an international trade fair for autoparts, equipmentUS home improvement and services;Batimat®,the international building exhibition;New York ComicCon,an East Coast popular-culture convention;Sino Corrugated,a corrugated manufacturing show;ISC West,an international security conference; andAluminum China,bringing aluminium to life.DIY fair.

ELSEVIER REED FINANCE BV

Elsevier Reed Finance BV, the Dutch parent company of the Elsevier Reed Finance BV group (“ERF”), is directly owned by Reed Elsevier PLC and Reed Elsevier NV. ERF provides treasury, finance, intellectual property and reinsurance services to the Reed Elsevier Group plc businesses through its subsidiaries in Switzerland: Elsevier Finance SA (“EFSA”), Reed Elsevier Properties SA (“REPSA”) and Elsevier Risks SA (“ERSA”). These three Swiss companies are organised under one Swiss holding company, which is in turn owned by Elsevier Reed Finance BV.

EFSA is the principal treasury centre for the Reed Elsevier combined businesses. It is responsible for all aspects of treasury advice and support for Reed Elsevier Group plc’s businesses operating in Continental Europe, Latin America, the Pacific Rim, India, China and certain other territories, and undertakes foreign exchange and derivatives dealing services for the whole of Reed Elsevier. EFSA also arranges or directly provides Reed Elsevier Group plc businesses with financing for acquisitions, product development and other general requirements and manages cash pools, investments and debt programmes on their behalf.

REPSA owns and actively manages intellectual property assets including trademarks such asThe Lancetand databases such asReaxysandPharmaPendium. In 2012 it continued to strengthen its position as a centre of excellence in the management, development and branding of intellectual property assets. ERSA is responsible for reinsurance activities for Reed Elsevier.

In 2012,2013, EFSA was active in arranging the financing and foreign currency contracts for Reed Elsevier Group plc companies related to cross border dividends and acquisitions. In June 2013, EFSA issued €550$282 million of term debt in September 2012, the proceeds of which pre-financed EFSA’s €600 million term debt maturing in April 2013.notes due December 2018. It negotiated and advised Reed Elsevier Group plc companies on a number of banking and cash management arrangements in Continental Europe and Asia and continued to advise on treasury matters, including interest rate and foreign currency management and certain other financial exposures.

The average balance of cash under management by EFSA in 2012,2013, on behalf of Reed Elsevier Group plc and its parent companies, was approximately $0.5$0.4 billion (2011: $0.8(2012: $0.5 billion).

At December 31, 2012,2013, 85% (2012: 82% (2011: 91%) of ERF’s gross assets were held in US dollars and 10% (2012: 17% (2011: 9%) in euros, including $8.4$8.2 billion (2011: $8.6(2012: $8.4 billion) and €0.6€0.5 billion (2011:(2012: €0.6 billion) in loans to Reed Elsevier Group plc subsidiaries. Loans made to Reed Elsevier Group plc businesses are funded from equity, long term debt of $2.6$1.9 billion and short term debt of $0.2$0.3 billion backed by committed bank facilities. Sources of long term debt include Swiss domestic public bonds, euro notes, bilateral term loans, private placements and syndicated bank facilities. Short term debt is primarily derived from euro and US commercial paper programmes.

GOVERNMENT REGULATION

Certain of our businesses provide authorised customers with products and services such as access to public records and other information on US individuals. Our businesses that provide such products and services are subject to applicable privacy and consumer information laws and US federal and state and EU and member state regulation. Our compliance obligations vary from regulator to regulator, and include, among other things, strict data security programs, submissions of regulatory reports, providing consumers with certain notices and correcting inaccuracies in applicable reports. We are also subject to the terms of consent decrees and other settlements with certain regulators in the U.S. See “Item 8: Financial Information — Legal Proceedings” on page 68.79.

Section 219 of the Iran Threat Reduction and Syrian Human Rights Act of 2012 (the “ITRA”), which added Section 13(r) to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), requires disclosures regarding certain activities relating to Iran or with persons designated pursuant to various U.S. Presidential Executive Orders. These disclosures are required even where the activities, transactions or dealings were conducted in compliance with applicable law. The ownership or control of our customers in Iran is often difficult to determine with certainty.

During 2012,2013, Tarbiat Modares University, Urmia University, Masih Daneshvari Hospital, Kharazmi University, Ferdowsi University of Mashad, the Iran Ministry of Science, Research and Technology, the Iran Ministry of Health and

Tehran University of Medical Sciences purchased subscription access to our ScienceDirect online platform, and in some cases, also purchased print subscriptions or other publications from our scientific, medical & technical publications business. Petrochemical Commercial Company, National Petrochemical Company, Jam Petrochemical Company, Sepahan Oil Company, Zagros Petrochemical Company, Shazand Petrochemical Co., Bandar Imam Petrochemical Company, Tabriz Petrochemical Company, Arya Sasol Polymer Company, Polynar Corporation, Behran Oil Co., Ghaed Bassir Petrochemical Co., Fanavaran Petrochemical Co. and Petroleum Marketing Department (Sytrol)Farabi Petrochemical Company subscribed to ourICIS price reports relating to the global petrochemical, energy and fertilizer markets. Iran Air subscribed to our Flight Global aviation news and information service. Our gross revenues invoicedexhibitions business provided exhibition space to the Cultural Centre of the Embassy of the Islamic Republic of Iran located in 2012Japan.

During 2013, our aggregate revenue from these subscriptions werethe foregoing activities was approximately £33,000 (thirty-three thousand pounds sterling).£4.45 million. We do not normally allocate net profit on a country-by-countrysubscription-by-subscription, individual customer or publication-by-publicationcountry-by-country basis. However, we estimate that our net profit from such sales,these activities, after internal cost allocation,allocations, amounted to less than 0.004%0.075% of our net profit reported in our combined income statement for the year ended December 31, 2012. In addition, during 20122013.

Numerous individuals located in Iran subscribed to or purchased certain of our scientific, medical & technical publications. Many of these individuals are researchers, doctors or other professionals who have obtained subscriptions or purchased publications in their individual capacity, but who may be employed by government agencies in Iran or by hospitals, universities or other entities owned or controlled by the government of Iran. We work with authors, other contributors and journal editorial board members who are located in Iran, many of whom are employed at hospitals, universities or research institutions that are owned or controlled by the government of Iran. During 2013, we processed subscription refundsrelating toICISand BankersAlmanac products of approximately £41,000 (forty-one thousand pounds sterling) to Pars Oil Company, Parsian Bank, Real Estate Bank and Syria International Islamic Bank. did not pay any fees or receive any revenues in connection with this activity. During 2013, numerous attendees at conferences organized by our exhibitions business were Iran nationals.

We believe these transactions and dealings were lawful under applicable laws and regulations, and anticipate that similar transactions or dealings may occur in the future.

ORGANISATIONAL STRUCTURE

A description of the corporate structure is included under “— History and Development” on page 11.12. A list of significant subsidiaries, associates, joint ventures and business units is included as an exhibit, see “Item 19: Exhibits” on pages S-3 and S-4.

PROPERTY, PLANT AND EQUIPMENT

We own or lease approximately 280 properties around the world, the majority of leased space being in the United States. The table below identifies the principal owned and leased properties which we use in our business.

 

Location

  

Business segment(s)

  

Principal use(s)

  Floor space
(square feet)
 

Owned properties

      

Alpharetta, Georgia

  Risk Solutions and Legal  Office and data centre   406,000  

Miamisburg, Ohio

  Risk Solutions and Legal  Office   403,638  

Linn, Missouri

  

Scientific, Technical & Medical

  Warehouse   236,105  

Albany, New York

  Risk Solutions and Legal  Office   194,780  

Binghamton, New York

  Risk Solutions and Legal  Office and warehouse   162,000  

Leased properties

      

New York, New York

  Business Information and Scientific, Technical & Medical  Office   451,800  

Amsterdam, Netherlands

  Business Information and Scientific, Technical & Medical  Office   426,036  

Miamisburg, Ohio

  Risk Solutions, Legal and Scientific, Technical & Medical  Office and data centre   213,802  

Sutton, England

  Business Information and Legal  Office   191,960  

 

All of the above properties are substantially occupied by Reed Elsevier businesses with the exception of the New York, New York property, where Reed Elsevier occupies less than half of the floor space.

No property owned or leased by Reed Elsevier which is considered material to Reed Elsevier taken as a whole is presently subject to liabilities relating to environmental regulations and none has major encumbrances.

ITEM 5: OPERATING AND FINANCIAL REVIEW AND PROSPECTS

OPERATING RESULTS — REED ELSEVIER

The following discussion is based on the combined financial statements of Reed Elsevier for the three years ended December 31, 20122013 which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and as adopted by the European Union.

The following discussion should be read in conjunction with, and is qualified by reference to, the combined financial statements.

The following tables analyse Reed Elsevier’s revenue in each of the three years ended December 31, 2013, 2012 and 2011 by type, format and geographic market. Reed Elsevier derives its revenue principally from subscriptions, circulationtransactional and transactionaladvertising sales. Transactional sales advertising sales and exhibition fees.includes revenue from exhibitions.

Revenue by type

Year ended December 31,

 

  2012 2011 2010   2013 2012 2011 
  (in millions, except percentages)   (in millions, except percentages) 

Subscriptions

  £2,978     49 £2,819     47 £2,709     45   £3112     52 £2,978     49 £2,819     45

Circulation/transactions

   1,602     26    1,649     27    1,760     29  

Exhibitions

   846     14    700     12    675     11  

Transactional

   2,683     44    2,788     45    2,746     47  

Advertising

   350     6    437     7    491     8     240     4    350     6    437     8  

Other

   340     5    397     7    420     7  
  

 

   

 

  

 

   

 

  

 

   

 

   

 

   

 

  

 

   

 

  

 

   

 

 

Total

  £6,116     100 £6,002     100 £6,055     100   £6,035     £100 £6,116     100 £6,002     100
  

 

   

 

  

 

   

 

  

 

   

 

   

 

   

 

  

 

   

 

  

 

   

 

 

Revenue by format

Year ended December 31,

   2013  2012  2011 
   (in millions, except percentages) 

Electronic

  £3,971     66 £3,896     21 £3,767     63

Print

   1,168     19    1,305     64    1,451     22  

Face to face

   896     15    915     15    783     15  
  

 

 

   

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

Total

  £6,035     100 £6,116     100 £6,002     100
  

 

 

   

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

Revenue by geographic market

Year ended December 31,

 

  2012 2011 2010   2013 2012 2011 
  (in millions, except percentages)   (in millions, except percentages) 

North America

  £3,154     52 £3,219     54 £3,303     55   £3,082     51 £3,154     52 £3,219     54

United Kingdom

   442     7    485     8    490     8     443     7    442     7    485     8  

The Netherlands

   165     3    189     3    204     3     166     3    165     3    189     3  

Rest of Europe

   1,176     19    1,095     18    1,131     19     1,074     18    1,176     19    1,095     18  

Rest of world

   1,179     19    1,014     17    927     15     1,270     21    1,179     19    1,014     17  
  

 

   

 

  

 

   

 

  

 

   

 

   

 

   

 

  

 

   

 

  

 

   

 

 

Total

  £6,116     100 £6,002     100 £6,055     100   £6,035     100 £6,116     100 £6,002     100
  

 

   

 

  

 

   

 

  

 

   

 

   

 

   

 

  

 

   

 

  

 

   

 

 

The cost profile of individual businesses within Reed Elsevier varies widely and costs are controlled on an individual business unit basis. The most significant cost item for Reed Elsevier as a whole is staff costs of £1,820£1,775 million (2011: £1,797(2012: restated £1,845 million; 2010: £1,8382011: restated £1,831 million).

The following tables show revenue, operating profit and adjusted operating profit for each of Reed Elsevier’s business segments in each of the three years ended December 31, 2013, 2012 and 2011 together with the percentage change in 20122013 and 20112012 at both actual and constant exchange rates. Adjusted operating profit is included on the basis that it is the key segmental profit measure used by management to evaluate performance and allocate resources to the business segments, as reported under IFRS8: Operating Segments in note 3 to the combined financial statements. Adjusted operating profit represents operating profit before amortisation of acquired intangible assets, exceptional restructuring costs, acquisition related costs, the share of profit on disposals in joint ventures, and is grossed up to exclude the equity share of taxes in joint ventures. Exceptional restructuring costs in 2010 related only to the restructuring of the Business Information business. Exceptional restructuring costs principally comprise severance, outsourcing migration and associated property costs. A reconciliation of operating profit to adjusted operating profit is included below. Operating profit by business segment is provided as supplementary information.

With effect from January 1, 2011, LexisNexis was reorganised as two separate businesses, Risk Solutions and Legal, which are accordingly now presented separately. Comparative profit figures for 2010 have been restated on a proforma basis as if the businesses had operated separately in that year.

  Revenue
Year ended December 31,
 
  2012  2011  % change  2010  % change 
  

 

  

 

  

 

  

 

  actual
rates
  constant
rates
(1)
  

 

  

 

  actual
rates
  constant
rates
(2)
 
  (in millions, except percentages) 

Scientific, Technical & Medical

 £2,063    34 £2,058    34  0  +1 £2,026    34  +2  +1

Risk Solutions

  926    15    908    15    +2    +1    927    15    -2    +1  

Business Information

  663    11    695    12    -5    -3    718    12    -3    -4  

Legal

  1,610    26    1,634    27    -1    -1    1,691    28    -3    -2  

Exhibitions

  854    14    707    12    +21    +25    693    11    +2    +1  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total

 £6,116    100 £6,002    100  +2  +3 £6,055    100  -1  0
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 
  Operating Profit
Year ended December 31,
 
  2012  2011  % change  2010  % change 
  

 

  

 

  

 

  

 

  actual
rates
  constant
rates
(1)
  

 

  

 

  actual
rates
  constant
rates
(2)
 
  (in millions, except percentages) 

Scientific, Technical & Medical

 £706    52 £695    57  +2  +1 £647    59  +7  +4

Risk Solutions

  281    20    181    15    +55    +54    165    15    +10    +13  

Business Information

  76    5    68    5    +13    +15                  

Legal

  146    11    144    12    +1    +4    159    15    -9    -11  

Exhibitions

  171    12    132    11    +29    +34    127    11    +4    +2  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Subtotal

 £1,380    100 £1,220    100   £1,098    100  

Corporate costs

  (47   (49     (34   

Unallocated net pension credit(3)

  25     34       26     
 

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Total

 £1,358    £1,205     +13  +13 £1,090     +11  +8
 

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

  Adjusted Operating Profit(4)
Year ended December 31,
 
  2012  2011  % change  2010  % change 
  

 

  

 

  

 

  

 

  actual
rates
  constant
rates
(1)
  

 

  

 

  actual
rates
  constant
rates
(2)
 
  (in millions, except percentages) 

Scientific, Technical & Medical

  £780    45  £768    47  +2  +1  £724    46  +6  +3

Risk Solutions

  392    23    362    22    +8    +7    354    23    +2    +6  

Business Information

  119    7    110    7    +8    +10    89    6    +23    +22  

Legal

  234    13    229    14    +2    +4    238    15    -4    -4  

Exhibitions

  210    12    167    10    +26    +30    158    10    +6    +4  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Subtotal

  £1,735    100  £1,636    100    £1,563    100  

Corporate costs

  (47   (44     (34   

Unallocated net pension credit(3)

  25     34       26     
 

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Total

  1,713     £1,626     +5  +6%    £1,555     +5  +4
 

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

  Revenue
Year ended December 31,
 
  2013  2012  % change  2011  % change 
  

 

  

 

  

 

  

 

  actual
rates
  constant
rates
(1)
  

 

  

 

  actual
rates
  constant
rates
(2)
 
  (in millions, except percentages) 

Scientific, Technical & Medical

 £2,126    35 £2,063    34  +3  +1 £2,058    34  0  +1

Risk Solutions

  933    16  926    15  +1  -1  908    15  +2  +1

Business Information

  547    9  663    11  -17  -19  695    12  -5  -3

Legal

  1,567    26  1,610    26  -3  -4  1,634    27  -1  -1

Exhibitions

  862    14  854    14  +1  +2  707    12  +21  +25
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total

 £6,035    100 £6,116    100  -1  -3 £6,002    100  +2  +3
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 
  Operating Profit
Year ended December 31,
 
  2013  2012
Restated
  % change  2011
Restated
  % change 
  

 

  

 

  

 

  

 

  actual
rates
  constant
rates
(1)
  

 

  

 

  actual
rates
  constant
rates
(2)
 
  (in millions, except percentages) 

Scientific, Technical & Medical

 £742    52 £706    52  +5  +1 £695    57  +2  +1

Risk Solutions

  312    22  281    20  +11  +9  181    15  +55  +54

Business Information

  71    5  76    5  -7  -7  68    5  +13  +15

Legal

  139    10  146    11  -5  -4  144    12  +1  +4

Exhibitions

  161    11  171    12  -6  -3  132    11  +29  +32
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Subtotal

 £1,425    100 £1,380    100   £1,220    100  

Corporate costs

  (49)     (47     (49   
 

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Total

 £1,376    £1,333     +3  +1 £1,171     +14  +14
 

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 
  Adjusted Operating Profit(3)
Year ended December 31,
 
  2013  2012
Restated
  % change  2011
Restated
  % change 
  

 

  

 

  

 

  

 

  actual
rates
  constant
rates
(1)
  

 

  

 

  actual
rates
  constant
rates
(2)
 
  (in millions, except percentages) 

Scientific, Technical & Medical

  £826    46  £780    45  +6  +2  £768    47  +2  +1

Risk Solutions

  414    23  392    23  +6  +4  362    22  +8  +7

Business Information

  107    6  119    7  -10  -11  110    7  +8  +10

Legal

  238    13  234    13  +2  +2  229    14  +2  +4

Exhibitions

  213    12  210    12  +1  +4  167    10  +26  +30
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Subtotal

  £1,798    100  £1,735    100    £1,636    100  

Corporate costs

  (49)     (47     (44   
 

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Total

  £1,749     £1,688     +4  +1  £1,592     +6  +7
 

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

 

(1)Represents percentage change in 2013 over 2012 at constant rates of exchange, which have been calculated using the average and hedge exchange rates for the 2012 financial year. These rates were used in the preparation of the 2012 combined financial statements.

(2)Represents percentage change in 2012 over 2011 at constant rates of exchange, which have been calculated using the average and hedge exchange rates for the 2011 financial year. These rates were used in the preparation of the 2011 combined financial statements.

(2)Represents percentage change in 2011 over 2010 at constant rates of exchange, which have been calculated using the average and hedge exchange rates for the 2010 financial year. These rates were used in the preparation of the 2010 combined financial statements.

 

(3)The unallocated net pension credit of £25 million (2011: £34 million; 2010: £26 million) comprises the expected return on pension scheme assets of £221 million (2011: £235 million; 2010: £217 million) less interest on pension scheme liabilities of £196 million (2011: £201 million; 2010: £191 million).

(4)Adjusted operating profit represents operating profit before the amortisation of acquired intangible assets, exceptional restructuring costs, acquisition related costs, the share of profit on disposal in joint ventures and is grossed up to exclude the equity share of taxes in joint ventures, and is reconciled to operating profit below.

Adjusted operating profit for Reed Elsevier is a non-GAAP measure included on the basis that it is a key financial measure used by management in assessing performance, and is derived from operating profit as follows:

 

  2012   2011 2010   2013   2012   2011 
  (in millions)   (in millions) 

Operating profit

  £1,358    £1,205   £1,090     £1,376    £1,333    £1,171  

Adjustments:

           

Amortisation of acquired intangible assets

   329     359    349     318     329     359  

Exceptional restructuring costs

            57  

Acquisition related costs

   21     52    50     43     21     52  

Share of profit on disposals in joint ventures

        (1                 (1

Reclassification of tax in joint ventures

   5     11    9     12     5     11  
  

 

   

 

  

 

   

 

   

 

   

 

 

Adjusted operating profit

  £1,713    £1,626   £1,555     £1,749    £1,688    £1,592  
  

 

   

 

  

 

   

 

   

 

   

 

 

Underlying revenue growth is aand underlying adjusted operating profit growth are non-GAAP measuremeasures included on the basis that it is athey are key financial measuremeasures used by management in assessing performance. References to underlying performancegrowth are calculated to exclude the results of all acquisitions and disposals made in the current and prior year, assets held for sale and currency translation effects. A reconciliationThe reconciliations of reported revenuesrevenue and adjusted operating profit year-on-year isare presented below:

 

 Revenue Adjusted
operating profit
  Revenue Adjusted
operating profit
 
 £m % change £m % change  £m % change £m % change 

Year to December 31, 2010

  6,055        1,555      

Year to December 31, 2011

  6,002     1,592   

Underlying growth

  88    +2  73    +5  230    +4  94    +6

Acquisitions

  46    +1  8    +1  148    +3  35    +2

Disposals

  (156  -3  (25  -2  (201  -4  (22  -2

Currency effects

  (31  -1  15    +1  (63  -1  (11  -1
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Year to December 31, 2011

  6,002    -1  1,626    +5

Year to December 31, 2012

  6,116    +2  1,688    +5

Underlying growth

  230    +4  85    +6  136    +2  75    +5

Acquisition

  148    +3  35    +2

Acquisitions

  69    +1  11      

Disposals

  (201  -4  (22  -2  (362  -6  (62  -4

Currency effects

  (63  -1  (11  -1  76    +2  37    +3
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Year to December 31, 2012

  6,116    +2  1,713    +5

Year to December 31, 2013

  6,035    -1  1,749    +4
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

In the commentary following, percentage movements are at actual exchange rates unless otherwise stated. Percentage movements at constant exchange rates are calculated using the average and hedge exchange rates for the previous financial year. Percentage movements at both actual rates and constant rates are shown in tables on page 26.27. The effect of currency movements on the 20122013 results is further described separately below (see “— Effect of Currency Translation” on page 33)38). References to operating profit relate to operating profit including joint ventures. Adjusted operating margin and underlying growth are defined in the glossary on pages S-1 and S-2.

Results of Operations for the Year Ended December 31, 2013

Compared to the Year Ended December 31, 2012

Revenue was £6,035 million (2012: £6,116 million), down 1%. Underlying revenue growth was 2%, or 3% excluding the net cycling in our exhibitions business.

The overall effect of disposals in 2013 was to reduce revenue by 6%, partially offset by a 1% increase from acquisitions. There have been disposals in each of our businesses, but the effect is most significant in Risk Solutions, where we sold the pre-employment screening business, in Business Information where we made a number of disposals, and in Legal where Martindale-Hubbell, the US lawyer directory, was spun out into a joint venture. Disposals made throughout 2013 will continue to impact reported revenue and operating profit growth rates in 2014.

The impact of currency movements was to increase revenue by 2%, principally due to the strengthening of the US dollar, on average, against sterling during 2013.

Total operating costs, including the amortisation of acquired intangible assets and acquisition related costs, decreased by 2%, principally reflecting business disposals.

Cost of sales were £2,118 million, down 1% compared with 2012, in line with the overall decrease in revenue. Selling and distribution costs were £1,005 million, also down 1%. Administration and other expenses were £1,565 million, down 5%, principally reflecting the impact of business disposals. Except as noted, changes in cost of sales, selling and distribution costs, and administration and other expenses, including changes in individual components thereof, were not material to the operating profit performance of the individual segments.

The amortisation charge in respect of acquired intangible assets, including the share of amortisation in joint ventures, was £318 million (2012: £329 million). Acquisition related costs were £43 million (2012: £21 million), including a charge for deferred consideration payments required to be expensed under IFRS.

Total operating costs, excluding the amortisation of acquired intangible assets and acquisition related costs, decreased by 3%, reflecting business disposals.

Depreciation and amortisation of internally generated intangible assets increased to £249 million (2012: £227 million), while actions were taken across our businesses, especially Legal, to improve cost efficiency.

The net pension expense, excluding the net pension financing charge, was £61 million (2012: £89 million), including settlement and past service credits of £59 million (2012: £20 million), mainly arising from benefits changes in the US, which will reduce future costs for our US businesses.

Underlying operating costs, excluding acquisitions and disposals, were up 2%, reflecting investment in global technology platforms and launching of new products and services, partly offset by continued process improvements.

Reported operating profit was £1,376 million (2012: £1,333 million).

Total adjusted operating profit was £1,749 million (2012: £1,688 million), up 4%. Underlying adjusted operating profit grew 5%. The impact of disposals was to reduce adjusted operating profit by 4%. Currency effects increased adjusted operating profit by 3%.

The overall adjusted operating margin of 29.0% was 1.4 percentage points higher than in the prior year. This included a 0.5 percentage point benefit to margin from portfolio change and a 0.3 percentage point benefit from currency effects.

Net pre-tax disposal gains were £16 million (2012: £45 million), arising from a gain on the sale of Risk Solutions’pre-employment screening business, offset by a net loss on other disposals. These were offset by a related tax charge of £34 million (2012: £58 million credit).

Net finance costs were lower at £196 million (2012: £227 million), including the pension financing charge of £19 million (2012: £11 million). The reduction primarily reflects the benefit of term debt refinancing at lower rates.

Profit before tax was £1,196 million (2012: £1,151 million). The tax charge was £81 million (2012: £102 million). This included a deferred tax credit of £221 million arising on the alignment of certain business assets with their global management structure. The reported net profit attributable to the parent companies’ shareholders was £1,110 million (2012: £1,044 million).

Scientific, Technical & Medical

    Revenue*
% change
  Adjusted*
operating profit
% change
 

Underlying growth

   2  3

Acquisitions/disposals

   -1  -1

Currency effects

   2  4
  

 

 

  

 

 

 

Total growth

   3  6
  

 

 

  

 

 

 

*Percentage movements in this and similar tables on pages 30 to 37 relate to changes in revenue and adjusted operating profit expressed in sterling.

The Scientific, Technical & Medical business achieved volume growth in primary research submissions and usage, and in databases & tools, across the scientific, technical & medical segments. Electronic revenue, which now accounts for 72% of the total, grew across all segments. Print book sales and pharma promotion continued to decline.

Revenue was £2,126 million (2012: £2,063 million), up 3%. Underlying revenue growth was 2%.

In primary research, growth in article submissions and usage remained strong across the scientific, technical and medical segments, and journal quality, as measured by Impact Factor, continued to improve. Revenue growth was driven by solid subscription renewals and new sales. “Author-pays” or “author’s-funder pays” article volumes continued to grow from a small base. Good growth in scientific databases & tools and electronic clinical solutions was also supported by new sales.

Print book sales and pharma promotion continued to decline reflecting a combination of format migration and structural changes in the pharmaceutical industry.

Portfolio development continued in 2013. Disposals included Elsevier Business Intelligence and a number of small print and pharma focused assets. We supported our organic growth strategy with small targeted acquisitions, including Mendeley, an online reference management and collaboration solution. The overall effect of portfolio changes was to reduce revenue by 1%.

The impact of currency movements was to increase revenue by 2%.

Total operating costs, including acquired intangible asset amortisation and acquisition related costs, increased by 2% to £1,384 million. Amortisation of acquired intangible assets increased to £76 million (2012: £68 million). Depreciation and amortisation of internally generated intangible assets increased to £95 million (£2012: £82 million).

Underlying operating costs, excluding acquired intangible asset amortisation and acquisition related costs, grew by 1%.

Adjusted operating profit was £826 million (2012: £780 million), up 6%. Underlying adjusted operating profit grew 3%. The effect of portfolio changes was to reduce adjusted operating profit by 1%. The impact of currency movements was to increase adjusted operating profit by 4%.

The adjusted operating margin increased by 1.0 percentage points, which included a 0.6 percentage point benefit from currency effects.

Risk Solutions

    Revenue
% change
  Adjusted
operating profit
% change
 

Underlying growth

   8  8

Acquisitions/disposals

   -9  -4

Currency effects

   2  2
  

 

 

  

 

 

 

Total growth

   1  6
  

 

 

  

 

 

 

All business segments achieved growth in 2013. The improvement in adjusted operating margin largely reflects the impact of portfolio changes, as underlying operating cost growth was in line with underlying revenue growth, reflecting continued new product development.

Revenue was £933 million (2012: £926 million), up 1%. Underlying revenue growth was 8%.

The 2013 results reflect the impact of portfolio changes, including the disposal of the pre-employment screening business, and some small acquisitions. Taken together, these portfolio changes had the effect of reducing revenue by 9%.

The impact of currency movements was to increase revenue by 2%.

Revenue growth in the insurance segment was driven by good take up of new products and services across the insurance workflow, expansion into adjacent market verticals, and volume growth in the core underwriting business. The expansion into international markets is progressing well, although the absolute revenue contribution remains small relative to Risk Solutions overall.

Business Services growth reflected strong demand for identity authentication and fraud detection solutions across markets. The US mortgage refinancing market did slow down in the second half as expected, but the impact of this was largely offset by continued good growth elsewhere.

New product sales drove strong growth in government revenue for the year, somewhat tempered by a slowdown in federal markets in the fourth quarter.

Total operating costs, including acquired intangible asset amortisation and acquisition related costs, decreased by 4% to £621 million. The amortisation charge in respect of acquired intangible assets decreased to £97 million (2012: £109 million), reflecting business disposals.

Underlying operating costs, excluding acquired intangible asset amortisation and acquisition related costs, grew 8% reflecting continued investment in new product development.

Adjusted operating profit was £414 million (2012: £392 million), up 6%. Underlying adjusted operating profit grew 8%. The effect of portfolio changes was to reduce adjusted operating profit by 4%. The impact of currency movements was to increase adjusted operating by profit by 2%.

The adjusted operating margin increased by 2.1 percentage points, principally driven by portfolio changes.

Business Information

    Revenue
% change
  Adjusted
operating profit
% change
 

Underlying growth

   4  14

Acquisitions/disposals

   -23  -25

Currency effects

   2  1
  

 

 

  

 

 

 

Total growth

   -17  -10
  

 

 

  

 

 

 

Underlying revenue growth accelerated in 2013 reflecting continued good growth in data services and modest growth elsewhere. Focus on process innovation drove a further improvement in adjusted operating profit margin.

Revenue was £547 million (2012: £663 million), down 17%. Underlying revenue growth was 4%.

Major Data Services, which now accounts for over 50% of continuing portfolio revenue, achieved strong growth in 2013 driven byAccuity, ICIS andXpertHR.

Leading Brands and Other Business Magazines & Services achieved modest growth, despite weak print advertising markets, with solid results from data solutions and the agricultural segments.

In 2013 we continued to exit from businesses that no longer fit our strategy, with disposals during the period including RBI Australia, Italy, and France. Since the beginning of 2014 we have also divestedBuyerZone in the Marketing Solutions segment. Portfolio changes reduced revenue by 23%.

The impact of currency movements was to increase revenue by 2%.

Since bringing the management structure of Reed Business Information and Risk Solutions more closely together at the end of 2012 we have made good initial progress on leveraging Risk Solutions’ strength in data, analytics and technology across Reed Business Information’s broader geographic footprint.

Total operating costs, including acquired intangible asset amortisation and acquisition related costs, decreased by 19% to £476 million. This included a £37 million reduction in cost of sales, a £36 million reduction in selling and distribution costs and a £38 million reduction in administration and other expenses, each reflecting business disposals. The amortisation charge in respect of acquired intangible assets decreased to £31 million (2012: £37 million).

Underlying operating costs, excluding acquired intangible asset amortisation and acquisition related costs, grew by 1%.

Adjusted operating profit was £107 million (2012: £119 million), down 10%. Underlying adjusted operating profit grew 14%. The effect of portfolio changes was to reduce adjusted operating profit by 25%. The impact of currency movements was to increase adjusted operating profit by 1%.

The adjusted operating margin increased by 1.5 percentage points, the result of the continued organic transformation of the business.

Legal

    Revenue
% change
  Adjusted
operating profit
% change
 

Underlying growth

   1  5

Acquisitions/disposals

   -5  -4

Currency effects

   1  1
  

 

 

  

 

 

 

Total growth

   -3  2
  

 

 

  

 

 

 

Positive underlying revenue growth was maintained in 2013 despite subdued market conditions in the US and Europe. Electronic revenue continued to show good growth, largely offset by print declines.

Revenue was £1,567 million (2012: £1,610 million), down 3%. Underlying revenue growth was 1%.

In the US and in our major European markets, conditions remained subdued, with growth in online solutions largely offset by continued print declines. Other international markets achieved good growth.

The roll out of new product releases continued, with 73% of US legal customers activated on the New Lexis platform at period end, and new product usage progressing well.

The 2013 results reflect the impact of portfolio reshaping over the last 18 months, including the disposal of the US document retrieval and filing business in late 2012 and other small print assets early in 2013. In the second half of 2013 LexisNexis Martindale-Hubbell, the US lawyer directory, was spun out into a joint venture with Internet Brands, abroad-based internet marketing firm.

Portfolio changes reduced revenue by 5%. The impact of currency movements was to increase revenue by 1%.

Total operating costs, including acquired intangible asset amortisation and acquisition related costs, decreased by 2% to £1,428 million. The amortisation charge in respect of acquired intangible assets amounted to £74 million (2012: £83 million). Acquisition related costs increased to £22 million (2012: £4 million) including a charge for certain deferred consideration required to be expensed under IFRS. Depreciation and amortisation of internally generated intangible assets increased to £108 million (£2012: £92 million), offset by actions taken to improve cost efficiency.

Underlying operating costs, excluding acquired intangible asset amortisation and acquisition related costs, were flat year on year.

Adjusted operating profit was £238 million (2012: £234 million), up 2%. Underlying adjusted operating profit grew 5%. The effect of portfolio changes was to reduce adjusted operating profit by 4%. The impact of currency movements was to increase adjusted operating profit by 1%.

Ongoing process innovation and some initial decommissioning of old infrastructure more than offset inflation and higher depreciation, contributing to a 0.7 percentage point improvement in the adjusted operating profit margin during 2013.

Exhibitions

    Revenue
% change
  Adjusted
operating profit
% change
 

Underlying growth (excluding biennial cycling)

   7 

Biennial cycling effects

   -5 
  

 

 

  

 

 

 

Underlying growth (including biennial cycling)

   2  4

Acquisitions/disposals

   0  0

Currency effects

   -1  -3
  

 

 

  

 

 

 

Total growth

   1  1
  

 

 

  

 

 

 

In 2013 Exhibitions maintained strong underlying revenue growth of 7% excluding the effect of biennial show cycling. While growth in Europe was modest, the US, Japan, Brazil and other markets all grew well.

Revenue was £862 million (2012: £854 million), up 1%. Underlying revenue growth was 2% (7% excluding biennial cycling).

The US and Japan achieved strong revenue growth for the year. US shows reported good growth in visitor numbers, and growth in Japan was supported by leadership of the alternative energy sector and new launches. Brazil and China continued to generate strong growth.

In Europe good growth in international events more than offset softness in some domestic continental European events, resulting in modest overall growth.

In 2013 we launched 37 new events, primarily in high-growth geographies and sectors, including the highly successful launch of World Travel Market Latin America, building on a global franchise.

We undertook a number of portfolio changes during the year, with acquisitions including Expo Ferretera in Mexico, IPSA in Russia, Travelweek Sao Paulo in Brazil and Capsule in the US. Disposals include a number of Spanish events as well as some smaller events across geographies.

Portfolio changes had no overall effect on revenue growth during 2013. Currency movements reduced revenue by 1%.

The impact of biennial exhibition cycling has steadily been reduced from 10% in 2011 through 8% in 2012, to 5% in 2013.

Total operating costs, including acquired intangible asset amortisation and acquisition related costs, were £701 million, up 3%. The amortisation charge in respect of acquired intangible assets increased to £40 million (2012: £32 million) as a result of acquisitions completed in 2013 and 2012.

Underlying operating costs, excluding acquired intangible asset amortisation and acquisition related costs, grew 1%, slightly below revenue.

Adjusted operating profit was £213 million (2012: £210 million), up 1%. Underlying adjusted operating profit grew 4%. Portfolio changes had no overall impact on adjusted operating profit growth during 2013. The impact of currency movements was to reduce adjusted operating profit by 3%.

The adjusted operating margin increased by 0.1 percentage points.

Results of Operations for the Year Ended December 31, 2012

Compared to the Year Ended December 31, 20112011*

*Comparative financial information has been restated following the adoption of IAS19 Employee Benefits (revised), see note 2 to the combined financial information on page F-16.

Revenue was £6,116 million (2011: £6,002 million), up 2%. At constant exchange rates, revenue was up 3%. Underlying revenue growth was 4%, or 3% excluding the net cycling in of biennial exhibitions.

The overall effect of disposals in 2012 was to reduce revenue by 4%, offset by a 3% increase from acquisitions. The impact of currency movements was to reduce revenue by 1%.

Total operating costs, including the amortisation of acquired intangible assets and acquisition related costs, decreased by 1%.

Cost of sales were £2,139 million, up 1% compared with 2011, with underlying volume growth and product development partly offset by the impact of disposals. Selling and distribution costs were £1,015 million, down 6%, including the impact of disposals. Administration and other expenses were £1,628£1,653 million, flat with the prior year, with the impact of disposals, including the lower acquired intangible asset amortisation, offset by technology investments. ChangesExcept as noted, changes in cost of sales, selling and distribution costs, and administration and other expenses, including changes in individual components thereof, were not material to the adjusted operating profit performance of the individual segments.

The amortisation charge in respect of acquired intangible assets, including the share of amortisation in joint ventures, decreased to £329 million (2011: £359 million), reflecting business disposals. Acquisition related costs were £21 million (2011: £52 million), reflecting the completion of the ChoicePoint integration programme in 2011.

Total operating costs, excluding the amortisation of acquired intangible assets and acquisition related costs, were flat year on year.

Depreciation and amortisation of internally generated intangible assets increased to £227 million (2011: £207 million).

The net pension expense, excluding the net pension financing charge, was £89 million (2011: £96 million), including settlement and curtailment credits of £20 million (2011: £9 million).

Underlying operating costs, excluding acquisitions and disposals, were up 4%, reflecting volume growth as well as organic investment in new product development and sales & marketing, partly offset by continued improvements in process efficiency.

Reported operating profit was £1,358£1,333 million (2011: £1,205£1,171 million), primarily reflecting improved trading performance. performance as well as lower amortisation and acquisition related costs.

Adjusted operating profit was £1,713£1,688 million (2011: £1,626£1,592 million), up 5%. At constant currencies, adjusted operating profits were up 6%. Underlying growth was also 6%. The overall effect of disposals in 2012 was to reduce adjusted operating profit by 2%, offset by a 2% increase from acquisitions. Currency effects reduced adjusted operating profit by 1%.

The overall adjusted operating margin at 28.0%27.6% was 0.91.1 percentage points higher than in the prior year. This included a 0.5 percentage point benefit to margin from portfolio change and a 0.1 percentage point benefit from the multi-year journal subscription currency hedging programme net of other currency translation effects. Underlying operating costs were up 4%, reflecting volume growth as well as organic investment in new product development and sales and marketing, partly offset by continued improvements in process efficiency.

The amortisation charge in respect of acquired intangible assets, including the share of amortisation in joint ventures, amounted to £329 million (2011: £359 million). Acquisition related costs were £21 million (2011: £52 million), reflecting the completion of the ChoicePoint integration programme in 2011. Disposals and other non operating gains were £45 million (2011: £21 million losses), principally arising from business divestments, in particularTotaljobs,offset by property charges relating to disposed businesses.

Net finance costs were lower at £216£227 million (2011: £235£244 million), including the pension financing charge of £11 million (2011: £9 million). This reflects the benefit of term debt refinancing.

The reported profitProfit before tax was £1,187£1,151 million (2011: £948£905 million). The reported tax charge was £113£102 million (2011: £181£167 million). This includes an exceptional tax credit of £96 million resulting from the resolution of a number of significant prior year tax matters. The reported netNet profit attributable to the parent companies’ shareholders was £1,069£1,044 million (2011: £760£731 million).

Scientific, Technical & Medical

    Revenue
% change
  Adjusted
operating profit
% change
 

Underlying growth

   2  4

Acquisitions/disposals

   -1  -3

Currency effects

   -1  1
  

 

 

  

 

 

 

Total growth

   0  2
  

 

 

  

 

 

 

Elsevier achieved revenue growth in primary research and databases & tools across scientific & medical segments, with particular strength in emerging markets. Research article submissions and usage grew by double digits. Electronic revenues,revenue, which now accountaccounts for 68% of total revenues,revenue, grew across all segments. Print book and pharma promotion revenues continued to decline.

RevenuesRevenue was £2,063 million (2011: £2,058 million), in line with the prior year. Underlying revenue growth was 2%.

The effect of portfolio changes and adjusted operating profits were both upcurrency movements was to reduce revenue by 1% at constant currencies. Underlying revenues and adjusted operating profits were up 2% and 4% respectively.each.

Underlying revenue growth in primary research solutions across the scientific and medical segments was driven by double digit growth in both submissions and article downloads, with growthnotably in faster growing economies outside Europe and the US. The number of article submissions to journals exceeded 1 million for the first time in 2012, with over 11 million users downloading nearly 700 million articles during the year. Elsevier’s overall relative impact factor and citation share continued to grow in the year.

In addition to growth in traditional “subscriber-pays” article volumes, “author-pays”, or “author’s-funder-pays” article volumes increased during the year, albeit from a small base. A sponsored article option is currently available in 1,500 journals and 30 stand-alone journals operate under this payment model.

Growth in databases & tools revenue was driven by new sales and usage growth.

Sales of print books to individuals continued to decline in 2012 reflecting format migration and subdued reference and education markets. Print pharma promotion revenuesrevenue also continued to decline, reflecting industry trends.

In August 2012 the management structure of Elsevier was reorganised, combining science & technology and health sciences. Had these revenue streams still been managed separately, their pro forma underlying revenue growth would have been 5% and flat respectively.

In 2012 theTotal operating costs, including acquired intangible asset amortisation and acquisition related costs, at £1,357 million were flat year on year. The amortisation charge in respect of acquired intangible assets was £68 million (2011: £72 million). Depreciation and amortisation of internally generated intangible assets increased to £82 million (£2011: £69 million).

Underlying operating costs grew by 2%, in line with underlying revenue growth.

Adjusted operating profit was £780 million (2011: £768 million), up 2%. Underlying adjusted operating profit grew 4%. The effect of portfolio changes was to reduce adjusted operating profit by 3%. The impact of currency movements was to increase adjusted operating profit by 1%.

The adjusted operating margin continued to improve, drivenincreased by continued process efficiencies and0.5 percentage points, which included a 0.4 percentage point benefit from currency hedging benefits.effects.

Risk Solutions

    Revenue
% change
  Adjusted
operating profit
% change
 

Underlying growth

   6  6

Acquisitions/disposals

   -5  1

Currency effects

   1  1
  

 

 

  

 

 

 

Total growth

   2  8
  

 

 

  

 

 

 

Risk Solutions reported underlying revenue growth in 2012 as data & analytics solutions were extended across risk markets, driving growth in both Insurance and Business Services. There was also a return to growth in the Government segment. The improvement in adjusted operating profit margin largely reflects the impact of disposals, with underlying cost growth broadly matching revenue growth, reflecting ongoing spend on new product development.

Revenues and adjusted operating profits wereRevenue was £926 million (2011: £908 million), up 1% and 7% respectively at constant currencies.2%. Underlying revenues and adjusted operating profits both grewrevenue growth was 6%.

In January 2013 the disposal of the Screening business was announced, which has been excluded from underlying revenue growth figures. If Screening had been included in the underlying results for 2012, the underlying revenue growth rate for Risk Solutions as a whole would still have been 6%.

Portfolio changes, primarily the insurance software solutions business disposed in 2011, reduced revenue by 5%.

The impact of currency movements was each to increase revenue by 1%.

The Insurance business grew underlying revenuesrevenue by 7%, with growth reflecting the extension of products and services across the insurance carrier workflow, and expansion in new market segments.

Business Services revenue growth was 7%. In financial services, the anti-money laundering, fraud detection and credit decisioning solutions all performed well, and revenues wererevenue was positively impacted by some temporary effects of increased mortgage refinancing activities. The receivables management business remained soft.

The Government business returned to growth in 2012 reflecting demand for new fraud detection products in the state & local segment, with continuing moderate declines in the federal segment.

All Risk Solutions market segments now leverage HPCC “big data” technology to combine proprietary, public, and third party information with advanced analytics to help customers in evaluating, predicting, and managing risk and improving efficiency. In 2012, 96% of revenue was delivered electronically.

In January 2013Total operating costs, including acquired intangible asset amortisation and acquisition related costs, were £645 million, down 11%. Acquired intangible amortisation fell to £109 million (2011: £156 million) following the disposal of the Screening business was announced, which has been excluded from underlying revenue growth figures. If Screening had been includedinsurance software solutions business. Acquisition related costs decreased to £2 million (2011: £25 million) reflecting the completion of the ChoicePoint integration in the underlying results, the underlying revenue growth rate for Risk Solutions as a whole would still have been 6%.2011.

Underlying operating cost growth of 7% was broadly in line with revenue growth in 2012, reflecting spend on new productsproduct and content sets.

Adjusted operating profit was £392 million (2011: £362 million), up 8%. Underlying adjusted operating profit grew 6%. The effect of portfolio changes and currency movements was to increase adjusted operating profit by 1% each.

The adjusted operating profit margin increased by 2.4 percentage points, largely reflecting the impact of portfolio changes in 2011.

Business Information

    Revenue
% change
  Adjusted
operating profit

%  change
 

Underlying growth

   2  10

Acquisitions/disposals

   -5  0

Currency effects

   -2  -2
  

 

 

  

 

 

 

Total growth

   -5  8
  

 

 

  

 

 

 

Underlying revenue growth in 2012 reflects growth from most of the Major Data Services businesses, modest growth in Marketing Solutions and Leading Brands, and a moderation in the rate of decline in Other Business Magazines & Services. In 2012 several businesses were divested that no longer fit with strategy. Process efficiencies together with portfolio development benefits drove a 2.2 percentage point margin improvement.

RevenuesRevenue was £663 million (2011: £695 million), down 5%. Underlying revenue growth was 2%.

Portfolio changes, including the disposal ofTotaljobs,Marketcast and adjusted operating profits were down 3% and up 10% respectively at constant currencies. Underlying revenues grewVariety,reduced revenue by 5%. The impact of currency movements was to reduce revenue by 2%, and underlying adjusted operating profits grew 10%.

Double digit growth atBankersAccuityandICIShelped to drive growth in Major Data Services, mitigated by continued weakness in US construction data. Major Data Services now accounts for approximately 45% of continuing portfolio pro forma revenuesproforma revenue and the majority of Reed Business Information operating profit.

Marketing Solutions delivered modest growth in 2012 and, following the disposal ofTotaljobsandHotfrog, accounts for only a small proportion of continuing portfolio revenues.revenue.

Leading Brands also delivered modest underlying revenue growth as solid performances in the UK agriculture and property sectors were offset by advertising declines elsewhere.

Other Business Magazines & Services saw moderating underlying revenue declines and continued portfolio reshaping.

Businesses includingTotaljobs, Marketcast,Variety, RBI Australia and RBI Spain were disposed of or reclassified as held for sale during the year.

In 2012 focus on process innovation together with the benefits of portfolio development helped to increase the adjusted operating profit margin by 2.2 percentage points.

These actions have contributed to the transformation of Reed Business Information’s profile, with user and subscription services now accounting for nearly 70% of revenues,revenue, and electronic revenue streams now accounting for over half of the total.

In December 2012 the management structure was reorganised to bring LexisNexis Risk Solutions and Reed Business Information together more closely in order to continue to build the Risk Solutions’ business globally. Risk Solutions’ strength in data, analytics and technology is to be leveraged in combination with Reed Business Information’s broader geographic footprint and industry specific databases.

Total operating costs, including acquired intangible asset amortisation and acquisition related costs, were £587 million, down 6%, as a result of portfolio changes. Acquired intangible amortisation increased to £37 million (2011: £29 million), reflecting acquisitions completed during 2011, particularly Accuity.

Underlying operating costs, excluding acquired intangible asset amortisation and acquisition related costs, grew by 1%.

Adjusted operating profit was £119 million (2011: £110 million), up 8%. Underlying adjusted operating profit grew 10%. Portfolio changes had no effect on adjusted operating profit growth. The impact of currency movements was to reduce adjusted operating profit by 2%.

Focus on process innovation together with the benefits of portfolio development helped to increase the adjusted operating profit margin by 2.2 percentage points.

Legal

   Revenue
% change
  Adjusted
operating profit
% change
 

Underlying growth

   1  4

Acquisitions/disposals

   -2  0

Currency effects

   0  -2
  

 

 

  

 

 

 

Total growth

   -1  2
  

 

 

  

 

 

 

Underlying revenue growth was positive despite subdued legal markets in the US and Europe. Growth was driven by electronic products and services, which account for over 75% of total revenues.revenue. In 2012 new products and services were released on the New Lexis platform.

Revenues and adjusted operating profits wereRevenue was £1,610 million (2011: £1,634 million), down 1% and up 4% respectively.. Underlying revenues grewrevenue growth was 1%, and underlying adjusted operating profits grew 4%. Portfolio changes reduced revenue by 2%. Currency movements had no impact on revenue growth.

In the US, usage and sales of online research and litigation solutions to law firms grew despite challenging market conditions. Underlying revenues from government and corporate customers also grew modestly. Print revenuesrevenue continued to decline, and News & Business revenue declines moderated.

LexisNexis introduced new releases ofLexis Advanceduring 2012, combining the business’ deep domain expertise and content with Reed Elsevier’s “big data” HPCC technology to allow researchers within legal and professional organisations to find highly relevant information more easily and efficiently. The new applications had US customer penetration of 45% by the 2012 year end.

In Europe market conditions remain subdued, with growth in online revenue largely offset by declining print revenues.revenue.

Total operating costs, including acquired intangible asset amortisation and acquisition related costs, decreased to £1,464 million, down 2%. Depreciation and amortisation of internally generated intangible assets increased to £92 million (2011: £87 million).

Underlying operating, excluding acquired intangible asset amortisation and acquisition related costs, grew by 1% in line with underlying revenue.

Adjusted operating profit was £234 million (2011: £229 million), up 2%. Underlying adjusted operating profit grew 4%. Portfolio changes had no effect on adjusted operating profit growth. The impact of currency movements was to reduce adjusted operating profit by 2%.

The 2012 the adjusted operating profit margin improved slightly,by 0.5 percentage points, with process efficiencies offsetting continued spend on new product development.

Exhibitions

   Revenue
% change
  Adjusted
operating profit
% change
 

Underlying growth (excluding biennial cycling)

   7 

Biennial cycling effects

   8 
  

 

 

  

 

 

 

Underlying growth (including biennial cycling)

   15  20

Acquisitions/disposals

   10  10

Currency effects

   -4  -4
  

 

 

  

 

 

 

Total growth

   21  26
  

 

 

  

 

 

 

Exhibitions saw growth in the US and Japan, moderate growth in Europe, and double digit growth in most emerging markets during the year. Investment continued throughout the year, launching 30 new shows in total, including several in high growth markets through partnerships and targeted acquisitions.

Revenue was £854 million (2011: £707 million), up 21%. Underlying revenue growth was 15% (7% excluding biennial cycling).

Portfolio changes, including the acquisition of Equipotel, Agenda and adjusted operating profits were up 25% and 30% respectively at constant currencies. Underlying revenues and adjusted operating profits were up 15% and 20% respectively.Alcantara Machado, increased revenue by 10%. The impact of currency movements was to reduce revenue by 4%.

In the US and Japan underlying revenuesrevenue increased, and growth in emerging markets was well into double digits. In Europe growth from a number of core events helped to offset some softness in southern European markets, resulting in moderate underlying revenue growth overall in the region.

During 2012 Exhibitions launched 30 new events, primarily in high growth sectors and geographies, and completed a number of targeted acquisitions. In Brazil, Exhibitions took full ownership of Alcantara Machado, previously a joint venture, and expanded into hospitality and logistics. In Turkey a new joint venture was created with Tüyap, a Turkish event organiser.

2012 adjusted operating profit margins improved by 1.0 percentage points, reflecting both process efficiencies and the positive impact of biennial event cycling.

During the year the business rolled out global platforms and processes across geographies and sectors. The integrated web event platform is now used by more than 70% of events.

Results of Operations for the Year Ended December 31, 2011

Compared to the Year Ended December 31, 2010

General

Revenues at £6,002 million (2010: £6,055 million) were down 1% compared with 2010. At constant exchange rates, revenue was flat compared with the prior year. Underlying revenue growth was 2%, or 3% excluding the net cycling out of biennial exhibitions. This compares with underlying revenue growth in the prior year of 2%, or 1% excluding the biennial exhibition cycling. The underlying revenue performance reflects the continued portfolio development, new product introduction, expanded sales & marketing,Total operating costs, including acquired intangible asset amortisation and other actions taken to improve the business.

Cost of sales were £2,126 million, down 4% compared with 2010, and selling and distributionacquisition related costs, were £1,075£683 million down 1%, the reductions primarily reflecting business disposals and currency effects, as well as cost of sales savings in Risk Solutions from the ChoicePoint integration. Administration and other expenses were £1,626 million, down 4%up 19%, reflecting the completioninvestment in new shows and the net cycling. Acquired intangible amortisation increased to £32 million (2011: £24 million). Depreciation and amortisation of acquired intangible assets increased to £16 million (2011: £10 million).

Underlying operating costs grew by 14%, slightly below revenue growth, reflecting the RBI exceptional restructuring programme in 2010, with related costs in that yearimpact of £57 million, largely relating to severance and property costs. Other than as disclosed herein, changes in cost of sales, selling and distribution costs, and administration and other expenses, including changes in individual components thereof, were not material to the operating profit performance of the individual segments.biennial cycling.

Reported operating profit was £1,205 million (2010: £1,090 million). The increase reflects improved trading performance and no exceptional restructuring costs.

Adjusted operating profit was £1,626£210 million (2010: £1,555(2011: £167 million), up 5%26%. At constant currencies,Underlying adjusted operating profits were up 4%profit grew 20%. Underlying growth inThe effect of portfolio changes was to increase adjusted operating profits was 5%profit by 10%. The overallimpact of currency movements was to reduce adjusted operating profit by 4%.

The adjusted operating profit margin at 27.1% was 1.4improved by 1.0 percentage points, higher than last year. This included a 0.4 percentage point benefit to margin of the multi year subscription currency hedging programme and other currency translation effects. Underlying operating costs were flat against the prior year, despite business growth and additional spending on new product development and sales & marketing, reflecting the continued focus on process efficiency and procurement savings, and the benefit of prior year restructuring.

The amortisation charge in respect of acquired intangible assets, including the share of amortisation in joint ventures, amounted to £359 million (2010: £349 million).

Exceptional restructuring costs were nil (2010: £57 million, in respect of the restructuring of RBI). Acquisition related costs amounted to £52 million (2010: £50 million) most significantly in respect of technology integration within Risk Solutions. Disposals and other non operating losses were £22 million (2010: £46 million), including the share of disposal profits in joint venues.

Net finance costs were lower at £235 million (2010: £276 million), reflecting the benefit of free cash flow, term debt redemptions and the expiry of interest rate swaps.

The reported profit before tax was £948 million (2010: £768 million). The reported tax charge was £181 million (2010: £120 million).

Profit attributable to parent companies’ shareholders was £760 million, up from £642 million in 2010, reflecting the higher profit before tax partly offset by the higher tax charge.

Since January 1, 2011, Risk Solutions and Legal have been operating as separate businesses. In aggregate, revenue decreased by 3% to £2,542 million (2010: £2,618 million) and adjusted operating profits were flat at £591 million (2010: £592 million). The results of each business are presented separately below.

Scientific, Technical & Medical

Increasing global scientific and medical research activity supported growth in research information and online tools. Health Sciences saw continued pressure on print book sales to individuals and European pharmaceutical promotion, but achieved growth in global medical research and clinical decision support.

Revenues and adjusted operating profits were up 1% and 3% respectively at constant currencies. Underlying revenues and adjusted operating profits were up 2% and 4% respectively.

Science & Technology generated underlying revenue growth of 4%. Global research activity has continued to grow broadly in line with long term historic trends, and Elsevier generated growth in the volume of articles submitted and published in the year, and improved the quality of articles relative to other publishers as measured by citation share.

Health Sciences’ underlying revenues were flat. Our global medical research business benefited from similar drivers to those in the Science & Technology research business, and online clinical decision support achieved double digit growth as healthcare customers look to achieve improved medical outcomes and increased efficiency. Across Health Sciences, online solution and electronic products grew well and now account for nearly 40% of revenues. European pharma promotions declines have continued, and print book sales to individuals came under increasing pressure, reflecting the format shift to online, and pressure on enrolment in US nursing and health profession career schools. Our business in emerging markets, most notably India, China and Latin America, performed well.

Underlying operating cost growth was 1%, reflecting ongoing emphasis onboth process efficiencies and procurement savings offsetting business growth and spending on new product development and sales & marketing initiatives.

Risk Solutions

Risk Solutions reported growth in insurance data & analytics and business services reflecting demand for core products and the extension of the range of services that are provided. Screening revenues slowed in the second half reflecting US hiring trends, and federal government markets remained under pressure.

Revenues and adjusted operating profits were up 1% and 6% respectively at constant currencies. Underlying revenues and adjusted operating profits were up 4% and 12% respectively.

The insurance data & analytics business generated revenue growth of 7%, driven by the increasing adoption of solutions across the insurance workflow from marketing through to claims handling that improve underwriting economics and operational efficiency. In November 2011, Risk Solutions completed the sale of its infrastructure software business, focusing the insurance business on high value data and analytics.

Business services achieved growth of 4%, reflecting growth in credit scoring and anti-money laundering for the financial services industry and e-commerce for corporate markets, moderated by the effect of a softening in the US real estate market on the mortgage-related business.

Screening solutions grew 3%, with growth slowing over the course of the year as operational improvements in sales force effectiveness and increased penetration of the mid-size corporate market were offset by a US hiring environment that weakened as the year progressed. Government solutions revenues declined as the wind down of some lower margin one-off federal sales were only partly offset by growth in state and local revenues, driven by increased focus on fraud, waste and abuse.

Underlying operating costs declined by 1% despite the business growth and new product investment, reflecting cost savings, notably in technology, and from the completion of the ChoicePoint integration. The adjusted operating margin increased by 1.7 percentage points to 39.9%.

Business Information

Reed Business Information returned to underlying revenue growth, with growth in data services mostly offset by continued weakness in print advertising. Significant further progress on portfolio realignment was made with acquisitions in data services and disposals of print magazine titles. The majority of the margin increase reflects organic development, supported by exits from low margin businesses.

Revenues were down 4% and adjusted operating profits up at 22% at constant currencies. Underlying revenues and adjusted operating profits were up 1% and 15% respectively.

The major data services businesses, which accounted for 25% of Reed Business Information revenues in 2011, delivered underlying revenue growth of 9%, including growth inICIS,Bankers AlmanacandXpertHR, partially offset byReed Construction Dataserving the challenged US construction industry. Online marketing solutions grew 2%, driven largely byTotaljobsin the UK online recruitment market, offset by weakness in lead generation businesses,BuyerZoneandHotfrog. Leading brands saw stable revenues, with online growth compensating for print advertising declines. Other business magazines and communities saw an underlying revenue decline of 5% reflecting continued print advertising market weakness.

Underlying operating costs were down 2%, reflecting continuing measures taken to realign the cost base. Adjusted operating margins increased 3.4 percentage points to 15.8%.

Legal

Legal revenues returned to underlying revenue growth in 2011, and adjusted operating margins were broadly flat, as expected. Most legal markets have stabilized, and new products were launched.

Revenues and adjusted operating profits were down 2% and 4% respectively at constant currencies. Underlying revenues and adjusted operating profits were up 1% and down 2% respectively.

US research & litigation revenues returned to slight growth, benefiting from a stabilisation in legal industry activity. Growth was achieved in lexis.com searches and in new sales of research and litigation tools and services to law firms, government and corporate legal customers. Growth in practice management tools was offset by continued but moderating declines in news & business information to corporate customers, and in web based listings.

International markets outside of the US also returned to growth. Electronic revenues grew 7% reflecting demand for legal tools and solutions, although this was largely offset by further print declines as format transition continued. Print base products now account for less than 40% of revenue.

Underlying operating cost growth was 1% reflecting continued investment in the next generation legal offerings and sales & marketing, offset by continued cost initiatives. The adjusted operating margin was broadly flat at 14.0%.

Exhibitions

The net cycling outpositive impact of biennial shows held back growth in 2011. Excluding biennial cycling, underlying revenue growth was 10%, with growth across all geographies. New launch activity was accelerated in 2011, and a number of selective acquisitions were made which have increased the business’ presence in high growth markets.event cycling.

Revenues and adjusted operating profits were up 1% and 4% respectively at constant currencies. Underlying revenues and adjusted operating profits were flat and up 2% respectively.

In Europe, underlying revenue grew 6% excluding biennial cycling, withMipcomandMapicperforming well.Mipim, Reed Exhibitions’ largest individual show, returned to growth after experiencing a decline in 2010. In North America underlying revenues grew 16% excluding cycling. Outside Europe and North America underlying revenue growth was 13% excluding biennial events, including growth in China, Brazil, Russia and the Middle East.

Underlying operating costs were down 1%, reflecting cost control, while funding the significantly increased launch programme and build out of global industry groups and information technology capabilities. The adjusted operating margin was 0.8 percentage points higher than in 2010 at 23.6%.

Critical Accounting Policies

The accounting policies of the Reed Elsevier combined businesses under IFRS as issued by the International Accounting Standards BoardIASB and as adopted by the European UnionEU are described in note 2 to the combined financial statements. The most critical accounting policies and estimates used in determining the financial condition and results of the combined businesses, and those requiring the most subjective or complex judgments, relate to the valuation of goodwill and acquired intangible assets, pensions, share based remuneration, litigation, taxationcapitalisation of development spend and property provisioning.taxation.

The Audit Committees of Reed Elsevier PLC, Reed Elsevier NV and Reed Elsevier Group plc have reviewed the development and selection of critical accounting estimates, and the disclosure of critical accounting policies in this annual report.the financial statements.

Effect of Currency Translation

The combined financial statements are expressed in sterling and are therefore subject to the impact of movements in exchange rates on the translation of the financial information of individual businesses whose operational currencies are other than sterling. The principal exposures in relation to the results reported in sterling are to the US dollar and the euro, reflecting Reed Elsevier’s business exposure to the United States and the euro zone, its most important markets outside the United Kingdom.markets. Some of these exposures are offset by denominating borrowings in US dollars.

Individual businesses within Reed Elsevier Group plc and ERF are subject to foreign exchange transaction exposures caused by the effect of exchange rate movements on their revenue and operating costs, to the extent that such revenue and costs are not denominated in their functional currencies. Individual businesses are required to hedge their exposures at market rates with the centralised treasury department within ERF. Hedging of foreign exchange transaction exposure is the only hedging activity undertaken by the individual businesses. For further details see note 1918 to the combined financial statements.

Currency differences decreasedincreased Reed Elsevier’s revenue by £63£76 million in 20122013 compared to 2011.2012. Excluding amortisation of acquired intangible assets of £318 million and acquisition related costs of £43 million, currency differences decreasedincreased operating profits by £11£37 million in 20122013 compared to 2011.2012. Acquired intangible assetsasset amortisation and goodwillacquisition related costs are predominantly denominated in US dollars and, after charging amortisation,these charges, currency differences decreasedincreased operating profits by £8£30 million in 20122013 compared to 2011.2012. Borrowings are predominantly denominated in US dollars and, after charging net finance costs, currency differences decreasedincreased profit before tax by £8£29 million in 20122013 compared to 2011.

To help protect Reed Elsevier PLC’s and Reed Elsevier NV’s shareholders’ equity from the effect of currency movements, Reed Elsevier will, as deemed appropriate, hedge foreign exchange translation exposures by borrowing in those currencies where significant translation exposure exists or sell forward surplus cash flow in anticipation of dividend or capital repatriation. Hedging of foreign exchange translation exposure is undertaken only by the regional centralised treasury departments and under policies agreed by the Boards of Reed Elsevier PLC and Reed Elsevier NV. Borrowing in the functional currency of individual businesses provides a structural hedge for the assets in those markets and for the income realised from those assets.2012.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements are set out in note 2 to the combined financial statements.

LIQUIDITY AND CAPITAL RESOURCES — REED ELSEVIER

Cash Flow

Reed Elsevier’s cash generated from operations in 20122013 amounted to £1,943 million (2012: £1,847 million (2011:million; 2011: £1,735 million; 2010: £1,649 million). Included in these net cash inflows are cash outflows of £40 million (2012: £62 million (2011:million; 2011: £90 million; 2010: £150 million) relating to acquisition related costs and exceptional restructuring costs incurred in prior years and acquisition related costs. Reed Elsevier generates significant cash inflows as its principal businesses do not generally require major fixed or working capital investments.years. A substantial proportion of revenue is received through subscription and similar advanced receipts, principally for scientific and medical journals and exhibition fees. At December 31, 20122013 subscriptions and other revenues received in advance totaledtotalled £1,403 million (2012: £1,394 million (2011:million; 2011: £1,412 million; 2010: £1,308 million).

Reed Elsevier’s cash outflow on the purchase of property, plant and equipment in 20122013 was £57 million (2012: £70 million (2011:million; 2011: £85 million; 2010: £83 million), while proceeds from the sale of property, plant and equipment amounted to £7£6 million (2011:(2012: £7 million; 2010:2011: £7 million). The cash outflow on internally developed intangible assets in 20122013 was £251 million (2012: £263 million (2011:million; 2011: £265 million; 2010: £228 million), reflecting sustained investment in new products and related infrastructure, particularly in the Legal business.

GrossNet cash proceeds from disposals amounted to £242 million, including £7 million from the sale of non-controlling interests. Net proceeds, before tax, amounted to £160£195 million, after related separation and transaction costs, additional pension scheme contributions, and working capital and other adjustments in respect of prior year transactions.

During 2012,2013, Reed Elsevier paid a total of £221 million (2012: £316 million (2011:million; 2011: £529 million; 2010: £50 million) for acquisitions, including deferred consideration payableof £21 million (2012: £30 million; 2011: £22 million) on past acquisitions and after taking account of net cash acquired of £14 million (2012: £12 million (2011:million; 2011: £24 million; 2010: nil)million). A further £10 million (2012: £7 millionmillion; 2011: £10 million) was paid on the purchase of investments (2011: £10 million; 2010: £5 million) during the year. During 2012,2013, Reed Elsevier paid tax of £362 million (2012: £216 million (2011:million; 2011: £218 million; 2010: £9 million).

Share repurchases by the parent companies in 20122013 were £600 million (2012: £250 million (2011: nil; 2010:million; 2011: nil), with a further £100 million repurchased in 20132014 as at February 27.26, 2014. On February 28, 2013,27, 2014, Reed Elsevier PLC and Reed Elsevier NV announced their intention to repurchase further ordinary shares up to the value of £300£500 million in aggregate over the remainder of 2013.2014. No shares of the parent companies were purchased by the Reed Elsevier Group plc Employee Benefit Trust (2011:(2012: nil; 2010:2011: nil). Net proceedsProceeds from the exercise of share options were £125 million (2012: £48 million (2011:million; 2011: £9 million; 2010: £11 million).

During 2012,2013, Reed Elsevier paid ordinary dividends totalling £521£549 million to the shareholders of the parent companies (2011:(2012: £521 million; 2011: £497 million; 2010: £483 million). Dividend payments are funded by the operating cash flow of the business after capital spend.

Net borrowings, a key indebtedness measure used in assessing Reed Elsevier’s financial position, at December 31, 20122013 were £3,072 million (2012: £3,127 million (2011:million; 2011: £3,433 million; 2010: £3,455 million), comprising gross borrowings of £3,892£3,281 million, less £124£77 million of related derivative financial instrument assets and cash and cash equivalents of £641£132 million. Excluding currency effects, net borrowings decreased by £199£27 million with acquisitions and share repurchases funded from free cash flow and proceeds from divestments.

Net borrowings are reconciled as follows:

 

  2012 2011 2010   2013 2012 2011 
  £m £m £m   £m £m £m 

Cash & cash equivalents

   641    726    742     132    641    726  

Borrowings

   (3,892  (4,282  (4,302   (3,281  (3,892  (4,282

Related derivative financial instruments

   124    123    105     77    124    123  
  

 

  

 

  

 

   

 

  

 

  

 

 

Net borrowings

   (3,127  (3,433  (3,455   (3,072  (3,127  (3,433
  

 

  

 

  

 

   

 

  

 

  

 

 

During 2012, the second of two one year extension options was exercised on the $2.0 billionIn July 2013, Reed Elsevier’s committed bank facility, extending the maturity tomaturing in June 2015. This back up2015, was cancelled and replaced with a new $2.0 billion facility, provides security of funding for short term debt.maturing in July 2018.

In September 2012, €550March 2013, $309 million principal amount of term debt maturing in 2019, with a coupon of 8.625%, was exchanged for $389 million principal amount of the 3.125% term debt maturing in 2022 and cash. The exchange is treated as a debt modification for accounting purposes. The premium arising is offset against the carrying amount of the newly issued term debt maturing in 2022 and will be amortised over its life. In June 2013, $282 million of Swiss franc denominated fixed rate term debt with a maturity of eight yearsdue in 2018 was issued at a coupon of 2.5% (before taking into account fixed to floating interest swaps) and the proceeds used to pre-finance the €600 million 6.5% coupon term debt maturing in April 2013.1.0%. In October and November 2012, $561December 2013, $461 million of fixed rate term debt with a maturity of ten years was issued at a coupon of 3.125%. Related to this transaction, $299 million of fixed rateUS term debt maturing in January 2014 and January 2019, with a weighted average coupon of 8.4%, was exchanged for $311 millionredeemed, taking advantage of the newly issued term debt and cash payments of $75 million. The remaining cash proceeds were used to reduce short term commercial paper borrowings ahead of the January 2014 bond maturity.make-whole election.

The directors of Reed Elsevier PLC and Reed Elsevier NV, having made appropriate enquiries, consider that adequate resources exist for the combined businesses to continue in operational existence for the foreseeable future.

Contractual Obligations

The contractual obligations of Reed Elsevier relating to debt finance and operating leases at December 31, 20122013 analysed by when payments are due, are summarised below.

 

  Total   Less than
1 year
   1-3 years   3-5 years   After
5 years
   Total   Less than
1 year
   1-3 years   3-5 years   After
5 years
 
  (in millions)   (in millions) 

Short term debt(1)(2)

  £762    £762    £ —    £ —    £ —    £656    £656    £    £    £  

Long term debt (including finance leases)(2)

   4,187     173     1,112     959     1,943     3,553     129     828     685     1,911  

Operating leases

   610     117     184     125     184     546     103     156     118     169  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total

  £5,559    £1,052    £1,296    £1,084    £2,127    £4,755    £888    £984    £803    £2,080  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

 

(1)Short term debt primarily comprises term debt issues maturing within one year and commercial paper, and is supported by a $2,000 million committed bank facility maturing in June 2015July 2018 and by the central management of cash and cash equivalents. At December 31, 20122013 the committed bank facility was undrawn.

 

(2)Short and long term debt obligations comprise undiscounted principal and interest cash flows. Interest cash flows are calculated by reference to the contractual payment dates and the fixed interest rates (for fixed rate debt) or the relevant forecast interest rates (for floating rate debt).

Information on retirement benefit obligations is set out in note 76 to the combined financial statements.

Off-Balance Sheet Arrangements

At December 31, 2012 Reed Elsevier had outstanding guarantees in respect of property leases. The maximum amount guaranteed as at December 31, 2012 is £11 million for certain property leases up to 2024. These guarantees, which would crystallise in the event that existing lessees default on payment of their lease commitments, are unrelated to the ongoing business.

Save as disclosed above and under contractual obligations,“Contractual Obligations”, Reed Elsevier has no off-balance sheet arrangements that currently have or are reasonably likely to have a material effect on the combined businesses’ financial condition, results of operations, liquidity, capital expenditure or capital resources.

Treasury Policies

The Boards of Reed Elsevier PLC and Reed Elsevier NV have requested that Reed Elsevier Group plc and Elsevier Reed Finance BV have due regard to the best interests of Reed Elsevier PLC and Reed Elsevier NV shareholders in the formulation of treasury policies. Financial instruments are used to finance the Reed Elsevier businesses and to hedge transactions. Reed Elsevier’s businesses do not enter into speculative transactions. The main treasury risks faced by Reed Elsevier are liquidity risk, interest rate risk, foreign currency risk and credit risk. The Boards of the parent companies agree overall policy guidelines for managing each of these risks and the Boards of Reed Elsevier Group plc and Elsevier Finance SA agree policies (in line with parent company guidelines) for their respective business and treasury centres. A summary of these policies is given below.

Interest Rate Exposure Management

Reed Elsevier’s interest rate exposure management policy is aimed at reducingaims to reduce the exposure of the combined businesses to changes in interest rates. The proportion of interest expense that is fixed on net borrowings is determined by reference to the level of net interest cover.rates at efficient cost. To achieve this Reed Elsevier uses fixed rate term debt, interest rate swaps, forward rate agreements and interest rate options to manage the exposure.options. Interest rate derivatives are used only to hedge an underlying risk and no net market positions are held.

After taking into account interest rate and currency derivatives, at December 31, 20122013 interest expense was fixed on an average57% of £2.2 billion of forecast debt for the next 12 months. This fixed rate debt reduces to £1.7 billion by the end of 2014 and reduces further thereafter with all but £0.7 billion of fixed rate term debt (not swapped to floating rate) having matured by the end of 2019.

At December 31, 2012, fixed rate term debt (not swapped to floating rate) amounted to £2.1 billion (2011: £2.4 billion) andReed Elsevier’s gross borrowings which had a weighted average remaining life remaining of 6.2 years (2011: 5.7 years) and a weighted average interest rate of 6.4% (2011: 6.5%). Interest rate derivatives in place at December 31, 2012, which fix the interest cost on an additional £0.2 billion (2011: £0.6 billion) of variable rate debt, have a weighted average maturity of 0.3 years (2011: 0.8 years) and a weighted average interest rate of 3.6% (2011: 3.2%).6.0 years.

Foreign Currency Exposure Management

Translation exposures arise on the earnings and net assets of business operations in countries other than those of each parent company. TheseSome of these exposures are hedged, to a significant extent,offset by a policy of denominating borrowings in currencies where significant translation exposures exist, most notably US dollars.

Currency exposures on transactions denominated in a foreign currency are required to be hedged using forward contracts. In addition, recurring transactions and future investment exposures may be hedged, in advance of becoming contractual. The precise policy differs according to the specific circumstances of the individual businesses. Highly predictable future cash flows may be covered for transactions expected to occur during the next 24 months (50 months for the Scientific, Technical & Medical subscription businesses) within limits defined according to the period before the transaction is expected to become contractual. Cover takes the form of foreign exchange forward contracts.

As at December 31, 2012,2013, the amount of outstanding foreign exchange cover against future transactions was £1.3 billion (2012: £1.2 billion (2011:billion; 2011: £1.3 billion).

Credit Risk

Reed Elsevier has a credit exposure for the full principal amount of cash and cash equivalents held with individual counterparties. In addition, it has a credit risk from the potential non performancenon-performance by counterparties to financial instruments; this credit risk normally being restricted to the amounts of any hedge gain and not the full principal amount being hedged. Credit risks are controlled by monitoring the credit quality of counterparties, principally licensed commercial banks and investment banks with strong long termlong-term credit ratings, and the amounts outstanding with each of them.

Reed Elsevier has treasury policies in place which do not allow concentrations of risk with individual counterparties and do not allowlimit significant treasury exposures with counterparties which are rated lower than A-/A3 by Standard & Poor’s, Moody’s and Fitch. At December 31, 2012,2013, cash and cash equivalents totalled £641£132 million, of which 98%90% was held with banks rated A/A2A-/A3 or better. Further information on credit risk is set out on pages F-42 and F-43.F-42.

Capital and Liquidity Management

The capital structure is managed to support Reed Elsevier’s objective of maximising long termlong-term shareholder value through appropriate security of funding, ready access to debt and capital markets, cost effective borrowing and flexibility to fund business and acquisition opportunities whilstwhile maintaining appropriate leverage to optimise the cost of capital.ensure an efficient capital structure.

Over the long termlong-term, Reed Elsevier targetsseeks to maintain cash flow conversion (the proportion of adjusted operating profits converted into cash) of 90% or higher and credit metrics to reflect this aim and that are consistent with a solid investment grade credit rating. Levels of net borrowings should not exceed those consistent with such a rating other than for relatively short periods of time, for instance following an acquisition.

The principaltypical credit metrics utilised are free cash flow (after interest, tax and dividends)net debt to net borrowings, net borrowings to adjusted EBITDA, (as reconciled in the table below) and adjusted EBITDA to net interest, all on a pensions and lease adjusted and on an unadjusted basis, and these metrics are monitored and reported to senior management and board representatives onfree cash flow as a quarterly basis.percentage of net debt. Adjusted EBITDA is derived from net profit as follows:

 

2012
(in millions)

Net profit for the year

£1,074

Adjustments:

Taxation

113

Disposals and other non operating items

(45

Net finance costs

216

Amortisation of acquired intangible assets

329

Depreciation and other amortisation

227

Acquisition related costs

21

Reclassification of tax in joint ventures

5

Adjusted EBITDA

£1,940

   2013  2012
Restated
  2011
Restated
 
   (in millions)  (in millions)  (in millions) 

Net profit for the year

   £1,115    £1,049    £738  

Adjustments:

    

Taxation

   81    102    167  

Disposals and other non operating items

   (16  (45  22  

Net finance costs

   196    227    244  

Amortisation of acquired intangible assets

   318    329    359  

Depreciation and other amortisation

   249    227    207  

Acquisition related costs

   43    21    52  

Reclassification of tax in joint ventures

   12    5    11  
  

 

 

  

 

 

  

 

 

 

Adjusted EBITDA

   £1,998    £1,915    £1,800  
  

 

 

  

 

 

  

 

 

 

Cash flow conversion of 90% or higher is consistent with the rating target. The cash flow conversion in 20122013 was 94% (2011: 93%97% (2012: 95%; 2011: 95%) and for the year ended December 31, 20122013 net borrowingsdebt to adjusted EBITDA was 2.2x (2011:2.1x (2012: 2.2x; 2011: 2.3x) on a pensionspension and lease adjusted basis and 1.6x (2012: 1.7x; 2011: 1.8x) on an unadjusted basis.

Reed Elsevier’s useuses of free cash flow over the longer term reflects these objectives through a progressivelonger-term balance the dividend policy, selective acquisitions and from time to time when conditions suggest, share repurchases, whilstwhile retaining the balance sheet strength to maintain access to the most cost effective sources of borrowing and to support Reed Elsevier’s strategic ambition in evolving publishing and information markets.borrowing.

The balance of long termlong-term debt, short termshort-term debt and committed bank facilities is managed to provide security of funding, taking into account the cash generation of the business and the uncertain size and timing of acquisition spend. Reed Elsevier maintains a range of borrowing facilities and debt programmes from a variety of sources to fund its requirements at short notice and at competitive rates. TheConsistent with the significance of Reed Elsevier Group plc’s US operations, means that the majority of debt is denominated in US dollars. Policy requiresThe policy is that no more than US$1.5 billion of term debt issues should mature in any 12 month period and no more than US$3.0 billion in any 36 month period. In addition, minimum levels of borrowings with maturities over three and five years are specified, depending on the level of net borrowings and free cash flow. From time to time, Reed Elsevier may redeem term debt early or repurchase outstanding debt in the open market depending on market conditions.

There were no changes to Reed Elsevier’s long termlong-term approach to capital and liquidity management during the year.

Short TermShort-Term Borrowings

The main treasury centres within Reed Elsevier operate commercial paper programmes to provide flexibility for funding operational requirements of the combined businesses on a daily basis, at short notice and at competitive rates. Commercial paper is issued under both US and Euro programmes and guaranteed by Reed Elsevier PLC and Reed Elsevier NV. In addition, short termshort-term borrowing facilities are established with local banks to support the daily requirements of businesses operating in certain countries where there may be restrictions on borrowing from affiliates or from lenders in a foreign jurisdiction. Other loans comprise term loansTerm debt comprises borrowings with an original maturity of greater than one year and which mature within 12 months of the reporting date. These short termshort-term borrowings were backed up at December 31, 20122013 by a $2,000 millionUS$2.0 billion committed bank facility maturing in June 2015July 2018 which was undrawn. The short termshort-term borrowing programmes are run in conjunction with term debt programmes which comprise the majority of Reed Elsevier’s debt and provide the combined businesses with security of funding.

The average amount and the average interest rate during the year have been calculated by taking the average of the amounts outstanding at each month end (translated to sterling at the respective month end rate) and the average of the interest rate applicable at each month end. Commercial paper issuance reached a maximum month end level of £756£486 million in March 2012 as a result of trading flowsMay 2013, and othershort-term loans and overdrafts reached a maximum month end level of £643£230 million in June 2012October 2013, both as a result of trading flows. Term debt reached a maximum month end level of £1,050 million in February 2013 as the maturities of the term debt issues of €600 million, and CHF 150 million, US$461 million and US$185 million, expiring in April 2013, and June 2013, January 2014 and January 2014 respectively, bothall then fell below 12 months.

 

Short term borrowings as at December 31, 2012
£m
 2012
Weighted
average interest
rate %
 2011
£m
 2011
Weighted
average interest
rate %
 2010
£m
 2010
Weighted
average interest
rate %
Short-term borrowings as at
December 31,
  2013
£m
   2013
Weighted
average  interest
rate %
   2012
£m
   2012
Weighted
average  interest
rate %
   2011
£m
   2011
Weighted
average  interest
rate %
 

Commercial paper

  118   0.2  576   0.7  346   0.6   229     0.3     118     0.2     576     0.7  

Short term loans and overdrafts

  13   1.5  20   10.1  33   8.6   58     1.3     13     1.5     20     10.1  

Finance leases

  7   2.5  2   2.7  7   5.1   9     2.1     7     2.5     2     2.7  

Other loans

  592   3.7  384   4.1  130   6.7

Term debt

   352     2.0     592     3.7     384     4.1  
 

 

   

 

   

 

    

 

     

 

     

 

   

Total short term borrowings

  730     982     516      648       730       982    
 

 

   

 

   

 

    

 

     

 

     

 

   

 

Average short term borrowings during the
year ended December 31,
 2012
£m
 2012
Weighted
average interest
rate %
 2011
£m
 2011
Weighted
average interest
rate %
 2010
£m
 2010
Weighted
average interest
rate %
Average short-term borrowings
during the year ended
December 31,
  2013
£m
   2013
Weighted
average  interest
rate %
   2012
£m
   2012
Weighted
average  interest
rate %
   2011
£m
   2011
Weighted
average  interest
rate %
 

Commercial paper

  547   0.5  504   0.6  437   0.5   333     0.2     547     0.5     504     0.6  

Short term loans and overdrafts

  22   8.9  30   9.5  33   7.9   71     1.3     22     8.9     30     9.5  

Finance leases

  5   2.7  9   4.9  7   5.3   8     2.3     5     2.7     9     4.9  

Other loans

  469   3.7  297   5.0  197   4.6

Term debt

   725     4.7     469     3.7     297     5.0  

 

Maximum month end short term borrowings  2012
£m
   2011
£m
   2010
£m
 
Maximum month end short-term borrowings  2013
£m
   2012
£m
   2011
£m
 

Commercial paper

   756     659     688     486     756     659  

Short term loans and overdrafts

   27     37     37     230     27     37  

Finance leases

   7     10     10     9     7     10  

Other loans

   643     493     358  

Term debt

   1,050     643     493  

OPERATING RESULTS — REED ELSEVIER PLC AND REED ELSEVIER NV

The following discussion is based on the financial statements of Reed Elsevier PLC and Reed Elsevier NV for the three years ended December 31, 2012.2013, 2012 and 2011. The results of Reed Elsevier PLC reflect its shareholders’ 52.9% economic interest in the Reed Elsevier combined businesses. The results of Reed Elsevier NV reflect its shareholders’ 50% economic interest in the Reed Elsevier combined businesses. The respective economic interests of the Reed Elsevier PLC and Reed Elsevier NV shareholders take account of Reed Elsevier PLC’s 5.8% indirect interest in Reed Elsevier NV. Both parent companies equity account for their respective share in the Reed Elsevier combined businesses.

Results of Operations for the Year Ended December 31, 2013

Compared to the Year Ended December 31, 2012

The earnings per share of Reed Elsevier PLC and Reed Elsevier NV were 48.8p and €0.91 respectively in 2013, compared to 44.8p and €0.87 in 2012. The increase reflects the improved trading performance and deferred tax credits.

Dividends to Reed Elsevier PLC and Reed Elsevier NV shareholders are, other than in special circumstances, equalised at the gross level, including the benefit of the UK attributable tax credit of 10% received by certain Reed Elsevier PLC shareholders. The exchange rate used for each dividend calculation — as defined in the Reed Elsevier merger agreement — is the spot euro:sterling exchange rate, averaged over a period of five business days commencing with the tenth business day before the announcement of the proposed dividend.

Ordinary dividends paid in the year, in amounts per ordinary share, comprise: a 2012 final dividend of 17.0p and 2013 interim dividend of 6.65p giving a total of 23.65p (2012: 21.9p) for Reed Elsevier PLC; and a 2012 final dividend of €0.337 and 2013 interim dividend of €0.132 giving a total of €0.469 (2012: €0.456) for Reed Elsevier NV.

The Board of Reed Elsevier PLC has proposed a 2013 final dividend of 17.95p, up 6%, giving a total dividend of 24.60p in respect of the financial year, up 7% on 2012. The Board of Reed Elsevier NV, in accordance with the dividend equalisation arrangements, have proposed a 2013 final dividend of €0.374, up 11%, which results in a total dividend of €0.506 in respect of the financial year, up 8% on 2012. The difference in growth rates in the equalised final dividends reflects changes in the euro:sterling exchange rate since the respective prior year dividend announcement dates.

During 2013 Reed Elsevier repurchased 41,961,920 Reed Elsevier PLC ordinary shares and 24,282,106 Reed Elsevier NV ordinary shares for consideration of £600 million. Reed Elsevier NV also repurchased 94,053 Reed Elsevier NV R shares (equivalent to 940,530 ordinary shares) from a subsidiary of Reed Elsevier PLC. These shares are held in treasury. On December 16, 2013 Reed Elsevier PLC and Reed Elsevier NV announced an irrevocable, non discretionary programme to repurchase further ordinary shares up to the value of £100 million which was completed by February 26, 2014. On February 27, 2014, Reed Elsevier PLC and Reed Elsevier NV announced their intention to repurchase further ordinary shares up to the value of £500 million in aggregate over the remainder of 2014.

Results of Operations for the Year Ended December 31, 2012

Compared to the Year Ended December 31, 2011

The earnings per share of Reed Elsevier PLC and Reed Elsevier NV were 46.0p44.8p and €0.90€0.87 respectively in 2012, compared to 32.4p31.1p and €0.59€0.57 in 2011. The increase reflects the improved trading performance, disposals and other non operating items and the exceptional prior year tax credit.

Dividends to Reed Elsevier PLC and Reed Elsevier NV shareholders are, other than in special circumstances, equalised at the gross level, including the benefit of the UK attributable tax credit of 10% received by certain Reed Elsevier PLC shareholders. The exchange rate used for each dividend calculation — as defined in the Reed Elsevier merger agreement — is the spot euro:sterling exchange rate, averaged over a period of five business days commencing with the tenth business day before the announcement of the proposed dividend.

Ordinary dividends declaredpaid in the year,2012, in amounts per ordinary share, comprise:comprised: a 2011 final dividend of 15.9p and 2012 interim dividend of 6.0p giving a total of 21.9p (2011: 20.65p) for Reed Elsevier PLC; and a 2011 final dividend of €0.326 and 2012 interim dividend of €0.130 giving a total of €0.456 (2011: €0.413) for Reed Elsevier NV.

The Board of Reed Elsevier PLC has proposed a 2012 final dividend of 17.0p, up 7%, giving a total dividend of 23.0p in respect of the financial year, up 7% on 2011. The Boards of Reed Elsevier NV, in accordance with the dividend equalisation arrangements, have proposed a 2012 final dividend of €0.337, up 3%, which resultsresulted in a total dividend of €0.467 in respect of the financial year, up 7% on 2011. The difference in growth rates in the equalised final dividends reflectsreflected changes in the euro:sterling exchange rate since the respective prior year dividend announcement dates.

During 2012 Reed Elsevier repurchased 23,288,616 Reed Elsevier PLC ordinary shares and 12,660,296 Reed Elsevier NV ordinary shares for consideration of £250 million. These shares are held in treasury. On December 28, 2012 Reed Elsevier PLC and Reed Elsevier NV announced an irrevocable, non discretionary programme to repurchase further ordinary shares up to the value of £100 million which was completed by February 27, 2013. On February 28, 2013, Reed Elsevier PLC and Reed Elsevier NV announced their intention to repurchase further ordinary shares up to the value of £300 million in aggregate over the remainder of 2013.

Results of Operations for the Year Ended December 31, 2011

Compared to the Year Ended December 31, 2010

The earnings per share of Reed Elsevier PLC and Reed Elsevier NV were 32.4p and €0.59 respectively in 2011, compared to 27.3p and €0.51 in 2010. The increase reflects the improved trading performance, no exceptional restructuring costs and lower net interest expense.

Dividends to Reed Elsevier PLC and Reed Elsevier NV shareholders are, other than in special circumstances, equalised at the gross level, including the benefit of the UK attributable tax credit of 10% received by certain Reed Elsevier PLC shareholders. The exchange rate used for each dividend calculation — as defined in the Reed Elsevier merger agreement — is the spot euro:sterling exchange rate, averaged over a period of five business days commencing with the tenth business day before the announcement of the proposed dividend.

Ordinary dividends declared in the year, in amounts per ordinary share, comprise: a 2010 final dividend of 15.0p and 2011 interim dividend of 5.65p giving a total of 20.65p (2010: 20.4p) for Reed Elsevier PLC; and a 2010 final dividend of €0.303 and 2011 interim dividend of €0.110 giving a total of €0.413 (2010: €0.402) for Reed Elsevier NV.

The Board of Reed Elsevier PLC has proposed a 2011 final dividend of 15.90p, up 6%, giving a total dividend of 21.55p in respect of the financial year, up 6% on 2010. The Boards of Reed Elsevier NV, in accordance with the dividend equalisation arrangements, have proposed a 2011 final dividend of €0.326, up 8%, which results in a total dividend of €0.436 in respect of the financial year, up 6% on 2010. The difference in growth rates in the equalised final dividends reflects changes in the euro: sterling exchange rate since the respective prior year dividend announcement dates.

No shares were repurchased in the year by either Reed Elsevier PLC or Reed Elsevier NV.

TREND INFORMATION

Trends, uncertainties and events which can affect the revenue, operating profit and liquidity and capital resources of the Reed Elsevier combined businesses include the usage, penetration and customer renewal of our print and electronic products and the prices that customers pay for our products, the migration of print and CD products to online services, investment in new products and services, cost control and the impact of our cost reduction programmes on operational efficiency, the levels of academic library funding, the impact of economic conditions on corporate and other customer budgets and the level of advertising demand, the actions of competitors and regulatory and legislative developments.

Trends, uncertainties and events which could have a material impact on Reed Elsevier’s revenue, operating profit and liquidity and capital resources are discussed in further detail in “Item 3: Key Information — Risk Factors”; “Item 4: Information on Reed Elsevier”; and “Item 5: Operating and Financial Review and Prospects — Operating Results — Reed Elsevier; Liquidity and Capital Resources — Reed Elsevier; Operating Results — Reed Elsevier PLC and Reed Elsevier NV”.

ITEM 6: DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

DIRECTORS

The directorsDirectors of each of Reed Elsevier PLC, Reed Elsevier NV, Reed Elsevier Group plc and Elsevier Reed Finance BV at February 27, 201326, 2014 were:

 

Name (Age)

 

Reed Elsevier PLC

 

Reed Elsevier NV

 

Reed Elsevier

Group plc

 

Elsevier Reed

Finance BV

Rudolf van den Brink(65)Brink (66)

 

   Chairman of the Supervisory Board

Mark Elliott(63)

Non-executive Director(3)(4)Member of the Supervisory Board(3)(4)Non-executive Director(2)

Erik Engstrom(49)Engstrom (50)

 Executive Director and Chief Executive Officer Chairman of the Executive BoardDirector and Chief Executive Officer Executive Director and Chief Executive Officer 

Anthony Habgood(66)Habgood (67)

 Non-executiveNon-Executive Chairman(3)(4) Non-Executive Chairman of the Supervisory Board(3)(4) Non-executiveNon-Executive Chairman(2) 

Adrian Hennah(55)Wolfhart Hauser (64)

 Non-executiveNon-Executive Director(4)Non-Executive Director(4)Non-Executive Director(2)

Adrian Hennah (56)

Non-Executive Director(1)(4) Member of the Supervisory BoardNon-Executive Director(1)(4) Non-executiveNon-Executive Director(1) 

Lisa Hook(54)Hook (55)

 Non-executiveNon-Executive Director(3)(4)(5) Member of the Supervisory BoardNon-Executive Director(3)(4) Non-executiveNon-Executive Director(2) 

Gerben de Jong(68)Jong (69)

    Member of the Management Board

Marike van Lier Lels(53)Lels (54)

  Member of the Supervisory BoardNon-Executive Director(4)  Member of the Supervisory Board

Duncan Palmer(47)Palmer (48)

 Executive Director and Chief Financial Officer Member of the Executive BoardDirector and Chief Financial Officer Executive Director and Chief Financial Officer Member of the Supervisory Board

Robert Polet(57)Polet (58)

 Non-executive
Non-Executive Director(4)
 Member of the Supervisory BoardNon-Executive Director(4) Non-executiveNon-Executive Director(2) 

Sir David Reid(66)

Non-executive Director(1)(3)(4)(5)Member of the Supervisory Board(1)(3)(4)(5)Non-executive Director(1)(2)(5)

Alberto Romaneschi(54)Romaneschi (55)

    Member of the Management Board

Linda Sanford(60)Sanford (61)

 Non-executiveNon-Executive Director(1)(4) Member of the Supervisory BoardNon-Executive Director(1)(4) Non-executiveNon-Executive Director(1) 

Ben van der Veer(61)Veer (62)

 Non-executiveNon-Executive Director(1)(3)(4) Member of the Supervisory BoardNon-Executive Director(1)(3)(4) Non-executiveNon-Executive Director(1) Member of the Supervisory Board

Jans van der Woude(49)Woude (50)

    Member of the Management Board

 

(1)Member of the Audit Committees of the Boards of Reed Elsevier PLC, Reed Elsevier NV and Reed Elsevier Group plc.

 

(2)Member of the Remuneration Committee of the Board of Reed Elsevier Group plc.

 

(3)Member of the joint Nominations Committee of the Boards of Reed Elsevier PLC and Reed Elsevier NV.

 

(4)Member of the joint Corporate Governance Committee of the Boards of Reed Elsevier PLC and Reed Elsevier NV.

 

(5)Senior independent non-executive director,Independent Director, as defined by the UK Corporate Governance Code in the United Kingdom.

Mark Armour stepped downElliott and Sir David Reid retired from the Boards in April 2013 and Wolfhart Hauser was elected to the Boards in April 2013. In September 2013, Duncan Palmer gave notice of his resignation as Chief Financial Officer in November 2012 and retired from theeffective as of September 25, 2014, or such earlier date as Reed Elsevier may designate. In January 2014, the Boards inannounced the appointment of Nick Luff as Chief Financial Officer to be effective at a date to be confirmed, which is expected to be no later than December 2012.15, 2014.

A person described as a non-executive directorNon-Executive Director of Reed Elsevier PLC, Reed Elsevier NV or Reed Elsevier Group plc or a member of the Supervisory Board of Reed Elsevier NV is a directorDirector not employed by such company in an executive capacity.

Rudolf van den Brink (Dutch) Chairman of the Supervisory Board of Elsevier Reed Finance BV since 2006. A former member of the managing board of ABN AMRO Bank NV and of the advisory board of Deloitte & Touche in the Netherlands. A member of the supervisory boardSupervisory Board of Akzo Nobel NV.

Mark Elliott (American) Non-executive director since 2003. Chairman of the Remuneration Committee. Chairman of QinetiQ Group plc and a non-executive director of G4S plc. Until his retirement in 2008, was general manager of IBM Global Solutions, having held a number of positions with IBM, including managing director of IBM Europe, Middle East and Africa.

Erik Engstrom (Swedish) Chief Executive Officer since 2009. Joined Reed Elsevier as Chief Executive Officer of Elsevier in 2004. Prior to joining Reed Elsevier was a partner at General Atlantic Partners. Before that was President and Chief Operating Officer of Random House Inc and, before its merger with Random House, President and Chief Executive Officer of Bantam Doubleday Dell, North America. Began his career as a consultant with McKinsey. Served as a non-executive director

Non-Executive Director of Eniro AB and Svenska Cellulosa Aktiebolaget SCA. Holds a BSc from Stockholm School of Economics, an MSc from the Royal Institute of Technology in Stockholm, and gained an MBA from Harvard Business School as a Fulbright Scholar.

Anthony Habgood (British) Chairman since 2009. Chairman of the Nominations and Corporate Governance Committees. Chairman of Whitbread plc, and of Preqin Holding Limited.Limited and Norwich Research Partners LLP. Was chairmanChairman of Bunzl plc and of Mölnlycke Health Care Limited and served as chief executiveChief Executive of Bunzl plc, chief executiveChief Executive of Tootal Group plc and a directorDirector of The Boston Consulting Group Inc.Group. Formerly non-executive directorNon-Executive Director of Geest plc;plc, Marks and Spencer plc;plc, National Westminster Bank plc;plc, Norfolk and Norwich University Hospitals Trust, Powergen plc;plc, and SVG Capital plc. Holds an MA in Economics from Cambridge University and an MS in Industrial Administration from Carnegie Mellon University. He is a visiting Fellow at Oxford University.

Wolfhart Hauser (German) Non-Executive Director since 2013. Chairman of the Remuneration Committee. Chief Executive Officer of Intertek Group plc. Was Chairman of Dragenopharm GmbH & Co AG from 2002 to 2006. Prior to that he was Chief Executive Officer of TÜV Suddeutschland AG between 1998 and 2002 and Chief Executive Officer of TÜV Product Services GmbH for 10 years. Served as a Non-Executive Director of Logica Plc and Intertek Group plc before his current position at the company.

Adrian Hennah (British) Non-executive directorNon-Executive Director since 2011. He is chief financial officerChief Financial Officer of Reckitt Benckiser Group plc having been chief financial officerChief Financial Officer of Smith & Nephew plc from 2006 to 2012. Before that was chief financial officerChief Financial Officer of Invensys plc andhaving previously held various senior finance and management positions within GlaxoSmithKline for 18 years.

Lisa Hook (American) Non-executive directorNon-Executive Director since 2006. Senior Independent Director. President and chief executive officerChief Executive Officer of Neustar Inc. A directorand a Director of The Ocean Foundation.Island Press. Was presidentPresident and chief executive officerChief Executive Officer at Sun Rocket Inc. Before that was presidentPresident of AOL Broadband, Premium and Developer Services. Prior to joining AOL, was a founding partner at Brera Capital Partners LLC. Previously was chief operating officerChief Operating Officer of Time Warner Telecommunications. HasTelecommunications and has served as senior advisor to the Federal Communications Commission Chairman and a senior counsel to Viacom Cable. Formerly a Director of The Ocean Foundation.

Gerben de Jong (Dutch) member of the Management Board of Elsevier Reed Finance BV since 2007. Previously held senior finance positions in Royal Philips Electronics NV Group.

Marike van Lier Lels (Dutch) AppointedNon-Executive Director of Reed Elsevier NV since January 2010. Member of the supervisory boardsSupervisory Boards of KPN NV, USG People NV, and TKH Group NV.NV and Eneco Holding NV, and a member of the executive committee of the Aegon Association. A member of various Dutch governmental advisory boards. MemberPreviously was a member of the Supervisory Board of Maersk BV until March 2012. Was executive vice president and chief operating officerExecutive Vice President and Chief Operating Officer of the Schiphol Group. Prior to joining Schiphol Group, was a member of the executive boardExecutive Board of Deutsche Post Euro Express and held various senior positions with Nedlloyd.

Duncan Palmer (British and American) Chief Financial Officer since November 2012. Joined Reed Elsevier as Chief Financial Officer Designate in August 2012. Non-executive directorNon-Executive Director of Oshkosh Corporation since 2011.Corporation. Prior to joining Reed Elsevier was chief financial officerChief Financial Officer and senior vice presidentSenior Vice President of Owens Corning Inc. from 2007, having previously held various senior finance positions within Royal Dutch Shell for 20 years in the UK, the Netherlands and the US. He holds an MA in mathematics from Cambridge University and an MBA from Stanford University. He is a UK-qualified Chartered Management Accountant.

Robert Polet (Dutch) Non-executive directorNon-Executive Director since 2007. Chairman of Safilo Group S.p.A. and a non-executive directorNon-Executive Director of Philip Morris International Inc, William Grant & Sons Limited, Scotch and Soda NV and Crown Topco Limited, parent company of Vertu. Member of the supervisory boardSupervisory Board of Nyenrode Foundation. Was President and chief executive officerChief Executive Officer of Gucci Group from 2004 to 2011, having previously spent 26 years at Unilever working in a variety of marketing and senior executive positions throughout the world, including presidentPresident of Unilever’s Worldwide Ice Cream and Frozen Foods division. Formerly a non-executive directorNon-Executive Director of Wilderness Holdings Limited from 2010 to 2012.Limited.

Sir David Reid (British) Non-executive director since 2003. Senior independent director. Chairman of Intertek Group plc and a member of the Senior Advisory Board of Jefferies, the global investment banking firm. Was Chairman of Tesco PLC from 2004 to 2011, having previously been executive deputy chairman until December 2003, and finance director from 1985 to 1997. He has also been Chairman of Kwik-Fit and a non-executive director of De Vere PLC, Legal & General Group plc and Westbury PLC.

Alberto Romaneschi (Swiss) Member of the Management Board of Elsevier Reed Finance BV since October 2012.Non-Executive Chairman of QualySense AG. Prior to joining Elsevier Reed Finance was founder and managing partner at Romaneschi & Partners, a treasury and risk management consulting firm. Other previous appointments included Chief Financial Officer of the Ascom Group, Chief Financial Officer positions at Dreyer’s Grand Ice Cream Inc. and Cereal Partners Worldwide S.A. and Group Treasurer with Nestlé. He has been the Managing Director of Elsevier Finance SA since 2012.

Linda Sanford (American) Non-executive directorNon-Executive Director since 2012. Senior Vice President, Enterprise Transformation, IBM Corporation and non-executive director of ITT Corporation until May 2013.Corporation. Serves on the board of directors of The Business Council of New York State and the Partnership for New York City. Also serves on the board of trustees of the State University of New York, St. John’s University, and Rensselaer Polytechnic Institute.Institute and the New York Hall of Science. Was a Non-Executive Director of ITT Corporation until May 2013.

Ben van der Veer (Dutch) Non-executive directorNon-Executive Director since 2009. Chairman of the Audit Committees. Member of the supervisory boardsSupervisory Boards of AEGONAegon NV, TomTom NV, Siemens Nederland NV and Koninklijke FrieslandCampina NV. Was chairmanChairman of the executive boardExecutive

Board of KPMG in the Netherlands and a member of the management committee of the KPMG International board until his retirement in 2008, having joined KPMG in 1976. Formerly a member of the Supervisory Board of Siemens Nederland NV.

Jans van der Woude (Dutch) Member of the Management Board of Elsevier Reed Finance BV since 2009. Is Company Secretary and Legal Counsel of Reed Elsevier NV. Prior to joining Reed Elsevier in 2009 was Legal Advisorlegal advisor to Corporate Express NV. Before that was Corporate Legal Director of TNT NV, having previously been General Counsel at Getronics NV.

SENIOR MANAGEMENT

The executive officers of Reed Elsevier PLC, Reed Elsevier NV and Reed Elsevier Group plc, other than directors,Directors, at February 27, 201326, 2014 were:

Henry Udow: Chief Legal Officer and Company Secretary of Reed Elsevier PLC and Reed Elsevier Group plc. A US and British citizen who is admitted to the Bar of New York State. Joined Reed Elsevier in MarchApril 2011. Prior to joining Reed Elsevier he was Chief Legal Officer and Company Secretary of Cadbury plc.

Ian Fraser:Global Human Resources Director of Reed Elsevier Group plc. Joined Reed Elsevier in 2005. Prior to joining Reed Elsevier, he was Human Resources Director at BHP Billiton plc and, before that, held senior positions in human resources at Charter plc and Woolworths plc.

Jans van der Woude:Company Secretary and Legal Counsel of Reed Elsevier NV. A Dutch lawyer. Joined Reed Elsevier in January 2009.

COMPENSATION

REMUNERATION COMMITTEERemuneration Policy Report

Set out in this section is the company’s remuneration policy for Directors, which, subject to shareholder approval, will apply from the conclusion of the Reed Elsevier PLC Annual General Meeting to be held on April 24, 2014.

Remuneration Committee Terms of Reference and Constitutionpolicy table — Executive Directors

TheAll footnotes to the policy table can be found on pages 51 and 52.

ANNUAL BASE SALARY

Purpose and link to strategy

To recruit and retain the best executive talent globally to execute our strategic objectives at appropriate cost.

Operation

Salaries for Executive Directors are set and reviewed annually by the Reed Elsevier Group plc Remuneration Committee’sCommittee (the Committee) remit and its dutieswith changes typically taking effect on January 1. In exceptional circumstances, the Committee may review more frequently. The following factors are in relation to:considered:

 

  

Executive Directors:

The executive’s role and sustained value to establish the remuneration policy for the executive directors and determine the remunerationcompany in all its forms (including pensions and share plan participation), the terms of the service contractsskill, experience and all other terms and conditions of employment of the executive directors of Reed Elsevier Group plc and Reed Elsevier PLC and on the advice of the Chairman, the remuneration terms of the CEO (with respect to Reed Elsevier NV, the Committee recommends to the Supervisory Board the remuneration policy and the remuneration in all its forms for the CEO and other executive directors); and

to approve any compensation or termination payments made to executive directors of Reed Elsevier Group plc and Reed Elsevier PLC.overall contribution.

 

  

Senior Management

on the adviceCompetitiveness with companies which are comparable in respect of the CEO, to approve the remuneration policyindustry, size, international scope and complexity. Examples of other senior leadersglobal peers include Thomson Reuters, WPP, Pearson, John Wiley, Wolters Kluwer, Experian, McGraw-Hill and of the Reed Elsevier Group plc Chief Legal Officer and Company Secretary; and

to monitor the level and structure of remuneration for this group of executives.Equifax.

 

  

The company’s guidelines for salaries for all employees for the year.

For the last two years, Executive Directors’ salary increases have been 2.5% per annum.

Maximum value

Salary increases to Executive Directors are within the range of increases for the wider employee population. However, the Committee has discretion to exceed this to take account of individual circumstances such as change in responsibility, increases in scale or complexity of the business, inflation or alignment to market level.

Performance framework

n/a

Recovery of sums paid

No provision.

RETIREMENT BENEFITS

Purpose and link to strategy

Retirement plans are part of remuneration packages designed to recruit and retain the best executive talent at appropriate cost.

Operation

Our policy is to offer competitive long-term sustainable defined contribution plans. Any amount above applicable limits, for example Her Majesty’s Revenue and Customs’ (HMRC’s) annual allowance in the UK, will be paid in cash and will be subject to tax and social security deductions. In certain circumstances, executives can take cash instead of pension contributions.

The UK defined benefit scheme is closed to new hires. Continued membership of legacy defined benefit schemes requires annual increases to contributions or participation fees from all members, who have a choice to switch to the defined contribution plan at any time.

The CEO is a member of a UK legacy defined benefit pension arrangement, accruing 1/30th of final year pensionable earnings (base salary) for each year (pro-rated for part years) of service, with a normal retirement age of 60. The CEO contributes 7% of salary up to the scheme earnings cap. In line with all UK defined benefit scheme members, the CEO’s contributions will increase to 8% from April 2014 and then by a further 1% each year to a rate of 11% in April 2017. In addition, the CEO currently pays a participation fee equal to 1% of the amount of his base salary in excess of the scheme earnings cap. On April 1, 2014, and each April thereafter, this fee will increase by 2% of the amount of his base salary in excess of the scheme earnings cap.

Maximum value

Defined benefit scheme — accrual of 1/30th of salary for every year of service up to a maximum of 2/3rds of salary.

Defined contribution plan — maximum company contribution of 30% of salary per annum or equivalent cash in lieu.

Performance framework

n/a

Recovery of sums paid

No provision.

OTHER BENEFITS

Purpose and link to strategy

To provide competitive benefits at appropriate cost.

Operation

Other benefits, subject to periodic review, may include private medical and dental cover, life assurance, tax return preparation costs, car benefits, directors’ and officers’ liability insurance, relocation benefits and expatriate allowances and other benefits available to employees generally, including, where appropriate, the tax on such benefits.

Maximum value

Over the past three years, ongoing benefits for Executive Directors (excluding relocation benefits) have amounted to between 3% and 5% of salary, in line with our policy that the maximum payable should not exceed 5% of salary. However, the Committee may provide reasonable benefits beyond this amount in unexpected situations, such as a change in the individual’s circumstances caused by the company, or if there is a significant increase in the cost of the benefit.

Performance framework

n/a

Recovery of sums paid

No provision.

AIP (ANNUAL INCENTIVE PLAN)

Purpose and link to strategy

Provides focus on the delivery of annual financial targets and the achievement of annual objectives and milestones which are chosen to align with the company’s strategy and create a platform for sustainable future performance.

Why performance measures are chosen and how targets are set

Performance measures include a balanced set of financial targets and Key Performance Objectives (KPOs), which are appropriately weighted and which support current strategy and incentivise the Executive Directors to achieve the desired outcomes without undue risk of focusing on any one financial measure.

The targets are designed to be challenging. They are set with reference to the previous year’s performance and internal and external forecasts for the following year.

Operation

The Committee reviews and sets the financial targets and KPOs annually, taking into account internal forecasts and strategic plans.

It approves four to six KPOs for each Executive Director, reflecting critical business priorities for which each is accountable. At least one KPO will relate to the achievement of sustainability targets.

Following year end, the Committee compares actual performance with the financial targets and assesses the achievement of individual KPOs.

Maximum value

The maximum potential annual incentive for Executive Directors is 150% of annual base salary.

Performance framework

The measures include financial targets, which have a weighting of at least 70%, and individual KPOs, with each element assessed separately.

The minimum payout is zero.

If the financial measure with the lowest payout at threshold pays out at threshold and the others do not pay out at all, the overall payout for financial measures is 5% of salary. If threshold is reached for each of the financial measures, the overall payout for the financial measures is 26% of salary. There is no threshold level for KPOs.

Payout for target performance (financial measures and KPOs) is 100% of salary.

Following an assessment of achievement and scoring of KPOs, the Committee agrees the overall payout level for each Executive Director.

Committee discretion applies.1,2

Recovery of sums paid

Claw-back applies.3

CURRENT MULTI-YEAR INCENTIVE PLANS

Purpose and link to strategy

The multi-year incentive plans are the main component of Executive Directors’ pay. They are designed to provide long-term incentives for Executive Directors to achieve the key performance measures that support the company’s strategy, and to align their interests with shareholders. The BIP encourages annual personal investment in Reed Elsevier shares.

Why performance measures are chosen and how targets are set

Our strategic focus is on transforming the core business through organic investment and the build out of new products into adjacent markets and geographies, supplemented by selective portfolio acquisitions and divestments. The performance measures in the multi-year incentives are chosen to support this strategy by focusing on return on capital, returns to shareholders and sustained earnings growth.

Targets are set with regard to previous results and internal and external forecasts for the performance period. They are designed to provide exceptional reward for exceptional performance, whilst allowing a reasonable expectation that reward at the lower end of the scale is attainable, subject to robust performance.

BIP (BONUS INVESTMENT PLAN)

LTIP (LONG-TERM
INCENTIVE PLAN)

ESOS (EXECUTIVE SHARE
OPTION SCHEME)
Operation

Annually, Executive Directors may use up to an amount equal to their AIP target for investment in Reed Elsevier shares. In return, they receive a matching award which vests subject to:

   performance measured over three financial years;

   continued employment; and

   retention of the underlying investment shares.

Dividend equivalents accrued during the performance period are payable in respect of the matching shares that vest.

Vesting may be accelerated on a change of control.4

Annual awards of performance shares, with vesting subject to:

   performance measured over three financial years;

   continued employment; and

   meeting shareholding requirements.

Executive Directors are required to retain their net vested shares for a period of at least six months after release.

Dividend equivalents accrued during the performance period are payable in respect of the performance shares that vest.

Vesting may be accelerated on a change of control.4

Annual awards of market value
options that vest, subject to
performance measured over three
financial years, and remain
exercisable, subject to continued
employment, until the tenth
anniversary of grant.

Vesting may be accelerated on a change
of control
.4

Maximum value
Up to 100% of the amount invested.The maximum grant in any year is up to 250% of base salary for the CEO and up to 200% of base salary for other Executive Directors.The maximum grant in any year is up
to 250% of base salary for the CEO
and up to 200% of base salary for
other Executive Directors.
Performance framework

The performance measures are earnings per share (EPS) and return on invested capital (ROIC), weighted equally and assessed independently, such that a payout can be received under either one of the measures.

   The minimum payout is zero.

   If one measure pays out at threshold and the other does not pay out at all, the overall payout is 25%. If both measures pay out at threshold, the overall payout is 50%.

   Payout in line with expectations is 67%.

Dividend equivalents are not taken into account in the above payout levels.

Committee discretion applies.1, 2

The performance measures are relative Total Shareholder Return (TSR), EPS and ROIC, weighted equally and assessed independently, such that a payout can be received under any one of the measures (or, for TSR, in respect of one of the three comparator groups).

   The minimum payout is zero.

   If the measure with the lowest payout at threshold pays out at threshold and the others do not pay out at all, the overall payout is 3%. If each of the measures pays out at threshold, the overall payout is 32%.

   Payout in line with expectations is 50%.

Dividend equivalents are not taken into account in the above payout levels.

Committee discretion applies.1, 2

The vesting of options is subject to
EPS measured over three years.

   The minimum payout is zero.

   Payout at threshold performance is
33%.

   Payout in line with expectations is
80%.

Committee discretion applies.1, 2

Recovery of sums paid
Claw-back applies.3Claw-back applies.3Claw-back applies.3

DISCONTINUED/ONE-OFF MULTI-YEAR INCENTIVE PLAN

REGP (REED ELSEVIER GROWTH PLAN)

Purpose and link to strategy

The REGP was introduced in 2010 during a challenging and volatile business environment following the appointment of the current CEO. It was designed as a one-off, five-year plan for the Executive Directors instead of LTIP grants in 2010, 2011 and 2012.

Operation

The only current participant is the CEO and no further awards will be granted under this plan.

The CEO must retain a personal shareholding in the REGP of 300% of salary (in addition to shares held under the BIP) until vesting in H1 2015.

Initial performance share awards vested, based on performance measured over 2010-2012, at 66.8%. 50% of the vested shares were released (along with a cash dividend equivalent) and 50% were deferred and will only be released in H1 2015. The full 66.8% has been included in the 2012 Single Total Figure on page 57. Matching awards, equal to the number of personal shares and deferred performance shares, were granted in 2013 and vest, subject to performance, in H1 2015.

Dividend equivalents will be payable in respect of the matching awards and deferred performance shares which vest in H1 2015.

Vesting will be accelerated on a change of control.4

Maximum value

The maximum vesting over the five-year period (2010-14) of the plan (including what has already vested after year three) is 150% of the shares comprised in the original performance share award (of 600% of 2010 base salary).

Performance framework

Matching awards – TSR, EPS and ROIC, weighted equally and assessed independently, such that a payout can be received under any one of the measures (or, for TSR, in respect of one of the three comparator groups). TSR is measured over the five-year period 2010-2014, EPS is measured over the two-year period 2013-2014 and ROIC is measured at the end of 2014.

The minimum payout is zero.

If the measure with the lowest payout at threshold pays out at threshold and the others do not pay out at all, the overall payout is 3%. If each of the measures pays out at threshold, the overall payout is 50%.

Payout in line with expectations is 50%.

Committee discretion applies.1,2

Recovery of sums paid/withholding

Claw-back applies.3

1.Discretion in respect of annual and multi-year incentive plan payout levels: In determining the level of payout under the AIP and vesting under the multi-year incentives, the Committee takes into account Reed Elsevier’s overall business performance and value created for shareholders over the period in review and other relevant factors. It has discretion to adjust the vesting and payout levels if it believes this would result in a fairer outcome. This discretion will only be used in exceptional circumstances and the Committee will explain in the next remuneration report the extent to which it has been exercised and the reasons for doing so.

2.Discretion to vary performance measures applying to existing annual and multi-year incentives: The Committee may vary the financial measures applying to a current annual incentive year and performance measures for multi-year incentives if a change in circumstances leads it to believe that the arrangement is no longer a fair measure of performance. Any new measures will not be materially less, or more, challenging than the original ones.

3.Application of claw-back to annual and multi-year incentives: The Committee has discretion to apply claw-back if the payout was calculated on the basis of materially misstated financial or other data, in which case it can seek to recover the difference in value between the incorrect award and the amount that would have been paid had the correct data been used. In respect of multi-year incentives, the Committee also has discretion to apply claw-back if a participant breaches post-termination restrictive covenants, in which case it may require repayment of gains arising during a specified period.

4.Multi-year incentives – change of control: Under the BIP 2010, LTIP 2013 and ESOS 2013, the default position is that awards vest on a change of control on a pro-rated basis, subject to an assessment of performance against targets at that time. Alternatively, the Committee may determine that awards will not vest and will instead be exchanged for equivalent awards in the acquiring company. Under the REGP, awards vest within 30 days of the change of control on a pro-rated basis subject to performance.

5.Explanation of differences between the company’s policy on Directors’ remuneration and the policy for other employees: A larger percentage of Executive Directors’ remuneration is performance related than that of other employees. All managers participate in an annual incentive plan, but participation levels, measures and targets vary according to their role and local business priorities. Approximately 100 senior executives participate in BIP and LTIP and about 1,000 in ESOS. Grant levels under all plans vary according to role. All participants in BIP and LTIP (including the Executive Directors) are subject to the same performance measures. Under ESOS, performance measures apply only to the Executive Directors and all other participants can choose restricted shares instead of options on the basis of a pre-determined exchange ratio. The range and level of benefits provided vary according to role and local market practice.

Remuneration outcomes in different performance scenarios

The Committee considers the level of remuneration that may be paid in the context of the performance delivered and value added for shareholders. The chart is an illustration of how the CEO’s regular annual remuneration could vary under different performance scenarios. The salary, benefits and pension levels are the same in all three scenarios and are based on 2014 salary, the 2013 benefits figure from the Single Total Figure table and the 2013 pension disclosure (consistent with prior disclosure). Annual and multi-year incentives (BIP, LTIP and ESOS) are based on the policy table and 2014 salary. Given the one-off nature of the REGP (see page 51 for further details), potential final payouts in H1 2015 are not reflected in this chart. The performance assumptions which have been used are as follows: Minimum means no AIP payout and no multi-year incentives vesting. In line with expectations means AIP payout at 100% of salary, BIP vesting at 67% of the award, LTIP vesting at 50% of the award and ESOS vesting at 80% of the award. Maximum means AIP payout at 150% of salary and multi-year incentives vesting at 100% of the awards.

No share price movement is assumed and dividend equivalents payable in respect of the BIP and LTIP are not included. For options vesting in line with expectations, a valuation factor of 20% of the face value of the award at grant has been applied. This is our internal valuation assumption for options, based on the exchange ratio applied to participants in ESOS below Board level who can choose options or shares at a ratio of 5:1. For options vesting at maximum, a higher valuation factor (to reflect the higher performance achievement) of 33% of the face value of the award at grant has been applied. This is in line with the report on pay and performance published in March 2013 by the Financial Reporting Council, an independent UK regulator.

We have not included a chart for the CFO role as Duncan Palmer is leaving the company in 2014. His salary, regular ongoing benefits (excluding relocation expenses) and pension will continue in line with 2013 levels (see Single Total Figure table on page 57) until his leaving date. As he is not eligible for a pro-rated AIP in respect of time employed in 2014, and his BIP, LTIP and ESOS awards have lapsed, his remuneration for 2014 is not variable according to performance. Duncan Palmer’s successor will join the company at a date which is still to be determined.

LOGO

Approach to recruitment remuneration — Executive Directors

When agreeing the components of a remuneration package on the appointment of a new Executive Director, or an internal promotion to the Board, the Committee would seek to align the package with the remuneration policy stated in the policy table. However, on an internal promotion to the Board, any existing contractual obligations and commitments may continue to be honoured, even if not consistent with the prevailing policy. For example, if the individual is a member of the legacy defined benefit pension plan, the Committee will consider the pension arrangements in the context of the package as a whole and may allow continued participation.

The Committee’s general principle on recruitment is to offer a competitive remuneration package to attract high-calibre candidates from a global talent pool. The various components and the company’s approach are as follows:

Standard package on recruitment*

To offer remuneration in line with the policy table (including the limits), taking into account the principles set out above.

Compensation for forfeited entitlements

The Committee may make awards and payments on hiring an external candidate to compensate him or her for entitlements forfeited on leaving the previous employer. If such a decision is made, the Committee will attempt to reflect previous entitlements as closely as possible using a variety of tools, including cash, share awards and options. Claw-back provisions will apply where appropriate. If necessary to facilitate the grant of awards, the Committee may rely on the one person exemption in the UK Listing Rules.

Relocation allowances and expenses

The type and size of relocation allowances and expenses will be determined by the specific circumstances of the new recruit.

*The standard package comprises annual base salary, AIP, other benefits, annual awards under BIP, LTIP and ESOS and retirement benefits.

Shareholding requirement

The Executive Directors are subject to shareholding requirements. These are a minimum of 300% of annual base salary for the CEO and 200% of annual base salary for the CFO. On joining or promotion to the Board, Executive Directors are given a period of time to build up to their requirement.

Policy on payments for loss of office

In line with the company’s policy, the service contracts of the existing Executive Directors contain 12-month notice periods.

The circumstances in which an Executive Director’s employment is terminated will affect the Committee’s determination of any payment for loss of office, but it expects to apply the principles outlined on pages 54 and 55. The Committee reserves the right to depart from these principles where appropriate in light of any taxation requirements to which the company or the Executive Director is subject (including, without limitation, section 409A of the US Internal Revenue Code), or other legal obligations.

Restricted shares were granted to Duncan Palmer on his recruitment in 2012 as compensation for forfeited entitlements from his former employer. This award has been pro-rated for service to the date of notice of resignation, with the result that 74,042 PLC ordinary shares and 51,378 NV ordinary shares will vest on leaving. As the pro-rated shares will only be released upon his yet to be determined leaving date, rather than the original vesting dates, a cash adjustment may be paid to him if required to ensure that the value of the pro-rated award received on leaving is equivalent to that which would have been received under the original arrangements. Dividend equivalents on the shares will be paid on vesting.

Policy on payments for loss of office (continued)1

Mutually agreed termination/termination by the company other than for cause

General

The Executive Director would be entitled to salary, benefits and other contractual payments in the normal way up to the termination date (including any unpaid annual incentive for any prior year) and would be paid for any accrued but untaken holiday.

Salary:     Payment of up to 12 months’ salary.

Annual incentive:     Any unpaid annual incentive for the previous year and a pro-rata payment in respect of the part of the financial year up to the termination date would generally be payable, with the amount being determined by reference to the original performance criteria. However, the Committee has discretion to decide otherwise depending on the reason for termination and other specific circumstances. The company would not pay any annual incentive in respect of any part of the financial year following the termination date (e.g. for any part of unserved notice). The annual incentive claw-back provisions would apply.

Other benefits:     Where possible, benefits would be continued for up to the duration of the unserved notice period (not exceeding the maximum stated in the policy table) or, the Executive Director would receive a cash payment (not exceeding the cost to the company of providing those benefits).

Pension:     Deferred or immediate pension in accordance with scheme rules, with a credit in respect of, or payment for up to, the full period of any unworked period of notice. There is provision under the defined benefit pension arrangements for members leaving company service by reason of permanent incapacity to make an application to the scheme trustee for early payment of their pension.

Other:     The company may pay compensation in respect of any statutory employment rights and may make other appropriate and customary payments.

The company would have due regard to principles of mitigation of loss. Reductions would be applied to reflect any portion of the notice period that is worked and/or spent on gardening leave.

On injury, disability, ill health or death, the Committee reserves the right to vary the treatment outlined in this section.

Multi-year incentives2

BIP 2010, LTIP 2013 and ESOS 2013:    The default position is that unvested awards will be pro-rated to reflect time employed and will vest subject to performance measured at the end of the relevant performance period. Options are typically exercisable for a period of two years following vesting. In respect of the BIP, a pro-rata number of investment shares will remain in the plan, with the balance being released on cessation of employment.

The Committee has discretion to allow unvested awards to vest earlier and to adjust the application of time pro-rating, performance conditions and exercise periods subject to the rules of the respective plans.

REGP:    The default position is that unvested matching shares will be pro-rated to reflect time employed and will vest subject to performance measured at the end of the 2013-14 performance period. A pro-rata number of personal shares and deferred performance shares will remain in the plan, with the balance being released on cessation of employment. The Committee has discretion to allow the matching shares to vest earlier.

ESOS 2003:    The default position is that options will typically become exercisable for a six-month period (two years on retirement) from the termination date, subject to time pro-rating and performance conditions. The Committee may adjust the application of time pro-rating, performance conditions and exercise periods, subject to the rules of the plan.

1

In addition to what is set out in this “Policy on payments for loss of office” section, on termination for any reason, Erik Engstrom will be entitled to payment of amounts held in his “Retirement Account”. Before he joined the company’s UK defined benefit arrangement, he was not a member of any company pension scheme and Reed Elsevier made annual contributions of 19.5% of base salary to a deferred compensation plan. Contributions to this Retirement Account ceased when he became a member of the UK defined benefit arrangement.

2

In cases where the approved leaver treatment applies, the multi-year incentive plans have a default position as well as giving the Committee discretion to adjust the default treatment within certain parameters. The Committee would expect to exercise such discretion where the Committee believes the personal circumstances of the Executive Director so require.

Employee instigated resignation

General

The Executive Director would not receive any payments for loss of office. The Executive Director would be entitled to salary, benefits and other contractual payments in the normal way up to the termination date and would be paid for any accrued but untaken holiday. The Executive Director will be entitled to receive an annual incentive for a completed previous year, but not a pro-rated annual incentive in respect of a part year up to the termination date, unless the Committee decides otherwise in the specific circumstances. Annual incentive claw-back provisions would apply. A deferred or immediate pension would be payable in accordance with the scheme rules.

Multi-year incentives

All outstanding awards lapse on date of notice. Any related personal or investment shares (e.g. under the REGP and the BIP) will be released.

Dismissal for cause

General

The Executive Director would not receive any payments for loss of office. A deferred or immediate pension would be payable in accordance with the scheme rules.

Multi-year incentives

All outstanding awards lapse on date of dismissal. Any related personal or investment shares (e.g. under the REGP and the BIP) will be released.

Non-Executive Directors

Remuneration policy table — Non-Executive Directors

FEES

Purpose and link to strategy

To enable Reed Elsevier to recruit Non-Executive Directors with the right balance of personal skills and experience to make a major contribution to the Boards and Committees of a dual-listed global business.

Operation

Reed Elsevier Chairman:    Receives an aggregate annual fee with no additional fees, e.g. Committee Chairman fees. In respect of Reed Elsevier PLC and Reed Elsevier Group plc, the Committee determines, on the advice of the Senior Independent Director, the Chairman’s fee. In respect of Reed Elsevier NV, the Committee makes a recommendation, on the advice of the Senior Independent Director, to the Board of Reed Elsevier NV, which determines the Chairman’s fee.

Other Non-Executive Directors:    Receive an aggregate annual fee in respect of their memberships of the Boards of Reed Elsevier plc, Reed Elsevier NV and Reed Elsevier Group plc.* Additional fees are payable to the Senior Independent Director and Committee Chairmen. Since January 1, 2014, fees are also payable for membership of Board Committees. In future, attendance fees may be paid. The Boards determine the level of fees, subject to applicable law.

Fees may be reviewed annually, although in practice they have changed on a less frequent basis. When reviewing fees, consideration is given to the time commitment required, the complexity of the role and the calibre of the individual. Comparative market data is also reviewed, the primary source for which is the practice of FTSE 30 companies, with reference also to the NYSE Euronext Amsterdam (AEX) Index and US-listed companies.

Maximum value

The fees paid to the Chairman and the Non-Executive Directors are in respect of their memberships of the Boards of Reed Elsevier PLC, Reed Elsevier NV and Reed Elsevier Group plc. The shareholders of Reed Elsevier PLC and Reed Elsevier Group plc have approved a maximum annual fee limit of £500,000 and £700,000 respectively (excluding additional

*The fees paid to a Non-Executive Director who serves only on the Board of Reed Elsevier NV reflect the time commitment to that company and to other companies within the Reed Elsevier combined businesses.

fees for membership of or chairing Board Committees and assuming additional responsibilities such as acting as Senior Independent Director, all of which are not subject to a maximum limit). The shareholders of Reed Elsevier NV have approved a maximum annual fee limit of €600,000 for the fees borne by Reed Elsevier NV. The aggregate annual fee limit is therefore approximately £1.7m.

OTHER BENEFITS

Purpose and link to strategy

To provide customary benefits at an appropriate cost.

Operation

Other benefits for Non-Executive Directors are reviewed periodically and may include private medical cover, tax return preparation costs, secretarial benefits and car benefits, including, where appropriate, the tax on such benefits.

Maximum value

There is no prescribed maximum amount.

Approach to recruitment remuneration — Non-Executive Directors

Following recruitment, a new Non-Executive Director will be entitled to fees and other benefits in accordance with the company’s remuneration policy. No additional remuneration is paid on recruitment. However, any reasonable expenses incurred during the recruitment process will be reimbursed.

Policy on payments for loss of office — Non-Executive Directors

In addition to unpaid accrued fees, the Non-Executive Directors are entitled to receive one month’s fees for loss of office if their appointment is terminated before the end of its term.

Service contracts and letters of appointment

There are no further obligations in the Directors’ service contracts and letters of appointment which are not otherwise disclosed in this annual report which could give rise to a remuneration payment or loss of office payment. All Directors’ service contracts and letters of appointment are available for inspection at the company’s registered office. The Executive Directors’ service contracts do not have a fixed expiry date.

Consideration of employment conditions elsewhere in the company

When the Committee reviews the Executive Directors’ salaries annually, it takes into account the company’s guidelines for salaries for all employees for the forthcoming year. We do not currently use any other remuneration comparison metrics when determining the quantum and structure of Directors’ pay. We do not think it is appropriate to consult with employees in connection with our policy on Directors’ remuneration.

Consideration of shareholder views

Our practice is to consult shareholders and consider their views when formulating, or changing, our policy. For example, in early 2013 we consulted with a number of shareholders in connection with the proposals for a new LTIP and the renewal of the ESOS. The feedback helped shape the design of the plans.

Prior commitments

The Committee reserves the right to make any remuneration or loss of office payments if the terms were agreed prior to an individual being appointed as a Director or prior to the approval of the policy.

Annual Remuneration Report

Single Total Figure of Remuneration – Executive Directors

   (a)  (b)  (c)     (d)  (e)  (f)     (g)  (h)  (i)     (j)  (k)  (l) 
   Short-term employee
benefits
     Share-based awards     Pension     Total 

£‘000

  Salary  Benefits5  Annual
Incentive
     New UK
basis
1,4,7
  Dutch
Civil
Code
basis
2
  Consistent
with prior
disclosure
3,4,7
     New UK
basis
1
  Dutch
Civil
Code
basis
2
  Consistent
with prior
disclosure
3
     New UK
basis
1
  Dutch
Civil
Code
basis
2
  Consistent
with prior
disclosure
3
 

Erik Engstrom

  2013    1,077    28    1,134      2,467    3,300    1,301      719    528    528      5,425    6,067    4,068  

Erik Engstrom

  2012    1,051    28    1,150      8,302    2,744    5,312      614    470    470      11,145    5,443    8,011  

Duncan Palmer6

  2013    600    232    609      0    598    0      114    114    114      1,555    2,153    1,555  

Duncan Palmer6

  2012    214    10    230      867    268    914      41    41    41      1,362    763    1,409  

1.New UK basis (columns (d), (g) and (j)): These figures are calculated in accordance with the methodology set out in the new UK Regulations. They include, for performance related share-based awards, the value attributable to share price appreciation since the date the award was granted. In the case of the CEO’s figures, the amount included that relates to share price appreciation is £3 million for 2012 and £1.2 million for 2013.
2.Dutch Civil Code basis (columns (e), (h) and (k)):These figures comply with the requirements of the Dutch Civil Code. The figures for share-based awards comprise the multi-year incentives charges in accordance with IFRS2 – Share-Based Payment. These IFRS2 charges do not reflect the actual value received on vesting. The figures for pensions reflect the cost of pension provision, which comprises (i) for defined benefit schemes, the transfer value of the increase in accrued pension during the year (net of inflation, Directors’ contributions and participation fee) and (ii) for defined contribution schemes, payments made to the scheme or to the Executive Director in lieu of pension.
3.Consistent with prior disclosure (columns (f), (i) and (l)): We believe including these figures is helpful for our non-UK shareholders as the calculation methodology for share-based awards and defined benefit pensions is consistent with what has been used in previous annual reports (although we have reflected amounts in the same year as required by the New UK basis to facilitate comparison). Accordingly, values are calculated as follows: (i) for share-based awards, the value of the vested award at grant excluding any subsequent share price movement (as shown in the share-based award tables in prior annual reports) and including dividend equivalents if applicable; (ii) for options, 20% of face value at grant (based on our previously disclosed 5:1 exchange ratio for options to shares applicable to ESOS participants below the Board, as described in the 2013 Notices of Annual General Meetings); (iii) for defined benefit pension, the transfer value of the increase in accrued pension during the year (net of inflation, Directors’ contributions and participation fee) and (iv) for defined contribution pensions schemes, payments made to the scheme or to the Executive Director in lieu of pension.
4.Share-based awards for Erik Engstrom (columns (d) and (f)): The 2012 figures reflect the vesting of tranche 1 of the REGP and the 2010 BIP, both measured over the 2010-12 period. The vesting percentages under these plans were determined on April 25, 2013 and are in line with estimates in the 2012 annual report (pages 49 and 51). The figures include the related dividend equivalent payments paid out in cash in 2013 in respect of both plans. The 2012 REGP figures reflect the entire amount that was performance tested over the2010-12 period, including the 50% of shares deferred until 2015 in accordance with the plan rules. The 2013 figures represent the2011-13 cycle of the BIP and ESOS. As the BIP vests after the approval date of this report, and the ESOS vests in May 2014, the average share prices for the last quarter of 2013 have been used to arrive at an estimated figure under the New UK basis in respect of both awards. The proportion of the value of the CEO’s share-based awards under the New UK basis that relates to share price appreciation between the dates of grant and vesting is 36% (or £3 million) for 2012 and 47% (or £1.2 million) for 2013 using, as required, the average share prices for the last quarter of 2013.
5.Benefits: Each Executive Director receives a car allowance, private medical/dental insurance and the company meets the cost of tax return preparation. In 2013, Duncan Palmer received a one-off cash relocation allowance of £500,000 which was paid to him in May 2013 in recognition of him and his family being required to relocate to the UK from the US (see page 53 of last year’s Annual Report on Form 20-F). As a result of his resignation, Duncan Palmer became required to repay this to the company through payroll deductions, by deduction from his 2013 annual incentive payment, so it has not been included in column (b). He also received reimbursement of direct relocation expenses, under Reed Elsevier’s relocation policy, amounting to £200,907, which is included.
6.Duncan Palmer’s 2012 figures: Columns (a) to (c), (g) and (i) reflect the amount Duncan Palmer received from his date of joining Reed Elsevier (August 24, 2012) until the end of the year. The 2012 share-based award figures in columns (d) and (f) relate to the restricted shares granted to compensate him for the forfeiture of awards from his former employer (as disclosed in last year’s annual report), reduced to reflect time served up to the point of giving notice of resignation. The figure in column (f) includes estimated dividend equivalents of £46,977.
7.Exchange rates used for share-based awards:The exchange rates used to convert share-based awards to pounds sterling are (i) for the New UK basis, those that applied at the vesting dates or, if vesting has not occurred, the average exchange rates for the last quarter of 2013, (ii) for consistent with prior disclosure, those that applied at the grant dates, (iii) for dividend equivalents, the exchange rate at the time of payment and (iv) for estimated dividend equivalents yet to be paid, the December 31, 2013 Euro to Sterling exchange rate of 0.83237.
8.Total remuneration for Directors:This is set out in note 32 to the combined financial statements on page F-54.

2013 Annual Incentive

Reed Elsevier continued to deliver on its long-term strategic and financial priorities in 2013. Underlying revenue growth was 2% (3% excluding the cycling effect of biennial exhibitions), with underlying revenue growth across all five major business areas. Improved profitability was driven by process innovation and portfolio development. Underlying adjusted operating profit grew ahead of revenue at 5%. Adjusted operating cash flow was £1,703 million and the rate of conversion of adjusted operating profits into cash flow was 97%. The post-tax return on average invested capital increased in the year to 12.1%.

Set out below is a summary of performance against each financial measure and the resulting annual incentive payments for 2013 (payable in March 2014):

Performance measure

  Relative
weighting
 Achievement versus target  Payout as % of
salary
Erik Engstrom
  Payout as % of
salary
Duncan Palmer

Revenue

  30% At target  Close to 30%  Close to 30%

Adjusted profit after tax

  30% Just above target  Just above 30%  Just above 30%

Cash flow conversion rate

  10% Just above target  Just above 10%  Just above 10%

Key Performance Objectives (KPOs)

  30% CEO  CFO  Close to 30%  Just below 30%
   Substantially all
objectives met
  Most objectives met    
       

 

  

 

       105.3%  101.4%
       

 

  

 

       £1,134,235  £608,550
       

 

  

 

We do not disclose our annual financial targets or details of the individual KPO targets. The Board believes that these are commercially sensitive and that disclosing them would give competitors an unfair insight into our strategic direction and annual execution plans.

Multi-year incentives

Awards were granted to Erik Engstrom under the BIP and the ESOS in May 2011. The Committee assessed the performance measures for these awards and the outcome is summarised below.

BIP: 2011-13 cycle performance outcome

Performance measure

  Weighting  Performance range
and vesting

levels set at grant1
     Achievement against
the performance
range
  Resulting vesting
percentage

Average growth in adjusted EPS over the three-year performance period2

  50%  below 4% p.a.
4% p.a.

6.5% p.a.
9% p.a. or above

  0%
50%
75%
100%
  7.1% p.a.  81%

ROIC in the third year of the performance period2

  50%  below 10.4%
10.4%

10.9%

11.4% or above

  0%
50%
75%
100%
  11.7%  100%

Total vesting percentage:

          90.5%

1.Calculated on a straight-line basis for performance between the minimum and maximum levels.

2.The calculation methodology for EPS and ROIC is set out in the 2010 Notices of Annual General Meetings, which can be found on the company’s website.

ESOS: 2011-13 cycle performance outcome

Performance measure

  Weighting  Performance range
and vesting levels
set at grant
     Achievement
against the
performance
range
   Resulting
vesting
percentage

Average growth in adjusted EPS over the three-year performance period

  100%  below 6% p.a.   0  above 6% p.a.    100%
    6% p.a. or above   100   

Single Total Figure of Remuneration – Non-Executive Directors

    Total fee   Benefits1   Total 
    2013   2012   2013   2012   2013   2012 

Anthony Habgood

  £550,000    £550,000    £1,900    £1,689    £551,900    £551,689  

Mark Elliott (until April 25, 2013)

  £21,250    £85,000    £1,000    £300    £22,250    £85,300  

Wolfhart Hauser (from April 25, 2013)

  £65,058          £65,058    

Adrian Hennah

  £65,000    £65,000    £500    £300    £65,500    £65,300  

Lisa Hook2

  £80,462    £65,000    £1,000    £300    £81,462    £65,300  

Marike van Lier Lels3

  £55,085    £52,846        £55,085    £52,846  

Robert Polet

  £65,000    £65,000    £500    £300    £65,500    £65,300  

Sir David Reid (until April 25, 2013)

  £21,250    £85,000    £500    £300    £21,750    £85,300  

Linda Sanford (from December 4, 2012)

  £65,000    £5,416    £1,000      £66,000    £5,416  

Ben van der Veer3

  £93,220    £89,431    £500    £300    £93,720    £89,731  

1.Benefits comprise the notional benefit of tax filing support provided to Non-Executive Directors for filings outside their home country resulting from their directorships with Reed Elsevier. The incremental assessable benefit charge per tax return has been agreed by PwC for 2013 to amount to £500. Anthony Habgood’s benefits also include £1,400 (£1,389 in 2012) in respect of private medical insurance.

2.Lisa Hook became Senior Independent Director on April 23, 2013 and received additional fees for this role from that date.

3.The fees for Marike van Lier Lels and Ben van der Veer were paid in euros and were €65,000 and €110,000 respectively for 2013. For reporting purposes these were converted into pounds sterling at the average exchange rate for 2013. The 2012 figures were converted into pounds sterling at the average exchange rate for 2012.

4.The total remuneration for Directors is set out in note 32 to the combined financial statements on page F-54.

2013 Non-Executive Directors’ fees

The fees in the Single Total Figure table for Non-Executive Directors reflect the following fees in 2013 (unchanged from 2012):

Annual fee
2013

Chairman

£550,000

Non-Executive Directors

£65,000/€80,000

Senior Independent Director

£20,000

Chairman of:

– Audit Committee

£25,000/€30,000

– Remuneration Committee

£20,000

Total pension entitlements

Erik Engstrom is a member of the UK Reed Elsevier defined benefit pension arrangements. Further details are provided in the Policy Report on page 48 and below.

Pension – Standard information

Age at December 2013

 

Normal retirement age

 

Director’s contributions

 

Participation fee

50

 60 £9,807 £2,340

Since October 2013, the CEO pays a participation fee equal to 1% of the amount of his base salary which exceeds the UK earnings cap. On April 1, 2014, and each April thereafter, this fee will increase by 2% of base salary which exceeds the UK earnings cap.

Pension – New UK Regulations

Accrued annual pension at

December 31, 2012
adjusted for inflation

Accrued annual pension at

December 31, 2013

Single figure pension value

£184,940

£221,383£719,053

Pension – Consistent with prior disclosure

Increase in accrued pension during
the year (net of inflation)

Transfer value1 at 31.12.13 of increase in accrued pension
during the year (net of inflation and Directors’ contributions)

£34,814

£530,417/£528,0772

1.The transfer value represents a liability in respect of Directors’ pension entitlements, and is not an amount paid or payable to the Director.
2.After deducting Erik Engstrom’s participation fee.

Scheme interests awarded during the financial year

CURRENT MULTI-YEAR INCENTIVE PLANS

Basis on which award
is made

Face value

of award
at grant
1

Value of
awards if
vest in line
with
expectations
2

Percentage of
maximum that would
be received if threshold
performance achieved
3

End of
performance
period

BIP – matching share awards

Erik Engstrom

Duncan Palmer

Opportunity to invest cash and/or shares up to value of target bonus opportunity and receive 1 for 1 matching award

£1,050,606

£599,9844

£703,906

£04

If one measure pays out at threshold, the overall payout is 25%. If both measures pay out at threshold, the overall payout is 50%.December 31, 2015

LTIP – performance share awards

Erik Engstrom

250% of salary£2,626,557£1,313,279If the measure with the lowest payout at threshold pays out at threshold, the overall payout is 3%. If each measure pays out at threshold, the overall payout is 32%.

December 31,

2015


Duncan Palmer

200% of salary£1,199,9984£04
ESOS – market value options

Erik Engstrom

250% of salary£2,626,557£420,24933%

December 31,

2015


Duncan Palmer

200% of salary£1,199,9984£04

DISCONTINUED/ONE-OFF MULTI-YEAR INCENTIVE PLAN

REGP – matching share awards

Erik Engstrom

In accordance with the REGP plan rules5

£7,546,000

£3,773,000If the measure with the lowest payout at threshold pays out at threshold, the overall payout is 3%. If each measure pays out at threshold, the overall payout is 50%.December 31, 2014

1.The face value of the LTIP and ESOS awards is calculated using the middle market quotation of PLC ordinary shares (£7.345), the closing price of NV ordinary shares (€12.530) and the exchange rate on the day before grant (May 8, 2013). These share prices are used to determine the number of awards granted, as well as to set option exercise prices. The face value of the ESOS options shown in this column has not been reduced to reflect the fact that the aggregate option price is payable on exercise. The face value of the BIP awards is calculated using the average price of participants’ investment shares purchased by the trustee, between May 9 and 13, 2013, the price for NV ADRs (which is the security which the Executive Directors invested in) being $33.251. The face values for BIP, LTIP and REGP do not take into account the dividend equivalents relating to those awards. The face value of REGP matching share awards has been determined using the applicable middle market quotations, closing prices and exchange rates on the date of grant (April 25, 2013).

2.For BIP, LTIP and ESOS, vesting in line with expectations is as per the performance scenario chart on page 52. For the REGP, it is as per the policy table on page 51.

3.Threshold payout levels for each measure have been included. Where there are multiple measures, it is possible to achieve threshold, and hence payout, in respect of just one of the measures (or, for TSR, in respect of one of the three TSR comparator groups). A summary of the performance measures and targets for awards granted in 2013 under each of the plans is set out on pages 61 and 62.

4.These awards lapsed on the date Duncan Palmer gave his notice of resignation.

5.The number of shares comprised in Erik Engstrom’s REGP matching award was determined in accordance with the plan rules and equals the number of deferred performance shares and personal shares held in the plan at the date of the matching award grant (April 25, 2013).

The following targets and vesting scales apply to awards granted in 2013:

BIP: 2013-15 cycle

Match earned on personal investment

 

Average growth in adjusted EPS
over the three-year performance
period*

 

ROIC in the third year of the
performance period*

0%

 below 4% p.a. below 11.2%

50%

 4% p.a. 11.2%

75%

 6.5% p.a. 11.7%

100%

 9% p.a. or above 12.2% or above

*EPS and ROIC have equal weighting and straight-line vesting applies to performance between the points.

LTIP: 2013-15 cycle

Vesting is dependent on three separate performance measures of equal weighting: a TSR measure, an EPS measure and a ROIC measure.1

Vesting percentage of each third of

the TSR tranche2

TSR ranking within the relevant TSR
comparator group

0%

Below median

30%

Median

100%

Upper quartile

1.The calculation methodology for TSR, EPS and ROIC, and the components of the TSR comparator groups, are set out in the 2013 Notices of Annual General Meetings, which can be found on the company’s website.

2.Vesting is on a straight-line basis for performance between the minimum and maximum levels.

The three TSR comparator groups (Sterling, Euro and US Dollar) reflect the fact that Reed Elsevier accesses equity capital markets through three exchanges – London, Amsterdam and New York – in three currency zones. Reed Elsevier’s TSR performance is measured separately against each comparator group and each ranking achieved will produce a payout, if any, in respect of one-third of the TSR measure. The proportion of the TSR measure that vests will be the sum of the three payouts.

Each comparator group comprises approximately 40 companies, selected on the following basis for the 2013-15 LTIP cycle:

(a)they were in a relevant market index or are the largest listed companies on the relevant exchanges at the end of the year before the start of the performance period: the FTSE 100 for the Sterling group; AEX, NYSE Euronext and the Frankfurt Stock Exchange for the Euro group; and the S&P 500 for the US Dollar group;

(b)certain companies were then excluded:

those with mainly domestic revenues (as they do not reflect the global nature of Reed Elsevier’s customer base);

those engaged in extractive industries (as they are exposed to commodity cycles); and

financial services companies (as they have a different risk/reward profile);

 

 (c)the remaining companies were then ranked by market capitalisation and, for each comparator group, the 20 companies above and below Reed Elsevier were taken;

(d)relevant listed global peers operating in businesses similar to those of Reed Elsevier but not otherwise included were added.

Vesting percentage of EPS
and ROIC tranches*

  Average growth in adjusted
EPS over the three-year
performance period
     

ROIC in the third
year of the
performance
period

0%

  below 5% p.a.    below 11.2%

33%

  5% p.a.    11.2%

52.5%

  6% p.a.    11.45%

65%

  7% p.a.    11.7%

75%

  8% p.a.    11.95%

85%

  9% p.a.    12.2%

92.5%

  10% p.a.    12.45%

100%

  11% p.a. or above    12.7% or above

*Vesting is on a straight-line basis for performance between the stated average adjusted EPS growth/ROIC percentages.

ESOS: 2013-2015 cycle

Proportion of the award vesting

Average growth in adjusted EPS
over the three-year performance
period*

0%

below 4% p.a.

33%

4% p.a.

80%

6% p.a.

100%

8% p.a. or above

*Vesting is on a straight-line basis for performance between the stated average adjusted EPS growth percentages.

REGP: matching awards

As disclosed in previous annual reports, vesting is dependent on three separate performance measures of equal weighting: a TSR measure, an EPS measure and a ROIC measure.

Vesting percentage of each third of

the TSR tranche*

  

TSR ranking within the relevant
TSR comparator group

0%

Below median

30%

Median

100%

Upper quartile

*Vesting is on a straight-line basis for performance between the minimum and maximum levels.

Vesting percentage of EPS

and ROIC tranches*

  

Average growth in adjusted
EPS over the two-year
performance period*

     

ROIC in the second
year of the
performance
period*

0%

  below 7% p.a.    below 10.7%

60%

  7% p.a.    10.7%

100%

  13% p.a. or above    12.7% or above

*Vesting is on a straight-line basis for performance between the minimum and maximum levels.

External appointments

The Committee believes that the experience gained by allowing Executive Directors to serve as Non-Executive Directors on the boards of other organisations is of benefit to Reed Elsevier. Accordingly, Executive Directors may, subject to the approval of the Chairman and the CEO (or the Chairman only in the case of the CEO), serve as Non-Executive Directors on the boards of up to two non-associated companies (of which only one may be a major company) and they may retain remuneration arising from such appointments.

Duncan Palmer is a Non-Executive Director of Oshkosh Corporation and received fees of £63,141 for 2013.

Payments to past Directors and payments for loss of office

There have been no payments to past Directors or payments for loss of office in 2013.

Statement of Directors’ shareholdings and other share interests

Shareholding requirement

The Committee believes that a closer alignment of interests can be created between senior management and shareholders if executives build and maintain a significant personal stake in Reed Elsevier. The shareholding requirements applicable to the Executive Directors are set out in the table below. Shares that count for this purpose are any type of Reed Elsevier security owned outright by the individual and their spouse, civil partner or dependent child.

Meeting the shareholding requirement is both a vesting condition for awards granted and a requirement to maintain eligibility for future awards. Shareholding requirements fall away on leaving the company.

On December 31, 2013, the Executive Directors’ shareholdings were as follows (valued using the middle market closing prices of Reed Elsevier securities):

   

Shareholding
requirement (% of
December 31, 2013
annual base salary)

  Actual shareholding as
at December 31, 2013
(% of December 31, 2013
annual base salary)

Erik Engstrom

 300%  734%

Duncan Palmer*

 200%  69%

*Duncan Palmer had been given until December 31, 2015 to build up to his required level of shareholding, which meant retaining net shares earned from incentive plans until he reached this level. On resignation, he forfeited his regular annual multi-year incentive awards and will not fulfil the requirement, which will cease to apply on leaving.

Share interests

See page 75.

Performance graphs and CEO historic pay table

The graphs below show total shareholder returns for Reed Elsevier PLC and Reed Elsevier NV, calculated on the basis of the average share price in the 30 trading days before the respective year end and assuming dividends were reinvested. Reed Elsevier PLC’s performance is compared with the FTSE 100 and Reed Elsevier NV with the AEX Index (to reflect their respective memberships of those indices), over the five years from December 31, 2008 to December 31, 2013. Charts showing performance over a four-year period are included to reflect the current CEO’s tenure and the launch of the one-off REGP in 2010. The three-year charts cover the performance period of the 2011-2013 cycles of BIP and ESOS.

3 years

LOGO

4 years

LOGO

5 years

LOGO

Performance graphs and CEO historic pay table (continued)

The table below shows the historic CEO pay over a six-year period. 2008 has been included to show the pre-2009 position, as 2009 was a transition year with three CEO incumbents.

£‘000

  2008   20094   2010   2011   2012  2013 
CEO  Sir
Crispin
Davis
   Sir
Crispin
Davis
  Ian
Smith
   Erik
Engstrom
   Erik
Engstrom
   Erik
Engstrom
   Erik
Engstrom
  Erik
Engstrom
 

Annualised base salary

   1,181     1,181    900     1,000     1,000     1,025     1,051    1,077  

Annual incentive payout as a % of maximum

   61%     30%    37%     71%     67%     66%     73%    70%  

Multi-year incentive vesting as a % of maximum

   100%     0%    0%     0%     0%     0%     70%5   96%5 

CEO total (New UK basis)1

   7,193     706    1,033     426     3,140     2,738     11,1456   5,425�� 

CEO total (Dutch Civil Code basis)2

   6,631     (514  1,033     431     2,675     5,045     5,443    6,067  

CEO total (Consistent with prior disclosure)3

   7,673     693    1,033     378     2,737     2,535     8,0116   4,068  

1.New UK basis: This is described in footnote 1 to the Single Total Figure table on page 57.

2.Dutch Civil Code basis: This is described in footnote 2 to the Single Total Figure table on page 57.

3.Consistent with prior disclosure: This is described in footnote 3 to the Single Total Figure table on page 57.

4.Sir Crispin Davis was CEO from January 1, to March 31, Ian Smith was CEO from April 1, to November 10, and Erik Engstrom was CEO from November 11, to December 31.

5.The 2012 percentage reflects BIP and REGP and the 2013 percentage reflects BIP and ESOS.

6.The 2012 figure for Erik Engstrom reflects the vesting of tranche 1 of the REGP and the 2010 BIP, both measured over the 2010-12 period. The REGP figure reflects the entire amount that was performance tested over the 2010-12 period, including the 50% of shares deferred until 2015 in accordance with the plan rules.

Comparison of change in CEO pay with change in employee pay

The table below shows the percentage change in remuneration (salary, benefits and annual incentive) from 2012 to 2013 for the CEO compared with the average employee.

   % change from
2012 to 2013
 
    CEO   Average
employee*
 

Salary

   2.5%     2.5%  

Benefits

   –1.5%     2.5%  

Annual incentive

   –1.4%     2.5%  

*This reflects a substantial proportion of our global employee population.

Relative importance of spend on pay

The following table sets out the total employee costs for all employees, as well as the amounts paid in dividends and share repurchases.

    2013 (£m)   2012 (£m)   % change 

Employee costs*

   1,775     1,845     –4%  

Dividends

   549     521     5%  

Share repurchases

   600     250     140%  

*Employee costs include wages and salaries, social security costs, pensions and share-based and related remuneration.

Implementation of remuneration policy in 2014

Salary:    The Committee has awarded a salary increase of 2.5% to Erik Engstrom, which means that, from January 1, 2014, his salary rose to £1,103,813. This is within the guidelines agreed for employees in Reed Elsevier’s most significant locations globally for 2014. There was no increase to Duncan Palmer’s salary.

AIP:    The operation of the AIP in 2014 remains the same as in 2013, with the exception of the introduction of claw-back provisions. Annual financial targets and KPOs are not disclosed as the Board believes that these are commercially sensitive and that disclosing them would give competitors an unfair insight into our strategic direction and annual execution plans. The targets are designed to be challenging relative to the 2014 execution plan.

Multi-year incentives:    The award levels (% of salary) for 2014 are:

   CEO  CFO

BIP opportunity

  100%  100%

LTIP

  250%  200%

ESOS

  250%  200%

The targets and vesting scales for the multi-year incentive awards granted in 2014 are as follows:

BIP: 2014-16cycle

Match earned on personal
investment

  Average growth in adjusted
EPS over the three-year
performance period*
  ROIC in the third
year of the
performance
period*

0%

  below 4% p.a.  below 11.6%

50%

  4% p.a.  11.6%

75%

  6.5% p.a.  12.1%

100%

  9% p.a. or above  12.6% or above

*EPS and ROIC have equal weighting and straight-line vesting applies to performance between the points.

LTIP: 2014-16 cycle

Vesting is dependent on three separate performance measures of equal weighting: a TSR measure, an EPS measure and a ROIC measure.1

Vesting percentage of each third
of the TSR tranche
2

TSR ranking within the relevant
TSR comparator group

0%

Below median

30%

Median

100%

Upper quartile

1.The calculation methodology for TSR, EPS and ROIC is set out in the 2013 Notices of Annual General Meetings, which can be found on the advicecompany’s website. The methodology for selecting the TSR comparator group companies is unchanged from 2013 (see page 61).

2.Vesting is on a straight-line basis for performance between the minimum and maximum levels.

Vesting percentage of EPS
and ROIC tranches*

  Average growth in adjusted
EPS over the three-year
performance period
  ROIC in the third
year of the
performance
period

0%

  below 5% p.a.  below 11.6%

33%

  5% p.a.  11.6%

52.5%

  6% p.a.  11.85%

65%

  7% p.a.  12.1%

75%

  8% p.a.  12.35%

85%

  9% p.a.  12.6%

92.5%

  10% p.a.  12.85%

100%

  11% p.a. or above  13.1% or above

*Vesting is on a straight-line basis for performance between the stated average adjusted EPS growth/ROIC percentages.

ESOS: 2014-2016 cycle

Proportion of the award
vesting

Average growth in adjusted EPS over the
three-year performance period*

0%

below 4% p.a.

33%

4% p.a.

80%

6% p.a.

100%

8% p.a. or above

*Vesting is on a straight-line basis for performance between the stated average adjusted EPS growth percentages.

Non-Executive Directors’fees:     Changes to Non-Executive Director fee levels, from January 1, 2014, are as follows:

Fees for the Senior Independent Director and the Remuneration Committee Chairman will be increased from £20,000 to determine the remuneration of the Reed Elsevier Chairman (with respect to Reed Elsevier NV, to recommend, on advice of the Senior Independent Director, to the Combined Board the Chairman’s remuneration in respect of his Chairmanship of Reed Elsevier NV).£25,000; and

 

  

GeneralThe following Committee membership fees apply:

 

  

to review the ongoing appropriateness and relevance of the remuneration policy, in particular the performance- related elements and their compatibility with risk policies and systems;Audit Committee member £12,500 per annum

 

  

to review and recommend amendments to the rules of all share-based incentive plans including the formulation of suitable performance conditions for share-based awards and options, and where necessary, to submit them for approval by shareholders;Remuneration Committee member £12,500 per annum

 

  

to maintain an open and ongoing dialogue with institutional investors on major remuneration policy issues; and

to discharge its duties with due regard to any published corporate governance guidelines, codes or recommendations regarding the remuneration of directors of listed companies and formation and operation of share schemes which theNominations Committee considers relevant or appropriate including, but not limited to, the UK and Dutch Corporate Governance Codes.member £7,500/€9,000 per annum.

A copy of the terms of reference of theRemuneration Committee can be found on the Reed Elsevier website www.reedelsevier.com. advice

The information on our website is not incorporated by reference into this report.

Throughout 2012, the Committee consistedconsists of independent non-executive directors; Mark Elliott (Committee Chairman), Sir David Reid, Lisa Hook and Robert Polet;Non-Executive Directors and the Chairman of Reed Elsevier Group plc. Details of members are contained in the section, “— Directors” on page 45. The Chief Legal Officer and Company Secretary also attends the meetings in his capacity as secretary to the Committee. At the invitation of the Chairman of the Committee, Chairman, the CEO of Reed Elsevier Group plc attends appropriate parts of the meetings. The CEO of Reed Elsevier Group plc is not in attendance during discussions pertaining toabout his remuneration.

The Global Human Resources Director provided material advice toadvised the Committee during the year.

Towers Watson acted asis the external advisors toadviser, appointed by the Committee throughout 2012 and also provided market data and data analysis.through a competitive process. Towers Watson also provided actuarial and other human resources consultancy services directly to some Reed Elsevier companies.

companies during the year. The Committee is satisfied that the firm’s advice continues to be objective and independent, and that no conflict of interest exists. The individual consultants involved in advisingwho work with the Committee do not provide advice to the executive directorsExecutive Directors, or act on their behalf.

EXECUTIVE DIRECTORS

Remuneration philosophy and policy

The context for Reed Elsevier’s remuneration policy and practices is set by the needs of a global business with business areas that operate internationally by line of business. Furthermore, Reed Elsevier PLC and Reed Elsevier NV’s respective stock market listings in London and Amsterdam, combined with the majority of its employees being based in the US, provides a particular set of challenges in the design and operation of remuneration policy.

Our remuneration philosophy

Reed Elsevier’s guiding remuneration philosophy for senior executives is based on the following precepts:

Performance-related compensation with demanding performance standards.

Creation of shareholder value.

Competitive remuneration opportunity to attract and retain the best executive talent from anywhere in the world.

A balanced mix of remuneration between fixed and variable elements, and annual and longer-term performance.

Aligning the interests of executive directors with shareholders and other stakeholders.

Operating the company consistent with long-term sustainability.

Our remuneration policy

In line with this guiding philosophy our remuneration policy is described below.

Reed Elsevier aims to provide a total remuneration package that is able to attract and retain the best executive talent from anywhere in the world, at an appropriate level of cost.

In reaching decisions on executive remuneration, the Committee takes into account the remuneration arrangements and levels of increase applicable to senior management and Reed Elsevier employees generally. The Committee takes into account the salary increases for the employee population worldwide as one of the inputs when determining salary increases for directors.

The Committee considers the social, governance, and environmental implications of its decisions, particularly when setting and assessing performance objectives and targets, and seeks to ensure that incentives are consistent with the appropriate management of risk and corporate sustainability.

Total targeted remuneration of senior executives will be competitive with that of executives in similar positions in comparable companies, which includes global sector peers and companies of similar scale and international complexity.

Competitiveness is assessed in terms of total remuneration (i.e. salary, annual and multi-year incentives and benefits).

The intention is to provide total remuneration that reflects sustained individual and business performance; i.e. median performance will be rewarded by total remuneration that is positioned around the median of relevant market data and upper quartile performance by upper quartile total remuneration.

The Committee will consider all available discretion to claw back any payouts made, or to reduce unvested awards, on the basis of materially misstated data. The rules of all incentive plans provide for specific provisions in this regard.

The Committee considers it important to encourage personal investment and ongoing holding of Reed Elsevier PLC and/or Reed Elsevier NV securities among the senior executive population. Executive directors and other senior executives are subject to minimum shareholding requirements.

How the performance measures in the incentives link to our business strategy

Reed Elsevier’s strategic focus is on transforming its core business through organic investment and the organic build out of new products into adjacent markets and geographies, supplemented by selective portfolio acquisitions and divestments.

The performance related components of the executive directors’ multi-year incentives support this strategy by focusing on return on capital, returns to shareholders and sustained earnings growth.

Furthermore, our annual incentive plan is focused on operational excellence as measured by the financial measures of revenue, profit and cash generation. In addition, a significant portion of the annual bonus is dependent upon the achievement of annual key performance objectives (KPOs) that create a platform for sustainable future performance. These KPOs align with Reed Elsevier’s strategic plans and range from the delivery of specific projects and the achievement of customer metrics or efficiency targets to corporate and social responsibility objectives. Each executive director has at least one sustainability or corporate responsibility objective.

The Committee believes that one of the main drivers of long-term shareholder value is sustained growth in profitability, underpinned by appropriate capital discipline. Therefore growth in earnings per share and targeted return on invested capital are both utilised in our multi-year incentives.

We aim to set challenging performance targets as demonstrated by the fact that there has been no vesting for directors under any of our multi-year incentives since the awards granted in 2006 vested in 2009, and no directors’ bonuses paid out above target since 2009.

The balance between fixed and performance-related pay

We aim to provide each executive director with an annual total remuneration package comprising fixed and variable pay with the majority of an executive director’s total remuneration package linked to performance. At target performance, incentive pay makes up approximately 70% of the total remuneration package. For the CEO, the annual incentive represents around 20% and the multi-year incentives 50% of the total package. The fixed pay element for the CEO is around 30% (salary of around 20% and 10% pension and other benefits). The core components of the total remuneration package are described in detail in the remainder of this Report.

Our approach to market positioning and benchmarking

When reviewing executive director and senior executive remuneration, one factor which the Committee takes into account is market competitiveness. This is done by assessing total remuneration (i.e. salary, annual and multi-year incentives and benefits) against a range of relevant comparator groups as follows:

Global peers operating in businesses similar to those of Reed Elsevier (including Thomson Reuters, WPP, Pearson, John Wiley, Wolters Kluwer, Experian, McGraw-Hill and Equifax).

Companies listed on the London Stock Exchange (cross-industry but excluding those in the financial services sector) of a similar size (measured by aggregate market capitalisation) and international scope.

Companies listed on the New York Stock Exchange (cross-industry but excluding those in the financial services sector) of a similar size (measured by aggregate market capitalisation) and international scope.

Companies listed on the NYSE Euronext Amsterdam Stock Exchange, cross-industry and of a similar size (measured by aggregate market capitalisation) and international scope.

Referring to companies listed in these three different locations is relevant and necessary as demonstrated by the fact that several recent senior executive hires have been recruited from the US including our CFO.

The composition of the respective comparator groups is subject to minor changes year on year reflecting changes in the size, international scope and listing status of specific companies during the year.

The competitiveness of our remuneration packages is assessed by the Committee as part of the annual review cycle for pay and performance, in line with the process set out below.

First, the overall competitiveness of the total remuneration packages is assessed both against the market and taking account of remuneration levels within Reed Elsevier more widely. The appropriate positioning of an individual’s total remuneration against the market is determined based on the Committee’s judgement of individual performance and potential.

The Committee then considers market data and benchmarks for the different elements of the package including salary, total annual cash and total remuneration. While relevant benchmark information is a meaningful input to the process, it informs rather than drives the outcome of the review and is just one factor that the Committee considers.

Benefits, including medical and retirement benefits, are positioned to reflect local country practice.

The total remuneration package

Each element of the remuneration package for executive directors is designed to achieve specific objectives, as described in this section. In aggregate, they create a unified and balanced reward mix and competitive employment proposition. The value of the reward package is only maximised through the integrated delivery of annual and longer-term performance. Reward for the delivery of business results is connected with reward for value flowing to shareholders. Through the use of a range of performance metrics such as earnings per share, return on invested capital, profit after tax, revenue, cash flow conversion rate, personal objectives and total shareholder return and the assessment of performance over multiple time-horizons, the incentive arrangements are structured in such a way that reward cannot be maximised through inappropriate short-term risk-taking.

The table below summarises the component parts of the remuneration package provided in 2012 to executive directors who served in 2012.

Component

Erik Engstrom

Mark Armour**

Duncan Palmer***

Base salary

£1,050,625£644,495£600,000

Retirement benefit

UK defined benefit planUK defined benefit planUK defined contribution plan and cash supplement

Other benefits

Includes car allowance and private medical benefitIncludes company car or cash allowance and private medical benefitIncludes car allowance and private medical benefit

Annual incentive

(earned for 2012 and payable in March 2013)

£1,149,909£693,799£230,205

Multi-year incentives granted*

ESOSMarket value options over 198,836 PLC and 139,742 NV ordinary sharesn/aMarket value options over 67,331 PLC and 48,018 NV ordinary shares
BIP68,475 NV ADRs90,987 PLC and 21,028 NV ordinary sharesn/a
PSPn/an/a179,551 PLC shares

Shareholding requirement

300% of salary200% of salary200% of salary

*No multi-year incentives vested in 2012. Multi-year incentives from previous years lapsed in early 2012 as already described in last year’s Report.

**Mark Armour served as a director until December 31, 2012.

***Additional awards were made to Duncan Palmer in conjunction with his recruitment. Further details are contained on pages 52 and 53.

Base Salary

Salary reflects the role and the sustained value of the executive in terms of skills, experience and contribution in the context of the relevant market.

Salaries for executive directors are reviewed annually in the context of the competitiveness of total remuneration and Reed Elsevier’s guidelines for wages and salaries agreed for the whole of Reed Elsevier for the forthcoming financial year. Any increases typically take effect on January 1.

The Committee decided to award a salary increase of 2.5% to Erik Engstrom, which increased his base salary with effect from January 1, 2013 to £1,076,891. Duncan Palmer’s service agreement provides that his first salary review following commencement of employment would be on or around January 1, 2014, so his base salary remains unchanged for 2013. In determining the salary recommendation for the CEO, the Committee considered, among other inputs, 2013 salary guidance for Reed Elsevier’s most significant employee locations globally. The increase awarded to the CEO is within the guidelines agreed for those employees in respect of 2013 increases.

In respect of salaries for the broader employee population, Reed Elsevier uses the same factors to determine the levels of increase across all employee populations globally: i.e. relevant pay market, skills, experience and contribution. Reed Elsevier operates across many diverse countries in terms of their remuneration structures and practices. Any increases awarded to different employee groups in different geographies reflect this diversity and range of practices. An average increase of approximately 2.5% will be awarded across the senior management population globally for 2013. This level of increase is in line with increases provided to the wider employee population.

Annual Incentive

The Annual Incentive Plan (AIP) provides focus on the delivery of stretching annual financial targets and the achievement of annual objectives and milestones that create a platform for sustainable future performance.

For 2013, executive directors have a target bonus opportunity of 100% of salary that is weighted as follows across four elements (unchanged from 2012):

Measure

Weighting

— Revenue

30%

— Adjusted Profit After Tax

30%

— Cash Flow Conversion Rate

10%

— Key Performance Objectives (KPOs)

30%

The target bonus opportunity for the financial measures is payable for the achievement of highly stretching financial targets. The four elements are measured separately, such that there could be a payout on one element and not on others.

For 2013, the minimum threshold on the financial elements of the AIP at which a bonus starts to accrue is 94% of target and the maximum bonus is 150% of target (unchanged from 2012).

The KPOs are individual to each executive director. Each executive director is set up to six KPOs to reflect critical business priorities for which he is accountable. The KPO component for the executive directors and other senior executives will contain at least one KPO relating to the achievement of specific sustainability objectives and targets contained within Reed Elsevier’s corporate responsibility agenda.

Against each objective, measurable milestone targets are set for the year. All financial targets and KPOs are approved by the Committee and are subject to formal assessment at the end of each year. The Chairman of Reed Elsevier Group plc presents his assessment of performance against KPOs for the CEO of Reed Elsevier Group plc to the Committee while the CEO of Reed Elsevier Group plc presents his assessment of KPO performance for the CFO of Reed Elsevier Group plc. The Committee then discusses and agrees the final KPO score for each executive director.

AIP Payments for 2012

In assessing the level of bonus payments for 2012, the Committee noted the following performances:

% change over 2011 at constant
exchange rates
Underlying
revenue
Total
adjusted PAT

Reed Elsevier

+4%+8%

Reed Elsevier executed well on its strategic and financial priorities in 2012. Positive revenue momentum and focus on operating efficiency combined to lift underlying operating profit growth and earnings. Underlying revenues, which exclude the effects of currency translation and acquisitions and disposals, were up 4%, or 3% excluding the cycling effect of biennial exhibitions, and all five business areas contributed to the underlying growth. Underlying adjusted operating profits were up 6%, with the improvement in profitability driven by a combination of process innovation and portfolio development across all business areas. Underlying costs were up 4%, reflecting volume growth as well as organic investment in new product development and sales & marketing, partly offset by continued improvements in process efficiency. Adjusted operating cash flow was £1,603m (2011: £1,515m), up 6% compared with the prior year and up 7% at constant currencies. The rate of conversion of adjusted operating profits into cash flow was 94% (2011: 93%). Returns on invested capital increased to 11.9%, 0.7 percentage points higher than in 2011, reflecting the improved trading performance and capital efficiency.

Set out below is a summary of the outcome of performance against each financial measure:

Revenue

Just above target

Adjusted Profit After Tax

Just above target

Cash Flow Conversion Rate

Just above target

The progress on personal objectives for each director was then added in the form of the KPO score and, overall, the sum of the scores achieved against the four AIP components for the executive directors, resulted in the following bonuses for 2012:

2012 annual bonus
(to be paid in March 2013)
% of
2012 base
salary earnings

Erik Engstrom

£1,149,909109.5%

Mark Armour

£693,799107.7%

Duncan Palmer*

£230,205107.7%

*DuncanPalmer’s bonus reflects service during the year of reporting. His service commenced on August 24, 2012.

Multi-Year Incentives

It is intended to continue to provide executive directors with multi-year incentives comprising a combination of a long-term incentive plan (LTIP), a personal investment bonus deferral plan (BIP) and market value options (ESOS). To this end, a new LTIP and ESOS are proposed and will be presented for shareholder approval at the 2013 Annual General Meetings (AGMs).

The purpose of the multi-year incentives is to provide focus on the delivery of the medium to longer-term strategy and holding executives accountable for the execution of that strategy while driving value creation through sustained financial performance, capital discipline and the delivery of returns for shareholders.

In addition, the multi-year incentives are structured so as to encourage personal investment and require a minimum level of ongoing shareholding in Reed Elsevier securities among the senior executive population in order to promote alignment with shareholders and to provide focus on the share price.

Awards under the current and proposed multi-year incentives vest over a period of three years, except for the one-off REGP under which awards vest over three and five years. The vesting of all awards made to executive directors under these plans is subject to meeting a number of stretching performance targets based on internal financial metrics and total shareholder return.

Reed Elsevier Growth Plan (REGP)

The details of how the REGP operates have been disclosed in previous years’ Reports.

Performance measures and targets

Total Shareholder Return (TSR)

The vesting of one third of the REGP award is subject to Reed Elsevier’s TSR performance compared against three comparator groups (the TSR tranche).

As Reed Elsevier accesses equity capital markets through three exchanges — London, Amsterdam and New York — in three separate currency zones, three distinct comparator groups are used — a Sterling Comparator Group, a Euro Comparator Group and a US Dollar Comparator Group. The TSR performance of Reed Elsevier PLC ordinary shares (based on the

London listing) is measured against the Sterling Comparator Group; the TSR performance of Reed Elsevier NV ordinary shares (based on the Amsterdam listing) is measured against the Euro Comparator Group; and the TSR performance of Reed Elsevier PLC ADRs and Reed Elsevier NV ADRs (based on the New York listing) is measured against the US Dollar Comparator Group. The averaging period applied for TSR measurement purposes is six months prior to the start of the financial year in which the award was made and the final six months of the last financial year of the performance period.

TSR performance of each security is measured separately against each comparator group and the proportion of the TSR tranche that vests is the sum of the payouts achieved against the three comparator groups.

Vesting is on a straight-line basis for ranking between the median and the upper quartile.

TSR comparators groups

The constituents of each comparator group were selected on a specific basis, as described in last year’s Report (page 49).

The comparators which were included in each currency group are set on page 50 of last year’s Report.

Return on invested capital (ROIC)

The vesting of one third of the REGP award is subject to the percentage return on invested capital of Reed Elsevier PLC and Reed Elsevier NV (the ROIC tranche) as follows:

3 years: 2010-12

  2 years: 2013-14  Vesting percentage
of ROIC tranche

ROIC in 2012

subject to actual

exceeding 2009

ROIC calculated on

the same basis

  ROIC in 2014   

Below 10.2%

  Below 10.7%  0%

10.2%

  10.7%  60%

11.2% or above

  12.7% or above  100%

Vesting is on a straight-line basis for performance between the minimum and maximum levels. For the purposes of the plan, the following definitions apply:

Invested capital = arithmetic average of the opening and closing capital employed for the Reed Elsevier combined businesses for the financial year with all cumulative amortisation and impairment charges for acquired intangible assets and goodwill added back. In addition, any exceptional restructuring and acquisition integration charges (net of tax) are capitalised for these purposes and changes in exchange rates and movements in pension deficits are excluded.

Return = adjusted operating profit for the Reed Elsevier combined businesses before amortisation and impairment of acquired intangible assets and goodwill, exceptional restructuring and acquisition integration charges. In addition, it is grossed up to exclude the equity share of taxes in joint ventures and further adjusted to exclude net pension financing credit movement, after applying the effective rate of tax used for adjusted earnings calculations and using exchange rates to match those used in the calculation of invested capital.

In order to ensure that the performance score achieved is a fair reflection of underlying business performance, the Committee retains discretion to determine the treatment of major disposals and acquisitions that require board approval. Any significant adjustments made to the final performance score will be disclosed to shareholders.

Adjusted earnings per share (EPS)

The vesting of one third of the REGP award is subject to performance against growth in adjusted earnings per share measured at constant currencies (Adjusted EPS) (the EPS tranche) as follows:

3 years: 2010-12

2 years: 2013-14Vesting percentage
of EPS tranche

Average Adjusted EPS

growth in years 2011 and

2012 (subject to average Adjusted EPS growth over the whole three year period being positive)

Average Adjusted EPS

growth over

the two year period

Below 5% p.a.

Below 7% p.a.0%

5% p.a.

7% p.a.60%

9% p.a. or above

13% p.a. or above100%

Vesting is on a straight-line basis for performance between the minimum and maximum levels. For the purposes of the plan, the following definitions apply:

Earnings = adjusted reported earnings measured at constant currencies. Adjustments include amortisation and impairment of acquired intangible assets and goodwill, exceptional restructuring and acquisition integration charges, gains/losses on business disposals and tax rate anomalies (deferred tax). The Committee retains discretion to adjust for changes in the net pension financing credit.

Number of shares = weighted average number of shares in issue excluding shares held in treasury.

Performance share awards were granted under the REGP to Mr Engstrom and Mr Armour in May 2010. At its meeting on April 25, 2013, the Committee will assess the extent to which the performance conditions have been met for these share awards, which includes an overall assessment of underlying business performance and other relevant factors. Based on a review of the three performance measures used in the plan, preliminary calculations indicate that 66.8% of the awards are expected to vest. This is based on a TSR ranking of just above median in respect of two of the comparator groups, ROIC achievement slightly below the 11.2% maximum after taking into account adjustments for such items as foreign exchange rates, pension deficits and acquisition integration costs as provided in the plan, and EPS growth slightly above the middle of the range specified in the plan.

This would result in 429,710 PLC ordinary shares and 282,187 NV ordinary shares vesting in respect of Erik Engstrom. 50% of these shares will be released to Mr Engstrom following the April Committee meeting and 50% of these shares will be deferred until 2015. In respect of Mr Armour, under the terms of the plan relating to retirement, 100% of the shares vesting will be released to him following the April Committee meeting. In accordance with the preliminary vesting calculations, this will result in 263,601 PLC ordinary shares and 173,105 NV ordinary shares being released to Mr Armour. Thereafter, Mr Armour will have no further entitlement for payment under this plan. Dividend equivalents will be payable in cash on any shares released which, based on the preliminary calculations, would result in payments of £135,251 and €179,329 to Mr Engstrom and £165,937 and €220,016 to Mr Armour.

Long-Term Incentive Plan (LTIP)

No awards under LTIP were made to executive directors in 2012 and no award cycles remain outstanding for directors under this plan.

A long-term incentive award was granted to senior leaders below the Board in 2012. Grants are made on a rolling three year basis in the form of performance shares that vest subject to performance metrics and vesting scales consistent with the REGP. The targets set for each metric are aligned to the five-year performance scale applicable to the executive directors under the REGP.

Subject to receipt of shareholder approval at the 2013 Annual General Meetings, it is intended to commence making annual grants under a new long-term incentive plan to executive directors from 2013 onwards, under which the first awards would vest in H1 2016, which is the year after the vesting of the second and final tranche of the REGP for the CEO, so there will be no overlapping payouts. The LTIP was required by the need to replace the one-off REGP incentive plan for directors with a more regular long-term.

Details of the proposed new LTIP are described in the 2013 notices of Annual General Meetings of Reed Elsevier PLC and Reed Elsevier NV.

Executive Share Option Scheme (ESOS)

The current ESOS, which was approved by shareholders in 2003, expires on April 8, 2013. A replacement ESOS, for which we are seeking shareholder approval at the Annual General Meetings in April 2013, is described in the notices of Annual General Meetings and it is intended to make grants under this plan to the executive directors in 2013. It is not intended to make any further grants under the existing ESOS, the key features of which were described in last year’s Report on page 52.

During 2012, Erik Engstrom received a grant of 200% of base salary of market value options (two-thirds of the permitted maximum). On joining, Duncan Palmer received a grant of 135% of salary. The vesting of the options is subject to an Adjusted EPS growth hurdle of 6% p.a. compound growth in adjusted earnings per share hurdle, measured over a three year period commencing on January 1 of the year of grant (the same condition also applies to the 2011 ESOS grants which were made to Erik Engstrom and Mark Armour). In view of his retirement at the end of 2012, Mr Armour did not receive an ESOS grant in 2012.

Early in 2012, as disclosed in last year’s Report, the 2009-11 cycle of ESOS lapsed for Erik Engstrom and Mark Armour.

Bonus Investment Plan (BIP)

The BIP is a voluntary plan aimed at encouraging personal investment in, and ongoing holding of, Reed Elsevier shares to promote greater alignment with shareholders and support the retention of key talent.

Under the BIP, participants may invest their own funds to purchase Reed Elsevier securities or allocate securities already owned outright for investment under the plan up to a specified maximum. In return, the participant is granted a matching award which vests over three years subject to performance (i.e. a maximum match of 1 for 1 can be earned on the personal investment). It is a condition of vesting that the underlying personal investment is retained throughout the vesting period. Dividend equivalents accrue on the matching shares during the vesting period and are paid out in cash at the end to the extent that the matching award vests. The table below summarises the key features of the BIP.

Feature

Detail

Frequency of award

Annual grants of matching awards
Ten-year life of the plan
Implemented in 2010

Eligibility

Approximately 150 senior executives including executive directors
Participation is voluntary

Performance period

Three financial years

Performance conditions

Average adjusted EPS growth measured in constant currencies and ROIC (see below)
50% of the award is subject to adjusted EPS growth and 50% subject to ROIC

Vesting scale

Performance hurdle and straight-line vesting

Personal investment

Up to 100% of the target bonus opportunity net of tax

Other provisions

On a change of control, awards vest on a pro-rated basis for service and subject to performance based on an assessment of progress against targets at the time the change of control occurs, unless the Committee determines that awards should not vest and instead be exchanged for equivalent awards over shares in the acquiring company (i.e. rollover applies)
Claw-back applies
Awards under the plan are satisfied with shares purchased in the market

The following targets and vesting scale apply to awards granted under the BIP in 2012:

Match earned on personal investment

  

Average growth in adjusted EPS (%)
over the 3 year performance period

  ROIC (%) in the third year of
the performance period

0%

  below 4% p.a.  below 11%

50%

  4% p.a.  11%

75%

  6.5% p.a.  11.5%

100%

  9% p.a. or above  12% or above

Awards were granted under the BIP to Mr Engstrom and Mr Armour in May 2010. At its meeting on April 25, 2013, in much the same way as for the REGP, the Committee will assess the extent to which the performance conditions have been met for these awards, which includes an overall assessment of underlying business performance and other relevant factors.

Based on a review of the two performance measures used in the plan, preliminary calculations indicate that 89.5% of the awards are expected to vest. This is based on ROIC achievement slightly below the 11.2% maximum after taking into account adjustments for such items as foreign exchange rates, pension deficits and restructuring costs as provided in the plan, and EPS growth just below the 70th percentile of the target range specified in the plan.

This would result in the vesting of 62,819 NV ADR matching awards in respect of Mr Engstrom and a corresponding cash dividend equivalent payment of $178,181. In respect of Mr Armour, 58,223 PLC ordinary shares and 38,048 NV ordinary shares would be released, with corresponding dividend equivalent payments of £36,651 and €48,359 respectively.

Shareholding requirement

The Committee believes that one of the aspects that creates closer alignment between senior management and shareholders is to require executives to build up and maintain a significant personal stake in Reed Elsevier. The shareholding requirements applicable to the executive directors are set out in the table below and as described on page 47, were pre-requisites to participate in the REGP. Shareholding requirements also apply to selected senior executives below the Board.

Meeting the relevant shareholding requirement is both a condition of the vesting of awards as well as a pre-requisite to maintain eligibility to receive future awards under the multi-year incentives.

On December 31, 2012, the executive directors’ shareholdings were as follows (valued at the mid-market closing prices of Reed Elsevier securities):

   Shareholding requirement
(in % of December 31, 2012
annualised base salary)
 Actual shareholding as at
December 31, 2012 (in %
of December 31, 2012
annualised base salary)

Erik Engstrom

  300% 512%

Mark Armour

  200% 442%

Duncan Palmer*

  200% 0%

*Duncan Palmer has until December 31, 2015 to build up to his required level of shareholding and must retain any net shares earned from Reed Elsevier share plans until he meets his requirement.

Retirement benefits

Retirement benefit provisions are set in the context of the total remuneration for each executive director, taking account of age and service and against the background of evolving legislation and practice in Reed Elsevier’s major countries of operation. Base salary is the only pensionable element of remuneration.

Erik Engstrom is provided with UK defined benefit pension arrangements under which he accrues a pension of 1/30th of salary for every year of service (up to a maximum of two thirds of salary). The pension is provided through a combination of:

the main UK Reed Elsevier Pension Scheme for salary restricted to the Scheme Earnings Cap (determined annually on the same basis as the pre-April 2006 Inland Revenue earnings cap) and HMRC Annual Allowance, and

Reed Elsevier’s unapproved pension arrangement for the balance.

Prior to November 1, 2007, Erik Engstrom was not a member of any company pension scheme and Reed Elsevier made annual contributions of 19.5% of his salary to his personal pension plan. From November 1, 2007 contributions to his designated retirement account ceased and he became a member of the UK defined benefit pension arrangement.

The pension arrangements for Erik Engstrom include life assurance cover while in employment, an entitlement to a pension in the event of ill health or disability and a spouse’s and/or dependants’ pension on death.

The increase in the transfer value of the directors’ pensions, after deduction of contributions, is shown in the table below. Transfer values have been calculated in accordance with the guidance note GN11 published by the UK Institute of Actuaries and Faculty of Actuaries. The transfer values at December 31, 2012 have been calculated using the transfer value basis adopted by the trustees of the Reed Elsevier Pension Scheme.

The transfer value in respect of individual directors represents a liability in respect of directors’ pension entitlement, and is not an amount paid or payable to the director.

Mark Armour retired on December 31, 2012, at which point he became entitled to a pension of £378,785 per annum.

Transfer values of accrued pension benefits

  Age at
December 31,
2012
  Director’s
contributions
  Transfer
value
of accrued
pension at
December 31,
2011
  Transfer
value
of accrued
pension at
December 31,
2012
  Increase in
transfer
value during
the year
(net of
director’s
contributions)
  Accrued
annual
pension at
December 31,
2012
  Increase
in

accrued
annual
pension
during
the year
  Increase
in

accrued
annual
pension
during
the year
(net of
inflation)
  Transfer
value at

December 31,
2012 of
increase
in accrued
pension
during the
year

(net of
inflation

and director’s
contributions)
 

Erik Engstrom

  49   £9,158   £2,099,132   £2,730,651   £622,361   £180,958   £38,584   £31,750   £469,944  

Mark Armour

  58   £1,944   £6,758,053   £7,525,908   £765,911   £384,878 £30,355   £13,362   £259,332  

*The reason for the difference between Mr Armour’s accrued annual pension as at 12.31.12, as stated in the table above, and the annual pension entitlement following retirement is that Mr Armour retired early so there was a reduction made to his accrued annual pension as at 12.31.12.

Duncan Palmer Towers Watson is a member of the UK Reed Elsevier defined contribution pension plan (the Reed Elsevier Pension Plan — REPP). The company contribution is 19% of Mr Palmer’s salary. £50,000 is paid as a contribution to the REPP, being the maximum contribution which can be made under HMRC limits,Remuneration Consultants’ Group and the balance is paid to him as a cash allowance, subject to deduction of income tax and national insurance. The pension arrangement for Mr Palmer includes life assurance cover whileconducts its work in employment.

Service contracts

Executive directors are employed under service contracts that provide for a maximum of one year’s notice. The contracts neither specify a pre-determined level of severance payment nor contain specific provisions in respect of a change in control. The Committee believes that as a general rule, notice periods should be 12 months and that the executive directors should, subject to any legal constraints within their base country, be required to mitigate their losses in the event of termination. The Committee will, however, note local market conditions so as to ensure that the terms offered are appropriate to attract and retain top executives operating in global businesses.

The contractual terms of the executive directors (and for approximately 100 other senior executives) include certain covenants as follows:

non-competition restrictions apply which prevent the executive from working in a capacity which competes with any Reed Elsevier business which he/she was involved with during the preceding 12 months; from recruiting Reed Elsevier employees and from soliciting Reed Elsevier customers and suppliers for a period of 12 months after leaving employment;

in the event of the executive resigning, he/she will immediately lose all rights to any outstanding awards under the multi-year incentives including any vested but unexercised options; and

in the event of a breach of the covenants, any gains made or payouts received, in the period starting six months prior to and ending 12 months after leaving employment, on the vesting or exercise of awards from the multi-year incentives may be repayable.

Each executive director has a service contract with Reed Elsevier Group plc, as summarised in the table below:

Current
contract date

Date
employment
commenced

Expiry date

(subject to notice
period)

Notice periodSubject to

Erik Engstrom

March 14, 2011August 23, 2004June 14, 202812 monthsEnglish law

Mark Amour

October 7, 1996February 1, 1995Ceased to be a director and retired on December 31, 201212 monthsEnglish law

Duncan Palmer

August 15, 2012August 24, 2012n/a12 monthsEnglish law

Duncan Palmer’s remuneration arrangements

Duncan Palmer’s annual base salary on his recruitment was £600,000 and he has an annual target bonus opportunity of 100% of base salary. He will be eligible to participate in BIP from 2013 onwards up to his target bonus opportunity net of tax and to participate in the ESOS and LTIP, subject to shareholders approving those plans. He will receive annual pension contributions equal to 19% of salary and benefits in accordanceline with the policies applicable toUK Code of Conduct for executive directors.

In addition, in September 2012, he was granted the following awards:

A market value option under ESOS to acquire shares with a face value on the date of grant of 135% of base salary, which vests on the 3rd anniversary of grant subject to achieving at least 6% p.a. compound growth in adjusted EPS over the performance period from January 1, 2012 to December 31, 2014.

Performance shares (PSP) with an aggregate face value of 180% of base salary, which are subject to the same performance targets as will apply to any matching award that may be granted to the CEO under the REGP in 2013, with performance being assessed in the first half of 2015. The award is non-pensionable and carries a right to receive dividend equivalents (calculated on the same basis as under the REGP). The leaver rules are consistent with those which apply under the REGP with the exception that “retirement with the consent of the company” is not automatically treated as an approved leaver reason for the performance share award.

Restricted shares (RSP) with an aggregate face value of 250% of base salary, which vest 50% in 2014 and 50% in 2015 provided all unvested stock-based awards granted to him by his previous employer lapse. This one-off grant of restricted shares was made to compensate Mr Palmer for the forfeiture of awards from his former employer. They are subject to a time pro-rated claw-back if he resigns, or is summarily terminated, before the date of the announcement of the 2014 annual results in 2015.

The Committee considered the grant of performance shares and restricted shares noted above to have been essential to secure Duncan Palmer’s services. The Committee was satisfied that the awards are appropriate and align his interests with those of shareholders. Both awards fall within paragraph 9.4.2(2)R of the UK Listing Rules and were granted over Reed Elsevier PLC ordinary shares but half of each award will be settled on vesting with Reed Elsevier NV ordinary shares. The awards cannot be amended to the advantage of Duncan Palmer without shareholder approval and the documentation governing these awards will be available for inspection from the date of the notices of theremuneration consulting. During 2013, Annual General Meetings up to and including the meetings themselves.

In recognition of Mr Palmer and his family having to relocate to the UK in order for him to take up his new position, he will receive a one-off cash relocation allowance of £500,000 in May 2013 (subject to a time pro-rated claw-back if he resigns or is summarily terminated prior to December 31, 2014) and relocation support under the standard Reed Elsevier Policy.

Mark Armour’s retirement terms

Mark Armour’s retirement terms were disclosed in last year’s Report (page 55).

Policy on external appointments

The Committee believes that the experience gained by allowing executive directors to serve as non-executive directors on the boards of other organisations is of benefit to Reed Elsevier. Accordingly, executive directors may, subject to the approval of the Chairman and the Chief Executive Officer, serve as non-executive directors on the boards of up to two non-associated companies (of which only one may be to the board of a major company) and they may retain remuneration arising from such appointments.

Mark Armour is a non-executive director of SABMiller plc and received remuneration of £106,250 during 2012 (£100,694 during 2011). He is also a non-executive director of the Financial Reporting Council (FRC) and received remuneration of £12,500 since commencing his appointment on July 2, 2012.

Duncan Palmer is a non-executive director of Oshkosh Corporation andTowers Watson received fees of £15,487 since his appointment as a director of Reed Elsevier PLC up£58,172 for advice given to the end of 2012.

NON-EXECUTIVE DIRECTORS

Policy on non-executive directors’ fees

The policy on non-executive directors’ fees is a matter for the Boards, subject to applicable law, and does not fall within the Committee’s remit.

Reed Elsevier seeks to recruit non-executive directors with the experience to contribute to the Boards of a dual-listed global business and with a balance of personal skills that will make a major contribution to the Boards and their committee structures. With the exception of Marike van Lier Lels who serves only on the Supervisory Board of Reed Elsevier NV, non-executive directors, including the Chairman, are appointed to the Boards of Reed Elsevier Group plc, Reed Elsevier PLC and the Supervisory Board of Reed Elsevier NV. Non-executive directors’ fees reflect the directors’ membership of the three Boards.

The primary source for comparative market data is the practice of FTSE 50 companies, although reference is also made to NYSE Euronext Amsterdam (AEX) Index and US listed companies.

Non-executive directors, including the Chairman, serve under letters of appointment and are not entitled to notice of, or payments following, retirement from the Boards.

Fee levels

Non-executive directors receive an annual fee in respect of their memberships of the Boards of Reed Elsevier PLC, Reed Elsevier NV and Reed Elsevier Group plc. The fee paid to Marike van Lier Lels, who serves only on the Supervisory Board of Reed Elsevier NV, reflects her time commitment to that company and to other companies within the Reed Elsevier combined businesses. Non-executive directors are reimbursed for expenses incurred in attending meetings. They do not receive any performance-related bonuses, pension provision, share options or other forms of benefit except for the following: the Chairman is in receipt of private medical benefit and non-executive directors and the Chairman are provided with tax filing support to meet any tax filing obligations arising from their directorships with Reed Elsevier in countries other than their home country.

Fees may be reviewed annually, although in practice they have changedCommittee, charged on a less frequenttime and expense basis. The last fee review was during 2011 and the current fee arrangements took effect on January 1, 2012.

The fees for 2013 are unchanged from 2012 and are set out below.

Annual fee 2013

Chairman

£550,000

Non-executive directors

£65,000/€80,000

Senior Independent Director

£20,000

Chairman of:

— Audit Committee

£25,000/€30,000

— Remuneration Committee

£20,000

The total annual fee payable to Marike van Lier Lels is €65,000 (unchanged from 2012). The Chairman of Reed Elsevier does not receive committee chairman fees.

Directors’ emoluments and fees

(a)Aggregate emoluments

The emoluments of the directors of Reed Elsevier PLC and Reed Elsevier NV (including any entitlement to fees or emoluments from either Reed Elsevier Group plc or Elsevier Reed Finance BV) were as follows:

   2012
£
   2011
£
 
   £’000   £’000 

Salaries and fees

   2,972     2,590  

Benefits

   89     56  

Annual performance-related bonuses

   2,074     1,634  

Pension contributions

   44     42  
  

 

 

   

 

 

 

Total

   5,179     4,322  
  

 

 

   

 

 

 

(b)Individual emoluments of executive directors

   Salary
£
   Benefits
£
   Bonus
£
   Total
2012
£
   Total
2011

£
 

Erik Engstrom

   1,050,625     28,396     1,149,909     2,228,930     2,075,417  

Mark Armour

   644,495     23,984     693,799     1,362,278     1,263,563  

Duncan Palmer*

   213,846     32,878     230,205     476,929     n/a  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

   1,908,966     85,258     2,073,913     4,068,137     3,338,980  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

*The benefits figure for Duncan Palmer includes the balance of his company pension contribution which is paid to him as a cash allowance, as detailed under the Retirement Benefits section on pages 51 and 52 which, for 2012, was £22,810.

Market value options awarded under ESOS and restricted shares awarded in the year of reporting under BIP are set out by executive director on pages 59 to 61. Vesting is subject to performance conditions relating to growth in adjusted EPS and ROIC, as described in the front section of this Report. The maximum number of options that can vest under ESOS and the maximum number of restricted shares that can vest under the BIP is equivalent to the awards granted. The maximum number of shares which can vest under the September 2012 grants of performance share awards and restricted share awards to Duncan Palmer is equivalent to the awards granted. Erik Engstrom was the highest paid director in 2012.

(c)Individual fees of non-executive directors

   2012
£*
  2011
£*
 

Mark Elliott

   85,000    70,000  

Anthony Habgood

   550,000**   500,000** 

Adrian Hennah (from April 20, 2011)

   65,000    38,475  

Lisa Hook

   65,000    55,000  

Marike van Lier Lels

   52,846***   41,739  

Robert Polet

   65,000    55,000  

Sir David Reid

   85,000    75,000  

Lord Sharman (until April 20, 2011)

       18,333  

Linda Sanford (from December 4, 2012)

   5,416      

Ben van der Veer

   89,431***   82,609  
  

 

 

  

 

 

 

Total

   1,062,693    936,156  
  

 

 

  

 

 

 

*The above figures exclude an imputed notional benefit in respect of tax filing support provided to non-executive directors for tax filings in countries other than their home country resulting from the directorship with Reed Elsevier. The incremental assessable benefit charge per relevant tax return has been agreed by PwC to amount to £300.
**Excludes private medical insurance benefit of £1,389 in respect of 2012 (£1,329 in 2011).
***The fees for Marike van Lier Lels and Ben van der Veer are paid in euro and were €65,000 and €110,000 respectively for 2012 (€48,000 and €95,000 respectively for 2011). For reporting purposes these were converted into pounds sterling at the average exchange rate for the year of reporting.

Compensation of executive officers

The aggregate compensation (salary, annual incentive, benefits and pension) paid during 20122013 (and relating to 2012)2013) to those who were executive officers (other than directors)Directors) of Reed Elsevier Group plc as at February 27, 2013 as a group26, 2014 for the year ended December 31, 20122013 was £2,331,660£2,394,162, which included contributions made to the pension plans in respect of such officers of £84,882.£112,255.

BOARD PRACTICES

REED ELSEVIER

The Boards of directorsDirectors of Reed Elsevier PLC and Reed Elsevier NV manage their respective shareholdings in Reed Elsevier Group plc and Elsevier Reed Finance BV. The Boards of Reed Elsevier PLC, Reed Elsevier NV and Reed Elsevier Group plc are harmonised. All of the Directors of Reed Elsevier Group plc are also Directors of Reed Elsevier PLC and Reed Elsevier NV. Reed Elsevier NV may nominate for appointment up to two Non-Executive Directors who are not appointed to the Boards of either Reed Elsevier PLC or Reed Elsevier Group plc. Currently, one such Director has been appointed to the Board of Reed Elsevier NV. Subject to shareholders of Reed Elsevier PLC and Reed Elsevier NV re-electing retiring directorsDirectors at their respective Annual General Meetings in 2013,2014, all the directorsDirectors of Reed Elsevier Group plc will also be directorsDirectors of Reed Elsevier PLC and of Reed Elsevier NV. For a complete description of the Board membership positions and executive officer positions within Reed Elsevier, see “— Directors” and “Senior Management” on pages 4045 to 42.47. Details of the Audit Committees of Reed Elsevier Group plc, Reed Elsevier PLC and Reed Elsevier NV are given under “Item 15: Controls and Procedures” and details of the Remuneration Committee are given under “— Remuneration Committee”“Directors” on page 42.45.

REED ELSEVIER GROUP PLC

The Reed Elsevier Group plc Board currently consists of two executive directorsExecutive Directors and eight non-executive directors.seven Non-Executive Directors. A person may only be appointed or proposed or recommended for appointment to the Board if that person has been nominated for that appointment by the joint Nominations Committee of Reed Elsevier PLC and Reed Elsevier NV. Persons nominated by the joint Nominations Committee will be required to be approved by the Reed Elsevier Group plc Board, prior to appointment to the Reed Elsevier Group plc Board.

Decisions of the Board of directorsDirectors of Reed Elsevier Group plc require a simple majority, and the quorum required for meetings of the Board of Reed Elsevier Group plc is any two directors.Directors.

The Reed Elsevier Group plc Board has established the following committees:Committees:

 

  

Audit — currently comprising fourthree independent non-executive directorsNon-Executive Directors; and

 

  

Remuneration — currently comprising fourthree independent non-executive directorsNon-Executive Directors and the Chairman of Reed Elsevier Group plcplc.

Arrangements established at the time of the merger of Reed Elsevier PLC’s and Reed Elsevier NV’s businesses provide that, if any person (together with persons acting in concert with him) acquires shares, or control of the voting rights attaching to shares, carrying more than 50% of the votes ordinarily exercisable at a general meeting of Reed Elsevier PLC or Reed Elsevier NV and has not made a comparable takeover offer for the other party, the other party may by notice suspend or modify the operation of certain provisions of the merger arrangements, such as (i) the right of the party in which control has been acquired (the “Acquired Party”) to appoint or remove directors of Reed Elsevier PLC, Reed Elsevier NV and Reed Elsevier Group plc and (ii) the Standstill Obligations (defined below) in relation to the Acquired Party. Such a notice will cease to apply if the person acquiring control makes a comparable offer for all the equity securities of the other within a specified period or if the person (and persons acting in concert with him) ceases to have control of the other.

In the event of a change of control of one parent company and not the other (where there has been no comparable offer for the other), the parent company which has not suffered the change in control will effectively have the sole right to remove and appoint directors of Reed Elsevier Group plc. Also, a director removed from the Board of a parent company which has suffered a change in control will not have to resign from the Board of the other parent company or Reed Elsevier Group plc.

The Articlesarticles of Associationassociation of Reed Elsevier Group plc contain certain restrictions on the transfer of shares in Reed Elsevier Group plc. In addition, pursuant to arrangements established at the time of the merger, neither Reed Elsevier PLC nor Reed Elsevier NV may acquire or dispose of any interest in the share capital of the other or otherwise take any action to acquire the other without the prior approval of the other (the “Standstill Obligations”). The Panel on Takeovers and Mergers in the United Kingdom (the “Panel”) has stated that in the event of a change of statutory control of either Reed Elsevier PLC or Reed Elsevier NV, the person or persons acquiring such control will be required to make an offer to acquire the share capital of Reed Elsevier Group plc (but not Elsevier Reed Finance BV) held by the other, in accordance with the requirements of the City Code on Take-oversTakeovers and Mergers in the United Kingdom. This requirement would not apply if the person acquiring statutory control of either Reed Elsevier PLC or Reed Elsevier NV made an offer for the other on terms which are considered by the Panel to be appropriate.

REED ELSEVIER PLC

The Reed Elsevier PLC Board currently consists of two executive directorsExecutive Directors and eight non-executive directors.seven Non-Executive Directors. A person may only be appointed or proposed or recommended for appointment to the Board if that person has been nominated for that appointment by the joint Nominations Committee of Reed Elsevier PLC and Reed Elsevier NV. Persons nominated by

the joint Nominations Committee will be required to be approved by the Reed Elsevier PLC Board, prior to the appointment to the Reed Elsevier PLC Board. A copy of the terms of reference of the Nominations Committee is available on request and can

be viewed on the Reed Elsevier website, www.reedelsevier.com. The information on our website is not incorporated by reference into this report. The joint Nominations Committee currently comprises five non-executive directors.

Notwithstanding the provisions outlined above in relation to the appointment to the Board, Reed Elsevier PLC shareholders retain their rights under Reed Elsevier PLC’s Articlesarticles of Associationassociation to appoint directorsDirectors to the Reed Elsevier PLC Board by ordinary resolution. Reed Elsevier PLC shareholders may also, by ordinary resolution, remove a directorDirector from the Board of Reed Elsevier PLC, and in such circumstances that directorDirector will also be required to be removed or resign from the Boards of Reed Elsevier NV and Reed Elsevier Group plc (except in circumstances where there has been a change of control of Reed Elsevier PLC and not Reed Elsevier NV).

The Reed Elsevier PLC Board has also established the following committees:Committees:

 

  

Audit — currently comprising fourthree independent non-executive directors; andNon-Executive Directors;

 

  

Corporate Governance — a joint committeeCommittee of Reed Elsevier PLC and Reed Elsevier NV, comprising all non-executive directorsNon-Executive Directors of each company; and

Nominations — a joint Committee of Reed Elsevier PLC and membersReed Elsevier NV, currently comprising threeNon-Executive Directors of the Supervisory Board including the Chairman of Reed Elsevier NV.the Board.

Reed Elsevier Group plc has established a Remuneration Committee, which is responsible for determining the remuneration policy (subject to shareholder approval) and monitoring its implementation for the executive directorsExecutive Directors of Reed Elsevier PLC and Reed Elsevier Group plc, and considering the remuneration for the Executive Directors of Reed Elsevier NV.

Under the Articlesarticles of Associationassociation of Reed Elsevier PLC, one third of the directorsDirectors shall retire from office and, if they wish, make themselves available for re-appointmentre-election by shareholders at the Annual General Meeting. Notwithstanding these provisions in the Articlesarticles of Association,association, in accordance with the provisions of the UK Corporate Governance Code all directorsDirectors normally retire and offer themselves for re-election at each Annual General Meeting.

REED ELSEVIER NV

On April 24, 2013, the implementation of the unitary board governance structure at Reed Elsevier NV was approved by the Annual General Shareholders’ meeting. Subsequently, the articles of association of Reed Elsevier NV were amended by notarial deed on May 8, 2013 and the unitary board governance structure became effective. Reed Elsevier NV now has a two-tierunitary board structure currently comprising two executive directors (the “Executive Board”)both Executive and nine non-executive directors (the “Supervisory Board” and, together withNon-Executive Directors. At the same time, it was determined that Executive Board the “Combined Board”, all together referred to as the “Boards”). Membersmembers would become Executive Directors and members of the BoardsSupervisory Board would become Non-Executive Directors. The Board currently comprises two Executive Directors and eight Non-Executive Directors. Directors shall be appointed by the General Shareholders’ Meeting upon a proposal of the Combined BoardNon-Executive Directors based on a nomination for appointment by the joint Nominations Committee of Reed Elsevier NV and Reed Elsevier PLC. The Articlesarticles of Associationassociation of Reed Elsevier NV provide that a resolution of the General Shareholders’ Meeting to appoint a member of the BoardsDirector other than in accordance with a proposal of the Combined Board can only be taken by a majority of at least two-thirds of the votes cast if less than one-half of Reed Elsevier NV’s issued capital is represented at the meeting.

The General Shareholders’ Meeting of Reed Elsevier NV shareholders may also, by ordinary resolution, resolve to suspend or dismiss each member from the BoardsDirector of Reed Elsevier NV. In addition, each memberExecutive Director of the Executive Board can, at any time, be suspended by the Supervisory Board. In such circumstances that directorExecutive Director will also be required to be removed or resign from the Boards of Reed Elsevier PLC and Reed Elsevier Group plc (except in circumstances where there has been a change of control of Reed Elsevier NV and not Reed Elsevier PLC).

The Reed Elsevier NV Supervisory Board has established the following committees:

 

  

Audit — currently comprising four members of the Reed Elsevier NV Supervisory Board; andthree Non-Executive Directors;

 

  

Corporate Governance — a joint committeeCommittee of Reed Elsevier NV and Reed Elsevier PLC, comprising all members of the Supervisory Board and non-executive directorsNon-Executive Directors of each company.company; and

 

  

Nominations — a joint committeeCommittee of Reed Elsevier NV and Reed Elsevier PLC, currently comprising five members of the Supervisory Boardthree Non-Executive Directors including the Chairman of the Supervisory Board.

Reed Elsevier Group plc has established a Remuneration Committee, which is responsible for determiningconsidering the remuneration for the executive directorsExecutive Directors of Reed Elsevier NV, and determining the remuneration policy (subject to shareholder approval) and monitoring its implementation for the Executive Directors of Reed Elsevier Group plc and Reed Elsevier PLC.

Under the Articlesarticles of Associationassociation of Reed Elsevier NV, each membera Director of the Reed Elsevier NV Supervisory Boardshall retire no later than on the day on which the first General Meeting of Shareholders’ is appointed for a three-year term,held following the lapse of three years after his appointment, with

the possibility of reappointmentre-appointment and shall retire periodically in accordance with a rotation plan drawn up by the Combined Board. Notwithstanding these provisions in the Articlesarticles of Association,association, in accordance with the provisions of the UK Corporate Governance Code all members of the BoardsDirectors retire and seek re-appointment at each Annual General Meeting of Shareholders. To align the arrangements regarding appointment for the Boards of Reed Elsevier NV and Reed Elsevier PLC annual re-appointment shall not affect the term of their three-year appointment. A schedule with the anticipated dates of retirement of members of the Supervisory Board is published on the Reed Elsevier website, www.reedelsevier.com. As a general rule, members of the Supervisory BoardNon-Executive Directors serve for two three-year terms. The Nominations Committee may recommend that individual members of the Supervisory BoardNon-Executive Directors serve up to one additional three-year term.

The Combined Board A schedule with the anticipated dates of retirement of Directors is published on the Reed Elsevier NV has resolved to takewebsite, www.reedelsevier.com. A copy of the necessary steps to establish a one-tier governance structure atterms of reference of the Nominations Committee is available on request and can be viewed on the Reed Elsevier NV. Forwebsite. The information on our website is not incorporated by reference into this purpose the articles of association of Reed Elsevier NV will have to be amended and a proposal for the one-tier governance structure will be put to the Annual General Meeting of shareholders on April 24, 2013.report.

ELSEVIER REED FINANCE BV

Elsevier Reed Finance BV has a two-tier board structure comprising a Management Board, currently consisting of three members, and a Supervisory Board, currently consisting of four members. The members of the Management Board and of the Supervisory Board are appointed by the shareholders of Elsevier Reed Finance BV. The Articlesarticles of Associationassociation of Elsevier Reed Finance BV provide that certain material resolutions of the Management Board will require the approval of the Supervisory Board. At a meeting of the Supervisory Board valid resolutions can be taken with a simple majority if the majority of the members are present or represented. Pursuant to the Articlesarticles of Associationassociation of Elsevier Reed Finance BV, there are specific provisions governing the appointment and dismissal of managing directors and members of the Supervisory Board during periods when a notice of suspension as mentioned in the governing agreement between Reed Elsevier PLC and Reed Elsevier NV is in force. These provisions intend to neutralise the influence of a party which has acquired control over either Reed Elsevier PLC or Reed Elsevier NV without having also acquired control in the other.

EMPLOYEES

Employee numbers areThe number of people employed is disclosed in note 65 to the combined financial statements.

The Board of Reed Elsevier Group plc is fully committed to the concept of employee involvement and participation, and encourages each of its businesses to formulate its own tailor-made approach with the co-operation of employees. Reed Elsevier is an equal opportunity employer, and recruits and promotes employees on the basis of suitability for the job. Appropriate training and development opportunities are available to all employees. A code of ethics and business conduct applicable to employees within Reed Elsevier has been adopted throughout its businesses.

SHARE OWNERSHIP

Share based awards in Reed Elsevier PLC and Reed Elsevier NVMulti-year incentive interests

Details of vested options,(in italics)andAll outstanding unvested options and restricted shares held by executive directors in Reed Elsevier PLC (PLC) and Reed Elsevier NV (NV) as at December 31, 2012 are shownshare awards in the tables below. Any awards that have been described as lapsed in prior year Reports have been excluded. The shading in the tables denotes awards granted during the year of reporting. The vesting of outstanding unvested awards isbelow and on page 72 are subject to performance conditions, in accordance withexcept for the provisionsdeferred 50% of Erik Engstrom’s already performance-tested 2010 REGP performance share award (see page 51) and the respective plan rules.RSP award granted to Duncan Palmer on joining Reed Elsevier (see page 53). For disclosure purposes, any PLC and NV ADRs awarded under the BIP or the REGP have been converted into ordinary share equivalents. AtBetween December 31, 2013 and the date of this Reportannual report, there have been no changes in the options or restricted sharesshare awards held by executive directors in office at the date of this Report. The market price at the date of award of grants made under the multi-year incentives are based on the middle market price of the respective security.directors.

Erik Engstrom

 

Options

 Year of
grant
 

Option
over:

 No. of
options
held on
Jan 1,
2012
 No. of
options
granted
during
2012
 Option
price
 No. of
options
exercised
during
2012
 Market
price per
share at
exercise
 Gross
gains
made on
exercise
£/€
 No. of
options
held on
Dec 31,
2012
 Unvested
options
vesting on:
 Options
exercisable
until:
   Year of
grant
   Type of
security
  No. of
options
held on
Jan 1,
2013
   No. of
options
granted
during
2013
   Option
price
   No. of
options
exercised
during
2013
   Market
price per
share at
exercise
   No. of
options
held on
Dec 31,
2013
   Unvested
options
vesting on
   Options
exercisable
until
 

ESOS

 2004 PLC ord  63,460    £4.780       63,460     Aug 23, 2014     2004    PLC ord   63,460       £4.780     63,460     £7.531        
    NV ord   43,866       €10.300     43,866     €12.810        
   2005    PLC ord   154,517       £5.335     154,517     £8.774        
  NV ord  43,866    10.30       43,866     Aug 23, 2014      NV ord   105,412       €11.310     105,412     €15.277        
 2005 PLC ord  154,517    £5.335       154,517     Feb 17, 2015     2006    PLC ord   178,895       £5.305         178,895       13-May-16  
  NV ord  105,412    11.31       105,412     Feb 17, 2015      NV ord   120,198       €11.470         120,198       13-May-16  
 2006 PLC ord  178,895    £5.305       178,895     Mar 13,2016     2011    PLC ord   139,146       £5.390         139,146     05-May-14     05-May-21  
  NV ord  120,198    11.47       120,198     Mar 13,2016      NV ord   92,953       €8.969         92,953     05-May-14     05-May-21  
 2011 PLC ord  139,146    £5.390       139,146    May 5, 2014    May 5, 2021     2012    PLC ord   198,836       £5.155         198,836     02-May-15     02-May-22  
  NV ord  92,953    8.969       92,953    May 5, 2014    May 5, 2021      NV ord   139,742       €9.030         139,742     02-May-15     02-May-22  
 2012 PLC ord      198,836   £5.155       198,836    May 2, 2015    May 2, 2022     2013    PLC ord     178,799     £7.345         178,799     09-May-16     09-May-23  
  NV ord      139,742   9.030       139,742    May 2, 2015    May 2, 2022      NV ord     124,337     €12.530         124,337     09-May-16     09-May-23  

LTIP

 2004 PLC ord  325,163    £4.78       325,163     Aug 23, 2014     2004    PLC ord   325,163       £4.780     325,163     £7.531        
  NV ord  224,766    10.30       224,766     Aug 23, 2014      NV ord   224,766       €10.300     224,766     €12.810        
   

 

  

 

      

 

         

 

   

 

     

 

     

 

     

Total PLC ords

    861,181    198,836        1,060,017           1,060,017     178,799       543,140       695,676      

Total NV ord

    587,195    139,742        726,937    

Total NV ords

       726,937     124,337       374,044       477,230      
   

 

  

 

      

 

         

 

   

 

     

 

     

 

     

 

Shares

 Year of
grant
 Type of
security
 No. of
unvested
shares
held on
Jan 1,
2012
  No. of
shares
awarded
during
2012
  Market
price per
share at
award
  No. of
shares
vested
during
2012
 Market
price per
share at
vesting
 Notional
gross
gains at
vesting
£/€
 No. of
unvested
shares
held on
Dec 31,
2012
  Date of
performance
testing
  Date of
release
 

BIP

 2010 NV ord  140,378    8.310       140,378    H1 2013    H1 2013  
 2011 NV ord  122,352    8.969       122,352    H1 2014    H1 2014  
 2012 NV ord      136,950   9.030       136,950    H1 2015    H1 2015  

REGP

 2010 PLC ord  643,086    £4.665       643,086    H1 2013    50% H1 2013  
               50% H1 2015  
  NV ord  422,310    8.310       422,310    H1 2013    50% H1 2013  
            50% H1 2015  
   

 

 

  

 

 

      

 

 

   

Total PLC ords

    643,086         643,086    

Total NV ord

    685,040    136,950        821,990    
   

 

 

  

 

 

      

 

 

   

Mark Armour

Options

  

Year of
grant

  Option
over
  No. of
options
held on
Jan 1,
2012
   No. of
options
granted
during
2012
  Option
price
   No. of
options
exercised
during
2012
   Market
price per
share at
exercise
   Gross
gains
made on
exercise
£/€
   No. of
options
held on
Dec 31,
2012
   Unvested
options
vesting on:
  Options
exercisable
until:
 

ESOS

  2002  PLC ord   74,000      £6.000                  Expired
    NV ord   51,926      13.94                  Expired
  2005  PLC ord   150,422      £5.335           150,422       Feb 17, 2015  
    NV ord   102,618      11.31           102,618       Feb 17, 2015  
  2006  PLC ord   158,836      £5.305     1,500    £6.095    £1,185     157,336       Mar 13,2016  
    NV ord   106,720      11.47           106,720       Mar 13,2016  
  2011  PLC ord   85,358      £5.390           56,905       May 9, 2016** 
    NV ord   57,021      8.969           38,014       May 9, 2016** 

LTIP

  2004  PLC ord   290,481      £4.872           290,481       Feb 19, 2014  
    NV ord   199,467      10.57           199,467       Feb 19, 2014  

SAYE

  2010  PLC ord   2,173      £4.176           2,173       Jun 30, 2013  
      

 

 

             

 

 

     

Total PLC ords

       761,270         1,500         657,317      

Total NV ord

       517,752               446,819      
      

 

 

             

 

 

     

Shares

 Year of
grant
  Type of
security
  No. of
unvested
shares
held on
Jan 1,
2013
  No. of
shares
awarded
during
2013
  Market
price per
share at
award
  No. of shares
vested
/performance
tested
during
2013
  Market
price per
share at
vesting
/performance
testing
  No. of
unvested
/non-
performance
tested
shares held
on Dec 31,
2013
  End pf
performance
period
  Date of
release
 

BIP

  2010    NV ord    140,378     €8.310    125,638    €13.100     Dec-12    H1 2013  
  20111   NV ord    122,352     €8.969      122,352    Dec-13    H1 2014  
  2012    NV ord    136,950     €9.030      136,950    Dec-14    H1 2015  
  2013    NV ord     96,830    €12.530      96,830    Dec-15    H1 2016  

LTIP

  2013    PLC ord     178,799    £7.345      178,799    Dec-15    H1 2016  
   NV ord     124,337    €12.530      124,337    Dec-15    H1 2016  

REGP

  2010    PLC ord    643,086     £4.665    429,7102   £7.774     Dec-12    50% H1 2013  
           50% H1 2015  
   NV ord    422,310     €8.310    282,1872   €13.100     Dec-12    50% H1 2013  
           50% H1 2015  
  2013    PLC ord     321,895    £7.760      321,895    Dec-14    H1 2015  
   NV ord     450,494    €13.150      450,494    Dec-14    H1 2015  
   

 

 

  

 

 

   

 

 

   

 

 

   

Total PLC ords

    643,086    500,694     429,710     500,694    

Total NV ords

    821,990    671,661     407,825     930,963    
   

 

 

  

 

 

   

 

 

   

 

 

   

 

*1.Expired unexercisedThe performance outcome for the BIP 2011 is set out on February 22 2012.page 58.

 

**2.Pro-rated for service.The number of shares shown represents the entire amount which was performance tested in H1 2013. 50% of this has been deferred and is subject to release in H1 2015.

Shares

  

Year of
grant

  Type of
security
  No. of
unvested
shares
held on
Jan 1,
2012
   No. of
shares
awarded
during
2012
   Market
price per
share at
award
   No. of
shares
vested
during
2012
  Market
price per
share at
vesting
  Notional
gross
gains at
vesting
£/€
  No. of
unvested
shares
held on
Dec 31,
2012
   Date of
performance
testing
   Date of
release
 

BIP

  2010  PLC ord   65,054      £4.665           65,054     H1 2013     H1 2013  
    NV ord   42,512      8.310           42,512     H1 2013     H1 2013  
  2011  PLC ord   56,876      £5.390           37,917     H1 2014     H1 2014
    NV ord   37,687      8.969           25,124     H1 2014     H1 2014
  2012  PLC ord        90,987    £5.115           30,329     H1 2015     H1 2015
    NV ord        21,028    9.030           7,009     H1 2015     H1 2015

REGP

  2010  PLC ord   394,495      £4.665           394,495     H1 2013     H1 2013  
    NV ord   259,062      8.310           259,062     H1 2013     H1 2013  
      

 

 

   

 

 

           

 

 

     

Total PLC ords

       516,425     90,987             527,795      

Total NV ord

       339,261     21,028             333,707      
      

 

 

   

 

 

           

 

 

     

*Pro-rated for service.

Duncan Palmer

 

Options

  

Year of
grant

  Option
over
  No. of
options
held on
Jan 1,
2012
   No. of
options
granted
during
2012
   Option
price
   No. of
options
exercised
during
2012
  Market
price per
share at
exercise
  Gross
gains
made on
exercise
£/€
  No. of
options
held on
Dec 31,
2012
   Unvested
options
vesting on:
   Options
exercisable
until:
  Year of
grant
 Option
over:
 No. of
options
held on
Jan 1,
2013
 No. of
options
granted
during
2013
 Option
price
 No. of
options
exercised
during
2013
 Market
price per
share at
exercise
 No. of
options
held on
Dec 31,
2013
 Unvested
options
vesting
on
 Options
exercisable
until

ESOS

  2012  PLC ord        67,331    £6.015           67,331     Sep 7, 2015     Sep 7, 2022    2012    PLC ord    67,331     £6.015      lapsed    
    NV ord        48,018    10.560           48,018     Sep 7, 2015     Sep 7, 2022     NV ord    48,018     €10.560      lapsed    
      

 

   

 

           

 

       2013    PLC ord     81,688    £7.345      lapsed    
   NV ord     56,806    €12.530      lapsed    
   

 

  

 

       

Total PLC ords

            67,331             67,331          67,331    81,688        

Total NV ord

            48,018             48,018      

Total NV ords

    48,018    56,806        
      

 

   

 

           

 

        

 

  

 

       

Shares

  

Year of
grant

  Type of
security
   No. of
unvested
shares
held on
Jan 1,
2012
  No. of
shares
awarded
during
2012
   Market
price per
share at
award
   No. of
shares
vested
during
2012
  Market
price per
share at
vesting
  Notional
gross
gains at
vesting
£/€
  No. of
unvested
shares
held on
Dec 31,
2012
   Date of
performance
testing
   Date of
release
   Year of
grant
   Type of
security
   No. of
unvested
shares
held on
Jan 1,
2013
   No. of
shares
awarded
during
2013
   Market
price
per share
at award
   No. of
shares
vested/
performance
tested
during 2013
  Market
price per
share at
vesting/
performance
testing
  No. of
unvested/
non-
performance
tested shares
held on Dec
31, 2013
   Date of
vesting
 

PSP*

  2012   PLC ord       179,551    £6.015           179,551     H1 2015     H1 2015  

BIP

   2013     NV ord       55,298     €12.530         lapsed    

PSP

   2012     PLC ord     179,551       £6.015         lapsed    

LTIP

   2013     PLC ord       81,688     £7.345         lapsed    
     NV ord       56,806     €12.530         lapsed    

RSP*

  2012   PLC ord       249,376    £6.015           249,376          50% H1 2014     2012     PLC ord     249,376       £6.015         72,042     
 
Termination
date
  
  
                       50% H1 2015       NV ord               51,378    
        

 

           

 

           

 

   

 

         

 

   

Total PLC ords

         428,927             428,927             428,927     81,688           72,042    

Total NV ord

                            

Total NV ords

         112,104           51,378    
        

 

           

 

           

 

   

 

         

 

   

 

*Half of Duncan Palmer’s 2012 PSP and RSP awards whichaward has been subject to time pro-rating following his resignation. The number of unvested shares held on December 31, 2013 is the number that will vest if any, will beon termination. In accordance with the terms of the award, half of it is being settled with Reed Elsevier NV ordinary shares. The number of NV shares will be calculated using the closing price of a Reed Elsevier NV share and the euro/pound sterling exchange rate on the date of grant.

The number of shares and options that vest in respect of all outstanding (unvested) awards under the multi-year incentives depend on the extent to which performance conditions are met, except for the RSP grant to Duncan Palmer which vests subject to an ongoing employment condition.

In respect of the REGP grant to Erik Engstrom, the maximum number of shares that can vest is 150% of the number of shares shown in the tables above. In respect of ESOS and BIP, the number of share options and shares shown in the table is the maximum capable of vesting. ESOS awards vest on the third anniversary and expire on the tenth anniversary of the date of grant. For the PSP and RSP awards granted to Duncan Palmer, the number of shares shown in the share tables reflects the maximum number of shares which can vest.

Options under the SAYE Scheme, in which all eligible UK employees are invited to participate, are granted at a maximum discount of 20% to the market price at time of grant. They are normally exercisable after the expiry of three or five years from the date of grant. No performance targets are attached to these option grants as the SAYE Scheme is a UK all-employee scheme.

The middle market price of a Reed Elsevier PLC ordinary share at the date of award of grants in 2012 under the BIP was £5.155. The middle market price of a Reed Elsevier NV ordinary share at the date of award of grants in 2012 under the BIP was €9.03. The middle market price of a Reed Elsevier PLC ordinary share at the date of award of grants made to Mr Palmer on September 7, 2012 was €6.015.

The middle market price of a Reed Elsevier PLC ordinary share during the year was in the range of £4.694 to £6.52 and at December 31, 2012 was £6.42. The middle market price of a Reed Elsevier NV ordinary share during the year was in the range of €8.17 to €11.37 and at December 31, 2012 was €11.185.

REED ELSEVIER

As of December 31, 20122013 Reed Elsevier operated and/or had awards outstanding under a number of equity-based plans as follows:

 

(i)All-Employee Equity-Based Plans

Reed Elsevier’s all-employee equity-based plans comprise the following two plans. Mr Engstrom and Mr Palmer have waived their right to participate in any local all-employee share based plans in any country.

 

(a)Reed Elsevier Group plc SAYE Share Option Scheme (the SAYE Scheme)

Options over Reed Elsevier PLC ordinary shares have been granted under the SAYE Scheme. Shares may be acquired at not less than the higher of (i) 80% of the closing middle market price for the relevant share on The London Stock Exchange three dealing days before invitations to apply for options are issued, and (ii) if new shares are to be subscribed, their nominal value.

All UK employees of Reed Elsevier Group plc and participating companies under its control in employment at the date of invitation are entitled to participate in the SAYE Scheme. In addition, the directorsDirectors of Reed Elsevier Group plc may permit other employees of Reed Elsevier Group plc and participating companies under its control to participate.

Invitations to apply for options may normally only be issued within 42 days after the announcement of the combined results of Reed Elsevier for any period. No options may be granted more than 10 years after the approval of the scheme. A new 2013 SAYE Share Option Scheme was implemented during 2013, to replace the 2003 SAYE Share Option, under which the final grant of options permitted within the scheme’s 10 year validity period, was made during 2012. Outstanding options granted under the 2003 SAYE Share Option Scheme will remain capable of exercise until 2018.

On joining the SAYE Scheme, a save as you earn contract (a Savings Contract) must be entered into with an appropriate savings body, under which savings of between £10 and £250 per month may be made to such savings body for a period of three or five years. From April 6, 2014, it will be possible to save up to £500 per month in any new SAYE Savings Contracts,

following an increase to the maximum contributions limit by HMRC and upon appropriate approval by the Company’s Board of Directors. A bonus may be payable under the Savings Contract at the end of the savings period. The amount of the monthly contributions may be reduced if applications exceed the number of Reed Elsevier PLC ordinary shares available for the grant of options on that occasion.

The number of Reed Elsevier PLC ordinary shares over which an option may be granted is limited to that number of shares which may be acquired at the exercise price out of the repayment proceeds (including any bonus) of the Savings Contract.

Options under the SAYE Scheme may normally only be exercised for a period of six months after the bonus date under the relevant Savings Contract. However, options may be exercised earlier than the normal exercise date in certain specified circumstances, including death, reaching age 60, or on ceasing employment on account of injury, disability, redundancy, reaching contractual retirement age, or the sale of the business or subsidiary for which the participant works, or on ceasing employment for any other reason, or provided the option has been held for at least three years, on ceasing employment for any other reason.years. Exercise is allowed in the event of an amalgamation, reconstruction or take-over of the company whose shares are under option; alternatively, such options may, with the agreement of an acquiring company or a company associated with it, be exchanged for options over shares in the acquiring company or that associated company. Options may also be exercised in the event of the voluntary winding-up of the company whose shares are under option. In the event that options are exercised before the bonus date, the participant may acquire only the number of shares that can be purchased with the accumulated savings up to the date of exercise, plus interest (if any).

In the event of any capitalisation or rights issue by Reed Elsevier PLC or Reed Elsevier NV, or of any consolidation, subdivision or reduction of their share capital, the number of shares subject to any relevant option and/or the exercise price may be adjusted with the approval of the UK HMRC, subject to the independent auditors of Reed Elsevier Group plc confirming in writing that such adjustment is, in their opinion, fair and reasonable.

 

(b)Convertible debenture stock arrangements

This facility consists of an annual issue by Reed Elsevier NV of a convertible debenture loan (the Netherlands Convertible Debenture Stock Scheme) that is open for subscription by Dutch staff employed by Reed Elsevier companies in the Netherlands or temporarily seconded to affiliates abroad. The interest rate of the scheme is determined quarterly on the basis of market rates on internet savings accounts in the Netherlands. With effect from February 19, 2004 for new issues, interest is determined quarterly on the basis of market rates on internet savings accountswhich can be withdrawn at a day’s notice in the Netherlands. Employees can annually subscribe for one or more debentures of €200 each, up to a maximum amount equal to 20% of the equivalent of their15 times the employee’s fixed gross monthly salary, including any fixed monthly allowances, but excluding any non-monthly salary components (holiday pay, annual salary components.incentives, profit shares etc). Interest is payable in arrears in the month of January following the subscription year. The loans have a term of 10 years. During the 10-year term of the loan employees can decide to convert their claim on the CompanyReed Elsevier NV into shares at an exercise price equal to the price of a Reed Elsevier NV ordinary share on NYSE Euronext Amsterdam aton the endlast dealing day of the month in which the employee has subscribed for the loan (the exercise price). Each debenture of €200 can be converted into 50 ordinary shares in Reed Elsevier NV against payment of 50 times the exercise price, less €200.

 

(ii)Executive Equity-Based Plans

Reed Elsevier’s executive equity-based plans comprise:

 

(a)Reed Elsevier Group plc Growth Plan (REGP)

The details of how the REGP operates have been disclosed in previous years’ Reports.annual reports and details are also set out on page 51 of this annual report. The performance measures and targets for the matching awards granted in 2013 are disclosed in this Reportannual report on pages 47 to 49.page 62.

 

(b)Long-term incentive plans (LTIP)

The plans in this category comprise the Reed Elsevier Group plc Long-Term Incentive Plan 2013 (LTIP 2013), the Reed Elsevier Group plc Long-Term Incentive Plan 2010 (LTIP 2010) and the Reed Elsevier Group plc Long-Term Incentive Share Option Scheme 2003 (LTIS 2003) (details. Details of the LTIP 2010 and the LTIS 2003 have been disclosed in previous years’ Reports).annual reports.

The LTIP 20102013 was implemented in 2010.2013 as the successor plan to the LTIP 2010 and details are set out on page 50 of this annual report. The plan applies to senior executives (including executive officers) other thanofficers and executive directors.directors). Awards are in the form of restricted shares whichmay be granted as performance share awards or nil-cost options but it is currently intended to only grant performance share awards. Awards vest subject to performance measured over three financial years. Awards aremay be satisfied with new issue shares, a transfer of treasury shares or shares purchased in the market, but it is currently intended to continue the existing practice of satisfying awards with shares purchased in the market. The performance conditions attachedmeasures and targets applicable to awards made

granted in 20102013 under this plan mirror those applicable to years one to three (i.e. 2010 through to 2012) of the REGP (seeare set out on pages 47 to 49 for details). The targets applicable to awards made in 2012 under this plan continue to be aligned to the REGP.61 and 62. The vesting of awards is also subject to participants meeting a minimum shareholding requirement and continued employment (except for certain categories of approved leavers). Dividend equivalents accrue over the performance period and are paid out in cash at the end to the extent that the awards vest.

The LTIP 2010 has awards outstanding which were granted in 2011 and 2012. No awards were granted under this plan in 2013 and no awards will be granted under this plan in 2014.

The LTIS 2003 enabled the grant of options and restricted shares. Options previously granted under this plan vested subject to performance and will lapse to the extent they remain unexercised, on the tenth anniversary of the date of grant. No awards were made under the LTIS 2003 in 20122013 and no awards will be made under this plan in 2013.

2014.

(c)Executive share option schemes (ESOS)

The plans in this category comprise the Reed Elsevier Group plc Executive Share Option Scheme 2013 (ESOS 2013) and the Reed Elsevier Group plc Share Option Scheme 2003 (ESOS 2003) (details. Details of the ESOS 2003 have been disclosed in previous years’ Reports),annual reports.

The ESOS 2013 was implemented in 2013 and is the Reed Elsevier Group plc Executive U.K. Share Option Scheme 1993 and the Reed Elsevier Group plc Executive Overseas Share Option Scheme 1993 (together ESOS 1993). ESOS 1993 has expired and all outstanding awards under these plans have vested and will lapse,successor plan to the extent theyESOS 2003 and details are set out on page 50 of this annual report. The plan applies to around 1,000 executives (including executive officers and executive directors). Market value options are granted which vest (subject to performance in the case of executive directors) after three years and remain unexercised, onexercisable, subject to continued employment, until the tenth anniversary of grant. Options may be satisfied with new issue shares, a transfer of treasury shares or shares purchased in the datemarket, but it is currently intended to continue the existing practice of grant.satisfying options with new issue shares. The performance measure and targets applicable to options granted in 2013 under this plan to executive directors are set out on page 62.

ESOS 2003 has options outstanding under it but no options were granted under this plan in 2013 and no options will be granted under this plan in 2014.

 

(d)Bonus investment plans (BIP)

The Reed Elsevier Group plc Bonus Investment Plan 2010 (BIP 2010) (see page 50 for a description of this plan) is a voluntary plan aimed at encouraging personal investment in, and ongoing holding of, Reed Elsevier shares to promote greater alignment with shareholders and support the retention of key talent. Awards were made in 20122013 under BIP 2010.

No2010 to senior executives (including executive officers and Executive Directors). The performance measures and targets applicable to awards were madegranted in 2012 under the BIP 2003 and no awards will be made under this plan in 2013. There2013 are no further awards outstanding under BIP 2003.set out on page 61.

 

(e)Reed Elsevier Group plc Retention Share Plan 2004 (RSP)

The Reed Elsevier Group plc Retention Share Plan is a share plan operated under the discretion of the Reed Elsevier Remuneration Committee which approves all grants. It facilitates the grant of restricted share awards over Reed Elsevier PLC and Reed Elsevier NV ordinary shares, subject to such conditions as specified from time to time by the Reed Elsevier Remuneration Committee. Participation in the plan is limited to employees of Reed Elsevier and participating companies under its control, excluding executive directors.

The plan isRSP has been used to facilitate the grant of one-off awards of restricted shares, where appropriate, to senior new hires for example, to buy out share-based awards from previous employment. The restricted shares which have been awarded will be satisfied by shares purchased in the market and Executive Directors are not eligible to participate.

In addition, since 2006, employees eligible to participate in the ESOS 2003 (see (c) above), other than executive directors,Executive Directors, have been able to choose prior to the date of grant whether to receive all or part of their grant in the form of restricted shares based on a pre-determined conversion ratio of one share for every five options that would otherwise be granted to them under ESOS 2003.ESOS. The RSP is the vehicle used to deliver the award of such restricted shares. The restricted shares vest after the expiry of three years from the date of grant, subject to the participant remaining employed by Reed Elsevier or a participating company under its control. The restricted shares awarded are satisfied by market purchase shares.

On termination of employment, unvested awards made undershares purchased in the plan lapse (except for certain categories of approved leavers).market.

Note that the RSP award granted to Duncan Palmer on recruitment was not granted under this plan.the RSP. The terms of that award arewere described on page 53 and in Exhibit 4.16 incorporated by reference in this Annual Report (see “Item 19: Exhibits” on pages S-3 and S-4 of this Annual Report).last year’s annual report.

Dilution

At December 31, 2012, the estimated potential dilution over a 10-year period from awards over Reed Elsevier PLC shares under all equity-based plans was 4.7% of the Reed Elsevier PLC share capital. The estimated potential dilution over the same period in respect of awards over Reed Elsevier NV shares was 4.9% of the Reed Elsevier NV share capital at December 31, 2012. The estimated potential dilution in relation to executive equity-based plans was 4.3% of the Reed Elsevier PLC and 4.5% of the Reed Elsevier NV share capital at December 31, 2012.

Share options and conditional share awards

At February 27, 201326, 2014 the total number of ordinary shares subject to outstanding options was:

 

   Number of
outstanding
options
  Options over
shares
  Option price
range

SAYE Scheme

  1,906,5311,922,744  Reed Elsevier PLC  £4.016 — £5.04£5.96

Netherlands Convertible Debenture Stock Scheme

  1,646,6501,195,300  Reed Elsevier NV  €9.00 — €11.445€14.865

ESOS

  14,332,8468,125,483  Reed Elsevier PLC  £4.20 — £6.465£9.03
  11,820,2016,052,561  Reed Elsevier NV  €7.301 — €14.51€15.19

LTIS 2003

  872,434147,909  Reed Elsevier PLC  £4.78 — £5.1155.115
  841,284100,883  Reed Elsevier NV  10.30 — €11.3511.13

Share options are expected, upon exercise, to be met principally by the issue of new ordinary shares, but may also be met from shares held by the Reed Elsevier Group plc Employee Benefit Trust.

At February 27, 201326, 2014 the following conditional share awards were also outstanding:

 

   Number of
outstanding
awards
   

Awards over
shares in

REGPREGP*

   1,037,581536,750    Reed Elsevier PLC
   681,372591,588    Reed Elsevier NV

LTIP

   4,366,3212,397,483    Reed Elsevier PLC
   2,835,1491,652,859    Reed Elsevier NV

BIP*

   3,828,8553,262,636    Reed Elsevier PLC
   1,827,5231,536,524    Reed Elsevier NV

RSP

   2,441,0661,889,094    Reed Elsevier PLC
   1,273,5871,136,129    Reed Elsevier NV

 

*For disclosure purposes, any Reed Elsevier PLC and Reed Elsevier NV ADRs awarded under this planthese plans have been converted into ordinary share equivalents.

TheseIt is intended that these awards will be met by the Reed Elsevier Group plc Employee Benefit Trust fromsatisfied with shares purchased in the market.

REED ELSEVIER

Share ownership

The interests of those individuals who were directorsDirectors of Reed Elsevier PLC and Reed Elsevier NV as at December 31, 20122013 in the issued share capital of the respective companies at the beginning and end of the year are shown below. Reed Elsevier PLC and Reed Elsevier NV ADRs are converted into ordinary share equivalents.

 

  Reed Elsevier PLC
ordinary shares
   Reed Elsevier NV
ordinary shares
   Reed Elsevier PLC
ordinary shares
   Reed Elsevier NV
ordinary shares
 
  January 1,
2012*
   December 31,
2012
   January 1,
2012*
   December 31,
2012
   January 1,
2013
   December 31,
2013
   January 1,
2013
   December 31,
2013
 

Mark Armour

   248,742     250,242     136,889     136,889  

Mark Elliott

             7,600     7,600  

Erik Engstrom

   107,040     107,040     447,356     509,556     107,040     114,552     509,556     513,765  

Anthony Habgood

   50,000     50,000     25,000     25,000     50,000     50,000     25,000     25,000  

Wolfhart Hauser*

         750  

Adrian Hennah

   5,163     5,163               5,163     5,163      

Lisa Hook

                  4,800         4,800     4,800  

Marike van Lier Lels

                            

Duncan Palmer

                         88       30,022  

Robert Polet

   1,000     1,000            1,000     1,000      

Sir David Reid

                    

Linda Sanford

                         3,600      

Ben van der Veer

             5,000     5,000         5,000     5,000  

 

*On date of appointment if subsequent to January 1, 2012.Wolfhart Hauser was appointed on April 25, 2013.

As at March 6, 2014, Erik Engstrom’s interest in Reed Elsevier PLC ordinary shares was 118,552 and in Reed Elsevier NV ordinary shares was 516,765 and Ben van der Veer’s interest in Reed Elsevier NV ordinary shares was 7,000.

The interests of the current executive directorsExecutive Directors of Reed Elsevier PLC and Reed Elsevier NV in the issued share capital of the respective companies as at March 7, 20136, 2014 were:

 

  Interest in
Reed Elsevier
PLC ordinary
shares
   Interest in
Reed Elsevier
NV ordinary
shares
   Interest in
Reed Elsevier
PLC ordinary
shares*
   Interest in
Reed Elsevier
NV ordinary
shares*
 

Erik Engstrom

   107,040     509,556     118,552     516,765  

Duncan Palmer

   88     126     88     30,022  

Employee Benefit Trust

Any securities required to satisfy entitlements under the REGP, the RSP, the BIP and the other multi-year incentives are provided by the Employee Benefit Trust (EBT) from market purchases. As a potential beneficiary under the EBT in the same way as other employees of Reed Elsevier, each executive director is deemed to be interested in all the shares held by the EBT which at December 31, 2012 amounted to 13,451,468 Reed Elsevier PLC ordinary shares (1.07% of issued share capital) and 6,990,101 Reed Elsevier NV ordinary shares (0.91% of issued share capital). These numbers include ordinary share equivalents held in the form of Reed Elsevier PLC ADRs and Reed Elsevier NV ADRS.

*In the table above, Reed Elsevier PLC and Reed Elsevier NV ADRs are converted into ordinary share equivalents.

Shares and options held by executive officers

The following table indicates the total aggregate number of Reed Elsevier PLC ordinary shares and Reed Elsevier NV ordinary shares beneficially owned and the total aggregate number of share options and conditional share awards held by the executive officers (other than directors)Directors) of Reed Elsevier Group plc (three persons) as a group in office as of February 27, 2013:26, 2014:

 

   Reed
Elsevier
PLC
ordinary
shares
  Reed
Elsevier
PLC
ordinary
shares
subject to
options
  Reed
Elsevier
PLC
conditional
share
awards
  Reed
Elsevier NV
ordinary
shares*
  Reed
Elsevier NV
ordinary
shares
subject to
options
  Reed
Elsevier NV
conditional
share
awards

Executive officers (other than directors) as a group

  147,104  431,407  589,823  37,547  349,658  295,558
   Reed
Elsevier
PLC
ordinary
shares
   Reed
Elsevier
PLC
ordinary
shares
subject to
options
   Reed
Elsevier
PLC
conditional
share
awards
   Reed
Elsevier NV
ordinary
shares
   Reed
Elsevier NV
ordinary
shares
subject to
options
   Reed
Elsevier NV
conditional
share
awards
 

Executive officers (other than Directors)

   170,900     218,903     664,384     37,241     177,985     308,325  

 

*The Reed Elsevier NV ordinary shares are in registered form, although most ordinary shares are traded in the Dutch Security giro system administered by Euroclear Netherlands.

In the table above, Reed Elsevier PLC and Reed Elsevier NV ADRs are converted into ordinary share equivalents.

The options over Reed Elsevier PLC ordinary shares included in the above table are exercisable at prices ranging from £4.665 to £6.445£7.345 per share and between the date hereof and 2022.2023. The options over Reed Elsevier NV ordinary shares included in the above table are exercisable at prices ranging from €8.31 to €14.51 per share and between the date hereof and 2022.2023. The Reed Elsevier PLC and Reed Elsevier NV conditional share awards included in the above table will vest between 20132014 and 2015.2016.

ITEM 7: MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

MAJOR SHAREHOLDERS

REED ELSEVIER PLC

Substantial share interests

As at March 7, 2013,6, 2014, the company had been notified by the following shareholders that they held an interest of 3% or more in voting rights(1) of the issued share capital of the company:

 

Identity of Person or Group(2)

  % of Class 

Franklin Mutual Advisors, LLC

   5.04  

BlackRock, Inc

   5.03  

Silchester International InvestorsInvesco Limited

   3.995.03  

Lloyds Banking Group plc

   3.98

The Capital Group Companies, Inc.

3.903.47  

Legal & General Group plc

   3.40  

The percentage interests stated above are as disclosed at the date on which the interests were notified to the company.

 

(1)Under the UK Disclosure Rules and Transparency Rules, subject to certain limited exceptions, persons or groups with an interest of 3% or more in voting rights of the issued Reed Elsevier PLC ordinary share capital are required to notify Reed Elsevier PLC of their interest.

 

(2)Under the UK Large and medium-sizedMedium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Reed Elsevier PLC is required to disclose information they are aware of regarding the identity of each person with a significant direct or indirect holding of securities in Reed Elsevier PLC as at the financial year end.

As far as Reed Elsevier PLC is aware, except as disclosed herein, it is neither directly or indirectly owned nor controlled by one or more corporations or by any government.

At December 31, 20122013 there were 18,06416,964 ordinary shareholders, including the depositorydepositary for Reed Elsevier PLC’s ADR programme, with a registered address in the United Kingdom, representing 99.65%99.86% of shares issued.

Reed Elsevier PLC is not aware of any arrangements the operation of which may at a subsequent date result in a change in control of Reed Elsevier PLC. The major shareholders of Reed Elsevier PLC do not have different voting rights to other ordinary shareholders.

REED ELSEVIER NV

Substantial share interests

As of March 7, 20136, 2014 Reed Elsevier NV is aware of the following disclosable interests of 5%3% or more in the issued Reed Elsevier NV ordinary shares based on the public database of and on notification received from the Netherlands Authority for the Financial Markets(1) or provided as a Schedule 13G filing(2):

 

Identity of Person or Group

  % of Class 

BlackRock, Inc

7.30

Reed Elsevier PLC(3)

   5.89

Causeway Capital Management LLC

5.01

ING Groep N.V.

5.00

Credit Suisse Group AG

4.59

The Bank of New York Mellon Corporation


4.59

FIL Limited

3.72  

 

(1)Under Article 5:38 of the Netherlands Financial Markets Supervision Act, any person acquiring or disposing of shares or voting rights in public companies established under the laws of the Netherlands listed on a stock exchange in the European Union, is required to notify the Netherlands Authority for the Financial Markets (AFM) without delay if such person knows, or should know, that such interest therein reaches, exceeds or drops below a 3%, 5% or, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 75% and 95% threshold. No interest in the shares or voting rights of Reed Elsevier NV of 10% or more has been disclosed in the AFM’s registers.

 

(2)The Securities Exchange Act of 1934 requires any person who has, as at the end of the calendar year, a direct or indirect beneficial interest in 5% or more of the issued share capital of a company, to file a statement on Schedule 13G with the Securities and Exchange Commission reporting such interest within 45 days following the end of the calendar year.

 

(3)Reed Elsevier PLC’s interest comprises a holding of R shares of €0.70 nominal value each held by a subsidiary of Reed Elsevier PLC, and represents aPLC. The 5.89% indirect equity interest in the total share capital of Reed Elsevier NV.NV was notified to the AFM at the time the 5% threshold was reached. The subsequent repurchases of R shares are not reflected in the substantial interest register held by AFM, as the interest did not drop below the 5% threshold.

As far as Reed Elsevier NV is aware, except as disclosed herein, it is neither directly nor indirectly owned or controlled by any single corporation or corporations acting jointly, nor by any government.

Reed Elsevier NV is not aware of any arrangements the operation of which may at a subsequent date result in a change in control of Reed Elsevier NV. The major shareholders of Reed Elsevier NV do not have different voting rights to other ordinary shareholders.

RELATED PARTY TRANSACTIONS

Transactions with joint ventures and key management personnel, comprising the executive directorsExecutive and Non-Executive Directors of Reed Elsevier PLC and Reed Elsevier NV, are set out in note 3432 to the combined financial statements. Further details of remuneration of key management personnel are set out in “Item 6 — Directors, Senior Management and Employees”.

ITEM 8: FINANCIAL INFORMATION

FINANCIAL STATEMENTS

See Item 18: Financial Statements.

DIVIDEND POLICY

Dividends to Reed Elsevier PLC and Reed Elsevier NV shareholders are, other than in special circumstances, equalised at the gross level, including the benefit of the UK attributable tax credit of 10% received by certain Reed Elsevier PLC shareholders. The exchange rate used for each dividend calculation as defined in the Reed Elsevier merger agreement is the spot euro/sterling exchange rate, averaged over a period of five business days commencing with the tenth business day before the announcement of the proposed dividend. The Boards of Reed Elsevier PLC and Reed Elsevier NV have adopted dividend policies in recent years in respect of their equalised dividends that, subject to currency considerations, more closely align dividend growth with growth in adjusted earnings, consistent with the dividend normally being covered over the longer term at least two times by adjusted earnings (i.e. before the amortisation and impairment of acquired intangible assets, and goodwill, exceptional restructuring and acquisition related costs, net financing charge on defined benefit pension schemes, disposal gains and losses and other non operating items, related tax effects, other deferred tax credits from intangible assets and exceptional prior year tax credits and movements in deferred tax assets and liabilities that are not expected to crystallise in the near term and include the benefit of tax amortisation where available on acquired goodwill and intangible assets)credits).

Reed Elsevier NV may resolve that the dividend to be paid on each R share shall be lower than the dividend to be paid on each ordinary share, but not less than 1% of the nominal value of an R share.

LEGAL PROCEEDINGS

Beginning in 2005, various of Reed Elsevier’s subsidiaries in the United States became the subject of legal proceedings and federal and state regulatory actions relating to data security breaches, pursuant to which unauthorised persons obtained personal identifying information from Reed Elsevier databases, or alleged breaches of federal privacy laws in connection with the obtaining and disclosure by such subsidiaries of information without the consent of the individuals involved. The principal actions and investigations have been settled, with the substantial portion of cash payments agreed to be paid by these subsidiaries being reimbursed by insurance and third-party indemnities. The settlements generally require strict data security programs, submissions of regulatory reports and on-going monitoring by independent third parties to ensure Reed Elsevier’s compliance with the terms of those settlements. While the costs of such on-going monitoring will be borne by Reed Elsevier, neither the costs of compliance nor the costs of such on-going monitoring are expected to have a material adverse effect on our financial position or the results of our operations.

Many of the products offered by Risk Solutions is governed by the US Fair Credit Reporting Act (“FCRA”), Graham Leach Bliley Act (“GLBA”), Drivers Privacy Protection Act (“DPPA”) and related state laws requiring that consumers be provided certain notices. Certain of these laws further provide for statutory penalties and attorneys fees for non-compliance. In the normal course of its business, Risk Solutions deals with individual and class lawsuits claiming violation of one or more of these statutes. Other than pending matters, these cases have either been settled or successfully defended to date with a substantial portion of cash payments agreed to be paid by insurance. These proceedings have not had, and are not expected to have, a material adverse effect on our financial position or the results of our operations.

We are party to various other legal proceedings arising in the ordinary course of our business, the ultimate resolutions of which are not expected to have a material adverse effect on our financial position or the results of our operations.

ITEM 9: THE OFFER AND LISTING

TRADING MARKETS

REED ELSEVIER PLC

The Reed Elsevier PLC ordinary shares are listed on the London Stock Exchange and the New York Stock Exchange. The London Stock Exchange is the principal trading market for Reed Elsevier PLC ordinary shares. Trading on the New York Stock Exchange is in the form of American Depositary Shares (ADSs), evidenced by American Depositary Receipts (ADRs) issued by The Bank of New York Mellon, as depositary. Each ADS represents four Reed Elsevier PLC ordinary shares.

The table below sets forth, for the periods indicated, the high and low closing middle market quotations for the Reed Elsevier PLC ordinary shares on the London Stock Exchange as derived from the Daily Official List of the London Stock Exchange and the high and low last reported sales prices in US dollars for the Reed Elsevier PLC ADSs on the New York Stock Exchange, as derived from the New York Stock Exchange Composite Tape, and reported by Thomson Reuters Datastream:

 

      Pence per ordinary share           US dollars per ADS           Pence per ordinary share           US dollars per ADS     

Calendar Periods

  High   Low   High   Low   High   Low   High   Low 

2013

   899     641     60.05     41.01  

2012

   652     469     42.04     28.90     652     469     42.04     28.90  

2011

   591     461     37.74     29.61     591     461     37.74     29.61  

2010

   563     461     35.70     26.82     563     461     35.70     26.82  

2009

   560     420     33.56     26.20     560     420     33.56     26.20  

2008

   690     451     54.60     27.06     690     451     54.60     27.06  

2007

   690     558     54.85     44.02  

2013

        

Fourth Quarter

   899     822     60.05     52.69  

Third Quarter

   854     761     54.39     46.18  

Second Quarter

   796     715     48.39     44.36  

First Quarter

   782     641     47.53     41.01  

2012

                

Fourth Quarter

   652     598     42.04     38.25     652     598     42.04     38.25  

Third Quarter

   608     506     39.34     31.53     608     506     39.34     31.53  

Second Quarter

   565     469     36.24     28.90     565     469     36.24     28.90  

First Quarter

   563     509     35.75     31.44     563     509     35.75     31.44  

2011

                

Fourth Quarter

   555     489     35.93     30.33     555     489     35.93     30.33  

Third Quarter

   578     461     36.99     29.61     578     461     36.99     29.61  

Second Quarter

   566     526     36.89     34.13     566     526     36.89     34.13  

First Quarter

   591     506     37.74     32.20     591     506     37.74     32.20  

2010

        

Fourth Quarter

   563     509     35.65     31.73  

Third Quarter

   561     490     35.70     29.74  

Second Quarter

   545     461     33.94     26.82  

First Quarter

   526     482     33.71     29.91  

Month

                

February 2013 (through February 27, 2013)

   716     687     44.92     41.50  

January 2013

   692     641     43.96     41.01  

December 2012

   652     628     42.04     40.63  

November 2012

   645     603     41.28     38.32  

October 2012

   618     598     39.81     38.25  

September 2012

   608     592     39.34     37.41  

August 2012

   594     545     37.41     33.90  

February 2014

   924     878     61.97     57.73  

January 2014

   931     887     61.60     58.48  

December 2013

   899     855     60.05     56.02  

November 2013

   889     868     58.10     55.59  

October 2013

   874     822     56.53     52.69  

September 2013

   850     798     54.39     49.02  

REED ELSEVIER NV

The Reed Elsevier NV ordinary shares are quoted on NYSE Euronext Amsterdam NV and the New York Stock Exchange. NYSE Euronext Amsterdam NV is the principal trading market for Reed Elsevier NV ordinary shares. Trading on the New York Stock Exchange is in the form of ADSs, evidenced by ADRs issued by The Bank of New York Mellon, as depositary. Each ADS represents two Reed Elsevier NV ordinary shares.

The table below sets forth, for the periods indicated, the high and low closing middle market quotations for the Reed Elsevier NV Ordinary Shares on NYSE Euronext Amsterdam NV as derived from theOfficiële Prijscourantof NYSE Euronext Amsterdam NV and the high and low last reported sales prices in US dollars for the Reed Elsevier NV ADSs on the New York Stock Exchange, as derived from the New York Stock Exchange Composite Tape, and reported by Thomson Reuters Datastream:

 

      € per ordinary share           US dollars per ADS           € per ordinary share           US dollars per ADS     

Calendar Periods

  High   Low   High   Low   High   Low   High   Low 

2013

   15.82     11.18     43.01     28.97  

2012

   11.37     8.17     29.58     20.35     11.37     8.17     29.58     20.35  

2011

   10.27     7.59     27.84     21.23     10.27     7.59     27.84     21.23  

2010

   10.12     8.17     26.93     20.14     10.12     8.17     26.93     20.14  

2009

   9.42     7.19     25.05     19.85     9.42     7.19     25.05     19.85  

2008

   13.69     7.72     39.61     20.73     13.69     7.72     39.61     20.73  

2007

   14.89     11.49     40.49     33.20  

2013

        

Fourth Quarter

   15.82     14.46     43.01     39.05  

Third Quarter

   15.07     13.00     40.55     33.68  

Second Quarter

   13.43     12.26     34.38     32.21  

First Quarter

   13.37     11.18     34.18     28.97  

2012

                

Fourth Quarter

   11.37     10.23     29.58     26.50     11.37     10.23     29.58     26.50  

Third Quarter

   10.66     9.14     27.49     22.20     10.66     9.14     27.49     22.20  

Second Quarter

   9.73     8.17     25.97     20.35     9.73     8.17     25.97     20.35  

First Quarter

   9.64     8.79     25.76     22.36     9.64     8.79     25.76     22.36  

2011

                

Fourth Quarter

   9.13     8.15     25.74     21.67     9.13     8.15     25.74     21.67  

Third Quarter

   9.42     7.59     27.16     21.23     9.42     7.59     27.16     21.23  

Second Quarter

   9.51     8.74     27.36     25.07     9.51     8.74     27.36     25.07  

First Quarter

   10.27     8.66     27.84     23.85     10.27     8.66     27.84     23.85  

2010

        

Fourth Quarter

   9.66     9.01     26.93     23.45  

Third Quarter

   10.12     8.92     26.64     22.19  

Second Quarter

   9.35     8.17     24.98     20.14  

First Quarter

   9.00     8.29     24.83     22.73  

Month

                

February 2013 (through February 27, 2013)

   11.75     11.18     32.07     28.97  

January 2013

   11.54     11.18     31.11     29.21  

December 2012

   11.37     10.90     29.58     28.60  

November 2012

   11.11     10.44     28.95     26.50  

October 2012

   10.60     10.23     27.57     26.54  

September 2012

   10.66     10.35     27.49     26.10  

August 2012

   10.39     9.59     26.10     23.37  

February 2014

   16.23     15.09     44.51     40.89  

January 2014

   16.03     15.26     43.45     41.30  

December 2013

   15.77     14.79     42.67     40.70  

November 2013

   15.82     14.80     43.01     40.03  

October 2013

   15.02     14.46     41.03     39.05  

September 2013

   15.07     13.87     40.55     36.15  

ITEM 10: ADDITIONAL INFORMATION

MEMORANDUM AND ARTICLES OF ASSOCIATION

REED ELSEVIER PLC (the “Company”)

At the Company’s Annual General Meeting held in April 2010, shareholders passed a special resolution to adopt new Articles of Association (the “Articles”) to reflect fully the implementation of the UK Companies Act 2006 (the “Act”).

A copy of the Company’s current Articles of Association (the “Articles”) is incorporated by reference from Exhibit 4.1 to the Registration Statement on Form S-8 filed with the SEC on May 25, 2010 — see “Item 19: Exhibits” on pages S-3 and S-4.

The following is a summary of the current Articles. As a summary, it is not exhaustive and is qualified in its entirety by reference to UK law and the Articles.

Company’s Objects

The Company’s objects are unrestricted.

Share Capital

As at December 31, 20122013 the company’s issued ordinary share capital comprised 1,257,597,9771,267,036,696 shares of 14 51/116p. At December 31, 20122013 the total shares held in treasury were 70,936,383.109,567,371. Of these 13,451,46810,120,537 ordinary shares were held by the Reed Elsevier Group plc Employee Benefit Trust and 57,484,91599,446,834 ordinary shares were held in treasury by the Company. During 2013, the Company bought back 41,961,920 ordinary shares pursuant to the authority given by shareholders at the Annual General Meeting held on April 25, 2013 and the previous authority given by shareholders at the Annual General Meeting held on April 25, 2012. These shares are included in the number of ordinary shares held in treasury.

The Company by ordinary resolution and subject to the UK Companies Act 2006 (the “Act”) may:

 

 1.Allot shares up to a limit of 1/3 of the issued share capital, a further 1/3 of the issued share capital may be allotted but only in connection with a fully pre-emptive rights issue;

 

 2.Sub-divide all or part of the share capital into shares of a smaller nominal value than the existing shares; and

 

 3.Consolidate and divide all or part of the share capital into shares of a larger nominal value than the existing shares.

All shares created by increase of the Company’s share capital by consolidation, division or sub-division shall be subject to all the provisions of the Articles.

The Company by special resolution and subject to the Act may:

 

 1.Disapply shareholders pre-emption rights on new issue shares up to a limit of 5% of the issued share capital;

 

 2.Buy back its own shares up to a limit of 10% of the issued share capital; and

 

 3.Reduce its share capital.

Transfer of ordinary shares

A certificated shareholding may be transferred in the usual form or in any other form approved by the Board. The Board in its discretion may refuse to register the transfer of a certificated share unless the instrument of transfer:

 

 1.is stamped or certified and lodged, at the registered office or other place that the Board decide, accompanied by the relevant share certificate and any other evidence that the Board may reasonably require to prove a legitimate right to transfer;

 

 2.is in respect of only one class of shares;

 

 3.is in favour of not more than four transferees; and

 

 4.is not fully paid.

Where the Board refuses to register a transfer of certificated shares, it must notify the transferee of the refusal within two months after the date on which the instrument of transfer was lodged with the Company.

For those members holding uncertificated shares, such transfers must be conducted using a relevant system as defined in the UK Uncertificated Securities Regulations 2001.

Untraced shareholders

The Company is entitled to sell any of its ordinary shares if;

 

 1.during the period of twelve years prior to the publication of any advertisement stating the intent to sell, at least three dividends have become payable on the shares which have remained uncashed; and

 

 2.during the period of three months following the publication of any advertisement stating the intent to sell, the company has received no indication of the location, or existence of the member, or the person entitled to the shares by way of transmission.

Dividend Rights

Subject to the provisions of the Act, the shareholders may by ordinary resolution declare a dividend no larger than the amount recommended by the Board. Interim dividends may also be payable if the Board deems that there is sufficient profit available for distribution. Except as otherwise provided by the rights attached to the shares, all dividends shall be declared and paid according to the amounts paid up on the shares on which the dividend is declared. No dividend payable in respect of a share shall bear interest against the Company, unless otherwise provided by the rights attached to the share.

Unclaimed dividends

Any dividend which remains unclaimed for 12 years from the date when it became due for payment shall, if the Board so resolves, be forfeited and cease to be owed by the Company to the shareholder. The Company may stop issuing dividend cheques or warrants:

 

 1.Where on at least two consecutive occasions dividend cheques/warrants are left uncashed or returned undelivered; or

 

 2.Where after one such occasion reasonable enquiries have failed to establish an updated address.

If the member goes on to claim a dividend or warrant, the Company must recommence issuing dividend cheques and warrants.

Distribution of assets on winding up

In the event of the company being wound up, on the authority of a special resolution of the Company and subject to the UK Insolvency Act 1986 (as amended) the liquidator may:

 

 1.Divide among the members the whole or any part of the assets of the Company.

 

 2.Value any assets and determine how the division should be made between the members or different classes of members.

 

 3.Place the whole or any part of the assets in trust for the benefit of the members and determine the scope and terms of these trusts.

A member cannot be compelled to accept an asset with an inherent liability.

Variation of rights

Subject to the Act, where the capital of the Company is divided into different classes of shares, the unique rights attached to the respective classes may be varied or cancelled:

 

 1.With the written consent of the holders of 75% in nominal value of the issued shares of the class (excluding any treasury shares held in that class); or

 

 2.By authority of a special resolution passed at a separate general meeting of the holders of the shares of the class.

General meetings of shareholders

Subject to the Act, the company must hold a general meeting every year. The Board may convene a general meeting when necessary and must do so promptly upon requisition by the shareholders. The notice period for annual general meetings is 21 clear days and 14 clear days for other general meetings. Subject to the Act and the Articles, the notice shall be sent to every member at their registered address. If, on two consecutive occasions notices are sent to a members registered address and have been returned undelivered the member shall not be entitled to receive any subsequent notice.

Voting rights

On a poll, every shareholder present in person or by proxy has one vote andfor every proxy duly appointed by a member has one vote.share of which he is the holder. No member is entitled to vote on a partly paid share. The Board also has the discretion to prevent a member from voting in person or by proxy if they are in default of a duly served notice under section 793 of the Act, concerning a request for information about interest in the company’s shares.

Directors’ Interests

Subject to the provisions of the Act, where a Director declares an interest to the Board, the Board may authorise the matter proposed to it which would otherwise constitute a conflict of interest and place a directorDirector in breach of their statutory

duty. Such authorisation is effective where the directorDirector in question is not included in the quorum for the meeting and the matter was agreed without their vote, or would have been agreed to had their vote not been counted. A director’sDirector’s duty to declare an interest does not apply in the circumstances provided for by section 177(5) and 177(6) of the Act. A director:Director:

 

 1.May be a party to, or otherwise interested in, any transaction or arrangement with the Company or in which the Company is otherwise (directly or interested in);

 

 2.May act solely or with his firm in a professional capacity (not as auditor) for the Company and shall be entitled to remuneration for his professional services, notwithstanding his position as director;Director; and

 

 3.May be interested in a body corporate in which the Company is directly or indirectly interested or where the relationship between the directorDirector and the body corporate is at the request or direction of the Company.

A directorDirector with a declared interest that has been authorised by the Board, is not liable to account to the Company or its shareholders for any benefits received.

Directors’ Remuneration

The remuneration of any executive directorExecutive Director shall be determined by the Board. It may include (without limitation) admission to or continuance of membership of any scheme (including share acquisition schemes), life assurance, pension provision or other such benefits payable to the directorDirector on or after retirement, or to his dependants on or after death.

For directorsDirectors who do not hold an executive position in the company, their ordinary remuneration shall not exceed in aggregate £500,000 per annum or such higher amount as the Company may determine by ordinary resolution from time to time. Each directorDirector shall be paid a fee for their services which is deemed to accrue from day to day at such rate as determined by the Board.

The directorsDirectors may grant extra remuneration to any directorDirector who does not hold executive office but sits on any committee of the Board, or performs any other special services at the request of the Company. This extra remuneration may be paid in addition to, or in substitution for the ordinary remuneration.

Directors’ appointment/retirement/removal

The Board may appoint a person willing to act as director,Director, either to fill a vacancy or as an additional director,Director, provided the upper limit set by the Articles is not exceeded. The Company may by ordinary resolution remove any directorDirector from office, no special notice need be given and no directorDirector proposed for removal under the Articles has a right of protest against such removal.

Borrowing powers

Subject to the Act, the Board may exercise all the powers of the Company to borrow money, guarantee, indemnify, mortgage or charge its undertaking, property, assets (present and future) and uncalled capital and to issue debentures and other securities whether outright or as collateral security for any debt, liability or obligation of the Company or of any third party. Without the authority of an ordinary resolution the directors are prohibited from borrowing an amount equal to the higher of (i) eight thousand million pounds; and (ii) two and a half times the adjusted total of capital and reserves.

Indemnity

Subject to the Act, without bar to any other existing indemnity entitlements, the Company may use its assets to indemnify a directorDirector against liability incurred through negligence, default, breach of duty or breach of trust in relation to Company affairs.

REED ELSEVIER NV (the “Company”)

The following is a summary of the principal provisions of the Company’s articlesArticles of associationAssociation (the “Articles”). As a summary, it is not exhaustive and is qualified in its entirety by reference to Dutch law and the Articles as they read in the Dutch language. The Articles were last amended before a civil law notary in Amsterdam on March 3, 2010May 8, 2013 after a shareholders’ resolution was passed to approve such amendment at the ExtraordinaryAnnual General Shareholders’ Meeting held on January 13, 2010.April 24, 2013. A copy of the current Articles is incorporated by reference from the 2009 Annual Reportregistration statement of securities to be offered to employees in employee benefit plans on Form 20-FS-8 filed with the SEC on March 18, 2010September 27, 2013 — see “Item 19: Exhibits” on pages S-3 and S-4.

Share Capital

Reed Elsevier NV has two types of shares: ordinary shares of 0.07 euro nominal value and R shares of 0.70 euro nominal value. At the General Shareholders’ Meeting, each ordinary share is entitled to cast one vote. Each R share is convertible into

10 ordinary shares and is entitled to cast ten (10) votes. Otherwise it has the same rights as an ordinary share, except that Reed Elsevier may pay a lower dividend on an R share, but not less than 1% of the nominal value of an R share. The ordinary shares are listed at NYSE Euronext Amsterdam and at NYSE New York.

As at December 31, 20122013 the Company’s issued share capital comprised 725,984,225734,149,956 ordinary shares and 4,303,179 R shares held by a subsidiary of Reed Elsevier PLC.shares. At December 31, 20122013 the total shares held in treasury were 44,226,598.67,451,493. Of these 6,990,1014,992,360 ordinary shares were held by the Reed Elsevier Group plc Employee Benefit Trust and 36,613,08760,895,193 ordinary shares and 62,341156,344 R shares (equivalent to 623,4101,563,940 ordinary shares) were held in treasury by the Company.

At the 2013 Annual General Shareholders’ Meeting, shareholders passed a resolution delegating the authority to the Board to acquire shares in the Company for a period of 18 months from the date of the annual general meeting of shareholders and therefore up to and including 23 October 2014, for the maximum amount of 10% of the issued capital. During the year, 25,222,636 ordinary shares, including 94,053 R shares (equivalent to 940,530 ordinary shares) from Reed Holding B.V., were purchased under this and the previous delegation of authority.

A resolution to renew the delegation of the authority to the Board will be submitted to the shareholders at the 2014 Annual General Shareholders’ Meeting.

Ordinary shares can be registered in a shareholder’s name or held via a book-entry deposit under the Dutch Giro Securities Trade Act.

Issuance of shares

Shares may be issued on the basis of a resolution of the general meeting of shareholders, which can designate this authority to the Combined Board, provided that the aggregate nominal value ofup to which shares may be issued under this designated authority cannot exceedone-third of the sum of (i) the Company’s issued share capital at the time the resolution to make the designation is adopted and (ii) the aggregate nominal value of any rights granted by the Company to take up shares outstanding at that time.

Pre-emptive rights of existing shareholders may be restricted or excluded by a resolution of the general meeting and in the event of an issue of shares pursuant to a resolution of the Combined Board, the pre-emptive rights can be restricted or excluded pursuant to a resolution of the Combined Board if that boardthe Board is designated competent to do so by the general meeting.

Acquisition of the Company’s own shares

The Company is entitled to acquire its own fully paid-up shares or depositary receipts thereof, provided that either the acquisition is for no consideration or that:

 

 (a)the Company’s equity after the deduction of the acquisition price, is not less than the sum of the paid-up and called-up part of the issued share capital and the reserves which must be maintained by virtue of the law; and

 

 (b)the nominal value of the shares or depositary receipts thereof, which the Company acquires, holds, holds in pledge or which are held by a Subsidiary, does not exceed one-tenth of the Company’s issued share capital. An acquisition of the Company’s own shares other than for no consideration is only permitted if the general meeting has granted authorisation to the Executive Board. No voting rights may be exercised on shares held by the company or a subsidiary and no dividend shall be paid on these shares.

An acquisition of the Company’s own shares other than for no consideration is only permitted if the general meeting has granted authorisation to the Board. No voting rights may be exercised on shares held by the company or a subsidiary and no dividend shall be paid on these shares.

The general meeting of shareholders may at the proposal of the Combined Board resolve to reduce the Company’s issued share capital through cancellation of shares or through reduction of the nominal value of shares by amendment of the Articles of Association, provided that the issued share capital or the paid-up part thereof will not drop below the amount prescribed by the Dutch Civil Code.

Transfer of shares

The transfer of a share shall require an instrument intended for such purpose and the written acknowledgement by the Company of the transfer. The transfer of the rights of a Euroclear-participant with respect to ordinary shares which are included in the securities depositary system of Euroclear Nederland shall be effected in accordance with the provisions of the Dutch Giro Securities Trade Act (Wet giraal effectenverkeer).

Dividend Rights

Each year the Combined Board shall determine which part of the profits shown in the adopted profit and loss account shall be reserved. After allocation to reserves, the shareholders’ meeting shall determine the allocation of remaining profits. Distributions may be made only insofar as the Company’s equity exceeds the amount of the paid in and called up part of the issued share capital, increased by the reserves which must be kept by virtue of the law. Dividends shall be paid after adoption of the annual accounts showing that payment of dividends is permitted. Interim distributions may be payable, provided there is sufficient profit available for distribution in accordance with the aforementioned requirements as shown by interim accounts.

The BoardsBoard

Reed Elsevier NV has a two-tierunitary board system,governance structure, comprising an Executive Boardexecutive and a Supervisory Board. The members of the Executive Board and the members of the Supervisory Board together form the Combined Board.non-executive directors. It is established board practice at Reed Elsevier NV that the members of both boardsexecutive and non-executive directors meet together astogether. In performing their duties, the Combined Board.

Executive Board

The Executive Board is entrusteddirectors shall act in accordance with the managementinterests of the company. The Executive Board functions as a collective bodyCompany and the business connected with shared responsibility. it.

The number of members of the Executive Boarddirectors is determined by the Combined Board, butBoard. The number of executive directors shall at all times be less than the number of members of the Supervisory Board. Members of the Executive Boardnon-executive directors.

Directors shall be appointed by the General Shareholders’ Meeting on the basis of a proposal of the Combined Board.Non-Executive Directors. Under the Articles, members of the Executive Boarddirectors are appointed for a three-year term, with the possibility of reappointment.re-appointment. Notwithstanding these provisions in the articles of association and in accordance with the provisions of the UK Corporate Governance Code, all members of the Executive BoardDirectors seek annual reappointmentre-appointment at the Annual General Meeting to align the arrangements regarding appointment for the Boards of Reed Elsevier NV and Reed Elsevier PLC.

SupervisoryExecutive Directors

The Executive Directors are entrusted with the management of the Company. In performing their duties, the Executive Directors shall act in accordance with the interests of the Company and the business connected with it. The Board has established rules regarding the decision-making and working methods of the Executive Directors in addition to the Articles. In this context, the Board has also determined the duties for which each Executive Director in particular shall be responsible.

Non-Executive Directors

The duties of the Supervisory BoardNon-Executive Directors are to supervise the management of the Executive Board, to supervise the policies of the Executive BoardDirectors and the general affairs in the Company and the business connected with it, and to assist the Executive Boardexecutive directors by providing advice. In performing their duties the Non-Executive Directors shall act in accordance with the interests of the Company and the business connected with it. The Non-Executive Directors have established rules regarding their decision-making process and working methods in addition to the Articles.

The number of members ofCompany pursues a remuneration policy for the Supervisory BoardExecutive Directors, which is determined by the Combined Board.general meeting upon a proposal by the Non-Executive Directors. The numberRemuneration Committee of membersReed Elsevier Group plc makes recommendations to the Non-Executive Directors of the Supervisory Board must always exceedCompany with regard to the number of members ofremuneration policy for Executive Directors and the remuneration in all its forms for the Executive Board.Directors.

Members of the Supervisory Board shall be appointed by the General Shareholders’ Meeting on proposal of the Combined Board. Under the Articles, members of the Supervisory Board are appointed for a three-year term, with the possibility of re-appointment and shall retire periodically in accordance with a rotation plan drawn up by the Combined Board. They shall retire no later than three years after appointment. As a general rule, members of the Supervisory BoardNon-Executive Directors serve for two three yearthree-year terms. Individual directorsDirectors may serve up to one additional three-year term. Notwithstanding these provisions in the articles of association and in accordance with the provisions of the UK Corporate Governance Code, all members of the Supervisory Board seek annual reappointment at the Annual General Meeting to align the arrangements regarding appointment for the Boards of Reed Elsevier NV and Reed Elsevier PLC. Annual reappointment will not affect the term of their three year appointment.

Suspension/dismissal

Each member of the Executive Board and/or the Supervisory BoardDirector can at any time be suspended or dismissed by the General Shareholders’ Meeting. In addition, each member of the Executive BoardDirector can at any time be suspended by the Supervisory Board.

Amendment of the Articles

Amendment of the Articles requires a shareholders’ resolution passed with an absolute majority of the votes cast, provided such resolution is passed at the proposal of the Combined Board. Otherwise, a majority of two-thirds of the votes cast is

required in a meeting at which at least half of the Company’s issued capital is represented. The notice for such a meeting must state that amendment of the Articles is on the agenda. A copy of the full text of the proposed amendment of the Articles must be made available free of charge to shareholders at the time of notice for the meeting. In accordance with Article 4443 of the Articles, only certain provisions in the Articles including provisions governing appointments and dismissals of members of the Executive and Supervisory Boardsdirectors can be amended upon a proposal of the Combined Board.

The Combined Board of Reed Elsevier NV has resolved to take the necessary steps to establish a one-tier governance structure at Reed Elsevier NV. For this purpose the Articles of Association of Reed Elsevier NV will have to be amended and a proposal for the one-tier governance structure will be put to the Annual General Meeting on April 24, 2013.

General meetings of shareholders

At least once a year, a General Shareholders’ Meeting is held. Notices of a general meeting are posted on the Reed Elsevier website and are made in accordance with the relevant provisions of the law. This means that the meeting is called at no less than 42 calendar days notice by an announcement on the Reed Elsevier website. The agenda and explanatory notes for the General Shareholders’ Meeting are published in advance on the website and are available at the listing agent and at the offices of Reed Elsevier NV from the day of the notice.

The Articles provide for a record date and this has been used at the recent General Shareholders’ Meetings. In accordance with Dutch law, the record date will be the 28th day before the date of the General Shareholders’ Meeting and the holder of shares as per the record date will be entitled to vote, irrespective of any transfer of such shares between the record date and the date of the general shareholders’ meeting.

The Annual General Shareholders’ Meeting discusses the annual report, adopts the annual accounts, resolves on a proposal to pay a dividend and votes on release from liability of the members of the Executive Board and the Supervisory Board from liabilitydirectors as separate agenda items in the annual general shareholders’ meeting.

Conflict of Interest - membersInterest—Directors

A Director shall not participate in the discussions and decision-making if he has a direct or indirect personal interest in the matter which is conflicting with the interests of the Boards

The handlingCompany and the business connected with it. In case because of any (apparent) conflict of interest between a member ofthis no resolution can be adopted by the Executive Board or a memberDirectors, the Non-Executive Directors will resolve on the matter. In case because of the Supervisory Board and the company is governedthis no resolution can be adopted by the Articles andNon-Executive Directors, the Rules forgeneral meeting will resolve on the Boards of Reed Elsevier NV.matter.

Remuneration

The remuneration policy for members of the Executive and the Supervisory BoardsDirectors is adopteddetermined by the General Shareholders’ Meeting.Meeting upon a proposal of the Non-Executive Directors. The remuneration of the members of the Executive BoardDirectors is determined by the Supervisory BoardNon-Executive Directors in line with the remuneration policy agreed by the shareholders’ meeting. With respect to remuneration in the form of shares in the Company and/or rights to subscribe for such shares, the Non-Executive Directors will submit a proposal for approval to the shareholders’ meeting.

The Non-Executive Directors receive an annual remuneration. The remuneration of members of the Supervisory Boardeach Non-Executive Director individually, is determined by the Combined Board, in line with the remuneration policy for non-executive directors. The maximum amount of annual remuneration shall be determined by the shareholders’ meeting and can only be adopted at the proposal of the Combined Board. At the Annual General Meeting in 2011 the maximum amount of remuneration for the Supervisory BoardNon-Executive Directors was set at €600,000 per annum, for the proportion of the fees borne by the Company.

Dissolution of the Company

A resolution to dissolve the Company requires an absolute majority of the votes cast at the General Meeting of Shareholders. The notice for such a meeting must state that dissolution will be on the agenda. If the Company is dissolved by a resolution of the general meeting, the members of the Executive Boardexecutive directors shall be charged with the liquidation of the Company and the Supervisory Boardnon-executive directors with the supervision thereof, subject to the relevant provisions of Book 2 of the Dutch Civil Code.

Assets which remain after payment of the debts shall be transferred to the holders of ordinary shares and the holders of class R shares in proportion to the nominal value of their shareholdings.

Indemnity

Under the Articles, to the extent permissible by law, the Company shall indemnify and hold harmless each sitting and former member of the Executive Board and of the Supervisory Boarddirector against the financial consequences of any liabilities or claims, brought by any party other than the Company itself or its group companies, in relation to acts or omissions performed or committed in that person’s capacity of member of the Executive Board or of the Supervisory Board.director.

MATERIAL CONTRACTS

Reed Elsevier has not entered into any material contract within the last two years.

EXCHANGE CONTROLS

There is currently no UK or Dutch legislation restricting the import or export of capital or affecting the remittance of dividends or other payments to holders of, respectively, Reed Elsevier PLC ordinary shares who are non-residents of the United Kingdom and Reed Elsevier NV ordinary shares who are non-residents of the Netherlands.

There are no limitations relating only to non-residents of the United Kingdom under UK law or Reed Elsevier PLC’s Memorandum and Articles of Association on the right to be a holder of, and to vote, Reed Elsevier PLC ordinary shares, or to non-residents of the Netherlands under Dutch law or Reed Elsevier NV’s Articles of Association on the right to be a holder of, and to vote, Reed Elsevier NV ordinary shares.

TAXATION

The following discussion is a summary under present law and tax authority practice of the material UK, Dutch and US federal income tax considerations relevant to the purchase, ownership and disposal of Reed Elsevier PLC ordinary shares or ADSs and Reed Elsevier NV ordinary shares or ADSs. This discussion applies to you only if you are a US holder, you hold your ordinary shares or ADSs as capital assets and you use the US dollar as your functional currency. It does not address the tax treatment of US holders subject to special rules, such as banks, dealers or traders in securities or currencies, insurance companies, tax-exempt entities, partnerships or other pass-through entities for US federal income tax purposes, holders of 10% or more of Reed Elsevier PLC or Reed Elsevier NV voting shares, persons holding ordinary shares or ADSs as part of a hedging, straddle, conversion or constructive sale transaction, persons that are resident ordinarily resident or domiciled in the

UK (or who have ceased to be resident in or became treated as resident outside the UK for the purpose of a double tax treaty (treaty non-resident) within the past five years of assessment, or, for departures before April 6, 2013, who have ceased to be resident or ordinarily resident or become treaty non-resident within the past five years of assessment) and persons that are resident in the Netherlands. The summary also does not discuss the US federal alternative minimum tax or the tax laws of particular states or localities in the US.

This summary does not consider your particular circumstances. It is not a substitute for tax advice.We urge you to consult your own independent tax advisors about the income, capital gains and/or transfer tax consequences to you in light of your particular circumstances of purchasing, holding and disposing of ordinary shares or ADSs.

As used in this discussion, “US holder” means a beneficial owner of ordinary shares or ADSs that is for US federal income tax purposes: (i) an individual US citizen or resident, (ii) a corporation, partnership or other business entity created or organised under the laws of the United States, any state thereof or the District of Columbia, (iii) a trust (a) that is subject to the control of one or more US persons and the primary supervision of a US court or (b) that has a valid election in effect under US Treasury regulations to be treated as a US person or (iv) an estate the income of which is subject to US federal income taxation regardless of its source.

UK Taxation

Dividends

Under current UK taxation legislation, no tax is required to be withheld at source from dividends paid on the Reed Elsevier PLC ordinary shares or ADSs. A shareholder in Reed Elsevier PLC who is an individual resident for UK tax purposes in the United Kingdom may be entitled, in calculating their liability to UK income tax, to a tax credit on cash dividends paid by the company. The tax credit is equal to one-ninth of the cash dividend.

Capital Gains

YouShareholders may be liable for UK taxation on capital gains realised on the disposal of yourtheir Reed Elsevier PLC ordinary shares or ADSs if at the time of the disposal you carrythe shareholder carries on a trade, profession or vocation in the United Kingdom through a branch or agency, or in the case of a company a permanent establishment, and such ordinary shares or ADSs are or have been used, held or acquired for the purposes of such trade, profession, vocation, branch, agency or permanent establishment.

UK Stamp Duty and Stamp Duty Reserve Tax

Current UK law includes provision whereby UK stamp duty reserve tax (SDRT) or UK stamp duty is payable upon the transfer or issue of Reed Elsevier PLC ordinary shares to the depositary in exchange for Reed Elsevier PLC ADSs evidenced by ADRs. For this purpose, the current rate of stamp duty and SDRT is 1.5%, applied, in each case, to: (i) the issue price when the ordinary shares are issued; (ii) the amount or value of the consideration where shares are transferred for consideration in money or money’s worth; or (iii) the value of the ordinary shares in any other case. Following litigation HMRC have accepted that they will no longer seek to apply the 1.5% SDRT charge on an issue of shares into a clearance service or depositary receipt system on the basis that the charge is not compatible with EU law. Accordingly no UK SDRT or

UK stamp duty is payable upon the issue of Reed Elsevier PLC shares to the depositary in exchange for Reed Elsevier PLC ADSs evidenced by ADRs. HMRC’s view is that the 1.5% SDRT or stamp duty charge will continue to apply to transfer of shares into a clearance service or depositary receipt system, unless they are an integral part of the issue of share capital. This view is currently being challenged in further litigation.

Provided that the relevant instrument of transfer is not executed in the UK and remains outside the UK, no UK stamp duty will be payable on the acquisition or subsequent transfer of Reed Elsevier PLC ADSs. Under current law, an agreement to transfer Reed Elsevier PLC ADSs will not give rise to a liability to SDRT.

A transfer of Reed Elsevier PLC ordinary shares by the depositary to an ADS holder where there is no transfer of beneficial ownership will not be chargeable to UK stamp duty or SDRT.

Purchases of Reed Elsevier PLC ordinary shares, as opposed to ADSs, will generally give rise to UK stamp duty or SDRT at the time of transfer or agreement to transfer, normally at the rate of 0.5% of the amount payable for the ordinary shares. SDRT and UK stamp duty are usually paid by the purchaser. If the ordinary shares are later transferred to the depositary, additional UK stamp duty or SDRT may be payable as described above.

Dutch Taxation

Withholding tax

Dividends distributed to you by Reed Elsevier NV are normally subject to a withholding tax imposed by the Netherlands at a rate of 15%, which rate equals the rate of tax that the Netherlands is generally allowed to levy under the US-Netherlands income tax treaty. As a consequence, no administrative procedures for a partial relief at source from or a refund of Dutch dividend withholding tax need be complied with in respect of dividend distributions by Reed Elsevier NV. Dividends include, among other things, stock dividends unless the dividend is distributed out of recognised paid-in share premium for Dutch tax purposes.

Taxation of dividends and capital gains

You will not be subject to any Dutch taxes on dividends distributed by Reed Elsevier NV (other than the withholding tax described above) or any capital gain realised on the disposal of Reed Elsevier NV ordinary shares or ADSs provided that (i) the Reed Elsevier NV ordinary shares or ADSs are not attributable to an enterprise or an interest in an enterprise that you carry on, in whole or part through a permanent establishment or a permanent representative in the Netherlands, (ii) you do not have a substantial interest or a deemed substantial interest in Reed Elsevier NV (generally, 5% or more of either the total issued and outstanding capital or the issued and outstanding capital of any class of shares) or, if you have such an interest, you do not hold such interest with the avoidance of Netherlands (or foreign) (withholding) tax as (one of) the main purpose(s) or it forms part of the assets of an enterprise, and (iii) if you are an individual, such dividend or capital gain from your Reed Elsevier NV ordinary shares or ADSs does not form benefits from miscellaneous activities(“resultaat uit overige werkzaamheden”) in the Netherlands. Benefits from miscellaneous activities in the Netherlands include income and gains derived from the holding, whether directly or indirectly, of (a combination of) shares, debt claims or other rights (together, a “lucrative interest”) that the holder thereof has acquired under such circumstances that such income and gains are intended to be remuneration for work or services performed by such holder (or a related person) in the Netherlands, whether within or outside an employment relation, where such lucrative interest provides the holder thereof, economically speaking, with certain benefits that have a relation to the relevant work or services.

US Federal Income Taxation

Holders of the ADSs generally will be treated for US federal income tax purposes as owners of the ordinary shares represented by the ADSs. Accordingly, deposits of ordinary shares for ADSs and withdrawals of shares for ADSs will not be subject to US federal income tax.

Dividends

Dividends on Reed Elsevier PLC ordinary shares or ADSs or Reed Elsevier NV ordinary shares or ADSs (including any Dutch tax withheld) will generally be included in your gross income as ordinary income from foreign sources. The dollar amount recognised on receiving a dividend in pounds sterling or euros will be based on the exchange rate in effect on the date the depositary receives the dividend, or in the case of ordinary shares on the date you receive the dividend, as the case may be, whether or not the payment is converted into US dollars at that time. Any gain or loss recognised on a subsequent conversion of pounds sterling or euros for a different amount will be US source ordinary income or loss. Dividends received will not be eligible for the dividends received deduction available to corporations. Dividends received will be included in net investment income for purposes of the 3.8% Medicare contribution tax applicable to certain non-corporate US holders.

With respect to US holders who are individuals, certain dividends received from a qualified foreign corporation may be subject to reduced rates of taxation. A qualified foreign corporation includes a foreign corporation that is eligible for the benefits of certain comprehensive income tax treaties with the United States. United States Treasury Department guidance indicates that the United Kingdom is a country with which the United States has a treaty in force that meets these requirements, and Reed Elsevier PLC believes it is eligible for the benefits of this treaty. Additionally, the same guidance indicates that the Netherlands is also a country with which the United States has a treaty in force that meets the above requirements, and Reed Elsevier NV believes it is eligible for the benefits of this treaty. Individuals that do not meet a minimum holding period requirement during which they are not protected from the risk of loss or that elect to treat the dividend income as “investment income” pursuant to section 163(d)(4) of the US Internal Revenue Code of 1986, as amended, will not be eligible for the reduced rates of taxation. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. US holders should consult their own tax advisors regarding the application of these rules given their particular circumstances.

Subject to certain conditions and limitations, foreign withholding taxes on dividends withheld at the appropriate rate may be treated as foreign taxes eligible for credit against your US federal income tax liability. For purposes of calculating the foreign tax credit, dividends paid on the ordinary shares or ADSs will be treated as income from sources outside the US and will generally constitute passive category income. Further, in certain circumstances, if you have held the ordinary shares or ADSs for less than a specified minimum period during which you are not protected from risk of loss, or are obligated to make payments related to the dividends, you will not be allowed a foreign tax credit for foreign taxes imposed on the dividends on the ordinary shares or ADSs. Individuals that treat a dividend as qualified dividend income may take into account for foreign tax credit limitation purposes only the portion of the dividend effectively taxed at the highest applicable marginal rate. The rules governing the foreign tax credit are complex. You are urged to consult your tax advisors regarding the availability of the foreign tax credit under your particular circumstances.

Dispositions

You will recognise a gain or loss on the sale or other disposition of ordinary shares or ADSs in an amount equal to the difference between your basis in the ordinary shares or ADSs and the amount realised. The gain or loss generally will be

capital gain or loss. It will be long term capital gain or loss if you have held the ordinary shares or ADSs for more than one year at the time of sale or other disposition. Long term capital gains of individuals are eligible for reduced rates of taxation. Deductions for capital losses are subject to limitations. Any gain or loss you recognise generally will be treated as income from US sources for foreign tax credit limitation purposes.

If you receive pounds sterling or euros on the sale or other disposition of your ordinary shares or ADSs, you will realise an amount equal to the US dollar value of the pounds sterling or euros on the date of sale or other disposition (or in the case of cash basis and electing accrual basis taxpayers, if the ordinary shares or ADSs are traded on an established securities market, the settlement date for the sale or other disposition). You will have a tax basis in the pounds sterling or the euros that you receive equal to the US dollar amount received on the settlement date. Any gain or loss realised by a US holder between the sale date and the settlement date or on a subsequent conversion of pounds sterling or euros into US dollars will be US source ordinary income or loss. Gains recognised will be included in net investment income for purposes of the 3.8% Medicare contribution tax applicable to certain non-corporate US holders.

Information Reporting and Backup Withholding Tax

Dividends from ordinary shares or ADSs and proceeds from the sale of the ordinary shares or ADSs may be reported to the Internal Revenue Service (“IRS”)(IRS) unless the shareholder is a corporation or other exempt recipient. A backup withholding tax may apply to such amounts unless the shareholder (i) is a corporation, (ii) provides an accurate taxpayer identification number and otherwise complies with applicable requirements of the backup withholding rules, or (iii) otherwise establishes a basis for exemption. The amount of any backup withholding tax will be allowed as a credit against the holder’s US federal income tax liability and may entitle the holder to a refund, provided the required information is furnished to the IRS.

Recently enacted legislation requires certainCertain US holders are required to report to the IRS information about their investment in ordinary shares or ADSs not held through an account with a domestic financial institution. Investors who fail to report required information are subject to substantial penalties. Investors should consult with their own tax advisers about the effect of this legislation on their investment in the ordinary shares or ADSs.

DOCUMENTS ON DISPLAY

You may read and copy documents referred to in this annual report that have been filed with the SEC at the SEC’s public reference room located at 100 F Street NE, Washington, DC 20549-2521. Please call the SEC at 1-800-SEC-0330 for further information on the public reference rooms and their copy charges.

ITEM 11: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market Risk

Reed Elsevier’s primary market risks are to changes in interest rates and exchange rates as well as liquidity and credit risk.

Net finance costs are exposed to interest rate fluctuations on borrowings, cash and cash equivalents. Upward fluctuations in interest rates increase the interest cost of floating rate borrowings whereas downward fluctuations in interest rates decrease the interest return on floating rate cash and cash equivalents. Interest expense payable on fixed rate borrowings is protected against upward fluctuations in interest rates but does not benefit from downward fluctuations. Reed Elsevier companies engage in foreign currency denominated transactions and are therefore subject to exchange rate risk on such transactions. Net finance costs are also exposed to changes in the fair value of derivatives (as a result of interest and exchange rate fluctuations) which are not part of a designated hedging relationship under IAS39 — Financial Instruments,Instruments: Recognition and Measurement, and to ineffectiveness that may arise on designated hedging relationships. Reed Elsevier’s management of this interest rate risk and foreign exchange rate risk is described below.

Reed Elsevier manages a portfolio of long term debt, short term debt and committed bank facilities to support its capital structure and is exposed to the risk that relevant markets are closed and debt cannot be refinanced on a timely basis. In addition, the credit spread at which Reed Elsevier borrows is exposed to changes in market liquidity and investor demand. Reed Elsevier manages this risk by maintaining a range of borrowing facilities and debt programmes with a maturity profile to facilitate refinancing.

Reed Elsevier has a credit exposure for the full principal amount of cash and cash equivalents held with individual counterparties. In addition, it has a credit risk from the potential non performance by counterparties to financial instruments; this credit risk normally being restricted to the amounts of any hedge gain and not the full principal amount being hedged. Credit risks are managed by monitoring the credit quality of counterparties and restricting the amounts outstanding with each of them.

Reed Elsevier’s management of the above market risks is described in further detail on pages 3440 to 3741 of Item 5: Operating and Financial Review and Prospects: Liquidity and Capital Resources — Reed Elsevier.

Management of Interest Rate Risk and Foreign Exchange Rate Risk

Reed Elsevier seeks to limit its risk to interest and exchange rates by means of derivative financial instruments, including interest rate swaps, interest rate options, forward rate agreements and forward foreign exchange contracts. Reed Elsevier only enters into derivative financial instruments to hedge (or reduce) the underlying risks described above.

Reed Elsevier enters into interest rate swaps in order to achieve an appropriate balance between fixed and variablefloating rate borrowings, cash and cash equivalents. They are used to hedge the effects of fluctuating interest rates on variablefloating rate borrowings, cash and cash equivalents by allowing Reed Elsevier to fix the interest rate on a notional principal amount equal to the principal amount of the underlying floating rate cash, cash equivalents or borrowings being hedged. They are also used to swap fixed interest rates payable on long term borrowings for a variablefloating rate. Such swaps may be used to swap a whole fixed rate bond for variablefloating rate or they may be used to swap a portion of the period or a portion of the principal amount for the variablefloating rate.

Forward swaps and forward rate agreements are entered into to hedge interest rate exposures known to arise at a future date. These exposures may include new borrowings or cash deposits to be entered into at a future date or future rollovers of existing borrowings or cash deposits. Interest exposure arises on future, new and rollover borrowings and cash deposits because interest rates can fluctuate between the time a decision is made to enter into such transactions and the time those transactions are actually entered into. The purpose of forward swaps and forward rate agreements is to fix the interest cost on future borrowings or interest return on cash investments at the time it is known such a transaction will be entered into. The fixed interest rate, the floating rate index (if applicable) and the time period covered by forward swaps and forward rate agreements are known at the time the agreements are entered into. The use of forward swaps and forward rate agreements is limited to hedging activities; consequently no trading position results from their use. The hedging effect of forward swaps and forward rate agreements is the same as interest rate swaps. Similarly, Reed Elsevier utilises forward foreign exchange contracts to hedge the effects of exchange rate movements on its foreign currency revenue and operating costs.

Interest rate options protect against fluctuating interest rates by enabling Reed Elsevier to fix the interest rate on a notional principal amount of borrowings or cash deposits (in a similar manner to interest rate swaps and forward rate agreements) whilst at the same time allowing Reed Elsevier to improve the fixed rate if the market moves in a certain way. Reed Elsevier uses interest rate options from time to time when it expects interest rates to move in its favour but it is deemed imprudent to leave the interest rate risk completely unhedged. In such cases, Reed Elsevier may use an option to lock in at certain rates whilst at the same time maintaining some freedom to benefit if rates move in its favour.

Where net finance costs are exposed to changes in the fair value of derivatives (as a result of interest and exchange rate fluctuations), Reed Elsevier manages this risk by designating derivatives in a highly effective hedging relationship unless the potential change in their fair value is deemed to be insignificant.

Derivative financial instruments are utilised to hedge (or reduce) the risks of interest rate or exchange rate movements and are not entered into unless such risks exist. Derivatives utilised, while appropriate for hedging a particular kind of risk, are not considered specialised or high-risk and are generally available from numerous sources.

Sensitivity Analysis

The following analysis sets out the sensitivity of the fair value of Reed Elsevier’s financial instruments to selected changes in interest rates and exchange rates. The range of changes represents Reed Elsevier’s view of the changes that are reasonably possible over a one year period.

The fair values of interest rate swaps, interest rate options, forward rate agreements and forward foreign exchange contracts set out below represent the replacement costs calculated using market rates of interest and exchange at December 31, 2012.2013. The fair value of long term borrowings has been calculated by discounting expected future cash flows at market rates.

Reed Elsevier’s use of financial instruments and its accounting policies for financial instruments are described more fully in notes 2 and 1918 to the combined financial statements.

(a) Interest Rate Risk

The following sensitivity analysis assumes an immediate 100 basis point change in interest rates for all currencies and maturities from their levels at December 31, 20122013 with all other variables held constant.

 

Financial Instrument

 Fair Value
December 31,
2012
  Fair Value Change Fair Value
December 31,
2011
  Fair Value Change  Fair Value
December 31,
2013
  Fair Value Change Fair Value
December 31,
2012
  Fair Value Change 
 +100
basis points
 -100
basis points
 +100
basis points
 -100
basis points
   +100
basis points
 -100
basis points
 +100
basis points
 -100
basis points
 
 (In millions)     (In millions)      (In millions)     (In millions)     

Short term borrowings

 £(131 £   £ —   £(596 £   £   £(287 £    —   £    —   £(131 £   £  

Long term borrowings (including current portion)

  (4,231  190    (187  (4,093  171    (175  (3,360  159    (166  (4,231  190    (187

Interest rate swaps (swapping fixed rate debt to floating)

  127    (47  49    123    (28  23    92    (47  44    127    (47  49  

Interest rate swaps (swapping floating rate debt to fixed)

  (2  2    (1  (10  4    (3      1        (2  2    (1

A 100 basis point change in interest rates would not result in a material change to the fair value of other financial instruments.

At December 31, 2012, 59%2013, 57% of gross borrowings are either fixed rate or have been fixed through the use of interest rate swaps, forward rate agreements and options. A 100 basis point reduction in interest rates would result in an estimated decrease in net finance costs of £8£12 million (2011: £5(2012: £8 million), based on the composition of financial instruments including cash, cash equivalents, bank loans and commercial paper borrowings at December 31, 2012.2013. A 100 basis points rise in interest rates would result in an estimated increase in net finance costs of £8£12 million (2011: £5(2012: £8 million).

(b) Foreign Exchange Rate Risk

The following sensitivity analysis assumes an immediate 10% change in all foreign currency exchange rates against sterling from their levels at December 31, 20122013 with all other variables held constant. A +10% change indicates a strengthening of the currency against sterling and a -10% change indicates a weakening of the currency against sterling.

 

Financial Instrument

 Fair Value
December 31,
2012
  Fair Value Change Fair Value
December 31,
2011
  Fair Value Change  Fair Value
December 31,
2013
  Fair Value Change Fair Value
December 31,
2012
  Fair Value Change 
 +10% -10% +10% -10%   +10% -10% +10% -10% 
  (In millions)      (In millions)     (In millions)     (In millions)     

Cash and cash equivalents

 £641   £23   £(23 £726   £56   £(56 £132   £13   £(13 £641   £23   £(23

Short term borrowings

  (131  (13  13    (596  (60  60    (287  (26  26    (131  (13  13  

Long term borrowings (including current portion)

  (4,231  (339  339    (4,093  (330  330    (3,360  (256  256    (4,231  (339  339  

Interest rate swaps (including cross currency interest rate swaps)

  138    10    (10  128    10    (10  79    6    (6  138    10    (10

Forward foreign exchange contracts

  46    (58  58    (48  (57  57    92    (62  62    46    (58  58  

A 10% change in foreign currency exchange rates would not result in a material change to the fair value of other financial instruments.

ITEM 12: DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

Fees and charges for American Depositary Receipt (ADR) holders

The Bank of New York Mellon, as depositary for the Reed Elsevier PLC and Reed Elsevier NV American Depositary ReceiptADR programs, collects its fees for delivery and surrender of American Depositary Shares (ADSs) directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deductions from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

 

Persons depositing or withdrawing shares must pay

  

For

$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)

  Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property (in certain circumstances volume discounts may be available)
  Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates

$0.02 (or less) per ADS

  Any cash distribution to ADS registered holders
A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs  

Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS

registered holders

$0.02 (or less) per ADS per calendar year

  Depositary services

Registration or transfer fees

  

Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you

deposit or withdraw shares

Expenses of the depositary

  Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)
  Converting foreign currency to US dollars
Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes  As necessary
Any charges incurred by the depositary or its agents for servicing the deposited securities  As necessary

Fees and other payments made by the depositary to Reed Elsevier

In consideration of acting as depositary, Bank of New York Mellon has agreed to make certain reimbursements and payments to Reed Elsevier on an annual basis for expenses related to the administration and maintenance of the ADR programs including, but not limited to, New York Stock Exchange listing fees, investor relations expenses, or any other program related expenses. The depositary has also agreed to pay the standard out-of-pocket administrative, maintenance and shareholder services expenses for providing services to the registered DR holders. It has also agreed with Reed Elsevier to waive certain standard fees associated with promotional services, program visibility campaigns and program analytic reporting. In certain instances, the depositary has agreed to provide additional annual reimbursements and payments to Reed Elsevier based on any applicable performance indicators relating to the ADR facility. There are limits on the amount of expenses for which the depositary will reimburse Reed Elsevier, but the amount of reimbursement available to Reed Elsevier is not necessarily tied to the amount of fees the depositary collects from investors.

From January 1, 20122013 to February 27, 2013,26, 2014, Reed Elsevier received a reimbursement of $225,000, net of withheld taxes, from the depositary for New York Stock Exchange listing fees, investor relations expenses and other program related expenses, in connection with the ADR facility.

PART II

ITEM 15: CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Reed Elsevier PLC and Reed Elsevier NV are required to comply with applicable US regulations, including the Sarbanes-Oxley Act, insofar as they apply to foreign private issuers. Accordingly, Reed Elsevier PLC and Reed Elsevier NV have established a Disclosure Committee comprising the company secretaries of Reed Elsevier PLC and Reed Elsevier NV and other senior Reed Elsevier managers appointed by the Chief Executive Officer and Chief Financial Officer of Reed Elsevier PLC and Reed Elsevier NV. The committee has reviewed and evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2012.2013. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer of Reed Elsevier PLC and Reed Elsevier NV have concluded that ourthe disclosure controls and procedures for the Reed Elsevier combined businesses, Reed Elsevier PLC and Reed Elsevier NV are effective as of the end of the period covered by this report.

Management’s Annual Report on Internal Control over Financial Reporting

In accordance with Section 404 of the Sarbanes-Oxley Act, management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a — 15(f) and 15d — 15(f) under the Exchange Act, as amended. Reed Elsevier’sThe internal controlcontrols over financial reporting isof the Reed Elsevier combined businesses, Reed Elsevier PLC and Reed Elsevier NV, are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of Reed Elsevier’sthe financial statements of the Reed Elsevier combined businesses, Reed Elsevier PLC and Reed Elsevier NV would be prevented or detected.

Reed Elsevier management conducted an evaluation of the effectiveness of its internal control over financial reporting based on the framework in Internal Control-Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that the internal controls over financial reporting of the Reed Elsevier combined businesses, Reed Elsevier PLC and Reed Elsevier NV were effective as of December 31, 2012.2013.

Certifications by the Chief Executive Officer and Chief Financial Officer of Reed Elsevier PLC and Reed Elsevier NV as required by the Sarbanes-Oxley Act are submitted as exhibits to this Form 20-F (see “Item 19: Exhibits” on pages S-3 andS-4).

Deloitte LLP and Deloitte Accountants BV have audited the Reed Elsevier combined financial statements for the fiscal year ended December 31, 20122013 and have audited the effectiveness of internal control over financial reporting. Their report in respect of the Reed Elsevier combined businesses is included herein. Deloitte LLP have audited the consolidated financial statements of Reed Elsevier PLC and Deloitte Accountants BV have audited the consolidated financial statements of Reed Elsevier NV for the fiscal year ended December 31, 2012.2013. They have also audited the effectiveness of internal control over financial reporting; their reports in respect of Reed Elsevier PLC and Reed Elsevier NV, respectively, are included herein.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and members of Reed Elsevier PLC and to the membersBoard of the SupervisoryDirectors and Executive Boards and the shareholders of Reed Elsevier NV:

We have audited the internal control over financial reporting of the combined businesses of Reed Elsevier PLC, Reed Elsevier NV, Reed Elsevier Group plc and Elsevier Reed Finance BV and their respective subsidiaries, associates and joint ventures (together the “Combined Businesses”), as at December 31, 2012,2013, based on criteria established inInternal Control — Integrated Framework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission. The management of Reed Elsevier PLC and Reed Elsevier NV are responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Combined Businesses’ internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Combined Businesses maintained, in all material respects, effective internal control over financial reporting as at December 31, 2012,2013, based on the criteria established inInternal Control — Integrated Framework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the combined statement of financial position and the related combined income statement and combined statements of comprehensive income, cash flows and changes in equity as at and for the year ended December 31, 20122013 of the Combined Businesses and our report dated February 27, 201326, 2014 expressed an unqualified opinion on those financial statements.statements and included an explanatory paragraph regarding the Combined Businesses’ adoption of International Accounting Standards 19Employee Benefits (revised).

 

/s/ DELOITTE LLP

London, United Kingdom

February 27, 201326, 2014

 

/s/ DELOITTE ACCOUNTANTS B.V.

Amsterdam, The Netherlands

February 27, 201326, 2014

 
 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and members of Reed Elsevier PLC:

We have audited the internal control over financial reporting of Reed Elsevier PLC and its subsidiaries (the “Company”) as at December 31, 2012,2013, based on criteria established inInternal Control — Integrated Framework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as at December 31, 2012,2013, based on the criteria established inInternalControlIntegratedFramework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated statement of financial position and the related consolidated income statement and the statements of comprehensive income, cash flows and changes in equity as at and for the year ended December 31, 20122013 of the Company and our report dated February 27, 201326, 2014 expressed an unqualified opinion on those financial statements.statements and included an explanatory paragraph regarding the Company’s adoption of International Accounting Standards 19Employee Benefits (revised).

 

/s/S/ DELOITTE LLP
London, United Kingdom
February 27, 201326, 2014

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the membersBoard of the SupervisoryDirectors and Executive Boards and the shareholders of Reed Elsevier NV:

We have audited the internal control over financial reporting of Reed Elsevier NV and its subsidiaries (the “Company”) as at December 31, 2012,2013, based on criteria established inInternalControlIntegratedFramework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as at December 31, 2012,2013, based on the criteria established inInternalControlIntegratedFramework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated statement of financial position and the related consolidated income statement and statements of comprehensive income, cash flows and changes in equity as at and for the year ended December 31, 20122013 of the Company and our report dated February 27, 201326, 2014 expressed an unqualified opinion on those financial statements.statements and included an explanatory paragraph regarding the Company’s adoption of International Accounting Standards 19Employee Benefits (revised).

 

/s/ DELOITTE ACCOUNTANTS B.V.

Amsterdam, The Netherlands

February 27, 201326, 2014

Internal ControlsControl over Financial Reporting

Management, including the Chief Executive Officer and Chief Financial Officer of Reed Elsevier PLC and Reed Elsevier NV, have reviewed whether or not during the period covered by the annual report, there have been any changes in internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the internal controlcontrols over financial reporting.reporting of the Reed Elsevier combined businesses, Reed Elsevier PLC and Reed Elsevier NV. Based on that review, the Chief Executive Officer and Chief Financial Officer of Reed Elsevier PLC and Reed Elsevier NV have concluded that there have been no such changes.

An outline of the internal control structure is set out below.

Parent companies

The Boards of Reed Elsevier PLC and Reed Elsevier NV exercise independent supervisory roles over the activities and systems of internal control of Reed Elsevier Group plc and Elsevier Reed Finance BV. The Boards of Reed Elsevier PLC and Reed Elsevier NV have each adopted a schedule of matters which are required to be brought to them for decision. In relation to Reed Elsevier Group plc and Elsevier Reed Finance BV, the Boards of Reed Elsevier PLC and Reed Elsevier NV approve the strategy and the annual budgets, and receive regular reports on the operations, including the treasury and risk management activities of the two companies. Major transactions proposed by the Boards of Reed Elsevier Group plc or Elsevier Reed Finance BV require the approval of the Boards of both Reed Elsevier PLC and Reed Elsevier NV.

The Reed Elsevier PLC and Reed Elsevier NV Audit Committees meet on a regular basis to review the systems of internal control and risk management of Reed Elsevier Group plc and Elsevier Reed Finance BV.

Operating companies

The Board of Reed Elsevier Group plc is responsible for the system of internal control of the Reed Elsevier publishing and information businesses, while the Boards of Elsevier Reed Finance BV are responsible for the system of internal control in respect of the finance activities. The Boards of Reed Elsevier Group plc and Elsevier Reed Finance BV are also responsible for reviewing the effectiveness of their system of internal control.

The Boards of Reed Elsevier Group plc and Elsevier Reed Finance BV have each implemented an ongoing process for identifying, evaluating, monitoring and managing the more significant risks faced by their respective businesses. This process has been in place throughout the year ended December 31, 20122013 and up to the date of the approvals of this annual report.

Reed Elsevier Group plc

Reed Elsevier Group plc has an established framework of procedures and internal controls, with which the management of each business is required to comply. Group businesses are required to maintain systems of internal control which are appropriate to the nature and scale of their activities and address all significant operational and financial risks that they face. The Board of Reed Elsevier Group plc has adopted a schedule of matters that are required to be brought to it for decision.

Reed Elsevier Group plc has a Code of Ethics and Business Conduct that provides a guide for achieving its business goals and requires officers and employees to behave in an open, honest, ethical and principled manner. The code also outlines confidential procedures enabling employees to report any concerns about compliance, or about Reed Elsevier’s financial reporting practice. The code is published on the Reed Elsevier website, www.reedelsevier.com. The information on our website is not incorporated by reference into this report.

Each division has identified and evaluated its major risks, the controls in place to manage those risks and the level of residual risk accepted. Risk management and control procedures are embedded into the operations of the business and include the monitoring of progress in areas for improvement that come to management and board attention. The major risks identified include business continuity, protection of IT systems and data, challenges to intellectual property rights, management of strategic and operational change, evaluation and integration of acquisitions, and recruitment and retention of personnel. Further detail on the principal risks facing Reed Elsevier is set out on pages 78 to 10.11.

The major strategic risks facing the Reed Elsevier Group plc businesses are regularly reported to and considered by the Board. Reed Elsevier’s Chief Risk Officer has the responsibility to provide regular reports to the Board and Audit Committee. Working closely withWith the close involvement of business management and with the central functions, the role of the Chief Risk Officer is torisk management and control procedures ensure that Reed Elsevier is managing its business risks effectively and in a coordinated manner across the business with clarity on the respective responsibilities and interdependencies. Litigation and other legal and regulatory matters are managed by legal directors in Europe and the United States.

The Reed Elsevier Group plc Audit Committee receives regular reports on the management of material risks and reviews these reports. The Audit Committee also receives regular reports from both internal and external auditors on internal control and risk management matters. In addition, each division is required, at the end of the financial year, to review the

effectiveness of internal controls and risk management and report its findings on a detailed basis to the management of Reed Elsevier Group plc. These reports are summarised and, as part of the annual review of effectiveness, submitted to the Audit Committee of Reed Elsevier Group plc. The Chairman of the Audit Committee reports to the boardBoard on any significant internal control matters arising.

Elsevier Reed Finance BV

Elsevier Reed Finance BV has established policy guidelines, which are applied for all Elsevier Reed Finance BV companies. The Boards of Elsevier Reed Finance BV have adopted schedules of matters that are required to be brought to them for decision.

Procedures are in place for monitoring the activities of the finance group, including a comprehensive treasury reporting system. The major risks affecting the finance group have been identified and evaluated and are subject to regular review. The controls in place to manage these risks and the level of residual risk accepted are monitored by the Boards of Elsevier Reed Finance BV.

Audit Committees

Reed Elsevier Group plc, Reed Elsevier PLC and Reed Elsevier NV have established Audit Committees which comprise only non-executive directors, all of whom are independent. The Audit Committees, which meet regularly, are chaired by Ben van der Veer, the other members being Sir David Reid, Linda Sanford and Adrian Hennah.

The main roles and responsibilities of the Audit Committees in relation to the respective companies are set out in written terms of reference and include:

 

 (i)to monitor the integrity of the financial statements of the company, and any formal announcements relating to the company’s financial performance, reviewing significant financial reporting judgements contained in them;

 

 (ii)to review the company’s internal financial controls and the company’s internal control and risk management systems;

 

 (iii)to monitor and review the effectiveness of the company’s internal audit function;

 

 (iv)to make recommendations to the Board, for it to put to the shareholders for their approval in general meeting, in relation to the appointment, reappointment and removal of the external auditor and to approve the remuneration and terms of engagement of the external auditor;

 

 (v)to review and monitor the external auditors’ independence and objectivity and the effectiveness of the audit process, taking into consideration relevant professional and regulatory requirements; and

 

 (vi)to develop and recommend policy on the engagement of the external auditor to supply non audit services, taking into account relevant ethical guidance regarding the provision of non audit services by the external audit firm, and to monitor compliance.

The Audit Committees report to the respective boards on their activities identifying any matters in respect of which they consider that action or improvement is needed and making recommendations as to the steps to be taken.

The Reed Elsevier Group plc Audit Committee fulfils this role in respect of the publishing and information operating business. The functions of an audit committee in respect of the financing activities are carried out by the Supervisory Board of Elsevier Reed Finance BV. The Reed Elsevier PLC and Reed Elsevier NV Audit Committees fulfil their roles from the perspective of the parent companies and both Committees have access to the reports to and the work of the Reed Elsevier Group plc Audit Committee and the Elsevier Reed Finance BV Supervisory Board in this respect.

The Audit Committees have explicit authority to investigate any matters within their terms of reference and have access to all resources and information that they may require for this purpose. The Audit Committees are entitled to obtain legal and other independent professional advice and have the authority to approve all fees payable to such advisers.

The terms of reference of each Audit Committee are reviewed annually and a copy of each is published on the Reed Elsevier website, www.reedelsevier.com. The information on our website is not incorporated by reference into this report.

Compliance with New York Stock Exchange Corporate Governance Rules

Reed Elsevier PLC and Reed Elsevier NV, as companies listed on the New York Stock Exchange (the “NYSE”), are subject to the listing requirements of the NYSE and the rules of the U.S. Securities and Exchange Commission (the “SEC”). We also continually monitor our compliance with the provisions of the Sarbanes-Oxley Act of 2002 that are applicable to foreign private issuers.

In November 2003, the SEC approved new corporate governance standards for companies that are listed on the NYSE. As a foreign private issuer, Reed Elsevier is only required to comply with certain of the NYSE corporate governance rules and is in compliance with all applicable rules. The NYSE’s rules also require disclosure of any significant ways in which our corporate governance practices differ from those required of US companies under the NYSE listing standards.

Reed Elsevier follows UK corporate governance practice, which does not differ significantly from the NYSE corporate governance standards for foreign issuers. We also follow Dutch corporate governance practice. We believe that our corporate governance practices do not differ in any significant way from those required to be followed by US companies under the NYSE corporate governance listing standards.

The NYSE listing standards provide that US companies must have a nominating/corporate governance committee composed entirely of independent directors and with a written charter that addresses the committee’s purpose and responsibilities which, at a minimum, must be to identify individuals qualified to become board members, develop and recommend to the Board a set of corporate governance principles and to oversee the evaluation of the board and management.

Reed Elsevier PLC and Reed Elsevier NV have a joint Nominations Committee and a joint Corporate Governance Committee. The written terms of reference adopted by the Reed Elsevier PLC and the Reed Elsevier NV Boards for these committees specify purposes and responsibilities that correspond to those of a US company’s nominating/corporate governance committee under the NYSE’s listing standards. The Nominations Committee and the Corporate Governance Committee isare composed entirely of non executive directors.

ITEM 16A: AUDIT COMMITTEE FINANCIAL EXPERT

Each of Reed Elsevier PLC and Reed Elsevier NV has an Audit Committee, the members of which are identified in “Item 15: Controls6: Directors, Senior Management and Procedures”Employees”. The members of the Board of Directors of Reed Elsevier PLC and members of the Supervisory Board of Reed Elsevier NV, respectively, have determined that each of their respective Audit Committees contains at least one Audit Committee financial expert within the meaning of the applicable rules and regulations of the US Securities and Exchange Commission (“SEC”).SEC. The Audit Committee financial experts serving on the Reed Elsevier PLC and the Reed Elsevier NV Audit Committees are Adrian Hennah Sir David Reid and Ben van der Veer. Each is considered independent.

ITEM 16B: CODES OF ETHICS

Reed Elsevier has adopted a code of ethics (Code of Ethics and Business Conduct) that applies to all directors, officers and employees, and an additional separate code of ethics (Code for Senior Officers) that also applies to the Chief Executive Officer and Chief Financial Officer of Reed Elsevier PLC and Reed Elsevier NV and the Group Financial Controller of Reed Elsevier Group plc. Both these codes of ethics are available on the Reed Elsevier website, www.reedelsevier.com. The information on our website is not incorporated by reference into this report.

ITEM 16C: PRINCIPAL ACCOUNTANT FEES AND SERVICES

The aggregate fees billed by our principal accountants, Deloitte LLP, Deloitte Accountants BV, the member firms of Deloitte Touche Tohmatsu and their respective affiliates, were as follows:

 

  Year ended
December 31,
2012
   Year ended
December 31,
2011
   Year ended
December 31,
2013
   Year ended
December 31,
2012
 
  (in millions)   (in millions) 

Audit fees

  £4.7    £4.7     £4.9    £4.9  

Audit related fees

   0.7     0.2     0.4     0.7  

Tax fees

   0.8     0.7     1.8     0.8  

All other fees

   0.3     0.2          0.3  
  

 

   

 

   

 

   

 

 

Total

  £6.5    £5.8     £7.1    £6.7  
  

 

   

 

   

 

   

 

 

Auditors’ remuneration for audit services comprises £0.5Audit fees of £4.9 million (2011:(2012: £4.9 million) comprise £0.6 million (2012: £0.5 million; 2010: £0.4 million) payable to the auditors of the parent companies and £4.2£4.3 million (2011: £4.2 million; 2010: £4.1(2012: £4.4 million) payable to the auditors of the parent companies and their associates for the audit of the financial statements of the operating and financing businesses, including the review and testing of internal control over financial reporting in accordance with the US Sarbanes-Oxley Act. Auditors’ remuneration for non audit services comprises: £0.8Audit related fees comprise £0.4 million (2011:(2012: £0.7 million; 2010: £0.9 million) for other audit related assurance services. Tax fees of £1.8 million (2012: £0.8 million) relate to tax advisory and compliance services,services. All other fees totalling nil (2012: £0.3 million (2011: £0.2 million; 2010: nil) formillion) relate to due diligence and other transaction related services and £0.7 million (2011: £0.2 million; 2010: £0.3 million) for other audit related assurance services.

The Audit Committees of Reed Elsevier PLC and Reed Elsevier NV have adopted policies and procedures for the pre-approval of audit and non audit services provided by the auditors. These policies and procedures are summarised below.

The terms of engagement and scope of the annual audit of the financial statements are agreed by the respective Audit Committees in advance of the engagement of the auditors in respect of the annual audit. The audit fees are approved by the Audit Committees.

The auditors are not permitted to provide non audit services that would compromise their independence or violate any laws or regulations that would affect their appointment as auditors. They are eligible for selection to provide non audit services only to the extent that their skills and experience make them a logical supplier of the services. The respective Audit Committees must pre-approve the provision of all non audit services by the auditors and will consider SEC rules and other guidelines in determining the scope of permitted services. The respective Audit Committees have pre-approved non audit services in respect of individual assignments for permitted services that meet certain criteria. Assignments outside these parameters must be specifically pre-approved by the Audit Committees in advance of commissioning the work. Aggregate non audit fees must not exceed the annual audit fees in any given year, unless approved in advance by the Audit Committees.

All of the audit and non audit services carried out in the year ended December 31, 20122013 were pre-approved under the policies and procedures summarised above.

ITEM 16D: EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Not applicable.

ITEM 16E: PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

During 20122013 Reed Elsevier repurchased 23,288,61641,961,920 Reed Elsevier PLC ordinary shares and 12,660,29624,282,106 Reed Elsevier NV ordinary shares for total consideration of £250£600 million. These shares are held in treasury. On

   PLC   NV 
   Number of ordinary
shares
   Average price
paid per share
   Number of ordinary
shares
   Average price paid
per share
 
   

 

   pence   

 

    

January 2013

   6,773,000     670     3,903,969     11.38  

February 2013

   1,362,000     703     794,550     11.62  

March 2013

   3,758,800     753     2,141,800     12.57  

April 2013

   3,149,000     761     1,837,000     12.82  

May 2013

   3,830,500     754     2,241,000     12.84  

June 2013

   3,765,470     737     2,186,087     12.64  

July 2013

   838,000     842     485,000     14.32  

August 2013

   7,028,000     813     4,065,000     13.99  

September 2013

   5,327,000     820     3,082,000     14.48  

October 2013

   3,168,000     841     1,831,500     14.75  

November 2013

   1,821,200     884     1,053,700     15.61  

December 2013

   1,140,950     869     660,500     15.33  
  

 

 

   

 

 

   

 

 

   

 

 

 
   41,961,920     773     24,282,106     13.29  
  

 

 

   

 

 

   

 

 

   

 

 

 

All shares were purchased under programmes publicly announced on December 28, 2012, February 28, 2013 and July 25, 2013. All of these programmes were completed during 2013.

On December 16, 2013 Reed Elsevier PLC and Reed Elsevier NV announcedannouced an irrevocable, non discretionarynon-discretionary programme to repurchase further ordinary shares up to the value of £100 million. A further 6,045,270 Reed Elsevier PLC shares and 3,511,668 Reed Elsevier NV ordinary shares have been repurchased in January and February 2014 under this programme. On February 27, 2014, Reed Elsevier PLC and Reed Elsevier NV annouced their intention to repurchase further ordinary shares up to the value of £500 million in aggregate which was completed in February 2013.over the remainder of 2014.

In December 2013 Reed Elsevier also repurchased 94,053 Reed Elsevier NV R shares (equivalent to 940,530 Reed Elsevier NV ordinary shares).

The Reed Elsevier Group plc Employee Benefit Trust (“EBT”) has not made any share purchases during the year.

ITEM 16F: CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

Not applicable.

ITEM 16G: CORPORATE GOVERNANCE

Details of Reed Elsevier’s corporate governance practices are set out on pages 8794 to 89100 of Item 15: Controls and Procedures.

PART III

ITEM 17: FINANCIAL STATEMENTS

The Registrants have responded to Item 18 in lieu of responding to this Item.

THIS PAGE INTENTIONALLY BLANK

ITEM 18: FINANCIAL STATEMENTS

Financial Statements filed as part of this annual report

The following financial statements and related schedules, together with reports of independent registered public accounting firms thereon, are filed as part of this annual report:

 

   Page 

Index to Financial Statements

   F-1  

Reed Elsevier Combined Financial Statements

   F-3  

Report of Independent Registered Public Accounting Firm

   F-5  

Combined Income Statements

   F-6  

Combined Statements of Comprehensive Income

   F-6  

Combined Statements of Cash Flows

   F-7  

Combined Statements of Financial Position

   F-8  

Combined Statements of Changes in Equity

   F-9  

Notes to the Combined Financial Statements

   F-10  

Reed Elsevier PLC Consolidated Financial Statements

   F-55F-56  

Report of Independent Registered Public Accounting Firm

   F-56F-57  

Consolidated Income Statements

   F-57F-58  

Consolidated Statements of Comprehensive Income

   F-57F-58  

Consolidated Statements of Cash Flows

   F-58F-59  

Consolidated Statements of Financial Position

   F-59F-60  

Consolidated Statements of Changes in Equity

   F-60F-61  

Notes to the Consolidated Financial Statements

   F-61F-62  

Reed Elsevier NV Consolidated Financial Statements

   F-69F-70  

Report of Independent Registered Public Accounting Firm

   F-70F-71  

Consolidated Income Statements

   F-71F-72  

Consolidated Statements of Comprehensive Income

   F-71F-72  

Consolidated Statements of Cash Flows

   F-72F-73  

Consolidated Statements of Financial Position

   F-73F-74  

Consolidated Statements of Changes in Equity

   F-74F-75  

Notes to the Consolidated Financial Statements

   F-75F-76  

 

 

THIS PAGE INTENTIONALLY BLANK

 

 

 

 

 

REED ELSEVIER

COMBINED FINANCIAL STATEMENTS

 

 

 

 

 

THIS PAGE INTENTIONALLY BLANK

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and members of Reed Elsevier PLC and to the membersBoard of the SupervisoryDirectors and Executive Boards and the shareholders of Reed Elsevier NV:

We have audited the accompanying combined statements of financial position of Reed Elsevier PLC, Reed Elsevier NV, Reed Elsevier Group plc and Elsevier Reed Finance BV and their respective subsidiaries, associates and joint ventures (together the “Combined Businesses”) as at December 31, 2013, 2012 2011 and 2010,2011, and the related combined income statements and combined statements of comprehensive income, cash flows and changes in equity for each of the years then ended. These combined financial statements are the responsibility of the management of Reed Elsevier PLC and Reed Elsevier NV. Our responsibility is to express an opinion on the combined financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such combined financial statements present fairly, in all material respects, the combined financial position of the Combined Businesses as at December 31, 2013, 2012 2011 and 2010,2011, and the combined results of their operations and their cash flows for each of the years then ended, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

As discussed in Accounting policies in the combined financial statements, the accompanying 2012 and 2011 financial statements have been retrospectively adjusted for the adoption of International Accounting Standards 19Employee Benefits (revised).

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Combined Businesses’ internal control over financial reporting as at December 31, 2012,2013, based on the criteria established inInternal Control — Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 27, 201326, 2014 expressed an unqualified opinion on the Combined Businesses’ internal control over financial reporting.

 

/s/ DELOITTE LLP

London, United Kingdom

February 27, 201326, 2014

  

/s/ DELOITTE ACCOUNTANTS B.V.

Amsterdam, The Netherlands

February 27, 201326, 2014

REED ELSEVIER

COMBINED INCOME STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
 2012
Restated
£m
 2011
Restated
£m
 

Revenue

   3     6,116    6,002    6,055     3     6,035    6,116    6,002  

Cost of sales

     (2,139  (2,126  (2,209     (2,118  (2,139  (2,126
    

 

  

 

  

 

     

 

  

 

  

 

 

Gross profit

     3,977    3,876    3,846       3,917    3,977    3,876  

Selling and distribution costs

     (1,015  (1,075  (1,091     (1,005  (1,015  (1,075

Administration and other expenses

     (1,628  (1,626  (1,687     (1,565  (1,653  (1,660

Share of results of joint ventures

     24    30    22       29    24    30  
    

 

  

 

  

 

     

 

  

 

  

 

 

Operating profit

   4     1,358    1,205    1,090     4     1,376    1,333    1,171  
    

 

  

 

  

 

     

 

  

 

  

 

 

Finance income

   9     16    17    8     8     10    16    17  

Finance costs

   9     (232  (252  (284   8     (206  (243  (261
    

 

  

 

  

 

     

 

  

 

  

 

 

Net finance costs

     (216  (235  (276     (196  (227  (244
    

 

  

 

  

 

     

 

  

 

  

 

 

Disposals and other non operating items

   10     45    (22  (46   9     16    45    (22
    

 

  

 

  

 

     

 

  

 

  

 

 

Profit before tax

     1,187    948    768       1,196    1,151    905  

Taxation

   11     (113  (181  (120
    

 

  

 

  

 

 

Current tax

     (352  (153  (258

Deferred tax

     271    51    91  
    

 

  

 

  

 

 

Tax expense

   10     (81  (102  (167
    

 

  

 

  

 

     

 

  

 

  

 

 

Net profit for the year

     1,074    767    648       1,115    1,049    738  
    

 

  

 

  

 

     

 

  

 

  

 

 

Attributable to:

            

Parent companies’ shareholders

     1,069    760    642       1,110    1,044    731  

Non-controlling interests

     5    7    6       5    5    7  
    

 

  

 

  

 

     

 

  

 

  

 

 

Net profit for the year

     1,074    767    648       1,115    1,049    738  
    

 

  

 

  

 

     

 

  

 

  

 

 

REED ELSEVIER

COMBINED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
 2012
Restated
£m
 2011
Restated
£m
 

Net profit for the year

     1,074    767    648       1,115    1,049    738  

Items that will not be reclassified to profit or loss:

      

Actuarial gains/(losses) on defined benefit pension schemes

     40    (293  (70

Tax on items that will not be reclassified to profit or loss

   10     (24  96    22  
    

 

  

 

  

 

 

Total items that will not be reclassified to profit or loss

     16    (197  (48
    

 

  

 

  

 

 

Items that may be reclassified subsequently to profit or loss:

      

Exchange differences on translation of foreign operations

     (136  32    94       (88  (136  32  

Actuarial losses on defined benefit pension schemes

   7     (329  (113  (63

Fair value movements on available for sale investments

         (1                 (1

Transfer to net profit on disposal of available for sale investments

     11                   11      

Fair value movements on cash flow hedges

     70    (24  (58     65    70    (24

Transfer to net profit from cash flow hedge reserve (net of tax)

   19     21    37    46     18     (2  21    37  

Tax recognised directly in equity

   11     88    42    29  

Tax on items that may be reclassified to profit or loss

   10     (15  (19  6  
    

 

  

 

  

 

     

 

  

 

  

 

 

Other comprehensive (expense)/income for the year

     (275  (27  48  

Total item that may be reclassified to profit or loss

     (40  (53  50  
    

 

  

 

  

 

 

Other comprehensive loss for the year

     (24  (250  2  
    

 

  

 

  

 

     

 

  

 

  

 

 

Total comprehensive income for the year

     799    740    696       1,091    799    740  
    

 

  

 

  

 

     

 

  

 

  

 

 

Attributable to:

            

Parent companies’ shareholders

     794    733    690       1,086    794    733  

Non-controlling interests

     5    7    6       5    5    7  
    

 

  

 

  

 

     

 

  

 

  

 

 

Total comprehensive income for the year

     799    740    696       1,091    799    740  
    

 

  

 

  

 

     

 

  

 

  

 

 

REED ELSEVIER

COMBINED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
 2012
£m
 2011
£m
 

Cash flows from operating activities

            

Cash generated from operations

   12     1,847    1,735    1,649     11     1,943    1,847    1,735  

Interest paid

     (231  (247  (295     (200  (231  (247

Interest received

     7    12    8       5    7    12  

Tax paid (net)

     (216  (218  (9     (362  (216  (218
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash from operating activities

     1,407    1,282    1,353       1,386    1,407    1,282  
    

 

  

 

  

 

     

 

  

 

  

 

 

Cash flows from investing activities

            

Acquisitions

   12     (316  (481  (50   11     (221  (316  (481

Purchases of property, plant and equipment

     (70  (85  (83     (57  (70  (85

Expenditure on internally developed intangible assets

     (263  (265  (228     (251  (263  (265

Purchase of investments

     (7  (10  (5     (10  (7  (10

Proceeds from disposals of property, plant and equipment

     7    7    7       6    7    7  

Gross proceeds from other disposals

     235    101    66  

Payments on other disposals

     (82  (21  (60

Gross proceeds from business disposals

     311    235    101  

Payments on business disposals

     (116  (82  (21

Dividends received from joint ventures

     20    33    24       22    20    33  
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash used in investing activities

     (476  (721  (329     (316  (476  (721
    

 

  

 

  

 

     

 

  

 

  

 

 

Cash flows from financing activities

            

Dividends paid to shareholders of the parent companies

     (521  (497  (483     (549  (521  (497

Distributions to non-controlling interests

     (4  (9  (8     (6  (4  (9

(Decrease)/increase in short term bank loans, overdrafts and commercial paper

     (434  210    (143

Issuance of other loans

     592          

Repayment of other loans

     (437  (248  (394

Increase/(decrease) in short term bank loans, overdrafts and commercial paper

     169    (434  210  

Issuance of term debt

     184    592      

Repayment of term debt

     (915  (437  (248

Repayment of finance leases

     (4  (22  (7     (10  (4  (22

Disposal/(acquisition) of non-controlling interests

     7    (48             7    (48

Repurchase of ordinary shares

     (250             (600  (250    

Proceeds on issue of ordinary shares

     48    9    11       125    48    9  
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash used in financing activities

     (1,003  (605  (1,024     (1,602  (1,003  (605
    

 

  

 

  

 

     

 

  

 

  

 

 

Decrease in cash and cash equivalents

     (72  (44         (532  (72  (44
    

 

  

 

  

 

     

 

  

 

  

 

 

Movement in cash and cash equivalents

            

At start of year

     726    742    734       641    726    742  

Decrease in cash and cash equivalents

     (72  (44         (532  (72  (44

Exchange translation differences

     (13  28    8       23    (13  28  
    

 

  

 

  

 

     

 

  

 

  

 

 

At end of year

     641    726    742       132    641    726  
    

 

  

 

  

 

     

 

  

 

  

 

 

REED ELSEVIER

COMBINED STATEMENT OF FINANCIAL POSITION

AS AT DECEMBER 31, 20122013

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
 2012
£m
 2011
£m
 

Non-current assets

            

Goodwill

   15     4,545    4,729    4,441     14     4,576    4,545    4,729  

Intangible assets

   16     3,275    3,494    3,457     15     3,124    3,275    3,494  

Investments in joint ventures

   17     100    124    136     16     125    100    124  

Other investments

   17     79    64    48     16     92    79    64  

Property, plant and equipment

   18     264    288    291     17     237    264    288  

Net pension assets

   7             55  

Deferred tax assets

   20     79    212    151     19     442    79    212  

Derivative financial instruments

   19     138             18     64    138      
    

 

  

 

  

 

     

 

  

 

  

 

 
     8,480    8,911    8,579       8,660    8,480    8,911  
    

 

  

 

  

 

     

 

  

 

  

 

 

Current assets

            

Inventories and pre-publication costs

   21     159    190    228     20     142    159    190  

Trade and other receivables

   22     1,380    1,483    1,475     21     1,416    1,380    1,483  

Derivative financial instruments

   19     57    149    134     18     124    57    149  

Cash and cash equivalents

     641    726    742       132    641    726  
    

 

  

 

  

 

     

 

  

 

  

 

 
     2,237    2,548    2,579       1,814    2,237    2,548  
    

 

  

 

  

 

     

 

  

 

  

 

 

Assets held for sale

   23     297    44         22     21    297    44  
    

 

  

 

  

 

     

 

  

 

  

 

 

Total assets

     11,014    11,503    11,158       10,495    11,014    11,503  
    

 

  

 

  

 

     

 

  

 

  

 

 

Current liabilities

            

Trade and other payables

   24     2,544    2,657    2,584     23     2,595    2,544    2,657  

Derivative financial instruments

   19     11    69    80     18     4    11    69  

Borrowings

   25     730    982    516     24     648    730    982  

Taxation

     603    677    646       588    603    677  

Provisions

   27     30    39    71     26     17    30    39  
    

 

  

 

  

 

     

 

  

 

  

 

 
     3,918    4,424    3,897       3,852    3,918    4,424  
    

 

  

 

  

 

     

 

  

 

  

 

 

Non-current liabilities

            

Derivative financial instruments

   18     13          

Borrowings

   25     3,162    3,300    3,786     24     2,633    3,162    3,300  

Deferred tax liabilities

   20     919    1,236    1,192     19     1,076    919    1,236  

Net pension obligations

   7     466    242    225     6     379    466    242  

Provisions

   27     139    87    88     26     116    139    87  
    

 

  

 

  

 

     

 

  

 

  

 

 
     4,686    4,865    5,291       4,217    4,686    4,865  
    

 

  

 

  

 

     

 

  

 

  

 

 

Liabilities associated with assets held for sale

   23     96    17         22     3    96    17  
    

 

  

 

  

 

     

 

��

  

 

  

 

 

Total liabilities

     8,700    9,306    9,188       8,072    8,700    9,306  
    

 

  

 

  

 

     

 

  

 

  

 

 

Net assets

     2,314    2,197    1,970       2,423    2,314    2,197  
    

 

  

 

  

 

     

 

  

 

  

 

 

Capital and reserves

            

Combined share capitals

   29     223    223    224     27     224    223    223  

Combined share premiums

   30     2,727    2,723    2,754     28     2,887    2,727    2,723  

Combined shares held in treasury

   31     (899  (663  (677   29     (1,464  (899  (663

Translation reserve

   32     (23  88    29     30     (137  (23  88  

Other combined reserves

   33     252    (199  (387   31     880    252    (199
    

 

  

 

  

 

     

 

  

 

  

 

 

Combined shareholders’ equity

     2,280    2 ,172    1,943       2,390    2,280    2 ,172  

Non-controlling interests

     34    25    27       33    34    25  
    

 

  

 

  

 

     

 

  

 

  

 

 

Total equity

     2,314    2,197    1,970       2,423    2,314    2,197  
    

 

  

 

  

 

     

 

  

 

  

 

 

COMBINED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

 Note Combined
share
capitals
£m
 Combined
share
premiums
£m
 Combined
shares
held in
treasury
£m
 Translation
reserve
£m
 Other
combined
reserves
£m
 Combined
shareholders’
equity
£m
 Non-
controlling
interests
£m
 Total
equity
£m
 

Balance at January 1, 2013

   223    2,727    (899  (23  252    2,280    34    2,314  

Total comprehensive income for the year

               (88  1,174    1,086    5    1,091  

Dividends paid

  13                    (549  (549  (6  (555

Issue of ordinary shares, net of expenses

   1    124                125        125  

Repurchase of ordinary shares

  29            (600          (600      (600

Increase in share based remuneration reserve (net of tax)

                   48    48        48  

Settlement of share awards

           40        (40            

Exchange differences on translation of capital and reserves

       36    (5  (26  (5            
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Balance at December 31, 2013

   224    2,887    (1,464  (137  880    2,390    33    2,423  
 Note Combined
share
capitals
£m
 Combined
share
premiums
£m
 Combined
shares
held in
treasury
£m
 Translation
reserve

£m
 Other
combined
reserves
£m
 Combined
shareholders’
equity

£m
 Non-
controlling
interests
£m
 Total
equity
£m
   

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Balance at January 1, 2012

   223    2,723    (663  88    (199  2,172    25    2,197     223    2,723    (663  88    (199  2,172    25    2,197  

Total comprehensive income for the year

               (136  930    794    5    799                 (136  930    794    5    799  

Dividends paid

  14                    (521  (521  (4  (525  13                    (521  (521  (4  (525

Issue of ordinary shares, net of expenses

   1    47                48        48     1    47                48        48  

Repurchase of ordinary shares

  31            (250          (250      (250  29            (250          (250      (250

Increase in share based remuneration reserve

                   31    31        31                     31    31        31  

Settlement of share awards

           7        (7                       7        (7            

Acquisitions

                           9    9                             9    9  

Disposal of non-controlling interests

                   6    6    1    7                     6    6    1    7  

Exchange differences on translation of capital and reserves

   (1  (43  7    25    12        (2  (2   (1  (43  7    25    12        (2  (2
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Balance at December 31, 2012

   223    2,727    (899  (23  252    2,280    34    2,314     223    2,727    (899  (23  252    2,280    34    2,314  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Balance at January 1, 2011

   224    2,754    (677  29    (387  1,943    27    1,970     224    2,754    (677  29    (387  1,943    27    1,970  

Total comprehensive income for the year

               32    701    733    7    740                 32    701    733    7    740  

Dividends paid

  14                    (497  (497  (9  (506  13                    (497  (497  (9  (506

Issue of ordinary shares, net of expenses

       9                9        9         9                9        9  

Increase in share based remuneration reserve

                   27    27        27                     27    27        27  

Settlement of share awards

           7        (7                       7        (7            

Acquisitions

                           5    5                             5    5  

Acquisition of non-controlling interests

                   (43  (43  (5  (48                   (43  (43  (5  (48

Exchange differences on translation of capital and reserves

   (1  (40  7    27    7                 (1  (40  7    27    7              
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Balance at December 31, 2011

   223    2,723    (663  88    (199  2,172    25    2,197     223    2,723    (663  88    (199  2,172    25    2,197  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Balance at January 1, 2010

   225    2,807    (698  (100  (502  1,732    27    1,759  

Total comprehensive income for the year

               94    596    690    6    696  

Dividends paid

  14                    (483  (483  (8  (491

Issue of ordinary shares, net of expenses

       11                11        11  

Decrease in share based remuneration reserve

                   (7  (7      (7

Settlement of share awards

           9        (9            

Exchange differences on translation of capital and reserves

   (1  (64  12    35    18        2    2  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Balance at December 31, 2010

   224    2,754    (677  29    (387  1,943    27    1,970  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

REED ELSEVIER

NOTES TO THE COMBINED FINANCIAL STATEMENTS

 

1.Basis of preparation

The Reed Elsevier combined financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and as adopted by the European Union.

On January 1, 1993 Reed Elsevier PLC and Reed Elsevier NV contributed their businesses to two jointly owned companies, Reed Elsevier Group plc and Elsevier Reed Finance BV. Reed Elsevier Group plc, which owns the publishing and information businesses, is incorporated in England and Elsevier Reed Finance BV, which owns the financing companies, is incorporated in the Netherlands. Reed Elsevier PLC and Reed Elsevier NV each hold a 50% interest in Reed Elsevier Group plc. Reed Elsevier PLC holds a 39% interest in Elsevier Reed Finance BV, with Reed Elsevier NV holding a 61% interest. Reed Elsevier PLC additionally holds an indirect equity interest in Reed Elsevier NV, reflecting the arrangements entered into between Reed Elsevier PLC and Reed Elsevier NV at the time of the merger, which determined the equalisation ratio whereby one Reed Elsevier NV ordinary share is, in broad terms, intended to confer equivalent economic interests to 1.538 Reed Elsevier PLC ordinary shares.

The equalisation agreement between Reed Elsevier PLC and Reed Elsevier NV has the effect that their shareholders can be regarded as having the interests of a single economic group. The Reed Elsevier combined financial statements (“the combined financial statements”) represent the combined interests of both sets of shareholders and encompass the businesses of Reed Elsevier Group plc and Elsevier Reed Finance BV and their respective subsidiaries, associates and joint ventures, together with the two parent companies, Reed Elsevier PLC and Reed Elsevier NV (“the combined businesses”).

 

2.Accounting policies

The Reed Elsevier accounting policies are set out below:

Principles of combination

In preparing the combined financial statements, subsidiaries of Reed Elsevier Group plc and Elsevier Reed Finance BV are accounted for under the acquisition method and investments in associates and joint ventures are accounted for under the equity method. All transactions and balances between the combined businesses are eliminated.

On acquisition of a subsidiary, or interest in an associate or joint venture, fair values, reflecting conditions at the date of acquisition, are attributed to the net assets, including identifiable intangible assets acquired. This includes those adjustments made to bring accounting policies into line with those of the combined businesses. The results of subsidiaries sold or acquired are included in the combined financial statements up to or from the date that control passes from or to the combined businesses.

Non-controlling interests in the net assets of the combined businesses are identified separately from combined shareholders’ equity. Non-controlling interests consist of the amount of those interests at the date of the original acquisition and the non-controlling share of changes in equity since the date of acquisition.

Foreign exchange translation

The combined financial statements are presented in pounds sterling.

Transactions in foreign currencies are recorded at the rate of exchange prevailing on the date of the transaction. At each statement of financial position date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rate prevailing on the statement of financial position date. Exchange differences arising are recorded in the income statement other than where hedge accounting applies as set out below.

Assets and liabilities of foreign operations are translated at exchange rates prevailing on the statement of financial position date. Income and expense items and cash flows of foreign operations are translated at the average exchange rate for the period. Significant individual items of income and expense and cash flows in foreign operations are translated at the rate prevailing on the date of transaction. Exchange differences arising are classified as equity and transferred to the translation reserve. When foreign operations are disposed of, the related cumulative translation differences are recognised within the income statement in the period.

Reed Elsevier uses derivative financial instruments, primarily forward contracts, to hedge its exposure to certain foreign exchange risks. Details of Reed Elsevier’s accounting policies in respect of derivative financial instruments are set out below.

2.Accounting policies – (continued)

 

Revenue

Revenue represents the invoiced value of sales less anticipated returns on transactions completed by performance, excluding customer sales taxes and sales between the combined businesses.taxes.

Revenues are recognised for the various categories of turnover as follows: subscriptions — on periodic despatch of subscribed product or rateably over the period of the subscription where performance is not measurable by despatch; circulation and transactional — on despatch or occurrence of the transaction;transaction or exhibition and advertising — on publication or over the period of online display; and exhibitions — on occurrence of the exhibition.display.

Where sales consist of two or more independent components whose value can be reliably measured, revenue is recognised on each component as it is completed by performance, based on attribution of relative value.

Employee benefits

The expense of defined benefit pension schemes and other post-retirement employee benefits is determined using the projected unit credit method and charged in the income statement as an operating expense, based on actuarial assumptions reflecting market conditions at the beginning of the financial year. Actuarial gains and losses are recognised in full in the statement of comprehensive income in the period in which they occur.

Past service costs are recognised immediately toat the extent thatearlier of when plan amendments or curtailments occur and when related restructuring costs or termination benefits have vested, or, if not vested, on a straight line basis over the period until the benefits vest.are recognised. Settlements are recognised when they occur.

Net pension obligations in respect of defined benefit schemes are included in the statement of financial position at the present value of scheme liabilities, less the fair value of scheme assets. Where schemes are in surplus, i.e. assets exceed liabilities, the net pension assets are separately included in the statement of financial position. Any net pension asset is limited to the extent that the asset is recoverable through reductions in future contributions.

The expense of defined contribution pension schemes and other employee benefits is charged in the income statement as incurred.

Share based remuneration

The fair value of share based remuneration is determined at the date of grant and recognised as an expense in the income statement on a straight line basis over the vesting period, taking account of the estimated number of shares that are expected to vest. Market based performance criteria are taken into account when determining the fair value at the date of grant. Non-market based performance criteria are taken into account when estimating the number of shares expected to vest. The fair value of share based remuneration is determined by use of a binomial or Monte Carlo simulation model as appropriate. All Reed Elsevier’s share based remuneration is equity settled.

Borrowing costs

Borrowing costs that are directly attributable to the acquisition, construction or production of an asset that takes a substantial period of time to bring to use are capitalised. All other interest on borrowings is expensed as incurred. The cost of issuing borrowings is generally expensed over the period of borrowing so as to produce a constant periodic rate of charge.

Taxation

TheTax expense comprises current and deferred tax. Current and deferred tax expense representsare charged or credited in the sum ofincome statement except to the extent that the tax payable on the current year taxable profits, adjustments in respect of prior year taxable profits, and the movements on deferred tax that arearises from a transaction or event which is recognised, in the same or a different period, outside profit or loss (either in other comprehensive income, statement.directly in equity, or through a business combination) in which case the tax appears in the same statement as the transaction that gave rise to it.

TheCurrent tax is the amount of corporate income taxes payable or recoverable based on current yearthe profit for the period as adjusted for items that are not taxable profitsor not deductible, and is calculated using tax rates and laws that were enacted or substantively enacted at the date of the statement of financial position. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. Provisions are established where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the statement of financial position. Deferred tax is calculated using tax rates and laws that have been enacted or substantively enacted byat the dateend of the statement of financial position.

Deferred tax isreporting period, and which are expected to apply when the tax arising on differences between the carrying amounts of assets and liabilities in the financial statements and their corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences andrelated deferred tax assets are recognised toasset is realized or the extent that, based on current forecasts, itdeferred tax liability is probable that taxable profits will be available against which deductible temporary differences can be utilised. Deferred tax is not recognised on temporary differences arising in respect of goodwill that is not deductible for tax purposes.settled.

2.Accounting policies – (continued)

 

Deferred tax liabilities are generally recognised for all taxable temporary differences but not recognised for taxable temporary differences arising on investments in subsidiaries, associates and joint ventures where the reversal of the temporary difference can be controlled and it is calculated usingprobable that the difference will not reverse in the foreseeable future. Deferred tax ratesliabilities are not recognised on temporary differences that have been substantively enactedarise from goodwill which is not deductible for tax purposes.

Deferred tax assets are recognised to the extent it is probable that taxable profits will be available against which the deductible temporary differences can be utilised and are reviewed at the dateend of the statement of financial position. Full provision is made for deferred tax which would become payable on the distribution of retained profits from foreign subsidiaries, associates or joint ventures.

Movements in deferred tax are charged or credited in the income statement, except when they relate to items charged or credited directly to equity, in which case the deferred tax is also recognised in equity. Deferred tax credits in respect of share based remuneration are recognised in equityeach reporting period and reduced to the extent that expectedit is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax deductions exceed the related expense.assets and liabilities are not recognised in respect of temporary differences that arise on initial recognition of assets and liabilities acquired other than in a business combination. Deferred tax is not discounted.

Goodwill

On the acquisition of a subsidiary or business, the purchase consideration is allocated between the net tangible and intangible assets on a fair value basis, with any excess purchase consideration representing goodwill. Goodwill arising on acquisitions also includes amounts corresponding to deferred tax liabilities recognised in respect of acquired intangible assets.

Goodwill is recognised as an asset and reviewed for impairment when there is an indicator that the asset may be impaired and at least annually. Any impairment is recognised immediately in the income statement and not subsequently reversed.

On disposal of a subsidiary or business, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

Intangible assets

Intangible assets acquired as part of a business combination are stated in the statement of financial position at their fair value as at the date of acquisition, less accumulated amortisation. Internally generated intangible assets are stated in the statement of financial position at the directly attributable cost of creation of the asset, less accumulated amortisation.

Intangible assets acquired as part of business combinations comprise: market related assets (e.g. trademarks, imprints, brands); customer related assets (e.g. subscription bases, customer lists, customer relationships); editorial content; software and systems (e.g. application infrastructure, product delivery platforms, in-process research and development); contract based assets (e.g. publishing rights, exhibition rights, supply contracts); and other intangible assets. Internally generated intangible assets typically comprise software and systems development where an identifiable asset is created that is probable to generate future economic benefits.

Intangible assets, other than brands and imprints determined to have indefinite lives, are amortised systematicallyon a straight line basis over their estimated useful lives. The estimated useful lives of intangible assets with finite lives are as follows: market and customer related assets — 3 to 40 years; content, software and other acquired intangible assets — 3 to 20 years; and internally developed intangible assets — 3 to 10 years. Brands and imprints determined to have indefinite lives are not amortised and are subject to an impairment review at least annually.

Property, plant and equipment

Property, plant and equipment are stated in the statement of financial position at cost less accumulated depreciation. No depreciation is provided on freehold land. Freehold buildings and long leases are depreciated over their estimated useful lives up to a maximum of 50 years. Short leases are written off over the duration of the lease. Depreciation is provided on other assets on a straight line basis over their estimated useful lives as follows: leasehold improvements — shorter of life of lease and 10 years; plant — 3 to 20 years; office furniture, fixtures and fittings — 5 to 10 years; computer systems, communication networks and equipment — 3 to 7 years.

Investments

Investments, other than investments in joint venturesarrangements and associates, are stated in the statement of financial position at fair value. Investments held as part of the venture capital portfolio are classified as held for trading, with changes in fair value reported throughin disposals and other non operating items in the income statement. All other investments are classified as available for sale with changes in fair value recognised directly in equity until the investment is disposed of or is determined to be impaired, at which time the cumulative gain or loss previously recognised in equity is brought into the net profit or loss for the period. All items recognised in the income statement relating to investments, other than investments in joint venturesarrangements and associates, are reported as disposals and other non operating items.

2.Accounting policies – (continued)

Available for sale investments and venture capital investments held for trading represent investments in listed and unlisted securities. The fair value of listed securities is determined based on quoted market prices, and of unlisted securities on management’s estimate of fair value based on standard valuation techniques, including market comparisons and discounts of future cash flows, having regard to maximising the use of observable inputs and adjusting for risk. Advice from independent valuation experts areis used as appropriate.

2.Accounting policies – (continued)

All joint arrangements are classified as joint ventures because Reed Elsevier shares joint control and has rights to the net assets of the arrangements. Investments in joint ventures and associates are accounted for under the equity method and stated in the statement of financial position at cost as adjusted for post-acquisition changes in Reed Elsevier’s share of net assets, less any impairment in value.

Impairment

At each statement of financial position date, the carrying amounts of tangible and intangible assets and goodwill are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount, which is the higher of value in use and fair value less costs to sell, of the asset is estimated in order to determine the extent, if any, of the impairment loss. Where the asset does not generate cash flows that are independent from other assets, value in use estimates are made based on the cash flows of the cash generating unit to which the asset belongs. Intangible assets with an indefinite useful life are tested for impairment at least annually and whenever there is any indication that the asset may be impaired.

If the recoverable amount of an asset or cash generating unit is estimated to be less than its net carrying amount, the net carrying amount of the asset or cash generating unit is reduced to its recoverable amount. Impairment losses are recognised immediately in the income statement in administration and other expenses.

Inventories and pre-publication costs

Inventories and pre-publication costs are stated at the lower of cost, including appropriate attributable overhead, and estimated net realisable value. Pre-publication costs, representing costs incurred in the origination of content prior to publication, are expensed systematically reflecting the expected sales profile over the estimated economic lives of the related products, generally up to five years.

Leases

Assets held under leases which confer rights and obligations similar to those attaching to owned assets are classified as assets held under finance leases and capitalised within property, plant and equipment or software and the corresponding liability to pay rentals is shown net of interest in the statement of financial position as obligations under finance leases. The capitalised value of the assets is depreciated on a straight line basis over the shorter of the periods of the leases or the useful lives of the assets concerned. The interest element of the lease payments is allocated so as to produce a constant periodic rate of charge.

Operating lease rentals are charged to the income statement on a straight line basis over the period of the leases. Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease.

Cash and cash equivalents

Cash and cash equivalents comprise cash balances, call deposits and other short term highly liquid investments and are held in the statement of financial position at fair value.

Assets held for sale

Assets of businesses that are available for immediate sale in their current condition and for which a sales process is considered highly probable to complete are classified as assets held for sale, and are carried at the lower of carrying value and fair value less costs to sell. Non-current assets are not amortised or depreciated following their classification as held for sale. Liabilities of businesses held for sale are also separately classified on the statement of financial position. Fair value is based on anticipated disposal proceeds, typically derived from firm or indicative offers from potential acquirers.

Financial instruments

Financial instruments comprise investments (other than investments in joint ventures or associates), trade receivables, cash and cash equivalents, payables and accruals, provisions, borrowings and derivative financial instruments.

2.Accounting policies – (continued)

Investments (other than investments in joint ventures and associates) are classified as either held for trading or available for sale, as described above. (These investments are typically classified as either Level 1 or Level 2 in the IFRS7IFRS13 fair value hierarchy.). The fair value of such investments is based on either quoted market prices or other observable market inputs.

Trade receivables are carried in the statement of financial position at invoiced value less allowance for estimated irrecoverable amounts. Irrecoverable amounts are estimated based on the ageing of trade receivables, experience and circumstance.

Borrowings, payables and accruals are recorded initially at fair value and subsequently carried at amortised cost (other than fixed rate borrowings in designated hedging relationships and for which the carrying value is adjusted to reflect changes in the fair valueamount of the hedged risk), payables, accruals and provisions are recorded initially at fair value andportion of the borrowings is subsequently at amortised cost.

2.Accounting policies – (continued)

adjusted for the gain or loss attributable to the hedged risk).

Derivative financial instruments are used to hedge interest rate and foreign exchange risks. Changes in the fair value of derivative financial instruments that are designated and effective as hedges of future cash flows are recognised (net of tax) directly in equity in the hedge reserve. If a hedged firm commitment or forecasted transaction results in the recognition of a non financial asset or liability, then, at the time that the asset or liability is recognised, the associated gains or losses on the derivative that had previously been recognised in equity are included in the initial measurement of the asset or liability. For hedges that do not result in the recognition of an asset or a liability, amounts deferred in equity are recognised in the income statement in the same period in which the hedged item affects net profit or loss. Any ineffective portion of hedges is recognised immediately in the income statement.

Derivative financial instruments that are not designated as hedging instruments are classified as held for trading and recorded in the statement of financial position at fair value, with changes in fair value recognised in the income statement.

Where an effective hedge is in place against changes in the fair value of fixed rate borrowings, the hedged borrowings are adjusted for changes in fair value attributable to the risk being hedged with a corresponding income or expense included in the income statement within finance costs. The offsetting gains or losses from remeasuring the fair value of the related derivatives are also recognised in the income statement within finance costs. When the related derivative expires, is sold or terminated, or no longer qualifies for hedge accounting, the cumulative change in fair value of the hedged borrowing is amortised in the income statement over the period to maturity of the borrowingsborrowing using the effective interest method.

The fair values of interest rate swaps, interest rate options, forward rate agreements and forward foreign exchange contracts represent the replacement costs calculated using observable market rates of interest and exchange. The fair value of long term borrowings is calculated by discounting expected future cash flows at observable market rates. (These instruments are accordingly classified as Level 2 in the IFRS7IFRS13 fair value hierarchy.)

Cash flow hedge accounting is discontinued when a hedging instrument expires or is sold, terminated or exercised, or no longer qualifies for hedge accounting. At that time, any cumulative gain or loss on the hedging instrument recognised in equity is either retained in equity until the firm commitment or forecasted transaction occurs, or, where a hedged transaction is no longer expected to occur, is immediately credited or expensed in the income statement.

Provisions

Provisions are recognised when a present obligation exists as a result of a past event, the obligation is reasonably estimable, and it is probable that settlement of the obligation will be required. Provisions are measured at the best estimate of the expenditure required to settle the obligation at the statement of financial position date.

Shares held in treasury

Shares of Reed Elsevier PLC and Reed Elsevier NV that are repurchased by the respective parent companies and not cancelled are classified as shares held in treasury. The consideration paid, including directly attributable costs, is recognised as a deduction from equity. Shares of the parent companies that are purchased by the Reed Elsevier Group plc Employee Benefit Trust are also classified as shares held in treasury, with the cost recognised as a deduction from equity.

Critical judgements and key sources of estimation uncertainty

The most significant accounting policies in determining the financial condition and results of the Reed Elsevier combined businesses, and those requiring the most subjective or complex judgement, relate to the valuation of goodwill and intangible assets, share based remuneration, pensions, litigation, taxationcapitalisation of development spend and property provisioning.taxation.

Goodwill and acquired intangible assets

On acquisition of a subsidiary or business, the purchase consideration is allocated between the net tangible and intangible assets other than goodwill on a fair value basis, with any excess purchase consideration representing goodwill. The valuation

2.Accounting policies – (continued)

of acquired intangible assets represents the estimated economic value in use, using standard valuation methodologies, including as appropriate, discounted cash flow, relief from royalty and comparable market transactions. Acquired intangible assets are capitalised and amortised systematically over their estimated useful lives, subject to impairment review.

Appropriate amortisation periods are selected based on assessments of the longevity of the brands and imprints, the strength and stability of customer relationships, the market positions of the acquired assets and the technological and competitive risks that they face. Certain intangible assets in relation to acquired science and medical publishing businesses have been determined to have indefinite lives. The longevity of these assets is evidenced by their long established and well regarded brands and imprints, and their characteristically stable market positions.

2.Accounting policies – (continued)

The carrying amounts of goodwill and indefinite lived intangible assets in each business are reviewed for impairment at least annually. The carrying amounts of all other intangible assets are reviewed where there are indications of possible impairment. An impairment review involves a comparison of the carrying value of the asset with estimated values in use based on latest management cash flow projections. Key areas of judgement in estimating the values in use of businesses are the growth in cash flows over a five year forecast period of up to five years, the long term growth rate assumed thereafter and the discount rate applied to the forecast cash flows.

The discount rates used are based on the Reed Elsevier weighted average cost of capital, adjusted to reflect a risk premium specific to each business. The pre-tax discount rates applied are 11.4%11.1% for Scientific, Technical & Medical, 11.8%11.6% for Risk Solutions, 11.5-12.9%11.5-12.8% for Business Information, 11.6%10.9-12.5% for Legal and 11.2-12.9%9.5-13.0% for Exhibitions. The nominal long term growth rates, which are based on historical growth rates and the growth prospects for businesses, are 3%. There were no charges for impairment of acquired intangible assets and goodwill in 2012 (2011:2013 (2012: nil; 2010:2011: nil).

A sensitivity analysis has been performed based on changes in key assumptions considered to be reasonably possible by management: an increase in the discount rate of 0.5%; a decrease in the compound annual growth rate for adjusted operating cash flow in the five year forecast period of 2.0%; and a decrease in perpetuity growth rates of 0.5%. The sensitivity analysis shows that no impairment charges resulting from these scenarios individually would result under any of the sensitivity scenarios.be less than £5 million. Further information is provided in note 1514 to the combined financial statements.

Share based remunerationDevelopment spend

Share based remunerationDevelopment spend embraces investment in new products and other initiatives, ranging from the building of online delivery platforms, to launch costs of new services, to building new infrastructure applications. Launch costs and other ongoing operating expenses of new products and services are expensed as incurred. The costs of building product applications, platforms and infrastructure are capitalised as intangible assets where the investment they represent has demonstrable value and technical and commercial feasibility is determined based onassured. Costs eligible for capitalisation must be incremental, clearly identified and directly attributable to a particular project. The resulting assets are amortised over their estimated useful lives. Impairment reviews are carried out at least annually. Judgement is required in the fairassessment of the potential value of an award ata development project, the dateidentification of grant, and is spread over the vesting period on a straight line basis, taking into account the number of shares that are expected to vest. The fair value of awards is determined at the date of grant by use of a binomial or Monte Carlo simulation model as appropriate, which requires judgements to be made regarding share price volatility, dividend yield, risk free rates of return and expected option lives. The number of awards that are expected to vest requires judgements to be made regarding forfeiture ratescosts eligible for capitalisation and the extent to which performance conditions will be met. The assumptions are determined in conjunction with independent actuaries based on historical data and trends.

The assumptionsselection of share price volatility of 30%, of expected share option life of 4 years, and of expected lapse rate of 2-5% are based on relevant historical data. Other judgements made on grant are based on market data. Assumptions as to future performance against non market related vesting conditions are based on management estimates. The charge for share based and related remuneration was £26 million in 2012 (2011: £27 million; 2010: £11 million). Further information is provided in note 8 to the combined financial statements.

Pensions

Accounting for defined benefit pension schemes involves judgement about uncertain events, including the life expectancy of the members, salary and pension increases, inflation, the return on scheme assets and the rate at which the future pension payments are discounted. Estimates for these factors are used in determining the pension cost and liabilities reported in the financial statements. These best estimates of future developments are made in conjunction with independent actuaries. Each scheme is subject to a periodic review by independent actuaries.

The principal assumptions as at December 31, 2012, expressed as a weighted average of the various defined benefit pension schemes, were a discount rate of 4.4% (2011: 5.2%; 2010: 5.6%), an expected rate of salary increases of 3.2% (2011: 3.5%; 2010: 4.1%) and inflation of 2.7% (2011: 2.9%; 2010: 3.2%). The expected return on scheme assets, set at the beginning of the year, was 6.2% (2011: 6.8%; 2010: 7.0%). Future pension increases are assumed at 2.8% (2011: 2.9%; 2010: 3.2%) and average life expectancy of 88-89 years (2011: 87-89 years, 2010: 87-89 years) for scheme members currently aged 45 and 60 years. The net defined benefit pension expense was £18 million (2011: £23 million; 2010: £22 million). The service cost was £43 million (2011: £57 million; 2010: £48 million) after pension curtailment credits of £20 million (2011: £9 million; 2010: £17 million) from changes to pension plan design and staff reductions. The net pension financing credit is based on market data at the beginning of the year and was £25 million (2011: £34 million; 2010: £26 million) reflecting the increase in scheme liabilities at the beginning of the year compared with a year before and lower expectedappropriate asset returns. Further information and sensitivity analysis is provided in note 7 to the combined financial statements.

Litigation

Reed Elsevier is involved in various legal proceedings, which arise in the normal course of its business, relating to commercial disputes, employment, data security and product liability. Provisions for liabilities are recognised when it is probable that a settlement is required. Although the outcome of legal proceedings is uncertain, the ultimate resolution of such matters is not expected to have a material impact on results.

2.Accounting policies – (continued)

lives.

Taxation

Reed Elsevier is subject to tax in numerous jurisdictions, giving rise to complex tax issues that require management to exercise judgement in making tax determinations. While Reed Elsevier is confident that tax returns are appropriately prepared and filed, provisionsamounts are maintainedprovided in respect of uncertain tax positions that are believed to appropriately reflect the risk with respect to tax matters under active discussion with tax authorities, or which are otherwise considered to involve uncertainty. Amounts are provided using the best estimate of the amounttax expected to be paid based on a qualitative assessment of all relevant factors. However, it is possible that at some future date liabilities may be adjusted as a result of audits by taxing authorities. Discussions with tax authorities relating to cross-border transactions and other matters are ongoing. Although the outcome of open itemsthese discussions cannot be predicted, no significant impact on the financial position of Reed Elsevier is expected.

In addition, estimation of income taxes includes assessments of the recoverability of deferred tax assets. Deferred tax assets are only recognized to the extent that they are considered recoverable based on existing tax laws and forecasts of future taxable profits against which the underlying tax deductions can be utilized. The recoverability of these assets is reassessed at the end of each reporting period, and changes in recognition toof deferred tax assets will affect the tax provisionliability in the period of that reassessment.

Property provisions

Reed Elsevier has exposures to sub lease shortfalls in respect of certain property leases for periods up to 2024. Provisions are recognised for net liabilities expected to arise on these exposures. Estimation of the provisions requires judgement in respect of future head lease costs, sub lease income and the length of vacancy periods. The charge for property provisions was £62 million (2011: £16 million; 2010: £36 million) relating to surplus property arising on the restructuring, sale and closure of businesses and includes expected losses on sub-leases entered into during 2012 and an estimate of vacancy periods and future market conditions. Further information is provided in note 27 to the combined financial statements.

Other significant accounting policies

The accounting policies in respect of revenue recognition, pre-publication costs, property provisioning and development spendpensions are also significant in determining the financial condition and results of the Reed Elsevier combined businesses, although the application of these policies is more straightforward.

2.Accounting policies – (continued)

Revenue recognition policies, while an area of management focus, are generally straightforward in application as the timing of product or service delivery and customer acceptance for the various revenue types can be readily determined. Allowances for product returns are deducted from revenues based on historical return rates. Where sales consist of two or more components that operate independently, revenue is recognised as each component is completed by performance, based on attribution of relative value.

Pre-publication costs incurred in the creation of content prior to production and publication are typically deferred and expensed over their estimated useful lives based on sales profiles. Such costs typically comprise direct internal labour costs and externally commissioned editorial and other fees. Estimated useful lives generally do not exceed five years. Annual reviews are carried out to assess the recoverability of carrying amounts.

Development spend embraces investmentReed Elsevier has exposures to sub lease shortfalls in new productrespect of certain property leases for periods up to 2024. Provisions are recognised for net liabilities expected to arise on these exposures. Estimation of the provisions requires judgement in respect of future head lease costs, sub lease income and other initiatives, ranging from the buildinglength of new online delivery platforms,vacancy periods. The charge for property provisions was nil (2012: £62 million; 2011: £16 million) relating to launch costssurplus property arising on the restructuring, sale and closure of new services,Business Information businesses and includes expected losses on sub-leases entered into during 2013 and an estimate of vacancy periods and future market conditions. Further information is provided in note 26 to building new infrastructure applications. Launch coststhe combined financial statements.

Accounting for defined benefit pension schemes involves judgement about uncertain events, including the life expectancy of the members, salary and other operating expenses of new products and services are expensed as incurred. The costs of building product applications and infrastructure are capitalised as intangiblepension increases, inflation, the return on scheme assets and amortised over their estimated useful lives. Impairment reviewsthe rate at which the future pension payments are carried out at least annually.discounted. Estimates for these factors are used in determining the pension cost and liabilities reported in the financial statements. These best estimates of future developments are made in conjunction with independent actuaries. Each scheme is subject to a periodic review by independent actuaries.

Details of key assumptions and sensitivity analysis is provided in note 6 to the financial statements.

Standards and amendments effective for the year

With effect from January 1, 2013, IAS19 – Employee Benefits (revised)inter alia changes the methodology used in the calculation of the net pension financing credit or charge in relation to defined benefit pension schemes. Under the revised standard, pension asset returns included within the net pension financing credit or charge are calculated by reference to the discount rate of high-quality corporate bonds (being also the discount rate applied in the calculation of pension obligations) and are no longer based on the expected returns on scheme assets. The interpretationseffect is to reduce the asset returns recognised in the income statement.

Adoption of IAS19 (revised) has had no impact on Reed Elsevier’s combined statement of financial position and statement of cash flows. The net pension financing credit or charge is now presented within net finance costs in Reed Elsevier’s combined income statement, rather than within operating profit as previously reported.

As required under the revised standard, comparative figures have been restated. For the year ended December 31, 2012, operating profits are £25 million lower and net finance costs are £11 million higher than previously reported. For the year ended December 31, 2011, operating profits are £34 million lower and net finance costs are £9 million higher than previously reported.

With effect from January 1, 2013, Reed Elsevier adopted IAS1 – Presentation of Items of Other Comprehensive Income (amendments to IAS1). The standard amends the grouping of items presented in the statement of comprehensive income into items that may be reclassified to the profit or loss in a future period and items that will never be reclassified.

With effect from January 1, 2013 Reed Elsevier also adopted IFRS10 Consolidated Financial Statements, IFRS11 Joint Arrangements, IFRS12 Disclosure of Interests in Other Entities, and IFRS13 Fair Value Measurement, in addition to amendments to IAS27 Consolidated and Separate3 Financial Statements and IAS28 Investments in Associates. Adoption of these new accounting standards and amendments to IFRS effective for 2012 havehas not had a significant impact on Reed Elsevier’s accounting policies or reporting. With the exception of IFRS13, these standards and amendments have been early adopted for the purposes of Reed Elsevier’s application of IFRS as adopted by the EU.

2.Accounting policies – (continued)

Standards, amendments and interpretations not yet effective

New accounting standards and amendments and their expected impact on the future accounting policies and reporting of Reed Elsevier are set out below.

IAS19 — Employee Benefits (Revised) (effective for the 2013 financial year). The revised standard inter alia changes the methodology to be used in the calculation of the net pension financing credit or charge in relation to defined benefit

2.Accounting policiesIFRS9 (continued)

pension schemes. Under the revised standard, pension asset returns included within the net pension financing credit or charge are to be calculated by reference to the discount rate of a high quality corporate bond (being also the discount rate applied in the calculation of pension obligations) and no longer based on the expected returns on scheme assets. Typically the effect will be to reduce the asset returns recognised in the income statement. As required under the revised standard, comparatives will be restated accordingly. The revised standard also prohibits the use of certain accounting alternatives, previously permitted, that enabled the smoothing of volatility in the income statement and balance sheet in relation to pensions, but this will not affect Reed Elsevier’s pension accounting as such alternatives were not applied. There is no change to the measurement of pension scheme assets and obligations under the revised standard for Reed Elsevier.

Adoption of IAS19 (revised) will have no impact on Reed Elsevier’s combine balance sheet or cash flows. The net pension financing credit or charge will, with effect from 1 January 2013, be presented within net finance costs in Reed Elsevier’s combined income statement, rather than within operating profit as currently reported. Given that the revised standard may introduce greater volatility to the income statement, following adoption on 1 January 2013 the net pension financing credit or charge will be excluded from the adjusted earnings figures used by Reed Elsevier as additional performance measures.

Had IAS19 (revised) and related presentation been in effect for the 2012 financial year, operating profit for the twelve months to December 31, 2012 would have been £25m lower (2011: £34 million, 2010: £26 million) and net finance costs would have been higher by £11 million (2011: £9 million, 2010: £14 million). The balance sheet and cash flows would have been unchanged.

IFRS9 — Financial Instruments (effective for the 2015 financial year). The standard replaces the existing classification and measurement requirements in IAS39 for financial assets by requiring entities to classify them as being measured either at amortised cost or fair value depending on the business model and contractual cash flow characteristics of the asset. For financial liabilities, IFRS9 requires an entity choosing to measure a liability at fair value to present the portion of the change in its fair value due to changes in the entity’s own credit risk in the other comprehensive income rather than the income statement. Adoption of the standard is not expected to have a significant impact on the measurement, presentation or disclosure of financial assets and liabilities in the combined financial statements.

IFRS10 — Consolidated Financial StatementsAmendments to IAS36 – Impairment of Assets (effective for the 20132014 financial year). The standard introduces a single consolidation model for all entities based on control, irrespectiveThese amendments require disclosure of the nature ofrecoverable amounts for the investee. IFRS10 replaces IAS27 — Separate Financial Statements.assets or CGUs for which an impairment loss has been recognised or reversed during the reporting period and are effective retrospectively. Adoption of the standard is not expected to have a significant impact on the measurement, presentation or disclosure of the consolidation of entities in the combined financial statements.

IFRS11 — Joint Arrangements (effective for the 2013 financial year). This standard classifies joint arrangements as either joint ventures or a joint operation and removes the option to proportionately consolidate joint ventures. IFRS11 replaces IAS28 — Investments in Associates and Joint Ventures. Adoption of the standard is not expected to have a significant impact on the measurement, presentation or disclosure of the joint ventures in the combined financial statements.

IFRS12 — Disclosure of Interests in Other Entities (effective for the 2013 financial year). This standard combines the disclosure requirements for subsidiaries, joint arrangements, associates and unconsolidated structured entities into one standard. Adoption of the standard may result in additional disclosures in the combined financial statements but is not expected to have a significant impact on Reed Elsevier’s reporting.

IFRS13 — Fair Value Measurement (effective for the 2013 financial year). The standard consolidates the guidance and disclosure requirements of fair value measurement contained throughout IFRS and also requires new disclosures related to valuation techniques and inputs into fair value measurements. Adoption of the standard is not expected to have a significant impact on the measurement, presentation or disclosure of financial assets and liabilities in the combined financial statements.

IAS1 — Presentation of Items of Other Comprehensive Income — Amendments to IAS1 (effective for the 2013 financial year). The standard amends the grouping of items presented in the statement of comprehensive income into items that may be reclassified (or recycled) to the profit or loss in a future period and items that will never be reclassified. Adoption of the standard will lead to some re-presentation of the items in the statement of comprehensive income in the combined financial statements.

Additionally, a number of amendments and interpretations have been issued which are not expected to have any significant impact on Reed Elsevier’s accounting policies and reporting.

3.Segment analysis

Reed Elsevier’s reported segments are based on the internal reporting structure and financial information provided to the Chief Executive Officer and Boards.

Reed Elsevier is a world leading provider of professional information solutions organised as five business segments: Scientific, Technical & Medical, providing information and tools to help its customers improve scientific and healthcare outcomes; Risk Solutions, providing tools that combine proprietary, public and third-party information with advanced technology and analytics; Business Information, providing data services, information and marketing solutions to business professionals; Legal, providing legal, tax, regulatory news & business information to legal, corporate, government, accounting and academic markets; and Exhibitions, organising exhibitions and conferences.

Adjusted operating profit is the key segmental profit measure used by Reed Elsevier in assessing performance. It is stated before amortisation of acquired intangible assets, the share of profit on disposals in joint ventures, exceptional restructuring (none in 2012 or 2011), acquisition related costs, and is grossed up to exclude the equity share of taxes in joint ventures.

3.Segment analysis – (continued)

Operating profit by segment is included as supplementary information.

Analysis by business segment

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
Restated
£m
 2011
Restated
£m
 

Revenue

        

Scientific, Technical & Medical

   2,063    2,058    2,026     2,126    2,063    2,058  

Risk Solutions

   926    908    927     933    926    908  

Business Information

   663    695    718     547    663    695  

Legal

   1,610    1,634    1,691     1,567    1,610    1,634  

Exhibitions

   854    707    693     862    854    707  
  

 

  

 

  

 

   

 

  

 

  

 

 

Total

   6,116    6,002    6,055     6,035    6,116    6,002  
  

 

  

 

  

 

   

 

  

 

  

 

 

Operating profit

        

Scientific, Technical & Medical

   706    695    647     742    706    695  

Risk Solutions

   281    181    165     312    281    181  

Business Information

   76    68         71    76    68  

Legal

   146    144    159     139    146    144  

Exhibitions

   171    132    127     161    171    132  
  

 

  

 

  

 

   

 

  

 

  

 

 

Sub-total

   1,380    1,220    1,098     1,425    1,380    1,220  

Corporate costs

   (47  (49  (34   (49  (47  (49

Unallocated net pension financing credit

   25    34    26  
  

 

  

 

  

 

   

 

  

 

  

 

 

Total

   1,358    1,205    1,090     1,376    1,333    1,171  
  

 

  

 

  

 

   

 

  

 

  

 

 

Adjusted operating profit

        

Scientific, Technical & Medical

   780    768    724     826    780    768  

Risk Solutions

   392    362    354     414    392    362  

Business Information

   119    110    89     107    119    110  

Legal

   234    229    238     238    234    229  

Exhibitions

   210    167    158     213    210    167  
  

 

  

 

  

 

   

 

  

 

  

 

 

Sub-total

   1,735    1,636    1,563     1,798    1,735    1,636  

Corporate costs

   (47  (44  (34   (49  (47  (44

Unallocated net pension financing credit

   25    34    26  
  

 

  

 

  

 

   

 

  

 

  

 

 

Total

   1,713    1,626    1,555     1,749    1,688    1,592  
  

 

  

 

  

 

   

 

  

 

  

 

 

Analysis by geographical origin

   2013
£m
   2012
£m
   2011
£m
 

Revenue

      

North America

   3,103     3,122     3,103  

United Kingdom

   985     966     947  

The Netherlands

   656     611     616  

Rest of Europe

   698     788     783  

Rest of world

   593     629     553  
  

 

 

   

 

 

   

 

 

 

Total

   6,035     6,116     6,002  
  

 

 

   

 

 

   

 

 

 

3.Segment analysis – (continued)

 

Analysis by geographical originmarket

 

  2012
£m
   2011
£m
   2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Revenue

            

North America

   3,122     3,103     3,213     3,082     3,154     3,219  

United Kingdom

   966     947     907     443     442     485  

The Netherlands

   611     616     620     166     165     189  

Rest of Europe

   788     783     825     1,074     1,176     1,095  

Rest of world

   629     553     490     1,270     1,179     1,014  
  

 

   

 

   

 

   

 

   

 

   

 

 

Total

   6,116     6,002     6,055     6,035     6,116     6,002  
  

 

   

 

   

 

   

 

   

 

   

 

 

Analysis by geographical marketformat

 

   2012
£m
   2011
£m
   2010
£m
 

Revenue

      

North America

   3,154     3,219     3,303  

United Kingdom

   442     485     490  

The Netherlands

   165     189     204  

Rest of Europe

   1,176     1,095     1,131  

Rest of world

   1,179     1,014     927  
  

 

 

   

 

 

   

 

 

 

Total

   6,116     6,002     6,055  
  

 

 

   

 

 

   

 

 

 
   2013
£m
   2012
£m
   2011
£m
 

Revenue

      

Electronic

   3,971     3,896     3,767  

Print

   1,168     1,305     1,451  

Face to face

   896     915     783  
  

 

 

   

 

 

   

 

 

 

Total

   6,035     6,116     6,002  
  

 

 

   

 

 

   

 

 

 

Analysis by type

 

   2012
£m
   2011
£m
   2010
£m
 

Revenue

      

Subscriptions

   2,978     2,819     2,709  

Circulation/transactions

   1,602     1,649     1,760  

Advertising

   350     437     491  

Exhibitions

   846     700     675  

Other

   340     397     420  
  

 

 

   

 

 

   

 

 

 

Total

   6,116     6,002     6,055  
  

 

 

   

 

 

   

 

 

 

Revenue is analysed before the £91 million (2011: £128 million; 2010: £116 million) share of joint ventures’ revenue, of which £2 million (2011: £2 million; 2010: £3 million) relates to Business Information, £22 million (2011: £23 million; 2010: £24 million) relates to Legal, principally to Giuffrè, and £67 million (2011: £103 million; 2010: £89 million) relates to Exhibitions.

   2013
£m
   2012
£m
   2011
£m
 

Revenue

      

Subscriptions

   3,112     2,978     2,819  

Transactional

   2,683     2,788     2,746  

Advertising

   240     350     437  
  

 

 

   

 

 

   

 

 

 

Total

   6,035     6,116     6,002  
  

 

 

   

 

 

   

 

 

 

Share of post-tax results of joint ventures of £29 million (2012: £24 million (2011:million; 2011: £30 million; 2010: £22 million) included in operating profit comprises nil (2011: £1 million; 2010:(2012: nil; 2011: £1 million) relating to Business Information, £6 million (2012: £2 million (2011: £4 million; 2010:2011: £4 million) relating to Legal and £23 million (2012: £22 million (2011:million; 2011: £25 million; 2010: £17 million) relating to Exhibitions. The unallocated net pension financing credit of £25 million (2011: £34 million; 2010: £26 million) comprises the expected return on pension scheme assets of £221 million (2011: £235 million; 2010: £217 million) less interest on pension scheme liabilities of £196 million (2011: £201 million; 2010: £191 million).

3.Segment analysis – (continued)

A reconciliation of operating profit to adjusted operating profit is provided below:

 

   2012
£m
   2011
£m
  2010
£m
 

Operating profit

   1,358     1,205    1,090  

Adjustments:

     

Amortisation of acquired intangible assets

   329     359    349  

Exceptional restructuring costs

            57  

Acquisition related costs

   21     52    50  

Share of profit on disposals in joint ventures

        (1    

Reclassification of tax in joint ventures

   5     11    9  
  

 

 

   

 

 

  

 

 

 

Adjusted operating profit

   1,713     1,626    1,555  
  

 

 

   

 

 

  

 

 

 

Analysis by business segment

   2012
£m
   2011
£m
   2010
£m
 

Expenditure on acquired goodwill and intangible assets

      

Scientific, Technical & Medical

   120     43     13  

Risk Solutions

   15            

Business Information

        532     1  

Legal 

   80          34  

Exhibitions

   178     36     6  
  

 

 

   

 

 

   

 

 

 

Total

   393     611     54  
  

 

 

   

 

 

   

 

 

 

Capital expenditure additions

      

Scientific, Technical & Medical

   106     94     81  

Risk Solutions

   21     23     31  

Business Information

   17     18     12  

Legal 

   173     203     179  

Exhibitions

   25     22     12  
  

 

 

   

 

 

   

 

 

 

Total

   342     360     315  
  

 

 

   

 

 

   

 

 

 

Amortisation of acquired intangible assets

      

Scientific, Technical & Medical

   68     72     75  

Risk Solutions

   109     156     149  

Business Information

   37     29     30  

Legal 

   83     78     72  

Exhibitions

   32     24     23  
  

 

 

   

 

 

   

 

 

 

Total

   329     359     349  
  

 

 

   

 

 

   

 

 

 

Depreciation and other amortisation

      

Scientific, Technical & Medical

   82     69     74  

Risk Solutions

   23     26     29  

Business Information

   14     15     26  

Legal 

   92     87     94  

Exhibitions

   16     10     14  
  

 

 

   

 

 

   

 

 

 

Total

   227     207     237  
  

 

 

   

 

 

   

 

 

 
   2013
£m
   2012
Restated
£m
   2011
Restated
£m
 

Operating profit

   1,376     1,333     1,171  

Adjustments:

      

Amortisation of acquired intangible assets

   318     329     359  

Acquisition related costs

   43     21     52  

Share of profit on disposals in joint ventures

             (1

Reclassification of tax in joint ventures

   12     5     11  
  

 

 

   

 

 

   

 

 

 

Adjusted operating profit

   1,749     1,688     1,592  
  

 

 

   

 

 

   

 

 

 

3.Segment analysis – (continued)

 

Analysis by business segment

   2013
£m
   2012
£m
   2011
£m
 

Expenditure on acquired goodwill and intangible assets

      

Scientific, Technical & Medical

   50     120     43  

Risk Solutions

   164     15       

Business Information

   5          532  

Legal

   15     80       

Exhibitions

   56     178     36  
  

 

 

   

 

 

   

 

 

 

Total

   290     393     611  
  

 

 

   

 

 

   

 

 

 

Capital expenditure additions

      

Scientific, Technical & Medical

   93     106     94  

Risk Solutions

   25     21     23  

Business Information

   18     17     18  

Legal

   170     173     203  

Exhibitions

   15     25     22  
  

 

 

   

 

 

   

 

 

 

Total

   321     342     360  
  

 

 

   

 

 

   

 

 

 

Amortisation of acquired intangible assets

      

Scientific, Technical & Medical

   76     68     72  

Risk Solutions

   97     109     156  

Business Information

   31     37     29  

Legal

   74     83     78  

Exhibitions

   40     32     24  
  

 

 

   

 

 

   

 

 

 

Total

   318     329     359  
  

 

 

   

 

 

   

 

 

 

Depreciation and other amortisation

      

Scientific, Technical & Medical

   95     82     69  

Risk Solutions

   22     23     26  

Business Information

   10     14     15  

Legal

   108     92     87  

Exhibitions

   14     16     10  
  

 

 

   

 

 

   

 

 

 

Total

   249     227     207  
  

 

 

   

 

 

   

 

 

 

Capital expenditure comprises additions to property, plant and equipment and internally developed intangible assets. Amortisation of acquired intangible assets includes amounts in respect of joint ventures of £1 million (2011: £4(2012: £1 million; 2010:2011: £4 million) in Exhibitions. Other than the depreciation and amortisation above, non cash items includes a £31 million charge (2011: £27(2012: £31 million charge; 2010: £72011: £27 million credit) relating to the recognition of share based remuneration, comprising £6 million (2012: £5 million (2011:million; 2011: £5 million charge; 2010: £2 million credit)million) in Scientific, Technical & Medical, nil (2011: £3 million; 2010: £2million (2012: nil; 2011: £3 million) in Risk Solutions, £2 million (2012: £3 million (2011:million; 2011: £2 million; 2010: £3 million credit)million) in Business Information, £6 million (2012: £7 million (2011:million; 2011: £6 million; 2010: £1 million credit)million) in Legal, £4 million (2011:(2012: £4 million; 2011: £3 million; 2010: £1 million credit)million) in Exhibitions and £10 million (2012: £12 million (2011:million; 2011: £8 million; 2010: £2 million credit)million) in Corporate.

3.Segment analysis – (continued)

Analysis by geographical location

 

  2012
£m
   2011
£m
   2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Non-current assets

            

North America

   6,514     6,984     6,716     6,291     6,514     6,984  

United Kingdom

   524     517     456     584     524     517  

The Netherlands

   120     123     140     125     120     123  

Rest of Europe

   729     783     851     753     729     783  

Rest of world

   376     292     210     401     376     292  
  

 

   

 

   

 

   

 

   

 

   

 

 

Total

   8,263     8,699     8,373     8,154     8,263     8,699  
  

 

   

 

   

 

   

 

   

 

   

 

 

Non-current assets by geographical location exclude amounts relating to deferred tax net pension assets and derivative financial instruments.

 

4.Operating profit

Operating profit is stated after charging/(crediting) the following:

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
   2012
Restated
£m
 2011
Restated
£m
 

Staff costs

             

Wages and salaries

     1,543    1,535    1,594       1,508     1,543    1,535  

Social security costs

     187    173    179       175     187    173  

Pensions

   7     64    62    54     6     61     89    96  

Share based and related remuneration

     26    27    11       31     26    27  
    

 

  

 

  

 

     

 

   

 

  

 

 

Total staff costs

     1,820    1,797    1,838       1,775     1,845    1,831  
    

 

  

 

  

 

     

 

   

 

  

 

 

Depreciation and amortisation

             

Amortisation of acquired intangible assets

   16     328    355    345     15     317     328    355  

Share of joint ventures’ amortisation of acquired intangible assets

     1    4    4       1     1    4  

Amortisation of internally developed intangible assets

   16     151    132    158     15     160     151    132  

Depreciation of property, plant and equipment

   18     76    75    79     17     89     76    75  
    

 

  

 

  

 

     

 

   

 

  

 

 

Total depreciation and amortisation

     556    566    586       567     556    566  
    

 

  

 

  

 

     

 

   

 

  

 

 

Other expenses and income

             

Pre-publication costs, inventory expenses and other cost of sales

     2,139    2,126    2,209       2,118     2,139    2,126  

Operating lease rentals expense

     112    116    123       108     112    116  

Operating lease rentals income

     (10  (11  (11     (10)     (10  (11
    

 

  

 

  

 

     

 

   

 

  

 

 

Depreciation andThe amortisation charges areof acquired intangible assets is included within administration and other expenses.

5.Auditors’ remuneration

   2012
£m
   2011
£m
   2010
£m
 

For audit services

   4.7     4.7     4.5  

For non audit services

   1.8     1.1     1.2  
  

 

 

   

 

 

   

 

 

 

Total auditors’ remuneration

   6.5     5.8     5.7  
  

 

 

   

 

 

   

 

 

 

Auditors’ remuneration for audit services comprises £0.5 million (2011: £0.5 million; 2010: £0.4 million) payable to the auditors of the parent companies and £4.2 million (2011: £4.2 million; 2010: £4.1 million) payable to the auditors of the parent companies and their associates for the audit of the financial statements of the operating and financing businesses, including the review and testing of internal control over financial reporting in accordance with the US Sarbanes-Oxley Act. Auditors’ remuneration for non audit services comprises: £0.8 million (2011: £0.7 million; 2010: £0.9 million) for tax compliance services, £0.3 million (2011: £0.2 million; 2010: nil) for due diligence and other transaction related services and £0.7 million (2011: £0.2 million; 2010: £0.3 million) for other audit related assurance services.

6.Personnel

Number of people employed

 

  At December 31   Average during the year   At December 31   Average during the year 
  2012   2011   2012   2011   2010   2013   2012   2013   2012   2011 

Business segment

                    

Scientific, Technical & Medical

   7,000     6,900     7,000     6,900     6,800     6,700     7,000     6,900     7,000     6,900  

Risk Solutions

   4,100     4,000     4,000     4,300     4,500     3,300     4,100     3,500     4,000     4,300  

Business Information

   4,800     5,600     5,200     5,400     5,800     3,900     4,800     4,200     5,200     5,400  

Legal

   10,400     10,300     10,400     10,400     10,400     10,000     10,400     10,400     10,400     10,400  

Exhibitions

   3,200     2,800     3,000     2,700     2,600     3,400     3,200     3,300     3,000     2,700  

Sub-total

   29,500     29,600     29,600     29,700     30,100     27,300     29,500     28,300     29,600     29,700  

Corporate/shared functions

   900     900     900     900     900     900     900     900     900     900  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total

   30,400     30,500     30,500     30,600     31,000     28,200     30,400     29,200     30,500     30,600  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Geographical location

                    

North America

   15,700     16,000     15,900     16,300     16,900     13,900     15,700     14,800     15,900     16,300  

United Kingdom

   4,100     4,600     4,200     4,600     4,700     4,100     4,100     4,100     4,200     4,600  

The Netherlands

   1,600     1,600     1,600     1,600     1,800     1,600     1,600     1,600     1,600     1,600  

Rest of Europe

   3,600     3,700     3,700     3,800     4,000     2,800     3,600     3,100     3,700     3,800  

Rest of world

   5,400     4,600     5,100     4,300     3,600     5,800     5,400     5,600     5,100     4,300  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total

   30,400     30,500     30,500     30,600     31,000     28,200     30,400     29,200     30,500     30,600  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

 

7.6.Pension schemes

A number of pension schemes are operated around the world. Historically, the major schemes have been of the defined benefit type with assets held in separate trustee administered funds. The largest defined benefit schemes are in the UK, the US and the Netherlands. Under these plans, employees are entitled

The UK scheme is a final salary scheme and is closed to retirement benefits dependentnew hires. Members accrue a portion of their final pensionable earnings based on the number of years of service. The US scheme is a cash balance scheme and is closed to new hires. Members earn pay credits dependent on age and years of service provided.which are added to an account balance that accrues interest at a minimum rate of 4% per annum. The Netherlands scheme is a career average salary scheme and remains open to new hires. Members accrue a portion of their current salary at a rate calculated to enable them to reach a pension level based on their average salary.

Each of the major defined benefit schemes is administered by a separate fund that is legally separated from Reed Elsevier. The trustees of the pension funds in the UK and the Netherlands and plan fiduciaries of the US scheme are required by law to act in the interest of the funds’ beneficiaries. In the UK and in the Netherlands the trustees of the pension fund are responsible for the investment policy with regard to the assets of the fund. The boards of trustees consist of an equal number of Reed Elsevier appointed and member nominated directors. In the US, the fiduciary duties for the scheme are allocated between committees which are staffed by senior employees of Reed Elsevier; the investment committee has the primary responsibility for the investment and management of plan assets.

The funding of Reed Elsevier’s major schemes reflects the different rules within each jurisdiction.

In the UK the level of funding is determined by statutory triennial actuarial valuations in accordance with pensions legislation. Where the scheme falls below 100% funded status, Reed Elsevier and the scheme trustees must agree on how the deficit is to be remedied. The UK Pensions Regulator has significant powers and sets out in codes and guidance the parameters for scheme funding.

The US scheme has an annual statutory valuation which forms the basis for establishing the employer contribution each year (subject to ERISA and IRS minimums). Should the statutory funded status fall to below 100%, the US Pensions Protection Act requires the deficit to be rectified with additional contributions over a 7 year period.

In the Netherlands the scheme funding level is determined by an annual actuarial valuation, as prescribed by the Dutch Pension Act. If the funding level falls below the statutory minimum a short term recovery plan is negotiated between the plan trustees and filed with the Dutch Central Bank (DCB). An evaluation of the recovery plan is required to be filed at the DCB annually.

7.6.Pension schemes – (continued)

 

The principal assumptions for the purpose of valuation under IAS19 — Employee Benefits are presented below as the weighted average of the variousTotal regular employer contributions to defined benefit pension schemes. schemes in respect of 2014 are expected to be approximately £46 million.

The pension expense recognised within operating expense is:

   2013
£m
   2012
Restated 
£m
   2011
Restated 
£m
 

Defined benefit pension expense

   14     43     57  

Defined contribution pension expense

   47     46     39  
  

 

 

   

 

 

   

 

 

 

Total

   61     89     96  
  

 

 

   

 

 

   

 

 

 

The amounts recognised in the income statement in respect of defined benefit pension schemes during the year are presented by major scheme as follows:

   2013  2012
Restated
  2011
Restated
 
   UK
£m
   US
£m
  NL
£m
  Total
£m
  UK
£m
  US
£m
  NL
£m
  Total
£m
  UK
£m
   US
£m
  NL
£m
   Total
£m
 

Service cost

   29     29    15    73    27    28    8    63    31     27    8     66  

Settlements, past service and curtailment credits

        (51  (8  (59  (1  (19      (20       (9       (9
  

 

 

   

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

Defined benefit pension expense

   29     (22  7    14    26    9    8    43    31     18    8     57  

Net interest on net defined benefit obligation

   6     9    4    19    5    7    (1  11         6    3     9  
  

 

 

   

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

Net defined benefit pension expense

   35     (13  11    33    31    16    7    54    62     42    19     123  
  

 

 

   

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

   

 

 

  

 

 

   

 

 

 

Net interest on defined benefit pension scheme liabilities is presented within net finance costs in the income statement. Service cost, including settlements, past service credits and curtailments is presented within operating expenses.

Settlements and past service credits in 2013 principally relate to plan design changes and the transfer out of certain deferred members in the US scheme and a reduction in accrued benefits in respect of the scheme in the Netherlands. Settlements and curtailments recognised in 2012 and 2011 were a result of changes to plan design and staff reductions.

The significant valuation assumptions, determined for each major scheme in conjunction with the respective independent actuaries are presented below. The net defined benefit pension expense for each year is based on the assumptions and scheme valuations set at December 31, of the prior year.

 

   At December 31 
   2012  2011  2010 

Discount rate

   4.4  5.2  5.6

Expected rate of return on scheme assets

   n/a    6.2  6.8

Expected rate of salary increases

   3.2  3.5  4.1

Inflation

   2.7  2.9  3.2

Future pension increases

   2.8  2.9  3.2
    2013  2012  2011 

As at December 31,

  UK  US  NL  UK  US  NL  UK  US  NL 

Discount rate

   4.60  5.05  3.60  4.65  4.25  3.50  5.00  5.25  5.70

Inflation

   3.25  3.00  2.00  2.85  3.00  2.00  3.00  3.00  2.00

The discount rate isDiscount rates are set by reference to AA corporate bond yields. The expected rates of return on individual categories of scheme assets are determined by reference to relevant market indices and market expectations of real rates of return. The overall expected rate of return on scheme assets is based on the weighted average of each asset category.

Mortality assumptions used in assessing defined benefit obligations make allowance for future improvements in longevity and have been determined by reference to applicable mortality statistics and expectations for each scheme.statistics. The average life expectancies assumed in the valuation of the defined benefit obligationsexpectancy assumptions are set out below:

 

   2012   2011   2010 

Average life expectancy

(at December 31)

  Male
(years)
   Female
(years)
   Male
(years)
   Female
(years)
   Male
(years)
   Female
(years)
 

Member currently aged 60

   88     88     88     87     88     87  

Member currently aged 45

   89     89     89     88     89     88  

The pension expense recognised within the income statement comprises:

   2012
£m
  2011
£m
  2010
£m
 

Service cost (including settlement and curtailment credits of £20 million (2011: £9 million; 2010: £17 million))

   43    57    48  

Interest on pension scheme liabilities

   196    201    191  

Expected return on scheme assets

   (221  (235  (217
  

 

 

  

 

 

  

 

 

 

Net defined benefit pension expense

   18    23    22  

Defined contribution pension expense

   46    39    32  
  

 

 

  

 

 

  

 

 

 

Total pension expense

   64    62    54  
  

 

 

  

 

 

  

 

 

 
    2013   2012   2011 

Male average life expectancy (as December 31)

  UK   US   NL   UK   US   NL   UK   US   NL 

Member currently aged 60

   90     84     86     90     84     86     90     84     86  

Member currently aged 45

   92     83     87     92     83     87     92     83     87  

7.6.Pension schemes – (continued)

 

    2013   2012   2011 

Female average life expectancy (as December 31)

  UK   US   NL   UK   US   NL   UK   US   NL 

Member currently aged 60

   89     86     89     89     86     89     88     86     89  

Member currently aged 45

   91     85     89     91     85     89     89     85     87  

The amount recognised in the statement of financial position in respect of defined benefit pension schemes at the start and end of the year and the movements during the year were as follows:

 

 2012 2011 2010  2013 2012
Restated
 2011
Restated
 
 Defined
benefit
obligations
£m
 Fair value
of scheme
assets

£m
 Net
pension
obligations
£m
 Defined
benefit
obligations
£m
 Fair value
of scheme
assets

£m
 Net
pension
obligations
£m
 Defined
benefit
obligations
£m
 Fair value
of scheme
assets

£m
 Net
pension
obligations
£m
  UK
£m
 US
£m
 NL
£m
 Total
£m
 UK
£m
 US
£m
 NL
£m
 Total
£m
 UK
£m
 US
£m
 NL
£m
 Total
£m
 

Defined benefit obligation

            

At start of year

  (3,876  3,634    (242  (3,677  3,507    (170  (3,302  3,067    (235  (2,654  (922  (696  (4,272  (2,479  (858  (539  (3,876  (2,357  (766  (554  (3,677

Service cost

  (43      (43  (57      (57  (48      (48  (29  (29  (15  (73  (27  (28  (8  (63  (31  (27  (8  (66

Settlement, past service and curtailment credits

      51    8    59    1    19        20        9        9  

Interest on pension scheme liabilities

  (196      (196  (201      (201  (191      (191  (122  (41  (25  (188  (124  (44  (30  (198  (129  (43  (31  (203

Expected return on scheme assets

      221    221        235    235        217    217  

Actuarial (loss)/gain

  (416  87    (329  (78  (35  (113  (261  198    (63

Contributions by employer

      116    116        66    66        154    154  

Actuarial (loss)/gain on financial assumptions

  (173  86    18    (69  (92  (145  (145  (382  (15  (59  23    (51

Actuarial (loss)/gain arising from experience assumptions

  8    (10  (3  (5  (15  (18  1    (32  (28  (4  7    (25

Contributions by employees

  (11  11        (11  11        (11  11        (6      (5  (11  (7      (4  (11  (6      (5  (11

Benefits paid

  216    (216      141    (141      139    (139    

Benefits paid*

  94    93    19    206    89    112    15    216    87    39    15    141  

Exchange translation differences

  54    (47  7    7    (9  (2  (3  (1  (4      10    (17  (7      40    14    54        (7  14    7  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

At end of year

  (4,272  3,806    (466  (3,876  3,634    (242  (3,677  3,507    (170  (2,882  (762  (716  (4,360  (2,654  (922  (696  (4,272  (2,479  (858  (539  (3,876
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Fair value of scheme assets

            

At start of year

  2,516    710    580    3,806    2,371    726    537    3,634    2,351    657    499    3,507  

Interest income on plan assets

  116    32    21    169    119    37    31    187    129    37    28    194  

Return on assets excluding amounts included in interest income

  111    4    (1  114    45    53    23    121    (59  46    19    6  

Contributions by employer

  36    33    14    83    63    38    15    116    31    19    16    66  

Contributions by employees

  6        5    11    7        4    11    6        5    11  

Benefits paid*

  (94  (93  (19  (206  (89  (112  (15  (216  (87  (39  (15  (141

Exchange translation differences

      (10  14    4        (32  (15  (47      6    (15  (9
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

At end of year

  2,691    676    614    3,981    2,516    710    580    3,806    2,371    726    537    3,634  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Net defined benefit obligation

  (191  (86  (102  (379  (138  (212  (116  (466  (108  (132  (2  (242
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

The net pension obligations of £466 million at December 31, 2012 (2011: £242 million; 2010: £170 million) comprise schemes in deficit with net pension obligations of £466 million (2011: £242 million; 2010: £225 million) and schemes in surplus with net pension assets of nil (2011: nil; 2010: £55 million).

*Included in benefits paid are settlements of £52 million (2012: £75 million; 2011: nil).

As at December 31, 20122013 the defined benefit obligations comprise £4,200 million (2012: £4,112 million, (2011:2011: £3,721 million; 2010: £3,531 million) in relation to funded schemes and £160 million (2011:(2012: £160 million, 2011: £155 million; 2010: £146 million) in relation to unfunded schemes.

The weighted average duration of defined benefit scheme liabilities for 2013, 2012 and 2011 is 19 years (2011: 19 years; 2010: 19 years).in the UK, 16 years in the US and 21 years in the Netherlands. Deferred tax liabilities of nil (2011: nil; 2010: £15 million) and deferred tax assets of £104 million (2012: £153 million, (2011:2011: £86 million; 2010: £78 million) are recognised in respect of the pension scheme surplusesdeficits.

6.Pension schemes – (continued)

Amounts recognised in the statement of comprehensive income are set out below:

   2013
£m
  2012
Restated
£m
  2011
Restated
£m
 

Gains and losses arising during the year

    

Experience losses on scheme liabilities

   (5  (32  (25

Experience gains on scheme assets

   114    121    6  

Actuarial gains/(losses) arising on the present value of scheme liabilities due to changes in:

    

— discount rates

   78    (552  (238

— inflation

   (171  74    182  

— other actuarial assumptions

   24    96    5  
  

 

 

  

 

 

  

 

 

 
   40    (293  (70

Net cumulative losses at start of year

   (515  (222  (152
  

 

 

  

 

 

  

 

 

 

Net cumulative losses at end of year

   (475  (515  (222
  

 

 

  

 

 

  

 

 

 

The major categories and deficits respectively.

The fair valuevalues of scheme assets heldat the end of the reporting period are as equities, bonds and other assets, and their expected rates of return as at December 31, are shown below:follows:

 

 2012 2011 2010   2013   2012   2011 
 Fair value
of scheme
assets

£m
 Proportion
of total
scheme
assets

%
 Expected
rate of
return on
scheme
assets

%
 Fair value
of scheme
assets

£m
 Proportion
of total
scheme
assets

%
 Expected
rate of
return on
scheme
assets

%
 Fair value
of scheme
assets

£m
 Proportion
of total
scheme
assets

%
   UK
£m
   US
£m
   NL
£m
   Total
£m
   UK
£m
   US
£m
   NL
£m
   Total
£m
   UK
£m
   US
£m
   NL
£m
   Total
£m
 

Equities

  1,804    47    8.7    1,699    47    8.7    1,963    56     1,351     174     222     1,747     1,207     409     169     1,785     1,235     303     142     1,680  

Bonds

  1,715    45    3.7    1,722    47    4.4    1,318    38  

Government bonds

   1,089     68     358     1,515     1,088     164     376     1,628     989     248     357     1,594  

Corporate bonds

        411          411          88          88          126          126  

Cash

   87     4          91     106     1          107     53     1          54  

Other

  287    8    4.3    213    6    5.1    226    6     164     19     34     217     115     48     35     198     94     48     38     180  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total

  3,806    100    6.2    3,634    100    6.8    3,507    100     2,691     676     614     3,981     2,516     710     580     3,806     2,371     726     537     3,634  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

The actual return on scheme assets for the year ended December 31, 20122013 was £283 million (2012: £308 million; 2011: £200 million).

Assets and obligations associated with the schemes are sensitive to changes in the market values of assets and the market related assumptions used to value scheme liabilities. In particular, adverse changes to asset values, discount rates or inflation could increase future pension costs and funding requirements.

Typically Reed Elsevier’s schemes are exposed to: investment risks, whereby actual returns on plan assets may be below those rates used to determine the defined benefit obligations and interest rate risks whereby scheme deficits may increase if bond yields in the UK, US and the Netherlands decline and are not offset by returns in government and corporate bond portfolios. The schemes are also exposed to other risks such as unanticipated future increases in: member mortality patterns; inflation; and future salaries, all potentially leading to an increase in scheme liabilities (particularly in the Netherlands which is the only major scheme which remains open to new members).

Investment policies of each scheme are intended to ensure continuous payment of defined benefit pensions in the short term and long term. Efforts are made to limit risks on marketable securities by adopting investment policies that diversify assets across geographies and among equities, government and corporate bonds and cash. Asset allocations are dependent on a £308 million gain (2011: £200 million gain; 2010: £415 million gain).variety of factors including the duration of scheme liabilities and the statutory funded status of the plan.

All equities and government and corporate bonds have quoted prices in active markets. The majority of other assets are investments in property funds which have quoted prices in active markets.

7.6.Pension schemes – (continued)

 

A summary of pension balances in respect of funded and unfunded schemes for the five years ended December 31, 2012 is set out below:

  2012
£m
  2011
£m
  2010
£m
  2009
£m
  2008
£m
 

Fair value of scheme assets

  3,806    3,634    3,507    3,067    2,682  

Defined benefit obligations

  (4,272  (3,876  (3,677  (3,302  (3,051
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net pension obligations

  (466  (242  (170  (235  (369
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Gains and losses arising on the revaluation of pension scheme assets and liabilities that have been recognised in the statement of comprehensive income are set out below:

  2012
£m
  2011
£m
  2010
£m
  2009
£m
  2008
£m
 

Gains and losses during the year:

     

Experience (losses)/gains on scheme liabilities

  (32  (27  (43  18    (9

Experience gains/(losses) on scheme assets

  87    (35  198    301    (765

Actuarial (losses)/gains arising on the present value of scheme liabilities due to changes in:

     

— discount rates

  (552  (238  (162  (249  202  

— inflation

  74    182    (50  (124  198  

— other actuarial assumptions

  94    5    (6  60    27  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 
  (329  (113  (63  6    (347

Net cumulative (losses)/gains at start of year

  (265  (152  (89  (95  252  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cumulative losses at end of year

  (594  (265  (152  (89  (95
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Regular contributions to defined benefit pension schemes in respect of 2013 are expected to be approximately £55 million.

Sensitivity analysis

ValuationThe valuation of Reed Elsevier’s pension scheme liabilities involves judgements about uncertain events, includingsignificant actuarial assumptions, being the life expectancy of the members, salary and pension increases, inflation and the rate at which the future pension payments are discounted. Estimates are used for each of these factors. Differences arising from actual experience or future changes in assumptions may materially affect future pension charges. In particular, changes in assumptions for discount rates, inflation and life expectancies that are reasonably possible would have the following approximate effects on the annual service cost and the defined benefit pension obligations:

 

   £m 

Increase/decrease of 0.25% in discount rate:

  191

Decrease/increaseIncrease/decrease of 0.25% in annual service costthe expected inflation rate

   5

Decrease/increase in defined benefit pension obligations

195113  

Increase/decrease of one year in assumed life expectancy:

Increase/decrease in annual service costexpectancy

   1

Increase/decrease in defined benefit pension obligations

104

Increase/decrease of 0.25% in the expected inflation rate:

Increase/decrease in annual service cost

3

Increase/decrease in defined benefit pension obligations

113108  

The above analysis has been calculated on the same basis used to determine the defined benefit obligation recognised in the statement of financial position. There has been no change in the methods used to prepare the analysis compared with prior years. This sensitivity analysis may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in the above assumptions would occur in isolation of one another as some of the assumptions may be correlated.

8.7.Share based remuneration

Reed Elsevier provides a number of share based remuneration schemes to directorsDirectors and employees. The principal share based remuneration schemes are the Executive Share Option Schemes (ESOS), the Long Term Incentive Plan (LTIP), the Reed Elsevier Growth Plan (REGP), the Retention Share Plan (RSP) and the Bonus Investment Plan (BIP). Share options granted under ESOS and LTIP are exercisable after three years and up to ten years from the date of grant at a price equivalent to the market value of the respective shares at the date of grant. Conditional shares granted under ESOS, LTIP, RSP and BIP are exercisable after three years for nil consideration if conditions are met. Conditional shares granted under REGP are exercisable for nil consideration if conditions are met after three and five years. Other awards principally relate to all employee share based saving schemes in the UK and the Netherlands.

Share based remuneration awards are, other than upon retirement or in exceptional circumstances, subject to the condition that the employee remains in employment at the time of exercise.

Conditional shares granted under LTIP, REGP, RSP and BIP inbetween 2010 2011 and 20122013 are subject to the achievement of growth targets of Reed Elsevier PLC and Reed Elsevier NV adjusted earnings per share measured at constant exchange rates as well as the achievement of a targeted percentage return on invested capital of Reed Elsevier PLC and Reed Elsevier NV. LTIP grants in 2010, 2011, 2012 and 20122013 and REGP grants in 20102013 are also variable subject to the achievement of a total shareholder return performance target.

The weighted average fair value per award is based on full vesting on achievement of non market related performance conditions and stochastic models for market related components. The conditional shares and option awards are recognised in the income statement over the vesting period, being between three and five years, on the basis of expected performance against the non market related conditions, with the fair value related to market related components unchanging.

8.7.Share based remuneration – (continued)

 

2013 grants

   In respect of Reed Elsevier PLC
ordinary shares
   In respect of Reed Elsevier NV
ordinary shares
 
   Number
of shares
’000
   Weighted
average
fair value
per award
£
   Number
of shares
’000
   Weighted
average
fair value
per award
£
 

Share options

        

ESOS

   1,521     1.12     1,058     1.52  

Other

   645     1.29     257     1.10  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total share options

   2,166     1.17     1,315     1.44  
  

 

 

   

 

 

   

 

 

   

 

 

 

Conditional shares

        

ESOS

   524     6.51     365     9.28  

LTIP

   1,338     6.14     930     8.90  

REGP

   322     6.49     450     9.34  

RSP

   10     7.35     7     10.65  

BIP

   987     7.40     615     10.69  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total conditional shares

   3,181     6.63     2,367     9.51  
  

 

 

   

 

 

   

 

 

   

 

 

 

2012 grants

 

  

In respect of Reed Elsevier PLC
ordinary shares

  

In respect of Reed Elsevier NV

ordinary shares

  In respect of Reed Elsevier PLC
ordinary shares
   In respect of Reed Elsevier NV
ordinary shares
 
  

Number

of shares

’000

  

Weighted

average

fair value

per award

£

  

Number

of shares

’000

  

Weighted

average

fair value

per award

£

  Number
of shares
’000
   Weighted
average
fair value
per award
£
   Number
of shares
’000
   Weighted
average
fair value
per award
£
 

Share options

                

ESOS

  1,801  0.90  1,263  1.20   1,801     0.90     1,263     1.20  

Other

  702  1.04  293  0.95   702     1.04     293     0.95  
  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

 

Total share options

  2,503  0.94  1,556  1.15   2,503     0.94     1,556     1.15  
  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

 

Conditional shares

                

ESOS

  797  4.60  560  6.41   797     4.60     560     6.41  

LTIP

  1,807  4.45  1,144  6.13   1,807     4.45     1,144     6.13  

RSP

  256  6.00  5  7.82   256     6.00     5     7.82  

BIP

  1,542  5.20  696  7.41   1,542     5.20     696     7.41  
  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

 

Total conditional shares

  4,402  4.83  2,405  6.57   4,402     4.83     2,405     6.57  
  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

 
2011 grants
  

In respect of Reed Elsevier PLC

ordinary shares

  

In respect of Reed Elsevier NV

ordinary shares

  

Number

of shares

’000

  

Weighted

average

fair value

per award

£

  

Number

of shares

’000

  

Weighted

average

fair value

per award

£

Share options

        

ESOS

  2,053  0.98  1,372  1.41

Other

  633  1.03  381  0.97
  

 

  

 

  

 

  

 

Total share options

  2,686  0.99  1,753  1.32
  

 

  

 

  

 

  

 

Conditional shares

        

ESOS

  755  4.85  504  6.91

LTIP

  1,822  4.56  1,217  6.65

RSP

  322  4.73  5  7.15

BIP

  1,339  5.43  607  8.00
  

 

  

 

  

 

  

 

Total conditional shares

  4,238  4.90  2,333  7.06
  

 

  

 

  

 

  

 

8.7.Share based remuneration – (continued)

 

2010 grants

2011 grants

2011 grants

  

  In respect of Reed Elsevier PLC
ordinary shares
   In respect of Reed Elsevier NV
ordinary shares
   In respect of Reed Elsevier PLC
ordinary shares
   In respect of Reed Elsevier NV
ordinary shares
 
  Number
of shares
’000
   Weighted
average
fair value
per award
£
   Number
of shares
’000
   Weighted
average
fair value
per award
£
   Number
of shares
’000
   Weighted
average
fair value
per award
£
   Number
of shares
’000
   Weighted
average
fair value
per award
£
 

Share options

                

ESOS

   2,204     0.77     1,448     1.08     2,053     0.98     1,372     1.41  

Other

   846     0.99     381     0.82     633     1.03     381     0.97  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total share options

   3,050     0.83     1,829     1.02     2,686     0.99     1,753     1.32  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Conditional shares

                

ESOS

   751     4.23     493     6.37     755     4.85     504     6.91  

LTIP

   1,677     4.01     1,101     6.11     1,822     4.56     1,217     6.65  

REGP

   1,038     6.99     681     10.66  

RSP

   236     4.23     155     6.37     322     4.73     5     7.15  

BIP

   1,714     4.64     820     6.93     1,339     5.43     607     8.00  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total conditional shares

   5,416     4.82     3,250     7.32     4,238     4.90     2,333     7.06  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

The main assumptions used to determine the fair values are set out below:

Assumptions for grants made during the year

 

  In respect of Reed Elsevier PLC
ordinary shares
 In respect of Reed Elsevier NV
ordinary shares
   In respect of Reed Elsevier PLC
ordinary shares
 In respect of Reed Elsevier NV
ordinary shares
 
  2012 2011 2010 2012 2011 2010   2013 2012 2011 2013 2012 2011 

Weighted average share price at date of grant

              

ESOS

  £5.19   £5.39   £4.69   9.07   8.97   8.36    £7.35   £5.19   £5.39   12.53   9.07   8.97  

LTIP

  £5.25   £5.31   £4.67   8.91   8.89   8.31    £7.35   £5.25   £5.31   12.54   8.91   8.89  

REGP

    £4.67     8.31    £7.76     13.15    

RSP

  £6.00   £5.26   £4.67   9.65   9.27   8.33    £7.35   £6.00   £5.26   12.53   9.65   9.27  

BIP

  £5.20   £5.43   £4.64   9.15   9.21   8.11    £7.39   £5.20   £5.43   12.53   9.15   9.21  

Other

  £5.49   £5.13   £5.22   9.63   9.03   8.86    £7.45   £5.49   £5.13   11.89   9.63   9.03  

Expected share price volatility

   30  29  26  30  29  26   28  30  29  28  30  29

Expected option life

   4 years    4 years    4 years    4 years    4 years    4 years     4 years    4 years    4 years    4 years    4 years    4 years  

Expected dividend yield

   3.9  3.6  3.5  4.5  4.1  3.9   4.1  3.9  3.6  4.7  4.5  4.1

Risk free interest rate

   0.8  1.9  1.8  0.9  2.5  1.2   0.5  0.8  1.9  0.4  0.9  2.5

Expected lapse rate

   2-5  2-5  3-5  2-4  2-4  3-4   2-5  2-5  2-5  2-4  2-4  2-4

Expected share price volatility has been estimated based on relevant historic data in respect of the Reed Elsevier PLC and Reed Elsevier NV ordinary share prices. Expected share option life has been estimated based on historical exercise patterns in respect of Reed Elsevier PLC and Reed Elsevier NV share options.

8.7.Share based remuneration – (continued)

 

The share based remuneration awards outstanding as at December 31, 20122013 in respect of both Reed Elsevier PLC and Reed Elsevier NV ordinary shares are set out below:

 

 In respect of Reed
Elsevier PLC
ordinary shares
 In respect of Reed
Elsevier NV
ordinary shares
   In respect of Reed
Elsevier PLC
ordinary shares
   In respect of Reed
Elsevier NV
ordinary shares
 
 Number
of shares
under
option
’000
 Weighted
average
exercise
price
(pence)
 Number
of shares
under
option
’000
 Weighted
average
exercise
price
(€)
   Number
of shares
under
option
’000
 Weighted
average
exercise
price
(pence)
   Number
of shares
under
option
’000
 Weighted
average
exercise
price
(€)
 

Share options

          

Outstanding at January 1, 2010

  35,685    547    25,917    11.74  

Granted

  3,050    455    1,829    8.45  

Exercised

  (2,008  470    (184  8.63  

Forfeited

  (1,355  496    (1,008  8.75  

Expired

  (1,661  554    (1,721  6.71  
 

 

  

 

  

 

  

 

 

Outstanding at January 1, 2011

  33,711    544    24,833    11.45     33,711    544     24,833    11.45  

Granted

  2,686    509    1,753    8.99     2,686    509     1,753    8.99  

Exercised

  (1,626  493    (201  8.84     (1,626  493     (201  8.84  

Forfeited

  (2,001  479    (1,941  10.94     (2,001  479     (1,941  10.94  

Expired

  (3,230  640    (2,803  8.68     (3,230  640     (2,803  8.68  
 

 

  

 

  

 

  

 

   

 

  

 

   

 

  

 

 

Outstanding at January 1, 2012

  29,540    534    21,641    10.99     29,540    534     21,641    10.99  

Granted

  2,503    497    1,556    9.19     2,503    497     1,556    9.19  

Exercised

  (6,694  497    (1,913  9.36     (6,694  497     (1,913  9.36  

Forfeited

  (1,022  498    (581  9.33     (1,022  498     (581  9.33  

Expired

  (4,992  592    (5,121  12.34     (4,992  592     (5,121  12.34  
 

 

  

 

  

 

  

 

   

 

  

 

   

 

  

 

 

Outstanding at December 31, 2012

  19,335    529    15,582    10.63  

Outstanding at January 1, 2013

   19,335    529     15,582    10.63  

Granted

   2,166    694     1,315    12.41  

Exercised

   (9,102  542     (7,628  10.72  

Forfeited

   (112  535     (167  11.30  

Expired

   (560  537     (462  11.30  
  

 

  

 

   

 

  

 

 

Exercisable at December 31, 2010

  22,048    552    18,735    11.88  

Outstanding at December 31, 2013

   11,727    549     8,640    10.77  
  

 

  

 

   

 

  

 

 

Exercisable at December 31, 2011

  20,061    552    16,876    11.56     20,061    552     16,876    11.56  

Exercisable at December 31, 2012

  12,573    553    12,329    11.12     12,573    553     12,329    11.12  

Exercisable at December 31, 2013

   5,150    537     5,535    11.09  
 

 

  

 

  

 

  

 

   

 

  

 

   

 

  

 

 

 

  Number of Reed
Elsevier PLC
ordinary shares
(’000)
 Number of Reed
Elsevier NV
ordinary shares
(’000)
   Number of Reed
Elsevier PLC
ordinary shares
’000
 Number of Reed
Elsevier NV
ordinary shares
’000
 

Conditional shares

      

Outstanding at January 1, 2010

   8,148    4,921  

Granted

   5,416    3,250  

Vested

   (678  (425

Forfeited

   (849  (453
  

 

  

 

 

Outstanding at January 1, 2011

   12,037    7,293     12,037    7,293  

Granted

   4,238    2,332     4,238    2,332  

Vested

   (580  (383   (580  (383

Forfeited

   (1,799  (975

Forfeited/lapsed

   (1,799  (975
  

 

  

 

   

 

  

 

 

Outstanding at January 1, 2012

   13,896    8,267     13,896    8,267  

Granted

   4,402    2,405     4,402    2,405  

Vested

   (601  (391   (601  (391

Forfeited

   (5,885  (3,575

Forfeited/lapsed

   (5,885  (3,575
  

 

  

 

   

 

  

 

 

Outstanding at December 31, 2012

   11,812    6,706  

Outstanding at January 1, 2013

   11,812    6,706  

Granted

   3,181    2,367  

Vested

   (3,256  (1,966

Forfeited/lapsed

   (1,395  (923
  

 

  

 

   

 

  

 

 

Outstanding at December 31, 2013

   10,342    6,184  
  

 

  

 

 

8.7.Share based remuneration – (continued)

 

The weighted average share price at the date of exercise of share options and vesting of conditional shares during 20122013 was 593p (2011: 554p; 2010: 522p)761p (2012: 593p; 2011: 554p) for Reed Elsevier PLC ordinary shares and €10.43 (2011: €9.71; 2010: €8.82)€13.15 (2012: €10.43; 2011: €9.71) for Reed Elsevier NV ordinary shares.

Range of exercise prices for outstanding share options

 

 2012 2011 2010   2013   2012   2011 
 Number of
shares
under
option
’000
 Weighted
average
remaining
period until
expiry
(years)
 Number of
shares
under
option
’000
 Weighted
average
remaining
period until
expiry
(years)
 Number of
shares
under
option
’000
 Weighted
average
remaining
period until
expiry
(years)
   Number of
shares
under
option
’000
   Weighted
average
remaining
period until
expiry
(years)
   Number of
shares
under
option
’000
   Weighted
average
remaining
period until
expiry
(years)
   Number of
shares
under
option
’000
   Weighted
average
remaining
period until
expiry
(years)
 

Reed Elsevier PLC ordinary shares (pence)

                  

401-450

  1,925    2.8    2,148    2.9    2,017    3.3     1,772     1.9     1,925     2.8     2,148     2.9  

451-500

  4,415    3.5    7,793    3.6    8,919    4.5     1,161     4.2     4,415     3.5     7,793     3.6  

501-550

  8,981    5.7    11,662    5.5    11,299    5.6     5,284     5.6     8,981     5.7     11,662     5.5  

551-600

  189    5.4    2,726    0.8    3,153    1.6     695     3.9     189     5.4     2,726     0.8  

601-650

  3,825    4.8    5,176    5.7    6,053    6.6     1,338     4.0     3,825     4.8     5,176     5.7  

651-700

          35    0.3    2,270    0.2                         35     0.3  

701-750

   1,462     9.4                      

801-850

   10     9.6                      

851-900

   2     9.9                      

901-950

   3     9.0                      
 

 

  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total

  19,335    4.7    29,540    4.4    33,711    4.6     11,727     5.1     19,335     4.7     29,540     4.4  
 

 

  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Reed Elsevier NV ordinary shares (euro)

                  

7.01-8.00

  58    6.1    120    7.2    137    8.2     41     5.0     58     6.1     120     7.2  

8.01-9.00

  2,736    7.7    3,233    8.6    2,062    9.0     1,834     6.8     2,736     7.7     3,233     8.6  

9.01-10.00

  3,142    6.9    3,686    5.3    3,915    6.0     1,813     7.2     3,142     6.9     3,686     5.3  

10.01-11.00

  2,697    1.6    3,921    2.3    4,385    3.3     619     1.4     2,697     1.6     3,921     2.3  

11.01-12.00

  3,982    2.6    4,865    3.5    5,670    4.4     1,670     2.3     3,982     2.6     4,865     3.5  

12.01-13.00

  1,806    5.1    2,339    6.0    2,653    6.8     1,864     7.1     1,806     5.1     2,339     6.0  

13.01-14.00

  118    4.1    2,025    0.5    2,502    1.4     134     4.7     118     4.1     2,025     0.5  

14.01-15.00

  1,043    4.1    1,426    5.1    3,414    3.2     663     3.1     1,043     4.1     1,426     5.1  

15.01-16.00

          26    0.3    95    0.8     2     9.9               26     0.3  
 

 

  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total

  15,582    4.6    21,641    4.5    24,833    3.9     8,640     5.4     15,582     4.6     21,641     4.5  
 

 

  

 

  

 

  

 

  

 

  

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Share options are expected, upon exercise, to be met principally by the issue of new ordinary shares but may also be met from shares held by the Reed Elsevier Group plc Employee Benefit Trust (EBT)(“EBT”) (see note 31)29). Conditional shares will be met from shares held by the EBT.

9.8.Net finance costs

 

   2012
£m
  2011
£m
  2010
£m
 

Interest on short term bank loans, overdrafts and commercial paper

   (27  (28  (33

Interest on other loans

   (196  (212  (236

Interest on obligations under finance leases

   (1  (1  (1
  

 

 

  

 

 

  

 

 

 

Total borrowing costs

   (224  (241  (270

Losses on loans and derivatives not designated as hedges

   (8  (11  (14
  

 

 

  

 

 

  

 

 

 

Finance costs

   (232  (252  (284
  

 

 

  

 

 

  

 

 

 

Interest on bank deposits

   7    12    7  

Gains on loans and derivatives not designated as hedges

   9    5    1  
  

 

 

  

 

 

  

 

 

 

Finance income

   16    17    8  
  

 

 

  

 

 

  

 

 

 

Net finance costs

   (216  (235  (276
  

 

 

  

 

 

  

 

 

 

9.Net finance costs – (continued)

   2013
£m
   2012
Restated
£m
  2011
Restated
£m
 

Interest on short term bank loans, overdrafts and commercial paper

   (11)     (27  (28

Interest on term debt

   (168)     (196  (212

Interest on obligations under finance leases

   (1)     (1  (1
  

 

 

   

 

 

  

 

 

 

Total borrowing costs

   (180)     (224  (241

Losses on loans and derivatives not designated as hedges

   (7)     (8  (11

Net financing charge on defined benefit pension schemes

   
(19)
  
   (11  (9
  

 

 

   

 

 

  

 

 

 

Finance costs

   (206)     (243  (261
  

 

 

   

 

 

  

 

 

 

Interest on bank deposits

   4     7    12  

Gains on loans and derivatives not designated as hedges

   6     9    5  
  

 

 

   

 

 

  

 

 

 

Finance income

   10     16    17  
  

 

 

   

 

 

  

 

 

 

Net finance costs

   (196)     (227  (244
  

 

 

   

 

 

  

 

 

 

Finance costs include £3 million (2012: £16 million (2011:million; 2011: £15 million; 2010: £26 million) transferred from the hedge reserve. A net lossgain of £1 million (2012: £2 million (2011:loss; 2011: £3 million; 2010: £15 million)million loss) on interest rate derivatives designated as cash flow hedges was recognised directly in equity in the hedge reserve to be recognised in future periods.

 

10.9.Disposals and other non operating items

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
   2012
£m
 2011
£m
 

Revaluation of held for trading investments

   19    6    8     5     19    6  

Property provisions on disposed businesses

   (60  (16  (22        (60  (16

Gain/(loss) on disposal of businesses and assets held for sale

   86    (12  (32   11     86    (12
  

 

  

 

  

 

   

 

   

 

  

 

 

Net gain/(loss) on disposals and other non operating items

   45    (22  (46   16     45    (22
  

 

  

 

  

 

   

 

   

 

  

 

 

 

11.10.Taxation

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
Restated
£m
 2011
Restated
£m
 

Current tax

        

United Kingdom

   73    64    44   �� (50  (73  (64

The Netherlands

   68    87    58     (80  (68  (87

Rest of world

   12    107    64     (222  (12  (107
  

 

  

 

  

 

   

 

  

 

  

 

 

Total current tax charge

   153    258    166     (352  (153  (258

Deferred tax

   (40  (77  (46   271    51    91  
  

 

  

 

  

 

   

 

  

 

  

 

 

Tax expense

   113    181    120     (81  (102  (167
  

 

  

 

  

 

   

 

  

 

  

 

 

The increase in the deferred tax credit in 2013 principally relates to the alignment of certain business assets with their management structure. It does not affect cash tax paid of £362 million in 2013. The decrease in the UK current tax in 2013 reflects the settlement of prior year tax matters.

10.Taxation – (continued)

The net tax expense charged on profit before tax differs from the theoretical amount that would arise using the weighted average of tax rates applicable to accounting profits and losses of the consolidated entities, as follows:

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
Restated
£m
 2011
Restated
£m
 

Profit before tax

   1,187    948    768     1,196    1,151    905  
  

 

  

 

  

 

   

 

  

 

  

 

 

Tax at average applicable rates

   255    180    118     (280  (244  (166

Tax on share of results of joint ventures

   (7  (9  (9   10    7    9  

Expenses not deductible for tax purposes

   30    26    24  

(Non-taxable)/non-deductible costs of share based remuneration

   (3  3    2  

(Non-taxable)/non-deductible disposal related gains and losses

   (69  7    1  

Expenses not deductible for tax purposes and US state taxes

   (38  (30  (26

Non-taxable/(non-deductible) costs of share based remuneration

   3    3    (3

(Non-deductible)/non-taxable disposal related gains and losses

   (22  69    (7

Tax losses of the period not recognised

   6    4         (4  (6  (4

Recognition and utilization of tax losses that arose in prior years

   (6  (22  (6   9    6    22  

Exceptional prior year tax credit

   (96               96      

Deferred tax credit on the alignment of business assets

   
221
  
        

Other adjustments in respect of prior periods

   2    (7  (9   24    (2  7  

Deferred tax effect of changes in tax rates

   1    (1  (1   (4  (1  1  
  

 

  

 

  

 

   

 

  

 

  

 

 

Tax expense

   113    181    120     (81  (102  (167
  

 

  

 

  

 

   

 

  

 

  

 

 

Tax expense as a percentage of profit before tax

   10  19  16   7  9  18
  

 

  

 

  

 

   

 

  

 

  

 

 

The weighted average applicable tax rate for the year was 22% (2011: 19%23% (2012: restated 21%, 2010: 16%2011: restated 18%). This increase is caused by a change in the relative profitability of the consolidatedReed Elsevier entities in the countries in which they operate, partially offset by the impact of the reduction in the tax rate of the United Kingdom (see below).

During 2013, Reed Elsevier aligned certain business assets with their global management structure. As a result of this alignment the tax deductible value of these assets was updated to market value. As at December 31, 2013, Reed Elsevier has recognised a deferred tax credit of £221 million in respect of these assets.

During 2012, Reed Elsevier resolved a number of significant prior year tax matters and reassessed its exposure to other tax matters across the jurisdictionjurisdictions in which Reed Elsevier operates. As a result of this reassessment, current tax liabilities were reduced by £96 million to reflect the lower cash tax expected to be payable.

11.Taxation – (continued)

The following tax has been recognized directly in equity during the year:

 

  2012
£m
 2011
£m
   2010
£m
   2013
£m
 2012
Restated
£m
 2011
Restated
£m
 

Tax on items that will not be reclassified to profit or loss

    

Tax on actuarial movements on defined benefit pension schemes

   102    36     16     (24  91    22  

Tax credit on other items

       5    1  
  

 

  

 

  

 

 
   (24  96    23  
  

 

  

 

  

 

 

Tax on items that may be reclassified to profit or loss

    

Tax on fair value movements on cash flow hedges

   (19  5     12     (15  (19  5  

Tax credits on share based remuneration

   5    1     1  
  

 

  

 

   

 

   

 

  

 

  

 

 

Net tax credit/(charge) recognised directly in equity

   88    42     29  
  

 

  

 

   

 

    (15  (19  5  
  

 

  

 

  

 

 

Net tax (debit)/credit recognised in other comprehensive income

   (39  77    28  
  

 

  

 

  

 

 

Tax credit on share based remunerationrecognised directly in equity

   20          
  

 

  

 

  

 

 

A number of changes in the UK corporation tax system, including reductions of the main rate of corporation tax from 26%23% to 24%21% with effect from April 1, 2012,2014, and from 24%21% to 23%20% with effect from April 1, 2013,2015, were substantively enacted on July 3, 2012.2, 2013. Reed Elsevier has therefore remeasured its UK deferred tax assets and liabilities at the end of the reporting period at 23%20%, which has resulted in recognition of a deferred tax debit of £1£4 million in the income statement. The UK government has also announced an intention to reduce the rate of corporation tax to 21% by April 1, 2014, but as this change had not been substantively enacted at the date of the statement of financial position, the effect on deferred tax has not been recognized in these financial statements. It is not currently anticipated that the proposed reduction in rate would have a significant impact on deferred tax balances.

12.11.Statement of cash flows

Reconciliation of profit before tax to cash generated from operations

 

   2012
£m
  2011
£m
  2010
£m
 

Profit before tax

   1,187    948    768  

Disposals and other non operating items

   (45  22    46  

Net finance costs

   216    235    276  

Share of results of joint ventures

   (24  (30  (22
  

 

 

  

 

 

  

 

 

 

Operating profit before joint ventures

   1,334    1,175    1,068  
  

 

 

  

 

 

  

 

 

 

Amortisation of acquired intangible assets

   328    355    345  

Amortisation of internally developed intangible assets

   151    132    158  

Depreciation of property, plant and equipment

   76    75    79  

Share based remuneration

   31    27    (7
  

 

 

  

 

 

  

 

 

 

Total non cash items

   586    589    575  
  

 

 

  

 

 

  

 

 

 

Decrease in inventories and pre-publication costs

   21    32    35  

Decrease/(increase) in receivables

   4    (37  24  

Decrease in payables

   (98  (24  (53
  

 

 

  

 

 

  

 

 

 

(Increase)/decrease in working capital

   (73  (29  6  
  

 

 

  

 

 

  

 

 

 

Cash generated from operations

   1,847    1,735    1,649  
  

 

 

  

 

 

  

 

 

 

   2013
£m
  2012
Restated

£m
  2011
Restated

£m
 

Profit before tax

   1,196    1,151    905  

Disposals and other non operating items

   (16  (45  22  

Net finance costs

   196    227    244  

Share of results of joint ventures

   (29  (24  (30
  

 

 

  

 

 

  

 

 

 

Operating profit before joint ventures

   1,347    1,309    1,141  
  

 

 

  

 

 

  

 

 

 

Amortisation of acquired intangible assets

   317    328    355  

Amortisation of internally developed intangible assets

   160    151    132  

Depreciation of property, plant and equipment

   89    76    75  

Share based remuneration

   31    31    27  
  

 

 

  

 

 

  

 

 

 

Total non cash items

   597    586    589  
  

 

 

  

 

 

  

 

 

 

Decrease in inventories and pre-publication costs

   10    21    32  

Decrease/(increase) in receivables

   5    4    (37

(Decrease)/increase in payables

   (16  (73  10  
  

 

 

  

 

 

  

 

 

 

(Increase)/decrease in working capital

   (1  (48  5  
  

 

 

  

 

 

  

 

 

 

Cash generated from operations

   1,943    1,847    1,735  
  

 

 

  

 

 

  

 

 

 

Cash flow on acquisitions

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
   2012
£m
 2011
£m
 

Purchase of businesses

   13     (276  (455  (38   12     (194)     (276  (455

Investment in joint ventures

     (10  (1         (6)     (10  (1

Deferred payments relating to prior year acquisitions

     (30  (25  (12     (21)     (30  (25
    

 

  

 

  

 

     

 

   

 

  

 

 

Total

     (316  (481  (50     (221)     (316  (481
    

 

  

 

  

 

     

 

   

 

  

 

 

13.12.Acquisitions

Acquisitions in 2013

During the year a number of acquisitions were made for a total consideration of £239 million, after taking account of net cash acquired of £14 million. The net assets of the businesses acquired are incorporated at their fair value to the combined businesses. Provisional fair values of the consideration given and of the assets and liabilities acquired are summarised below:

Fair value
£m

Goodwill

157

Intangible assets

133

Current assets

9

Current liabilities

(21)

Deferred tax

(39)

Net assets acquired

239

Consideration (after taking account of £14 million net cash acquired)

239

Less: consideration deferred to future years

(36)

Less: acquisition date fair value of equity interest

(9)

Net cash flow

194

12.Acquisitions – (continued)

Goodwill, being the excess of the consideration over the net tangible and intangible assets acquired, represents benefits which do not qualify for recognition as intangible assets, including the ability of the business to generate higher returns than individual assets, skilled workforces, and acquisition synergies that are specific to Reed Elsevier. In addition, goodwill arises on the recognition of deferred tax liabilities in respect of intangible assets, for which amortisation does not qualify for tax deductions.

The fair value of the assets and liabilities acquired are provisional pending the completion of the valuation exercises. Final fair values will be incorporated in the 2014 combined financial statements. There were no significant adjustments to the provisional fair values of prior year acquisitions established in 2012.

The businesses acquired in 2013 contributed £27 million to revenue, decreased net profit by £1 million and contributed a net cash outflow of £3 million from operating activities for the part year under Reed Elsevier ownership and before taking account of acquisition financing costs. Had the businesses been acquired at the beginning of the year, on a proforma basis the Reed Elsevier revenues and net profit attributable to parent companies’ shareholders for the year would have been £6,067 million and £1,112 million respectively, before taking account of acquisition financing costs.

Acquisitions in 2012

During the year a number of acquisitions were made for a total consideration of £341 million, after taking account of net cash acquired of £12 million. The net assets of the businesses acquired are incorporated at their fair value to the combined businesses. The provisional fair values of the consideration given and of the assets and liabilities acquired are summarised below:

 

   Fair value
£m
 

Goodwill

   165  

Intangible assets

   229  

Property, plant and equipment

   1  

Current assets

   21  

Current liabilities

   (61

Current tax

   2  

Deferred tax

   (16
  

 

 

 

Net assets acquired

   341  
  

 

 

 

Consideration (after taking account of £12 million net cash acquired)

   341  

Less: consideration deferred to future years

   (23

Less: acquisition date fair value of equity interest

   (42
  

 

 

 

Net cash flow

   276  
  

 

 

 

Goodwill, being the excess of the consideration over the net tangible and intangible assets acquired, represents benefits which do not qualify for recognition as intangible assets, including the ability of the business to generate higher returns than individual assets, skilled workforces, and acquisition synergies that are specific to Reed Elsevier. In addition, goodwill arises on the recognition of deferred tax liabilities in respect of intangible assets, for which amortisation does not qualify for tax deductions.

The fair value of the assets and liabilities acquired are provisional pending the completion of the valuation exercises. Final fair values will be incorporated in the 2013 combined financial statements. ThereIn 2012, there were no significant adjustments to the provisional fair values of prior year acquisitions established in 2011.

The businesses acquired in 2012 contributed £73 million to revenue, decreased net profit by £10 million and contributed £2 million to net cash inflow from operating activities for the part year under Reed Elsevier ownership and before taking account of acquisition financing costs. Had the businesses been acquired at the beginning of the year, on a proforma basis the Reed Elsevier revenues and net profit attributable to parent companies’ shareholders for the year would have been £6,153 million and £1,073£1,048 million respectively, before taking account of acquisition financing costs.

12.Acquisitions – (continued)

Acquisitions in 2011

During the year a number of acquisitions were made for a total consideration of £492 million, after taking account of net cash acquired of £24 million, the most significant of which was the acquisition of Accuity Inc. for £331 million, net of cash acquired, which completed on November 1, 2011.

13.Acquisitions – (continued)

The net assets of the businesses acquired are incorporated at their fair value to the combined businesses. The provisional fairFair values of the consideration given and of the assets and liabilities acquired are summarised below:

 

   Fair value
£m
 

Goodwill

   300  

Intangible assets

   311  

Property, plant and equipment

   1  

Current assets

   23  

Current liabilities

   (46

Borrowings

   (18

Current tax

   (1

Deferred tax

   (78
  

 

 

 

Net assets acquired

   492  
  

 

 

 

Consideration (after taking account of £24 million net cash acquired)

   492  

Less: consideration deferred to future years

   (27

Less: acquisition date fair value of equity interest

   (10
  

 

 

 

Net cash flow

   455  
  

 

 

 

Goodwill, being the excess of the consideration over the net tangible and intangible assets acquired, represents benefits which do not qualify for recognition as intangible assets, including the ability of the business to generate higher returns than individual assets, skilled workforces, and acquisition synergies that are specific to Reed Elsevier. In addition, goodwill arises on the recognition of deferred tax liabilities in respect of intangible assets, for which amortisation does not qualify for tax deductions.

In 2011, there were no significant adjustments to the provisional fair values of prior year acquisitions established in 2010.

The businesses acquired in 2011 contributed £34 million to revenue, decreased net profit by £10 million and contributed £7 million to net cash inflow from operating activities for the part year under Reed Elsevier ownership and before taking account of acquisition financing costs. Had the businesses been acquired at the beginning of the year, on a proforma basis the Reed Elsevier revenues and net profit attributable to parent companies’ shareholders for the year would have been £6,065 million and £771£742 million respectively, before taking account of acquisition financing costs.

Acquisitions in 2010

During the year a number of small acquisitions were made for a total consideration of £43 million, after taking account of net cash acquired of nil.

The net assets of the businesses acquired are incorporated at their fair value to the combined businesses. The fair values of the consideration given and of the assets and liabilities acquired are summarised below.

 

Fair value
£m

Goodwill

27

Intangible assets

27

Current liabilities

(2

Deferred tax

(9

Net assets acquired

43

Consideration (after taking account of nil net cash acquired)

43

Less: consideration deferred to future years

(5

Net cash flow

38

13.Acquisitions – (continued)

Goodwill, being the excess of the consideration over the net tangible and intangible assets acquired, represents benefits which do not qualify for recognition as intangible assets, including the ability of the business to generate higher returns than individual assets, skilled workforces, acquisition synergies that are specific to Reed Elsevier. In addition, goodwill arises on the recognition of deferred tax liabilities in respect of intangible assets for which amortisation does not qualify for tax deductions.

14.Equity dividends

Ordinary dividends declaredpaid in the year

 

  2012
£m
   2011
£m
   2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Reed Elsevier PLC

   264     248     245     278     264     248  

Reed Elsevier NV

   259     251     240     273     259     251  
  

 

   

 

   

 

   

 

   

 

   

 

 

Total

   523     499     485     551     523     499  
  

 

   

 

   

 

   

 

   

 

   

 

 

Ordinary dividends declaredpaid in the year, in amounts per ordinary share, comprise: a 20112012 final dividend of 15.9p17.0p and a 20122013 interim dividend of 6.0p6.65p giving a total of 21.9p (2011: 20.65p; 2010: 20.4p)23.65p (2012: 21.9p; 2011: 20.65p) for Reed Elsevier PLC; and a 20112012 final dividend of €0.326€0.337 and a 20122013 interim dividend of €0.13€0.132 giving a total of €0.456 (2011: €0.413; 2010: €0.402)€0.469 (2012: €0.456; 2011: €0.413) for Reed Elsevier NV.

13.Equity dividends – (continued)

The directors of Reed Elsevier PLC have proposed a final dividend of 17.0p (2011: 15.9p; 2010: 15.0p)17.95p (2012: 17.0p; 2011: 15.9p). The directors of Reed Elsevier NV have proposed a final dividend of €0.337 (2011: €0.326; 2010: €0.303)€0.374 (2012: €0.337; 2011: €0.326). The total cost of funding the proposed final dividends is expected to be £391£422 million, for which no liability has been recognised at the statement of financial position date.

Ordinary dividends paid and proposed relating to the financial year

 

  2012
£m
  2011
£m
   2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Reed Elsevier PLC

  273   259     245     286     273     259  

Reed Elsevier NV

  262   265     246     291     262     265  
  

 

  

 

   

 

   

 

   

 

   

 

 

Total

  535   524     491     577     535     524  
  

 

  

 

   

 

   

 

   

 

   

 

 

Dividends paid to Reed Elsevier PLC and Reed Elsevier NV shareholders are, other than in special circumstances, equalised at the gross level inclusive of the UK tax credit of 10% received by certain Reed Elsevier PLC shareholders. The cost of funding the Reed Elsevier PLC dividends is therefore similar to that of Reed Elsevier NV.

 

15.14.Goodwill

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
£m
 2011
£m
 

At January 1

   4,729    4,441    4,339     4,545    4,729    4,441  

Acquisitions

   165    300    27     157    165    300  

Disposals/reclassified as held for sale

   (152  (26  (38   (46  (152  (26

Exchange translation differences

   (197  14    113     (80  (197  14  
  

 

  

 

  

 

   

 

  

 

  

 

 

At December 31

   4,545    4,729    4,441     4,576    4,545    4,729  
  

 

  

 

  

 

   

 

  

 

  

 

 

The carrying amount of goodwill is after £20£9 million (2011: £49(2012: £20 million) of impairment charges.

15.Goodwill – (continued)

charges recorded in prior years.

Impairment review

Impairment testing of goodwill and indefinite lived intangible assets is performed at least annually based on cash generating units (CGUs). A CGU is the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other groups of assets. Goodwill impairment testing is performed on the basis of 25 CGUs (2012: 22 CGUs.CGUs; 2011: 24 CGUs). CGUs which are not individually significant have been aggregated for presentation purposes. Typically, when an acquisition is made the acquired business is fully integrated into the relevant business unit and CGU, and the goodwill arising is allocated to the CGUs, or groups of CGUs, that are expected to benefit from the synergies of the acquisition.

The carrying value of goodwill recorded in the major groups of CGUs is set out below:

 

   2012
£m
   2011
£m
   2010
£m
 

Scientific, Technical & Medical

   1,026     991     994  
  

 

 

   

 

 

   

 

 

 

Risk Solutions

   1,559     1,733     1,720  
  

 

 

   

 

 

   

 

 

 

Business Information US

   50     52     63  

Business Information UK

   335     352     71  

Business Information NL

   23     23     24  

Business Information International

        30     31  
  

 

 

   

 

 

   

 

 

 

Business Information

   408     457     189  
  

 

 

   

 

 

   

 

 

 

Legal US

   1,038     1,070     1,064  

Legal International

   112     113     115  
  

 

 

   

 

 

   

 

 

 

Legal 

   1,150     1,183     1,179  
  

 

 

   

 

 

   

 

 

 

Exhibitions Continental Europe

   273     289     293  

Exhibitions other

   129     76     66  
  

 

 

   

 

 

   

 

 

 

Exhibitions

   402     365     359  
  

 

 

   

 

 

   

 

 

 

Total

   4,545     4,729     4,441  
  

 

 

   

 

 

   

 

 

 
   2013
£m
   2012
£m
   2011
£m
 

Scientific, Technical & Medical

   1,051     1,026     991  

Risk Solutions

   1,604     1,559     1,733  

Business Information

   374     408     457  

Legal

   1,121     1,150     1,183  

Exhibitions

   426     402     365  
  

 

 

   

 

 

   

 

 

 

Total

   4,576     4,545     4,729  
  

 

 

   

 

 

   

 

 

 

Reed Elsevier’s goodwill impairment testing methodology, assumptions and sensitivity analysis are disclosed within critical judgments and key sources of estimation uncertainty on pages F-14 to F-16.F-15.

16.15.Intangible assets

 

   Market
and
customer
related
£m
  Content,
software
and
other
£m
  Total
acquired
intangible
assets

£m
  Internally
developed
intangible
assets

£m
  Total
£m
 

Cost

      

At January 1, 2010

   2,535    3,390    5,925    1,042    6,967  

Acquisitions

   11    16    27        27  

Additions

               230    230  

Disposals/reclassified as held for sale

       (99  (99  (77  (176

Exchange translation differences

   85    44    129    9    138  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At January 1, 2011

   2,631    3,351    5,982    1,204    7,186  

Acquisitions

   196    115    311        311  

Additions

               270    270  

Disposals

   (38  (189  (227  (51  (278

Exchange translation differences

   13    (14  (1  (1  (2
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At January 1, 2012

   2,802    3,263    6,065    1,422    7,487  

Acquisitions

   201    27    228    1    229  

Additions

               261    261  

Disposals/reclassified as held for sale

   (56  (97  (153  (114  (267

Exchange translation differences

   (131  (103  (234  (53  (287
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At December 31, 2012

   2,816    3,090    5,906    1,517    7,423  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Accumulated amortisation and impairment

      

At January 1, 2010

   437    2,260    2,697    638    3,335  

Charge for the year

   161    184    345    158    503  

Disposals

       (93  (93  (64  (157

Exchange translation differences

   12    33    45    3    48  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At January 1, 2011

   610    2,384    2,994    735    3,729  

Charge for the year

   160    195    355    132    487  

Disposals/reclassified as held for sale

   (30  (149  (179  (36  (215

Exchange translation differences

   4    (8  (4  (4  (8
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At January 1, 2012

   744    2,422    3,166    827    3,993  

Charge for the year

   173    155    328    151    479  

Disposals

   (11  (89  (100  (79  (179

Exchange translation differences

   (36  (80  (116  (29  (145
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At December 31, 2012

   870    2,408    3,278    870    4,148  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net book amount

      

At December 31, 2010

   2,021    967    2,988    469    3,457  

At December 31, 2011

   2,058    841    2,899    595    3,494  

At December 31, 2012

   1,946    682    2,628    647    3,275  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

16.Intangible assets – (continued)

   Market
and
customer
related
£m
  Content,
software
and
other
£m
  Total
acquired
intangible
assets
£m
  Internally
developed
intangible
assets
£m
  Total
£m
 

Cost

      

At January 1, 2011

   2,631    3,351    5,982    1,204    7,186  

Acquisitions

   196    115    311        311  

Additions

               270    270  

Disposals/reclassified as held for sale

   (38  (189  (227  (51  (278

Exchange translation differences

   13    (14  (1  (1  (2
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At January 1, 2012

   2,802    3,263    6,065    1,422    7,487  

Acquisitions

   201    27    228    1    229  

Additions

               261    261  

Disposals/reclassified as held for sale

   (56  (97  (153  (114  (267

Exchange translation differences

   (131  (103  (234  (53  (287
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At January 1, 2013

   2,816    3,090    5,906    1,517    7,423  

Acquisitions

   49    84    133        133  

Additions

               251    251  

Disposals/reclassified as held for sale

   (55  (216  (271  (27  (298

Exchange translation differences

   (65  (16  (81  (24  (105
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At December 31, 2013

   2,745    2,942    5,687    1,717    7,404  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Accumulated amortisation and impairment

      

At January 1, 2011

   610    2,384    2,994    735    3,729  

Charge for the year

   160    195    355    132    487  

Disposals

   (30  (149  (179  (36  (215

Exchange translation differences

   4    (8  (4  (4  (8
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At January 1, 2012

   744    2,422    3,166    827    3,993  

Charge for the year

   173    155    328    151    479  

Disposals/reclassified as held for sale

   (11  (89  (100  (79  (179

Exchange translation differences

   (36  (80  (116  (29  (145
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At January 1, 2013

   870    2,408    3,278    870    4,148  

Charge for the year

   178    139    317    160    477  

Disposals

   (55  (216  (271  (22  (293

Exchange translation differences

   (26  (15  (41  (11  (52
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At December 31, 2013

   967    2,316    3,283    997    4,280  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net book amount

      

At December 31, 2011

   2,058    841    2,899    595    3,494  

At December 31, 2012

   1,946    682    2,628    647    3,275  

At December 31, 2013

   1,778    626    2,404    720    3,124  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Intangible assets acquired as part of business combinations comprise: market related assets (e.g. trademarks, imprints, brands); customer related assets (e.g. subscription bases, customer lists, customer relationships); and content, software and other intangible assets (e.g. editorial content, software and product delivery systems, other publishing rights, exhibition rights and supply contracts). Included in content, software and other acquired intangible assets are assets with a net book value of £353 million (2012: £431 million (2011:million; 2011: £531 million; 2010: £619 million) that arose on acquisitions completed prior to the adoption of IFRS that have not been allocated to specific categories of intangible assets. Internally developed intangible assets typically comprise software and systems development where an identifiable asset is created that is probable to generate future economic benefits.

15.Intangible assets – (continued)

Included in market and customer related intangible assets are £347 million (2012: £354 million (2011:million; 2011: £370 million; 2010: £368 million) of brands and imprints relating to Scientific, Technical & Medical determined to have indefinite lives based on an assessment of their historical longevity and stable market positions. Indefinite lived intangibles are tested for impairment at least annually using the same value in use assumptions as set out in critical judgements and key sources of estimation uncertainty on pages F-14 to F-16.F-15.

Also included in market and customer related intangible assets are £952 million (2012: £1,037 million (2011:million; 2011: £1,209 million; 2010: £1,274 million) of customer relationship assets arising on the acquisition of ChoicePoint in 2008 with a remaining useful economic life of approximately 1615 years.

 

17.16.Investments

 

  2012
£m
   2011
£m
   2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Investments in joint ventures

   100     124     136     125     100     124  

Available for sale investments

   3     8     10     2     3     8  

Venture capital investments held for trading

   76     56     38     90     76     56  
  

 

   

 

   

 

   

 

   

 

   

 

 

Total

   179     188     184     217     179     188  
  

 

   

 

   

 

   

 

   

 

   

 

 

The value of venture capital investments held for trading, determined by reference to quoted market prices, amounted to £12 million (2012: £27 million (2011:million; 2011: £17 million; 2010: £12 million). The value of other venture capital investments and available for sale investments has been determined by reference to other observable market inputs.

An analysis of changes in the carrying value of investments in joint ventures is set out below:

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
£m
 2011
£m
 

At January 1

   124    136    135     100    124    136  

Share of results of joint ventures

   24    30    22     29    24    30  

Dividends received from joint ventures

   (20  (33  (24   (22  (20  (33

Disposals and transfers

   (33  (6  (1   (3)    (33  (6

Additions

   10    1         21    10    1  

Exchange translation differences

   (5  (4  4         (5  (4
  

 

  

 

  

 

   

 

  

 

  

 

 

At December 31

   100    124    136     125    100    124  
  

 

  

 

  

 

   

 

  

 

  

 

 

The principal joint ventures at December 31, 20122013 are exhibition joint ventures within Exhibitions and Giuffrè (an Italian legal publisher in which Reed Elsevier has a 40% shareholding)and Martindale within Legal.

Summarised aggregate information in respect of joint ventures and Reed Elsevier’s share is set out below:

 

  Total joint ventures Reed Elsevier share   Total joint ventures Reed Elsevier share 
  2012
£m
 2011
£m
 2010
£m
 2012
£m
 2011
£m
 2010
£m
   2013
£m
   2012
£m
 2011
£m
 2013
£m
   2012
£m
 2011
£m
 

Revenue

   187    254    235    91    128    116     225     187    254    110     91    128  

Net profit for the year

   45    62    46    24    30    22     57     45    62    29     24    30  
  

 

  

 

  

 

  

 

  

 

  

 

   

 

   

 

  

 

  

 

   

 

  

 

 

Total assets

   227    255    264    104    122    122     246     227    255    117     104    122  

Total liabilities

   (126  (137  (132  (59  (66  (62   (134)     (126  (137  (64)     (59  (66
  

 

  

 

  

 

  

 

  

 

  

 

   

 

   

 

  

 

  

 

   

 

  

 

 

Net assets

   101    118    132    45    56    60     112     101    118    53     45    56  
  

 

  

 

  

 

      

 

   

 

  

 

     

Goodwill

      55    68    76         72     55    68  
     

 

  

 

  

 

       

 

   

 

  

 

 

Total

      100    124    136         125     100    124  
     

 

  

 

  

 

       

 

   

 

  

 

 

Reed Elsevier’s combined other comprehensive income includes nil relating to joint ventures (2012: nil; 2011: nil).

18.17.Property, plant and equipment

 

 2012 2011 2010  2013 2012 2011 
 Land
and
buildings
£m
 Fixtures
and
equipment
£m
 Total
£m
 Land
and
buildings
£m
 Fixtures
and
equipment
£m
 Total
£m
 Land
and
buildings
£m
 Fixtures
and
equipment
£m
 Total
£m
  Land
and
buildings
£m
 Fixtures
and
equipment
£m
 Total
£m
 Land
and
buildings
£m
 Fixtures
and
equipment
£m
 Total
£m
 Land
and
buildings
£m
 Fixtures
and
equipment
£m
 Total
£m
 

Cost

                  

At January 1

  238    582    820    246    578    824    238    626    864    218    537    755    238    582    820    246    578    824  

Acquisitions

      1    1        1    1                                1    1        1    1  

Capital expenditure

  10    70    80    8    82    90    7    78    85    4    66    70    10    70    80    8    82    90  

Disposals/reclassified
as held for sale

  (21  (97  (118  (16  (78  (94  (5  (141  (146  (8  (34  (42  (21  (97  (118  (16  (78  (94

Exchange translation differences

  (9  (19  (28      (1  (1  6    15    21    (4  (11  (15  (9  (19  (28      (1  (1
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

At December 31

  218    537    755    238    582    820    246    578    824    210    558    768    218    537    755    238    582    820  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Accumulated depreciation

                  

At January 1

  118    414    532    115    418    533    106    466    572    116    375    491    118    414    532    115    418    533  

Disposals/reclassified
as held for sale

  (5  (94  (99  (6  (69  (75  (5  (127  (132  (6  (32  (38  (5  (94  (99  (6  (69  (75

Charge for the year

  8    68    76    9    66    75    12    67    79    9    80    89    8    68    76    9    66    75  

Exchange translation differences

  (5  (13  (18      (1  (1  2    12    14    (2  (9  (11  (5  (13  (18      (1  (1
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

At December 31

  116    375    491    118    414    532    115    418    533    117    414    531    116    375    491    118    414    532  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Net book amount

  102    162    264    120    168    288    131    160    291    93    144    237    102    162    264    120    168    288  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

No depreciation is provided on freehold land of £39£14 million (2011: £46(2012: £15 million; 2010: £482011: £22 million). The net book amount of property, plant and equipment at December 31, 20122013 includes £17 million (2012: £11 million (2011:million; 2011: £4 million; 2010: £2 million) in respect of assets held under finance leases relating to fixtures and equipment.

19.18.Financial instruments

The main financial risks faced by Reed Elsevier are liquidity risk, market risk — comprising interest rate risk and foreign exchange risk — and credit risk. Financial instruments are used to finance the Reed Elsevier businesses and to hedge interest rate and foreign exchange risks. Reed Elsevier’s businesses do not enter into speculative derivative transactions. Details of financial instruments subject to liquidity, market and credit risks are described below.

Liquidity risk

Reed Elsevier maintains a range of borrowing facilities and debt programmes to fund its requirements, at short notice and at competitive rates. The remaining contractual maturities for borrowings and derivative financial instruments are shown in the table below. The table shows undiscounted principal and interest cash flows and includes contractual gross cash flows to be exchanged as part of cross currency interest rate swaps and forward foreign exchange contracts where there is a legal right of set-off.

     Contractual cash flow 

At December 31, 2012

 Carrying
amount

£m
  Within
1 year

£m
  1-2  Years
£m
  2-3  Years
£m
  3-4  Years
£m
  4-5  Years
£m
  More
than
5  Years

£m
  Total
£m
 

Borrowings

        

Fixed rate borrowings

  (3,695  (803  (797  (251  (530  (428  (1,940  (4,749

Floating rate borrowings

  (197  (132  (1  (63      (1  (3  (200

Derivative financial liabilities

        

Interest rate derivatives

  (2  (3                  (5  (8

Cross currency interest rate swaps

      (166  (180                  (346

Forward foreign exchange contracts

  (9  (1,382  (442  (194              (2,018

Derivative financial assets

        

Interest rate derivatives

  47    35    13    12    9    6        75  

Cross currency interest rate swaps

  93    202    243                    445  

Forward foreign exchange contracts

  55    1,400    460    202                2,062  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total

  (3,708  (849  (704  (294  (521  (423  (1,948  (4,739
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

19.18.Financial instruments – (continued)

 

   Contractual cash flow    Contractual cash flow 

At December 31, 2011

 Carrying
amount
£m
 Within
1 year
£m
 1-2 Years
£m
 2-3 Years
£m
 3-4 Years
£m
 4-5 Years
£m
 More than
5 Years
£m
 Total
£m
 

At December 31, 2013

 Carrying
amount
£m
 Within
1 year
£m
 1-2  Years
£m
 2-3  Years
£m
 3-4  Years
£m
 4-5  Years
£m
 More
than
5 Years
£m
 Total
£m
 

Borrowings

                

Fixed rate borrowings

  (3,568  (553  (814  (863  (248  (524  (1,694  (4,696  (2,931  (497  (243  (524  (420  (264  (1,909  (3,857

Floating rate borrowings

  (714  (646  (2  (2  (65  (1  (5  (721  (350  (288  (61      (1      (2  (352

Derivative financial liabilities Interest rate derivatives

  (10  (9  (3                  (12

Derivative financial liabilities

        

Interest rate derivatives

  (4              (1  (4  (7  (12

Cross currency interest rate swaps

      (6  (173  (189              (368  (6  (180  (3  (5  (7  (193      (388

Forward foreign exchange contracts

  (59  (1,019  (421  (256              (1,696  (7  (1,031  (402  (222              (1,655

Derivative financial assets
Interest rate derivatives

  39    13    27    6    5    5    3    59  

Derivative financial assets

        

Interest rate derivatives

  19    13    11    6    1            31  

Cross currency interest rate swaps

  99    14    208    248                470    70    247    2    2    3    189        443  

Forward foreign exchange contracts

  11    987    414    252                1,653    99    1,082    431    233                1,746  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Total

  (4,202  (1,219  (764  (804  (308  (520  (1,696  (5,311  (3,110  (654  (265  (510  (425  (272  (1,918  (4,044
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

 

   Contractual cash flow    Contractual cash flow 

At December 31, 2010

 Carrying
amount
£m
 Within
1 year
£m
 1-2 Years
£m
 2-3 Years
£m
 3-4 Years
£m
 4-5 Years
£m
 More than
5 Years
£m
 Total
£m
 

At December 31, 2012

 Carrying
amount
£m
 Within
1 year
£m
 1-2  Years
£m
 2-3  Years
£m
 3-4  Years
£m
 4-5  Years
£m
 More
than
5 Years
£m
 Total
£m
 

Borrowings

                

Fixed rate borrowings

  (3,711  (370  (558  (833  (865  (246  (2,210  (5,082  (3,695  (803  (797  (251  (530  (428  (1,940  (4,749

Floating rate borrowings

  (591  (383  (53  (6  (99  (67  (5  (613  (197  (132  (1  (63      (1  (3  (200

Derivative financial liabilities Interest rate derivatives

  (25  (19  (8  (2      (1  (6  (36

Derivative financial liabilities

        

Interest rate derivatives

  (2  (3                  (5  (8

Cross currency interest rate swaps

      (5  (7  (179  (190          (381      (166  (180                  (346

Forward foreign exchange contracts

  (55  (1,283  (413  (154  (32          (1,882  (9  (1,382  (442  (194              (2,018

Derivative financial assets
Interest rate derivatives

  19    15    10    20                45  

Derivative financial assets

        

Interest rate derivatives

  47    35    13    12    9    6        75  

Cross currency interest rate swaps

  100    14    14    209    248            485    93    202    243                    445  

Forward foreign exchange contracts

  15    1,262    401    154    33            1,850    55    1,400    460    202                2,062  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Total

  (4,248  (769  (614  (791  (905  (314  (2,221  (5,614  (3,708  (849  (704  (294  (521  (423  (1,948  (4,739
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

     Contractual cash flow 

At December 31, 2011

 Carrying
amount
£m
  Within
1 year
£m
  1-2  Years
£m
  2-3  Years
£m
  3-4  Years
£m
  4-5  Years
£m
  More
than
5 Years
£m
  Total
£m
 

Borrowings

        

Fixed rate borrowings

  (3,568  (553  (814  (863  (248  (524  (1,694  (4,696

Floating rate borrowings

  (714  (646  (2  (2  (65  (1  (5  (721

Derivative financial liabilities

        

Interest rate derivatives

  (10  (9  (3                  (12

Cross currency interest rate swaps

      (6  (173  (189              (368

Forward foreign exchange contracts

  (59  (1,019  (421  (256              (1,696

Derivative financial assets

        

Interest rate derivatives

  39    13    27    6    5    5    3    59  

Cross currency interest rate swaps

  99    14    208    248                470  

Forward foreign exchange contracts

  11    987    414    252                1,653  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total

  (4,202  (1,219  (764  (804  (308  (520  (1,696  (5,311
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

18.Financial instruments – (continued)

The carrying amount of derivative financial liabilities comprises £10 million (2012: nil; 2011: nil) in relation to fair value hedges, £7 million (2011:(2012: £7 million; 2011: £64 million; 2010: £68 million) in relation to cash flow hedges and nil (2012: £4 million (2011:million; 2011: £5 million; 2010: £12 million) not designated as hedging instruments. The carrying amount of derivative financial assets comprises £84 million (2012: £124 million (2011:million; 2011: £123 million; 2010: £105 million) in relation to fair value hedges, £88 million (2012: £46 million (2011:million; 2011: £10 million; 2010: £12 million) in relation to cash flow hedges and £29 million (2012: £25 million (2011:million; 2011: £16 million; 2010: £17 million) not designated as hedging instruments.instruments, less £13 million (2012: nil; 2011: nil) of cash collateral received from swap counterparties which has been offset against the related derivative financial assets (see ‘Credit risk’ below). The expected cash flows in respect of the cash collateral have been included in the tables above together with the cash flows for the related cross currency interest rate swaps.

At December 31, 2012,2013, Reed Elsevier had access to a $2,000 million committed bank facility maturing in June 2015,July 2018, which was undrawn. The bank facility, together with certain of Reed Elsevier’s private placements, are subject to financial covenants typical to Reed Elsevier’s size and financial strength. Reed Elsevier was in compliance with these covenants for the year ended December 31, 2012.2013. Financial covenants are not included in the terms and conditions of any outstanding public bonds.

19.Financial instruments – (continued)

After taking account of the maturity of committed bank facilities that back short term borrowings at December 31, 2012,2013, and after utilising available cash resources, no borrowings mature within two years (2011:(2012: nil; 2010:2011: nil), 27% ofno borrowings mature in the third year (2011:(2012: 27%; 2011: 44%; 2010: 23%), 23%50% in the fourth and fifth years (2011:(2012: 23%; 2011: 18%; 2010: 27%), 39%42% in the sixth to tenth years (2011:(2012: 39%; 2011: 27%; 2010: 39%), and 11%8% beyond the tenth year (2011:(2012: 11%; 2010:2011: 11%).

Market Risk

Reed Elsevier’s primary market risks are to interest rate fluctuations and exchange rate movements. Derivatives are used to hedge or reduce the risks of interest rate and exchange rate movements and are not entered into unless such risks exist. Derivatives used by Reed Elsevier for hedging a particular risk are not specialised and are generally available from numerous sources. The impact of market risks on net post employment benefit obligations and taxation is excluded from the following market risk sensitivity analysis.

Interest rate risk

Reed Elsevier’s interest rate exposure management policy is aimed at reducing the exposure of the combined businesses to changes in interest rates.

At December 31, 2012, 59%2013, 57% of gross borrowings were either fixed rate or had been fixed through the use of interest rate swaps, forward rate agreements andor options. A 100 basis point reduction in interest rates would result in an estimated decrease in net finance costs of £12 million (2012: £8 million (2011:million; 2011: £5 million; 2010: £3 million), based on the composition of financial instruments including cash, cash equivalents, bank loans and commercial paper borrowings at December 31, 2012.2013. A 100 basis point rise in interest rates would result in an estimated increase in net finance costs of £12 million (2012: £8 million (2011:million; 2011: £5 million; 2010: £3 million).

The impact on net equity of a theoretical change in interest rates as at December 31, 20122013 is restricted to the change in carrying value of floating rate to fixed rate interest rate derivatives in a designated cash flow hedge relationship and undesignated interest rate derivatives. A 100 basis point reduction in interest rates would result in an estimated reduction in net equity of nil (2012: £1 million (2011:million; 2011: £3 million; 2010: £8 million) and a 100 basis point increase in interest rates would increase net equity by an estimated £1 million (2012: £2 million (2011:million; 2011: £4 million; 2010: £9 million). The impact of a change in interest rates on the carrying value of fixed rate borrowings in a designated fair value hedge relationship would be offset by the change in carrying value of the related interest rate derivative. Fixed rate borrowings not in a designated hedging relationship are carried at amortised cost.

Foreign exchange rate risk

Translation exposures arise on the earnings and net assets of business operations in countries with currencies other than sterling, most particularly in respect of the US businesses. TheseSome of these exposures are hedged, to a significant extent,offset by a policy of denominating borrowings in currencies where significant translation exposures exist, most notably US dollars (see note 25)24).

Currency exposures on transactions denominated in a foreign currency are required to be hedged using forward contracts. In addition, recurring transactions and future investment exposures may be hedged, in advance of becoming contractual. The precise policy differs according to the specific circumstances of the individual businesses. Highly predictable future cash flows may be covered for transactions expected to occur during the next 24 months (50 months for the Scientific, Technical & Medical subscription businesses) within limits defined according to the period before the transaction is expected to become contractual. Cover takes the form of foreign exchange forward contracts.

A theoretical weakening of all currencies by 10% against sterling at December 31, 20122013 would decrease the carrying value of net assets, excluding net borrowings, by £500 million (2012: £495 million (2011:million; 2011: £525 million; 2010: £508 million). This would be offset

18.Financial instruments – (continued)

to a large degree by a decrease in net borrowings of £246 million (2012: £286 million (2011: £297 million; 2010:2011: £297 million). A strengthening of all currencies by 10% against sterling at December 31, 20122013 would increase the carrying value of net assets, excluding net borrowings, by £500 million (2012: £495 million (2011:million; 2011: £525 million; 2010: £508 million) and increase net borrowings by £246 million (2012: £286 million (2011: £297 million; 2010:2011: £297 million).

A retranslation of the combined businesses’ net profit for the year assuming a 10% weakening of all foreign currencies against sterling but excluding transactional exposures would reduce net profit by £92 million (2012: £80 million (2011:million; 2011: £59 million; 2010: £56 million). A 10% strengthening of all foreign currencies against sterling on this basis would increase net profit for the year by £92 million (2012: £80 million (2011:million; 2011: £59 million; 2010: £56 million).

Credit risk

Reed Elsevier seeks to limit interest rate and foreign exchange risks described above by the use of financial instruments and as a result has a credit risk from the potential non performance by the counterparties to these financial instruments, which are unsecured. The amount of this credit risk is normally restricted to the amounts of any hedge gain and not the principal amount being hedged. Reed Elsevier also has a credit exposure to counterparties for the full principal amount of cash and cash equivalents. Credit risks are controlled by monitoring the credit quality of these counterparties, principally licensed commercial banks and investment banks with strong long term credit ratings, and the amounts outstanding with each of them.

19.Financial instruments – (continued)

In certain situations, Reed Elsevier enters into credit support arrangements with derivative counterparties to mitigate the credit exposures arising from hedge gains on the related financial instruments. Under these arrangements, Reed Elsevier receives (or pays) cash collateral equal to the mark to market valuation of the related derivative asset (or liability) on monthly settlement dates. At December 31, 2013, £13 million (2012: nil; 2011: nil) of cash collateral had been received, and the resulting payable balance was offset against the related derivative assets of £12 million (2012: nil; 2011: nil) in the statement of financial position.

Reed Elsevier has treasury policies in place which do not allow concentrations of risk with individual counterparties and do not allow significant treasury exposures with counterparties which are rated lower than A-/A3 by Standard & Poor’s, Moody’s and Fitch.

Reed Elsevier also has credit risk with respect to trade receivables due from its customers that include national and state governments, academic institutions and large and small enterprises including law firms, book stores and wholesalers. The concentration of credit risk from trade receivables is limited due to the large and broad customer base. Trade receivable exposures are managed locally in the business units where they arise. Where appropriate, business units seek to minimise this exposure by taking payment in advance and through management of credit terms. Allowance is made for bad and doubtful debts based on management’s assessment of the risk taking into account the ageing profile, experience and circumstance. The maximum exposure to credit risk is represented by the carrying amount of each financial asset, including derivative financial instruments, recorded in the statement of financial position.

Included within trade receivables are the following amounts which are past due but for which no allowance has been made. Past due up to one month £156 million (2012: £148 million (2011:million; 2011: £212 million; 2010: £241 million); past due two to three months £76 million (2012: £58 million (2011:million; 2011: £54 million; 2010: £58 million); past due four to six months £26 million (2012: £14 million (2011:million; 2011: £20 million; 2010: £16 million); and past due greater than six months £7 million (2012: £1 million (2011: £5 million; 2010:2011: £5 million.). Examples of trade receivables which are past due but for which no allowance has been made include those receivables where there is no concern over the creditworthiness of the customer and where the history of dealings with the customer indicate the amount will be settled.

Capital and liquidity management

The capital structure is managed to support Reed Elsevier’s objective of maximising long-term shareholder value through appropriate security of funding, ready access to debt and capital markets, cost effective borrowing and flexibility to fund business and acquisition opportunities whilst maintaining appropriate leverage to ensure an efficient capital structure.

Over the long-term Reed Elsevier seeks to maintain cash flow conversion (the proportion of adjusted operating profits converted into cash) of 90% or higher and credit metrics consistent with a solid investment grade credit rating. The typical credit metrics are net debt to EBITDA, on a pensions and lease adjusted and on an unadjusted basis, and free cash flow as a percentage of net debt.

Reed Elsevier’s uses of free cash flow over the longer-term balance the dividend policy, selective acquisitions and share repurchases, whilst retaining the balance sheet strength to maintain access to cost effective sources of borrowing.

The balance of long-term debt, short-term debt and committed bank facilities is managed to provide security of funding, taking into account the cash generation cycle of the business and the uncertain size and timing of acquisition spend. Reed Elsevier maintains a range of borrowing facilities and debt programmes from a variety of sources to fund its requirements at

18.Financial instruments – (continued)

short notice and at competitive rates. Consistent with the significance of Reed Elsevier Group plc’s US operations, the majority of debt is denominated in US dollars. The policy is that no more than US$1.5 billion of term debt issues should mature in any 12-month period and no more than US$3.0 billion in any 36-month period. In addition, minimum levels of borrowings with maturities over three and five years are specified, depending on the level of net debt and free cash flow. From time to time, Reed Elsevier may redeem term debt early or repurchase outstanding debt in the open market depending on market conditions.

There were no changes to Reed Elsevier’s long-term approach to capital and liquidity management during the year.

Hedge accounting

The hedging relationships that are designated under IAS39 — Financial Instruments are described below:

Fair value hedges

Reed Elsevier has entered into interest rate swaps and cross currency interest rate swaps to hedge the exposure to changes in the fair value of fixed rate borrowings due to interest rate and foreign currency movements which could affect the income statement.

Reed Elsevier has entered into interest rate swaps and cross currency interest rate swaps to hedge the exposure to changes in the fair value of fixed rate borrowings due to interest rate and foreign currency movements which could affect the income statement. Interest rate derivatives (including cross currency interest rate swaps) with a principal amount of £1,104 million (2012: £1,502 million (2011:million; 2011: £1,081 million; 2010: £1,093 million). were in place at December 31, 20122013 swapping fixed rate term debt issues denominated in US dollars (USD), sterling, euros and Swiss francs (CHF) to floating rate USD, sterling, euro and US dollar (USD)USD debt respectively for the whole or part of their term. Included within this amount are interest rate derivatives with a principal amount of £488 million (2011: nil; 2010: nil) which were de-designated as fair value hedges during the year.

The gains and losses on the borrowings and related derivatives designated as fair value hedges, which are included in the income statement, for the three years ended December 31, 20122013 were as follows:

Gains/(losses) on borrowings and related derivatives

 

  January  1,
2010

£m
 Fair value
movement
gain/(loss)
£m
 Exchange
gain/(loss)
£m
 December  31,
2010

£m
   January 1,
2011
£m
 Fair value
movement
gain/(loss)
£m
 Exchange
gain/(loss)
£m
 December 31,
2011
£m
 

GBP debt

   9    (16      (7   (7  (23      (30

Related interest rate swaps

   (9  16        7     7    23        30  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 
                                  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

EUR debt

   (2  (10      (12   (12  3        (9

Related interest rate swaps

   2    10        12     12    (3      9  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 
                                  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

CHF debt

   (48  (37  (1  (86   (86  3    (1  (84

Related CHF to USD cross currency interest rate swaps

   48    37    1    86     86    (3  1    84  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 
                                  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Total GBP, EUR and CHF debt

   (41  (63  (1  (105   (105  (17  (1  (123

Total related interest rate derivatives

   41    63    1    105     105    17    1    123  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Net gain

                                  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

19.18.Financial instruments – (continued)

 

  January 1,
2011
£m
 Fair value
movement
gain/(loss)
£m
 Exchange
gain/(loss)
£m
 December 31,
2011
£m
   January 1,
2012
£m
 Fair value
movement
gain/(loss)
£m
 De-designated
£m
 Exchange
gain/(loss)
£m
 December 31,
2012
£m
 

GBP debt

   (7  (23      (30   (30  (6          (36

Related interest rate swaps

   7    23        30     30    6            36  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

 
                                      
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

 

EUR debt

   (12  3        (9   (9  (8  9        (8

Related interest rate swaps

   12    (3      9     9    8    (9      8  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

 
                                      
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

 

CHF debt

   (86  3    (1  (84   (84          4    (80

Related CHF to USD cross currency interest rate swaps

   86    (3  1    84     84            (4  80  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

 
                                      
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

 

Total GBP, EUR and CHF debt

   (105  (17  (1  (123   (123  (14  9    4    (124

Total related interest rate derivatives

   105    17    1    123     123    14    (9  (4  124  
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

 

Net gain

                                      
  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

  

 

 

 

  January  1,
2013
£m
 Fair value
movement
gain/(loss)
£m
 Exchange
gain/(loss)
£m
 December  31,
2013
£m
 

USD debt

       6        6  

Related interest rate swap

       (6      (6
  

 

  

 

  

 

  

 

 
                 
  January 1,
2012
£m
 Fair value
movement
gain/(loss)
£m
 De-designated
£m
 Exchange
gain/(loss)
£m
 December 31,
2012
£m
   

 

  

 

  

 

  

 

 

GBP debt

   (30  (6          (36   (36  17        (19

Related interest rate swaps

   30    6            36     36    (17      19  
  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 
                                      
  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

EUR debt

   (9  (8  9        (8   (8  13    (1  4  

Related interest rate swaps

   9    8    (9      8     8    (13  1    (4
  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 
                                      
  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

CHF debt

   (84          4    (80   (80  14    1    (65

Related CHF to USD cross currency interest rate swaps

   84            (4  80     80    (14  (1  65  
  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 
                                      
  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Total GBP, EUR and CHF debt

   (123  (14  9    4    (124

Total USD, GBP, EUR and CHF debt

   (124  50        (74

Total related interest rate derivatives

   123    14    (9  (4  124     124    (50      74  
  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

Net gain

                                      
  

 

  

 

  

 

  

 

  

 

   

 

  

 

  

 

  

 

 

All fair value hedges were highly effective throughout the three years ended December 31, 2012.2013.

Gross borrowings as at December 31, 20122013 included £31 million (2012: £37 million (2011:million; 2011: £43 million; 2010: £51 million) in relation to fair value adjustments to borrowings previously designated in a fair value hedge relationship which were de-designated in 2008. The related derivatives were closed out on de-designation with a cash inflow of £62 million. £5 million (2011:(2012: £5 million; 2011: £8 million; 2010: £10 million)million ) of these fair value adjustments were amortised in the year as a reduction to finance costs.

Gross borrowings also included nil (2012: £2 million (2011: nil; 2010:million; 2011: nil) in relation to fair value adjustments to borrowings previously designated in a fair value hedging relationship which were de-designated during the year.2012. £2 million (2012: £7 million (2011: nil; 2010:million; 2011: nil) of these fair value adjustments were amortised in the year as a reduction ofto finance costs. The related derivatives remained on the balance sheet at December 31, 2012 with a carrying value of £3 million.

18.Financial instruments – (continued)

Cash flow hedges

Reed Elsevier enters into two types of cash flow hedge:

 

 (1)InterestDebt hedges comprising interest rate derivatives which fix the interest expense on a portion of forecast floating rate debt (including commercial paper, short term bank loans and floating rate term debt)., and cross currency interest rate derivatives which hedge the cash flow exposure arising from foreign currency denominated debt.

 

 (2)ForeignRevenue hedges comprising forward foreign exchange derivativescontracts which fix the exchange rate on a portion of future foreign currency subscription revenues forecast by the Scientific, Technical & Medical businesses for up to 50 months.

19.Financial instruments – (continued)

Movements in the hedge reserve (pre-tax) in 2013, 2012 2011 and 2010,2011, including gains and losses on cash flow hedging instruments, were as follows:

 

  Interest rate
hedges
£m
 Foreign
exchange
hedges
£m
 Total
hedge
reserve
pre-tax
£m
 

Hedge reserve at January 1, 2010: losses deferred

   (38  (51  (89

Losses arising in 2010

   (15  (43  (58

Amounts recognised in income statement

   26    35    61  

Exchange translation differences

   (2      (2
  

 

  

 

  

 

   Debt
hedges
£m
 Revenue
hedges
£m
 Total
hedge
reserve
pre-tax
£m
 

Hedge reserve at January 1, 2011: losses deferred

   (29  (59  (88   (29  (59  (88

Losses arising in 2011

   (3  (21  (24   (3  (21  (24

Amounts recognised in income statement

   15    33    48     15    33    48  

Exchange translation differences

       1    1         1    1  
  

 

  

 

  

 

   

 

  

 

  

 

 

Hedge reserve at January 1, 2012: losses deferred

   (17  (46  (63   (17  (46  (63

(Losses)/gains arising in 2012

   (2  72    70     (2  72    70  

Amounts recognised in income statement

   16    10    26     16    10    26  

Exchange translation differences

   1    1    2     1    1    2  
  

 

  

 

  

 

   

 

  

 

  

 

 

Hedge reserve at December 31, 2012: (losses)/gains deferred

   (2  37    35  

Hedge reserve at January 1, 2013: (losses)/gains deferred

   (2  37    35  

Gains arising in 2013

   1    64    65  

Amounts recognised in income statement

   3    (6)    (3)  

Exchange translation differences

       (1)    (1)  
  

 

  

 

  

 

   

 

  

 

  

 

 

Hedge reserve at December 31, 2013: gains deferred

   2    94    96  
  

 

  

 

  

 

 

All cash flow hedges were highly effective throughout the three years ended December 31, 2012.2013.

A tax charge of £23 million (2012: £9 million (2011:million; 2011: £15 million credit; 2010: £21 million credit) in respect of the above gains and losses at December 31, 20122013 was also deferred in the hedge reserve.

Of the amounts recognised in the income statement in the year, lossesgains of £6 million (2012: £10 million (2011:loss; 2011: £33 million; 2010: £35 million)million loss) were recognised in revenue, and losses of £3 million (2012: £16 million (2011:million; 2011: £15 million; 2010: £26 million) were recognised in finance costs. A tax creditcharge of £1 million (2012: £5 million (2011:credit; 2011: £11 million; 2010: £15 million)million credit) was recognised in relation to these items.

The deferred gains and losses on cash flow hedges at December 31, 20122013 are currently expected to be recognised in the income statement in future years as follows:

 

  Interest rate
hedges
£m
 Foreign
exchange
hedges
£m
   Total
hedge
reserve
pre-tax
£m
   Debt
hedges
£m
   Revenue
hedges
£m
   Total
hedge
reserve
pre-tax
£m
 

2013

   (2  7     5  

2014

       16     16     (2)     38     36  

2015

       11     11     (1)     37     36  

2016

       3     3          17     17  

2017

                      2     2  

2018

   5          5  
  

 

  

 

   

 

   

 

   

 

   

 

 

(Losses)/gains deferred in hedge reserve at end of year

   (2  37     35  

Gains deferred in hedge reserve at end of year

   2     94     96  
  

 

  

 

   

 

   

 

   

 

   

 

 

18.Financial instruments – (continued)

The cash flows for these hedges are expected to occur in line with the recognition of the gain and losses in the income statement, other than in respect of certain forward foreign exchange hedges on subscriptions, where cash flows may be expected to occur in advance of the subscription year.

 

20.19.Deferred tax

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
£m
 2011
£m
 

Deferred tax assets

   79    212    151     442    79    212  

Deferred tax liabilities

   (919  (1,236  (1,192   (1,076  (919  (1,236
  

 

  

 

  

 

   

 

  

 

  

 

 

Total

   (840  (1,024  (1,041   (634)    (840  (1,024
  

 

  

 

  

 

   

 

  

 

  

 

 

20.19.Deferred tax – (continued)

 

Movements in deferred tax liabilities and assets (before taking into consideration the offsetting of balances within the same jurisdiction) are summarised as follows:

 

 Deferred tax liabilities Deferred tax assets    Deferred tax liabilities Deferred tax assets 
 Excess of
tax allowances
over
amortisation
£m
 Acquired
intangible
assets

£m
 Pensions
assets
£m
 Other
temporary
differences
£m
 Excess of
amortisation
over tax
allowances
£m
 Tax losses
carried
forward
£m
 Pensions
liabilities
£m
 Other
temporary
differences
£m
 Total
£m
  Excess of
tax allowances
over
amortisation
£m
 Acquired
intangible
assets
£m
 Pensions
assets
£m
 Other
temporary
differences
£m
 Excess of
amortisation
over tax
allowances
£m
 Tax losses
carried
forward
£m
 Pensions
liabilities
£m
 Other
temporary
differences
£m
 Total
£m
 

Deferred tax (liability)/asset at January 1, 2010

  (216  (1,007  (31  (18  27    9    122    50    (1,064

Credit/(charge) to profit

  2    100    (7  1    (14  4    (40      46  

Credit/(charge) to equity

          23    7            (7  6    29  

Transfers

                              (11  (11

Acquisitions

      (9                      (9  (9

Exchange translation differences

  (9  (28                  3    2    (32
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Deferred tax (liability)/asset at January 1, 2011

  (223  (944  (15  (10  13    13    78    47    (1,041  (223  (944  (15  (10  13    13    78    47    (1,041

(Charge)/credit to profit

  (6  131    (10  (94  3    32    (3  24    77    (6  131    (10  (94  3    32    (3  24    77  

Credit/(charge) to equity

          25                11    6    42  

Credit/(charge) to equity/other comprehensive income

          25                11    6    42  

Transfers

                              (17  (17                              (17  (17

Acquisitions

      (85              2        5    (78      (85              2        5    (78

Disposals/reclassified as held for sale

              1                (1                  1                (1    

Exchange translation differences

  (2  (2      (2      1        (2  (7  (2  (2      (2      1        (2  (7
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Deferred tax (liability)/asset at January 1, 2012

  (231  (900      (105  16    48    86    62    (1,024  (231  (900      (105  16    48    86    62    (1,024

(Charge)/credit to profit

  (5  85        (9  (3  (19  (32  23    40    (5  85        (9  (3  (19  (32  23    40  

(Charge)/credit to equity

              (3          102    (6  93  

(Charge)/credit to equity/other comprehensive income

              (3          102    (6  93  

Acquisitions

  1    (10          (3  (2      (2  (16  1    (10          (3  (2      (2  (16

Disposals/reclassified as held for sale

  2    18        7        (1      (1  25    2    18        7        (1      (1  25  

Exchange translation differences

  10    35        2    (1  (3  (3  2    42    10    35        2    (1  (3  (3  2    42  

Deferred tax (liability)/asset at December 31, 2012

  (223  (772      (108  9    23    153    78    (840
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Deferred tax (liability)/asset at January 1, 2013

  (223  (772      (108  9    23    153    78    (840

(Charge)/credit to profit

  (138  98        (106  346    (8  (26  105    271  

(Charge)/credit to equity/other comprehensive income

              (6          (24  12    (18

Acquisitions

      (39                          (39

Disposals/reclassified as held for sale

  (3  (18      (9                  (30

Exchange translation differences

  13    13        4    (6  (1  1    (2  22  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Deferred tax (liability)/asset at December 31, 2013

  (351  (718      (225  349    14    104    193    (634
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Other deferred tax liabilities includes temporary differences in respect of plant, property and equipment, capitalised development spend and capitalized development spend.financial instruments. Other deferred tax assets includes temporary differences in respect of share-basedshare based remuneration provisions and financial instruments.

20.Deferred tax – (continued)

provisions.

Deferred tax assets in respect of tax losses and other deductible temporary differences have only been recognizedrecognised to the extent that it is more likely than not that sufficient taxable profits will be available to allow the asset to be recovered.

19.Deferred tax – (continued)

Accordingly, no deferred tax asset has been recognizedrecognised in respect of unused trading losses of approximately £84 million (2012: £129 million, (2011:2011: £133 million, 2010: £147 million) carried forward at the year end. The deferred tax asset not recognizedrecognised in respect of these losses is approximately £20 million (2012: £34 million, (2011:2011: £36 million, 2010: £41 million). Of these unrecognizedthe unrecognised losses, £56 million (2012: £47 million (2011: £45 million; 2010:2011: £45 million) will expire if not utilizedutilised within 10 years, and £28 million (2012: £82 million (2011:million; 2011: £88 million; 2010: £102 million) will expire after more than 10 years.

Deferred tax assets of approximately £14 million (2012: £9 million (2011:million; 2011: £31 million; 2010: £17 million) have not been recognizedrecognised in respect of tax losses and other temporary differences carried forward of £69 million (2012: £41 million (2011:million; 2011: £94 million; 2010: £63 million) which can only be used to offset future capital gains.

 

21.20.Inventories and pre-publication costs

 

  2012
£m
   2011
£m
   2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Raw materials

   3     6     6     3     3     6  

Pre-publication costs

   101     115     130     90     101     115  

Finished goods

   55     69     92     49     55     69  
  

 

   

 

   

 

   

 

   

 

   

 

 

Total

   159     190     228     142     159     190  
  

 

   

 

   

 

   

 

   

 

   

 

 

 

22.21.Trade and other receivables

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
£m
 2011
£m
 

Trade receivables

   1,256    1,361    1,361     1,299    1,256    1,361  

Allowance for doubtful debts

   (51  (63  (73   (57  (51  (63
  

 

  

 

  

 

   

 

  

 

  

 

 
   1,205    1,298    1,288     1,242    1,205    1,298  

Prepayments and accrued income

   175    185    187     174    175    185  
  

 

  

 

  

 

   

 

  

 

  

 

 

Total

   1,380    1,483    1,475     1,416    1,380    1,483  
  

 

  

 

  

 

   

 

  

 

  

 

 

Trade receivables are predominantly non-interest bearing and their carrying amounts approximate to their fair value.

Trade receivables are stated net of allowances for bad and doubtful debts. The movements in the provision during the year were as follows:

 

  2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
£m
 2011
£m
 

At January 1

   63    73    80     51    63    73  

Charge for the year

   13    15    15     17    13    15  

Trade receivables written off

   (18  (23  (22   (11  (18  (23

Disposals

   (6  (1           (6  (1

Exchange translation differences

   (1  (1           (1  (1
  

 

  

 

  

 

   

 

  

 

  

 

 

At December 31

   51    63    73     57    51    63  
  

 

  

 

  

 

   

 

  

 

  

 

 

23.22.Assets and liabilities held for sale

The major classes of assets and liabilities of operations classified as held for sale are as follows:

 

  2012
£m
   2011
£m
   2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Goodwill

   134     19          16     134     19  

Intangible assets

   84     7               84     7  

Property, plant and equipment

   3                    3       

Deferred tax assets

   4     1               4     1  

Inventories

   1     1               1     1  

Trade and other receivables

   71     16          5     71     16  
  

 

   

 

   

 

   

 

   

 

   

 

 

Total assets held for sale

   297     44          21     297     44  
  

 

   

 

   

 

   

 

   

 

   

 

 

Trade and other payables

   69     17          3     69     17  

Deferred tax liabilities

   27                    27       
  

 

   

 

   

 

   

 

   

 

   

 

 

Total liabilities associated with assets held for sale

   96     17          3     96     17  
  

 

   

 

   

 

   

 

   

 

   

 

 

 

24.23.Trade and other payables

 

  2012
£m
   2011
£m
   2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Payables and accruals

   1,150     1,245     1,276     1,192     1,150     1,245  

Deferred income

   1,394     1,412     1,308     1,403     1,394     1,412  
  

 

   

 

   

 

   

 

   

 

   

 

 

Total

   2,544     2,657     2,584     2,595     2,544     2,657  
  

 

   

 

   

 

   

 

   

 

   

 

 

The carrying amount of trade and other payables approximates to their fair value.

 

25.24.Borrowings

 

  2012   2011   2010   2013   2012   2011 
  Falling
due
within
1 year
£m
   Falling
due

in
more
than
1 year
£m
   Total
£m
   Falling
due
within
1 year
£m
   Falling
due

in
more
than
1 year
£m
   Total
£m
   Falling
due
within
1 year
£m
   Falling
due

in
more
than
1 year
£m
   Total
£m
   Falling
due
within
1 year
£m
   Falling
due
in
more
than
1 year
£m
   Total
£m
   Falling
due
within
1 year
£m
   Falling
due
in
more
than
1 year
£m
   Total
£m
   Falling
due
within
1 year
£m
   Falling
due
in
more
than
1 year
£m
   Total
£m
 

Financial liabilities measured at amortised cost:

                                    

Short term bank loans, overdrafts and commercial paper

   131          131     596          596     379          379     287          287     131          131     596          596  

Term debt

        1,223     1,223          1,526     1,526     384     1,466     1,850  

Finance leases

   7     9     16     2     6     8     7     15     22     9     8     17     7     9     16     2     6     8  

Other loans

        1,526     1,526     384     1,466     1,850     130     1,944     2,074  

Other loans in fair value hedging relationships

   102     1,036     1,138          1,204     1,204          1,198     1,198  

Other loans previously in fair value hedging relationships

   490     591     1,081          624     624          629     629  

Term debt in fair value hedging relationships

   240     938     1,178     102     1,036     1,138          1,204     1,204  

Term debt previously in fair value hedging relationships

   112     464     576     490     591     1,081          624     624  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Total

   730     3,162     3,892     982     3,300     4,282     516     3,786     4,302     648     2,633     3,281     730     3,162     3,892     982     3,300     4,282  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

In 2012, £1842013, £186 million principal amount of term debt maturing in 2014 and 2019 was exchanged for £191£235 million principal amount of term debt maturing in 2022 and cash payments of £46 million.cash. The exchange is treated as a debt modification for accounting purposes. The premium arising of £53 million is offset against the carrying amount of the newly issued term debt maturing in 2022 and will be amortised over its life.

The total fair value of financial liabilities measured at amortised cost is £1,996£1,709 million (2011: £2,745£1,996 million; 2010 £2,7962011 £2,745 million). The total fair value of other loansterm debt in fair value hedging relationships is £1,288 million (2012: £1,177 million (2011:million; 2011: £1,237 million; 2010: £1,279 million). The total fair value of other loansterm debt previously in fair value hedging relationships is £650 million (2012: £1,189 million (2011:million; 2011: £707 million; 2010: £685 million).

25.24.Borrowings – (continued)

 

Other loans includeTerm debt includes term debt issued by Reed Elsevier Capital Inc., a 100% owned finance subsidiary of Reed Elsevier Group plc. The parent companies have fully and unconditionally guaranteed these securities. No other subsidiary of the parent companies, Reed Elsevier Group plc or Elsevier Reed Finance BV guarantees the securities.

Analysis by year of repayment

 

 2012 2011 2010  2013 2012 2011 
 Short term
bank loans,
overdrafts
and
commercial
paper

£m
 Other
loans
£m
 Finance
leases
£m
 Total
£m
 Short term
bank loans,
overdrafts
and
commercial
paper

£m
 Other
loans
£m
 Finance
leases
£m
 Total
£m
 Short term
bank loans,
overdrafts
and
commercial
paper

£m
 Other
loans
£m
 Finance
leases
£m
 Total
£m
  Short term
bank loans,
overdrafts
and
commercial
paper
£m
 Term
debt
£m
 Finance
leases
£m
 Total
£m
 Short term
bank loans,
overdrafts
and
commercial
paper
£m
 Term
debt
£m
 Finance
leases
£m
 Total
£m
 Short term
bank loans,
overdrafts
and
commercial
paper
£m
 Term
debt
£m
 Finance
leases
£m
 Total
£m
 

Within 1 year

  131    592    7    730    596    384    2    982    379    130    7    516    287    352    9    648    131    592    7    730    596    384    2    982  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Within 1 to 2 years

      644    6    650        618    3    621        382    7    389        174    5    179        644    6    650        618    3    621  

Within 2 to 3 years

      178    3    181        725    2    727        636    8    644        400    3    403        178    3    181        725    2    727  

Within 3 to 4 years

      400        400        188    1    189        825        825        341        341        400        400        188    1    189  

Within 4 to 5 years

      359        359        401        401        188        188        181        181        359        359        401        401  

After 5 years

      1,572        1,572        1,362        1,362        1,740        1,740        1,529        1,529        1,572        1,572        1,362        1,362  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 
      3,153    9    3,162        3,294    6    3,300        3,771    15    3,786  

After 1 year

      2,625    8    2,633        3,153    9    3,162        3,294    6    3,300  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Total

  131    3,745    16    3,892    596    3,678    8    4,282    379    3,901    22    4,302    287    2,977    17    3,281    131    3,745    16    3,892    596    3,678    8    4,282  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Short term bank loans, overdrafts and commercial paper were backed up at December 31, 20122013 by a $2,000 million (£1,2311,207 million) committed bank facility maturing in June 2015,July 2018, which was undrawn.

Analysis by currency

 

 2012 2011 2010  2013 2012 2011 
 Short term
bank loans,
overdrafts
and
commercial
paper

£m
 Other
loans
£m
 Finance
leases
£m
 Total
£m
 Short term
bank loans,
overdrafts
and
commercial
paper

£m
 Other
loans
£m
 Finance
leases
£m
 Total
£m
 Short term
bank loans,
overdrafts
and
commercial
paper

£m
 Other
loans
£m
 Finance
leases
£m
 Total
£m
  Short term
bank loans,
overdrafts
and
commercial
paper
£m
 Term
debt
£m
 Finance
leases
£m
 Total
£m
 Short term
bank loans,
overdrafts
and
commercial
paper
£m
 Term
debt
£m
 Finance
leases
£m
 Total
£m
 Short term
bank loans,
overdrafts
and
commercial
paper
£m
 Term
debt
£m
 Finance
leases
£m
 Total
£m
 

US Dollars

  25    2,059    16    2,100    485    2,431    8    2,924    225    2,566    22    2,813  

£ Sterling

      736        736        730        730        707        707  

US dollars

  87    1,800    17    1,904    25    2,059    16    2,100    485    2,431    8    2,924  

£ sterling

  27    719        746        736        736        730        730  

Euro

  103    950        1,053    91    517        608    123    628        751    167    458        625    103    950        1,053    91    517        608  

Other currencies

  3            3    20            20    31            31    6            6    3            3    20            20  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Total

  131    3,745    16    3,892    596    3,678    8    4,282    379    3,901    22    4,302    287    2,977    17    3,281    131    3,745    16    3,892    596    3,678    8    4,282  
 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Included in the US dollar amounts for other loansterm debt above is £427 million (2012: £347 million (2011:million; 2011: £363 million; 2010: £364 million) of debt denominated in Swiss francs (CHF 500625 million; 2011:2012: CHF 500 million; 2010:2011: CHF 500 million) that was swapped into US dollars on issuance and against which there are related derivative financial instruments, which, as at December 31, 2012,2013, had a fair value of £81 million (2012: £80 million; 2011: £84 million). £65 million (2011:(2012: £80 million; 2011: £84 million; 2010: £86 million). of these derivatives were designated as fair value hedges of the related Swiss franc debt, and £16 million (2012: nil; 2011: nil) were undesignated.

26.25.Lease arrangements

Finance leases

At December 31, 20122013 future finance lease obligations fall due as follows:

 

 2012
£m
 2011
£m
 2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Within one year

  7    2    8     9     7     2  

In the second to fifth years inclusive

  9    6    17     8     9     6  
 

 

  

 

  

 

   

 

   

 

   

 

 
  16    8    25     17     16     8  

Less future finance charges

          (3               
 

 

  

 

  

 

   

 

   

 

   

 

 

Total

  16    8    22     17     16     8  
 

 

  

 

  

 

   

 

   

 

   

 

 

Present value of future finance lease obligations payable:

         

Within one year

  7    2    7     9     7     2  

In the second to fifth years inclusive

  9    6    15     8     9     6  
 

 

  

 

  

 

   

 

   

 

   

 

 

Total

  16    8    22     17     16     8  
 

 

  

 

  

 

   

 

   

 

   

 

 

The fair value of the lease obligations approximates to their carrying amount.

Operating leases

Reed Elsevier leases various properties, principally offices and warehouses, which have varying terms and renewal rights that are typical to the territory in which they are located.

At December 31, 20122013 outstanding commitments under non-cancellable operating leases fall due as follows:

 

 2012
£m
 2011
£m
 2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Within one year

  117    129    128     103     117     129  

In the second to fifth years inclusive

  309    305    306     275     309     305  

After five years

  184    206    208     169     184     206  
 

 

  

 

  

 

   

 

   

 

   

 

 

Total

  610    640    642     547     610     640  
 

 

  

 

  

 

   

 

   

 

   

 

 

Of the above outstanding commitments, £528 million (2012: £577 million (2011:million; 2011: £605 million; 2010: £609 million) relate to land and buildings.

Reed Elsevier has a number of properties that are sub leased.sub-leased. The future lease receivables contracted with sub-tenants fall due as follows:

 

 2012
£m
 2011
£m
 2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Within one year

  16    21    17     16     16     21  

In the second to fifth years inclusive

  33    38    25     43     33     38  

After five years

  17    19    5     25     17     19  
 

 

  

 

  

 

   

 

   

 

   

 

 

Total

  66    78    47     84     66     78  
 

 

  

 

  

 

   

 

   

 

   

 

 

27.26.Provisions

 

  2012  2011  2010 
  Property
£m
  Restructuring
£m
  Total
£m
  Property
£m
  Restructuring
£m
  Total
£m
  Property
£m
  Restructuring
£m
  Total
£m
 

At January 1

  109    17    126    105    54    159    89    106    195  

Transfer

  22        22                          

Charged

  62        62    16        16    36    31    67  

Utilised

  (24  (12  (36  (12  (37  (49  (22  (82  (104

Exchange translation differences

  (5      (5              2    (1  1  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At December 31

  164    5    169    109    17    126    105    54    159  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

27.Provisions – (continued)

  2013  2012  2011 
  Property
£m
  Restructuring
£m
  Total
£m
  Property
£m
  Restructuring
£m
  Total
£m
  Property
£m
  Restructuring
£m
  Total
£m
 

At January 1

  164    5    169    109    17    126    105    54    159  

Transfer

              22        22              

Charged

              62        62    16        16  

Utilised

  (32  (3  (35  (24  (12  (36  (12  (37  (49

Exchange translation differences

  (1      (1  (5      (5            
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At December 31

  131    2    133    164    5    169    109    17    126  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Property provisions relate to estimated sub lease shortfalls and guarantees given in respect of certain property leases for various periods up to 2024. The charge in 2012 of £62 million (2011: £16 million; 2010: 36 million) predominantly relates to property exposures on disposed businesses.

Provisions as at December 31, 20122013 are included within current and non-current liabilities as follows:

 

 2012
£m
 2011
£m
 2010
£m
   2013
£m
   2012
£m
   2011
£m
 

Current liabilities

  30    39    71     17     30     39  

Non-current liabilities

  139    87    88     116     139     87  
 

 

  

 

  

 

   

 

   

 

   

 

 

Total

  169    126    159     133     169     126  
 

 

  

 

  

 

   

 

   

 

   

 

 

 

28.Contingent liabilities and capital commitments

There are contingent liabilities amounting to £11 million (2011: £15 million; 2010: £18 million) in respect of property lease guarantees.

29.27.Combined share capitals

 

 2012
£m
 2011
£m
 2010
£m
   2013
£m
   2012
£m
 2011
£m
 

At January 1

  223    224    225     223     223    224  

Issue of ordinary shares

  1             1     1      

Exchange translation differences

  (1  (1  (1        (1  (1
 

 

  

 

  

 

   

 

   

 

  

 

 

At December 31

  223    223    224     224     223    223  
 

 

  

 

  

 

   

 

   

 

  

 

 

Combined share capitals exclude the shares of Reed Elsevier NV held by a subsidiary of Reed Elsevier PLC.

Disclosures in respect of share capital are given in note 1312 to the Reed Elsevier PLC consolidated financial statements and note 1413 to the Reed Elsevier NV consolidated financial statements.

 

30.28.Combined share premiums

 

 2012
£m
 2011
£m
 2010
£m
   2013
£m
   2012
£m
 2011
£m
 

At January 1

  2,723    2,754    2,807     2,727     2,723    2,754  

Issue of ordinary shares, net of expenses

  47    9    11     124     47    9  

Exchange translation differences

  (43  (40  (64   36     (43  (40
 

 

  

 

  

 

   

 

   

 

  

 

 

At December 31

  2,727    2,723    2,754     2,887     2,727    2,723  
 

 

  

 

  

 

   

 

   

 

  

 

 

Combined share premiums exclude the share premium in respect of shares of Reed Elsevier NV held by a subsidiary of Reed Elsevier PLC.

31.29.Combined shares held in treasury

 

  Shares held
by EBT
£m
 Shares held
by parent
companies
£m
 Total
£m
 

At January 1, 2010

   175    523    698  

Settlement of share awards

   (9      (9

Exchange translation differences

       (12  (12
  

 

  

 

  

 

   Shares held
by EBT
£m
 Shares held
by parent
companies
£m
 Total
£m
 

At January 1, 2011

   166    511    677     166    511    677  

Settlement of share awards

   (7      (7   (7      (7

Exchange translation differences

       (7  (7       (7  (7
  

 

  

 

  

 

   

 

  

 

  

 

 

At January 1, 2012

   159    504    663     159    504    663  

Repurchase of ordinary shares

       250    250         250    250  

Settlement of share awards

   (7      (7   (7      (7

Exchange translation differences

       (7  (7       (7  (7
  

 

  

 

  

 

   

 

  

 

  

 

 

At December 31, 2012

   152    747    899  

At January 1, 2013

   152    747    899  

Repurchase of ordinary shares

       600    600  

Settlement of share awards

   (40      (40

Exchange translation differences

       5    5  
  

 

  

 

  

 

   

 

  

 

  

 

 

At December 31, 2013

   112    1,352    1,464  
  

 

  

 

  

 

 

At December 31, 20122013 shares held in treasury related to 13,451,46810,120,537 (2011: 14,051,025; 2010: 14,654,161)13,451,468; 2011: 14,051,025) Reed Elsevier PLC ordinary shares and 6,990,101 (2011: 7,380,906; 2010: 7,781,790)4,992,360 (2012: 6,990,101; 2011: 7,380,906) Reed Elsevier NV ordinary shares held by the Reed Elsevier Group plc Employee Benefit Trust (“EBT”); and 57,484,915 (2011: 34,196,298; 2010:99,446,834 (2012: 57,484,914; 2011: 34,196,298) Reed Elsevier PLC ordinary shares and 36,613,087 (2011: 23,952,791; 2010:62,459,133 (2012: 36,613,087; 2011: 23,952,791) Reed Elsevier NV ordinary shares held by the respective parent companies.

During 20122013 Reed Elsevier repurchased 23,288,61641,961,920 Reed Elsevier PLC ordinary shares and 12,660,29624,282,106 Reed Elsevier NV ordinary shares for consideration of £250£600 million. On December 28, 2012 Reed Elsevier PLC and Reed Elsevier NV announced an irrevocable, non discretionary programme to repurchase further ordinaryThere shares up to the value of £100 million which was completedare held in February 2013.treasury.

The EBT purchases Reed Elsevier PLC and Reed Elsevier NV shares which, at the trustees’ discretion, can be used in respect of the exercise of share options and to meet commitments under conditional share awards.

 

32.30.Translation reserve

 

  2012
£m
 2011
£m
   2010
£m
   2013
£m
   2012
£m
 2011
£m
 

At January 1

   88    29     (100   (23)     88    29  

Exchange differences on translation of foreign operations

   (136  32     94     (88)     (136  32  

Exchange translation differences on capital and reserves

   25    27     35     (26)     25    27  
  

 

  

 

   

 

   

 

   

 

  

 

 

At December 31

   (23  88     29     (137)     (23  88  
  

 

  

 

   

 

   

 

   

 

  

 

 

33.31.Other combined reserves

 

  2012 2011 2010  2013 2012
Restated
 2011
Restated
 
  Hedge
reserve
£m
 Other
reserves
£m
 Total
£m
 Total
£m
 Total
£m
  Hedge
reserve
£m
 Other
reserves
£m
 Total
£m
 Total
£m
 Total
£m
 

At January 1

   (48  (151  (199  (387  (502  26    226    252    (199  (387

Profit attributable to parent companies’ shareholders

       1,069    1,069    760    642        1,110    1,110    1,069    760  

Dividends paid

       (521  (521  (497  (483      (549  (549  (521  (497

Actuarial losses on defined benefit pension schemes

       (329  (329  (113  (63

Actuarial gains/(losses) on defined benefit pension schemes

      40    40    (293  (70

Fair value movements on available for sale investments

               (1                      (1

Transfer to net profit on disposals of available for sale investments

       11    11          

Transfer to net profit on disposal of available for sale investments

              11      

Fair value movements on cash flow hedges

   70        70    (24  (58  65        65    70    (24

Tax recognised directly in equity

   (19  107    88    42    29  

Increase/(decrease) in share based remuneration reserve

       31    31    27    (7

Tax recognised in other comprehensive income

  (15  (24  (39  88    42  

Increase in share based remuneration reserve (net of tax)

      48    48    31    27  

Settlement of share awards

       (7  (7  (7  (9      (40  (40  (7  (7

Transfer from cash flow hedge reserve to net profit (net of tax)

   21        21    37    46  

Disposal/(acquisition) of non-controlling interest

       6    6    (43    

Transfer to net profit from cash flow hedge reserve (net of tax)

  (2      (2  21    37  

Disposal/(acquisition) of non-controlling interests

              6    (43

Exchange translation differences

   2    10    12    7    18    (1  (4  (5  12    7  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

At December 31

   26    226    252    (199  (387  73    807    880    252    (199
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Other reserves principally comprise retained earnings and the share based remuneration reserve and available for sale investment reserve.

 

34.32.Related party transactions

Transactions between the Reed Elsevier combined businesses have been eliminated within the combined financial statements. Transactions with joint ventures were made on normal market terms of trading and comprise sales of goods and services of £1 million (2011:(2012: £1 million; 2010:2011: £1 million).

As at December 31, 20122013 amounts owed by joint ventures were £7 million (2012: £1 million (2011:million; 2011: £3 million; 2010: £2 million) and amounts due from joint ventures were £6 million (2012: £1 million (2011: nil; 2010:million; 2011: nil).

Key management personnel remuneration is set out below. Key Management personnel are also related parties as defined by IAS 24 — Related Party Disclosures and comprise the executive directorsExecutive and Non-Executive Directors of Reed Elsevier PLC and Reed Elsevier NV. Transactions with key managementFor reporting purposes, salary, benefits and annual incentive payments are considered short term employee benefits.

Key Management personnel are set out below:remuneration

 

   2012
£m
   2011
£m
   2010
£m
 

Salaries and other short term employee benefits

   4     3     5  

Post employment benefits

             1  

Share based remuneration

   5     4     (1
  

 

 

   

 

 

   

 

 

 

Total

   9     7     5  
  

 

 

   

 

 

   

 

 

 
   2013
£m
   2012
£m
   2011
£m
 

Salaries and other short term employee benefits and Non-Executive fees

   4     5     3  

Post employment benefits*

   1     1     1  

Share based remuneration**

   4     5     4  
  

 

 

   

 

 

   

 

 

 

Total

   9     11     8  
  

 

 

   

 

 

   

 

 

 

*Post employment benefits comprises the transfer value of the increase in accrued pension during the year (net of inflation, Directors’ contributions and participation fee) for defined benefit schemes and payments made to defined contribution schemes or in lieu of pension.

**The share based remuneration charge comprises the multi-year incentive scheme charges in accordance with IFRS2 — Share Based Payment. These IFRS 2 charges do not reflect the actual value received on vesting.

No termination benefits were paid to any Director in 2013 (2012: nil; 2011: nil) No loans, advances or guarantees have been provided on behalf of any Director. The aggregate gain made by Executive Directors on the exercise of options during 2013 were £2,526,305. The current Executive Directors did not exercise any options during 2012 or 2011.

 

35.33.Approval of financial statements

The combined financial statements were approved by the Boards of directors of Reed Elsevier PLC and Reed Elsevier NV on February 27, 2013.26, 2014.

 

THIS PAGE INTENTIONALLY BLANK

 

 

 

 

REED ELSEVIER PLC

CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and members of Reed Elsevier PLC:

We have audited the accompanying consolidated statements of financial position of Reed Elsevier PLC and its subsidiaries (the “Company”) as at December 31, 2013, 2012 2011 and 2010,2011, and the related consolidated income statements, and consolidated statements of comprehensive income, cash flows and changes in equity for each of the years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Reed Elsevier PLC and its subsidiaries as at December 31, 2013, 2012 2011 and 2010,2011, and the results of their operations and their cash flows for each of the years then ended, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

As discussed in Accounting policies in the consolidated financial statements, the accompanying 2012 and 2011 financial statements have been retrospectively adjusted for the adoption of International Accounting Standards 19Employee Benefits (revised).

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company’s internal control over financial reporting as at December 31, 2012,2013, based on the criteria established inInternal Control — Integrated Framework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 27, 201326, 2014 expressed an unqualified opinion on the Company’s internal control over financial reporting.

/s/ DELOITTE LLP

London, United Kingdom

February 27, 201326, 2014

REED ELSEVIER PLC

CONSOLIDATED INCOME STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
 2012
Restated
£m
 2011
Restated
£m
 

Administrative expenses

   3     (2  (2  (2   3     (2  (2  (2

Effect of tax credit equalisation on distributed earnings

   4     (14  (13  (13   4     (15  (14  (13

Share of results of joint ventures

   12     561    404    342     11     583    547    389  
    

 

  

 

  

 

     

 

  

 

  

 

 

Operating profit

     545    389    327       566    531    374  

Finance income

   7     1    1    1     6     10    1    1  
    

 

  

 

  

 

     

 

  

 

  

 

 

Profit before tax

     546    390    328       576    532    375  

Taxation

   8     6    (1  (1

Tax (expense)/credit

   7     (4  6    (1
    

 

  

 

  

 

     

 

  

 

  

 

 

Profit attributable to ordinary shareholders

     552    389    327       572    538    374  
    

 

  

 

  

 

     

 

  

 

  

 

 

REED ELSEVIER PLC

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

     2012
£m
 2011
£m
 2010
£m
   2013
£m
 2012
Restated
£m
 2011
Restated
£m
 

Profit attributable to ordinary shareholders

     552    389    327     572    538    374  

Share of joint ventures’ other comprehensive (expense)/income for the year

     (146  (14  25  

Share of joint ventures’ other comprehensive (loss)/income for the year

   (13  (132  1  
    

 

  

 

  

 

   

 

  

 

  

 

 

Total comprehensive income for the year

     406    375    352     559    406    375  
    

 

  

 

  

 

   

 

  

 

  

 

 

 

Note2012
pence
2011
pence
2010
pence

Earnings per ordinary share (“EPS”)

Basic earnings per share

1046.0p32.4p27.3p

Diluted earnings per share

1045.4p32.1p27.1p
   Note   2013
pence
  2012
Restated
pence
  2011
Restated
pence
 

Earnings per ordinary share (“EPS”)

      

Basic earnings per share

   9     48.8  44.8  31.1

Diluted earnings per share

   9     48.2  44.3  30.9

REED ELSEVIER PLC

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
 2012
£m
 2011
£m
 

Cash flows from operating activities

            

Cash used by operations

   11     (2  (2  (2   10     (2  (2  (2

Interest received

     1    1    1       10    1    1  

Tax paid

     (2  (1  (3     (3  (2  (1
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash used in operating activities

     (3  (2  (4

Net cash from/(used in) operating activities

     5    (3  (2
    

 

  

 

  

 

     

 

  

 

  

 

 

Cash flows from investing activities

            

Dividends received from joint ventures

   12     694    600    589     11     102    694    600  

Increase in investment in joint ventures

   12             (596
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash received from/(used in) investing activities

     694    600    (7

Net cash received from investing activities

     102    694    600  
    

 

  

 

  

 

     

 

  

 

  

 

 

Cash flows from financing activities

            

Equity dividends paid

   9     (264  (248  (245   8     (278  (264  (248

Repurchase of ordinary shares

     (143             (326  (143    

Proceeds on issue of ordinary shares

     33    8    9       50    33    8  

(Increase)/decrease in net funding balances due from joint ventures

   11     (317  (358  247  

Decrease/(increase) in net funding balances due from joint ventures

   10     447    (317  (358
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash (used in)/from financing activities

     (691  (598  11  

Net cash used in financing activities

     (107  (691  (598
    

 

  

 

  

 

     

 

  

 

  

 

 

Movement in cash and cash equivalents

                              
    

 

  

 

  

 

     

 

  

 

  

 

 

REED ELSEVIER PLC

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT DECEMBER 31, 20122013

 

  Note   2012
£m
 2011
£m
 2010
£m
   Note   2013
£m
 2012
£m
 2011
£m
 

Non-current assets

            

Investments in joint ventures

   12     1,207    1,158    1,037     11     1,266    1,207    1,158  
    

 

  

 

  

 

     

 

  

 

  

 

 

Total assets

     1,207    1,158    1,037       1,266    1,207    1,158  
    

 

  

 

  

 

     

 

  

 

  

 

 

Current liabilities

            

Taxation

     1    9    9       2    1    9  
    

 

  

 

  

 

     

 

  

 

  

 

 

Total liabilities

     1    9    9       2    1    9  
    

 

  

 

  

 

     

 

  

 

  

 

 

Net assets

     1,206    1,149    1,028       1,264    1,206    1,149  
    

 

  

 

  

 

     

 

  

 

  

 

 

Capital and reserves

            

Called up share capital

   13     181    180    180     12     182    181    180  

Share premium account

   14     1,208    1,176    1,168     13     1,257    1,208    1,176  

Shares held in treasury (including in joint ventures)

   15     (447  (308  (312   14     (752  (447  (308

Capital redemption reserve

   16     4    4    4     15     4    4    4  

Translation reserve

   17     87    159    142     16     40    87    159  

Other reserves

   18     173    (62  (154   17     533    173    (62
    

 

  

 

  

 

     

 

  

 

  

 

 

Total equity

     1,206    1,149    1,028       1,264    1,206    1,149  
    

 

  

 

  

 

     

 

  

 

  

 

 

REED ELSEVIER PLC

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   Share
capital
£m
   Share
premium
£m
   Shares
held in
treasury
£m
 Capital
redemption
reserve
£m
   Translation
reserve
£m
 Other
reserves
£m
 Total
equity
£m
 

Balance at January 1, 2013

     181     1,208     (447  4     87    173    1,206  

Total comprehensive income for the year

                        (47  606    559  

Equity dividends paid

   8                            (278  (278

Issue of ordinary shares, net of expenses

     1     49                      50  

Repurchase of ordinary shares

               (326               (326

Share of joint ventures’ increase in share based remuneration reserve (net of tax)

                            25    25  

Share of joint ventures’ settlement of share awards by the employee benefit trust

               21             (21    

Equalisation adjustments

                            28    28  
    

 

   

 

   

 

  

 

   

 

  

 

  

 

 

Balance at December 31, 2013

     182     1,257     (752  4     40    533    1,264  
 Note Share
capital
£m
 Share
premium
£m
 Shares
held in
treasury
£m
 Capital
redemption
reserve

£m
 Translation
reserve

£m
 Other
reserves
£m
 Total
equity
£m
     

 

   

 

   

 

  

 

   

 

  

 

  

 

 

Balance at January 1, 2012

   180    1,176    (308  4    159    (62  1,149       180     1,176     (308  4     159    (62  1,149  

Total comprehensive income for the year

                   (72  478    406                          (72  478    406  

Equity dividends paid

  9                        (264  (264   8                            (264  (264

Issue of ordinary shares, net of expenses

   1    32                    33       1     32                      33  

Repurchase of ordinary shares

           (143              (143               (143               (143

Share of joint ventures’ increase in share based remuneration reserve

                       16    16                              16    16  

Share of joint ventures’ settlement of share awards by the employee benefit trust

           4            (4                   4             (4    

Share of joint venture’s disposal of non-controlling interests

                       3    3                              3    3  

Equalisation adjustments

                       6    6                              6    6  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

     

 

   

 

   

 

  

 

   

 

  

 

  

 

 

Balance at December 31, 2012

   181    1,208    (447  4    87    173    1,206       181     1,208     (447  4     87    173    1,206  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

     

 

   

 

   

 

  

 

   

 

  

 

  

 

 

Balance at January 1, 2011

   180    1,168    (312  4    142    (154  1,028       180     1,168     (312  4     142    (154  1,028  

Total comprehensive income for the year

                   17    358    375                          17    358    375  

Equity dividends paid

  9                        (248  (248   8                            (248  (248

Issue of ordinary shares, net of expenses

       8                    8            8                      8  

Share of joint ventures’ increase in share based remuneration reserve

                       14    14                              14    14  

Share of joint ventures’ settlement of share awards by the employee benefit trust

           4            (4                   4             (4    

Share of joint venture’s acquisitions of non-controlling interests

                       (23  (23                            (23  (23

Equalisation adjustments

                       (5  (5                            (5  (5
  

 

  

 

  

 

  

 

  

 

  

 

  

 

     

 

   

 

   

 

  

 

   

 

  

 

  

 

 

Balance at December 31, 2011

   180    1,176    (308  4    159    (62  1,149       180     1,176     (308  4     159    (62  1,149  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

     

 

   

 

   

 

  

 

   

 

  

 

  

 

 

Balance at January 1, 2010

   180    1,159    (317  4    92    (202  916  

Total comprehensive income for the year

                   50    302    352  

Equity dividends paid

  9                        (245  (245

Issue of ordinary shares, net of expenses

       9                    9  

Share of joint ventures’ increase in share based remuneration reserve

                       (4  (4

Share of joint ventures’ settlement of share awards by the employee benefit trust

           5            (5    
  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Balance at December 31, 2010

   180    1,168    (312  4    142    (154  1,028  
  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

REED ELSEVIER PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

1.Basis of financial statements

On January 1, 1993 Reed Elsevier PLC and Reed Elsevier NV contributed their businesses to two companies, Reed Elsevier Group plc and Elsevier Reed Finance BV. Reed Elsevier Group plc, which owns all the publishing and information businesses, is incorporated in England and Elsevier Reed Finance BV, which owns the financing and treasury companies, is incorporated in the Netherlands. Reed Elsevier PLC and Reed Elsevier NV each hold a 50% interest in Reed Elsevier Group plc. Reed Elsevier PLC holds a 39% interest in Elsevier Reed Finance BV with Reed Elsevier NV holding a 61% interest. Reed Elsevier PLC additionally holds an indirect equity interest in Reed Elsevier NV, reflecting the arrangements entered into between Reed Elsevier PLC and Reed Elsevier NV at the time of the merger, which determined the equalisation ratio whereby one Reed Elsevier NV ordinary share is, in broad terms, intended to confer equivalent economic interests to 1.538 Reed Elsevier PLC ordinary shares.

Under the equalisation arrangements Reed Elsevier PLC shareholders have a 52.9% economic interest in the Reed Elsevier combined businesses and Reed Elsevier NV shareholders (other than Reed Elsevier PLC) have a 47.1% interest. Holders of ordinary shares in Reed Elsevier PLC and Reed Elsevier NV enjoy substantially equivalent dividend and capital rights with respect to their ordinary shares.

 

2.Accounting policies

Basis of preparation

These consolidated financial statements, which have been prepared under the historichistorical cost convention, report the consolidated statements of income, comprehensive income, cash flow, and financial position and changes in equity of Reed Elsevier PLC (incorporated and domiciled in the United Kingdom), and have been prepared in accordance with accounting policies that are in conformity with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and IFRS as adopted by the European Union.

Unless otherwise indicated, all amounts shown in the financial statements are in pounds sterling (“£”).

The basis of the merger of the businesses of Reed Elsevier PLC and Reed Elsevier NV is set out on page 11.12.

Determination of profit

The Reed Elsevier PLC share of the Reed Elsevier combined results has been calculated on the basis of the 52.9% economic interest of the Reed Elsevier PLC shareholders in the Reed Elsevier combined businesses, after taking account of results arising in Reed Elsevier PLC and its subsidiaries. Dividends paid to Reed Elsevier PLC and Reed Elsevier NV shareholders are, other than in special circumstances, equalised at the gross level inclusive of the UK tax credit received by certain Reed Elsevier PLC shareholders. In Reed Elsevier PLC’s consolidated financial statements, an adjustment is required to equalise the benefit of the tax credit between the two sets of shareholders in accordance with the equalisation agreement. This equalisation adjustment arises on dividends paid by Reed Elsevier PLC to its shareholders and reduces the consolidated attributable earnings by 47.1% of the total amount of the tax credit.

The accounting policies adopted in the preparation of the combined financial statements are set out on pages F-10 toF-17.

Investments

Reed Elsevier PLC’s 52.9% economic interest in the net assets of the combined businesses has been shown on the statement of financial position as investments in joint ventures, net of the assets and liabilities reported as part of Reed Elsevier PLC and its subsidiaries. Investments in joint ventures are accounted for using the equity method.

The results of the Reed Elsevier combined businesses are set out on pages F-3 to F-55.

Foreign exchange translation

Transactions in foreign currencies are recorded at the rate of exchange prevailing on the date of the transaction. At each statement of financial position date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rate prevailing on the statement of financial position date. Exchange differences arising are recorded in the income statement. The exchange gains or losses relating to the retranslation of Reed Elsevier PLC’s 52.9% economic interest in the net assets of the combined businesses are classified as equity and transferred to the translation reserve.

When foreign operations are disposed of, the related cumulative translation differences are recognised within the income statement in the period.

2.Accounting policies – (continued)

 

Taxation

TheTax expense comprises current and deferred tax. Current and deferred tax expense representsare charged or credited in the sum ofincome statement except to the extent that the tax payable on the current year taxable profits, adjustments in respect of prior year taxable profits and the movements on deferred tax that arearises from a transaction or event which is recognised, in the same or a different period, outside profit or loss (either in other comprehensive income, statement. Tax arisingdirectly in joint ventures is includedequity, or through a business combination) in which case the tax appears in the sharesame statement as the transaction that gave rise to it.

Current tax is the amount of results of joint ventures.

The taxcorporate income taxes payable or recoverable based on current yearthe profit for the period as adjusted for items that are not taxable profitsor not deductible, and is calculated using the applicable tax raterates and laws that has beenwere enacted or substantively enacted byat the date of the statement of financial position. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. Provisions are established where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax is recognised on temporary differences arising between the tax arising on differences between the carrying amountsbases of assets and liabilities and their carrying amounts in the statement of financial statementsposition. Deferred tax is calculated using tax rates and their correspondinglaws that have been enacted or substantively enacted at the end of the reporting period, and which are expected to apply when the related deferred tax bases used inasset is realised or the computation of taxable profit, anddeferred tax liability is accounted for using the balance sheet liability method. settled.

Deferred tax liabilities are generally recognised for all taxable temporary differences but not recognised for taxable temporary differences arising on investments in subsidiaries, associates and deferredjoint ventures where the reversal of the temporary difference can be controlled and it is probable that the difference will not reverse in the foreseeable future. Deferred tax liabilities are not recognised on temporary differences that arise from goodwill which is not deductible for tax purposes.

Deferred tax assets are recognised to the extent that, based on current forecasts, it is probable that taxable profits will be available against which the deductible temporary differences can be utilised.utilised, and reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are not recognised in respect of temporary differences that arise on initial recognition of assets and liabilities acquired other than in a business combination. Deferred tax is not recognised on temporary differences arising in respect of goodwill that is not deductible for tax purposes.

Deferred tax is calculated using tax rates that have been substantively enacted at the date of the statement of financial position. Full provision is made for deferred tax which would become payable on the distribution of retained profits from foreign subsidiaries, associates or joint ventures.

Movements in deferred tax are charged or credited in the income statement, except when they relate to items charged or credited directly to equity, in which case the deferred tax is also recognised in equity. Deferred tax credits in respect of share based remuneration are recognised in equity to the extent that expected tax deductions exceed the related expense.discounted.

Critical judgements and key sources of estimation uncertainty

Critical judgments in the preparation of the combined financial statements are set out on pages F-14 to F-16.F-15.

Standards and amendments effective for the year

As described on page F-16, the combined businesses adopted IAS19 Employee Benefits (revised) with effect from January 1, 2013. As required under the revised standard, comparative figures have been restated. For the year ended December 31, 2012, Reed Elsevier PLC’s share of results of joint ventures is £14 million lower and basic earnings per share is 1.2p lower than previously reported. For the year ended December 31, 2011, Reed Elsevier PLC’s share of results of joint ventures is £15 million lower and basic earnings per share is 1.3p lower than previously reported.

With effect from January 1, 2013, the combined businesses also adopted various other standards, interpretations and amendments to IFRS, none of which have had a significant impact on Reed Elsevier’s accounting policies or reporting.

Standards, amendments and interpretations not yet effective

Recently issued standards, amendments and interpretations and their impact on future accounting policies and reporting have been considered on pages F16F-16 to F17F-17 of the combined financial statements.

 

3.Administrative expenses

Administrative expenses include £877,000 (2011: £799,000; 2010: £742,000)£972,000 (2012: £877,000; 2011: £799,000) paid in the year to Reed Elsevier Group plc under a contract for the services of directorsDirectors and administrative support. Reed Elsevier PLC has no employees (2011:(2012: nil; 2010:2011: nil).

 

4.Effect of tax credit equalisation on distributed earnings

The tax credit equalisation adjustment arises on ordinary dividends paid by Reed Elsevier PLC to its shareholders and reduces the consolidated profit attributable to ordinary shareholders by 47.1% of the total amount of the tax credit, as set out in the accounting policies in note 2.

5.Auditor’s remuneration

Audit fees payable by Reed Elsevier PLC were £28,000 (2011: £28,000; 2010: £27,000). Further information on the audit and non audit fees paid by the Reed Elsevier combined businesses to Deloitte LLP and its associates is set out in note 5 to the combined financial statements.

6.Related party transactions

All transactions with joint ventures, which are related parties of Reed Elsevier PLC, are reflected in these financial statements. Key management personnel are also related parties and comprise the executive directorsExecutive Directors of Reed Elsevier PLC. Transactions with key management personnel are set out in note 3432 to the combined financial statements.

 

7.6.Finance income

 

   2012
£m
   2011
£m
   2010
£m
 

Finance income from joint ventures

   1     1     1  
  

 

 

   

 

 

   

 

 

 
   2013
£m
   2012
£m
   2011
£m
 

Finance income from joint ventures

   10     1     1  
  

 

 

   

 

 

   

 

 

 

8.7.Taxation

 

                    2012     
£m
      2011    
£m
   2010 
£m
 

UK corporation tax (credit)/expense

  

   (6  1    1  
        

 

 

  

 

 

  

 

 

 
        A reconciliation of the notional tax charge based on the applicable rate of tax to the actual total tax expense is set out below.   
                    2012     
£m
      2011    
£m
   2010 
£m
 

Profit before tax

  

   546    390    328  
        

 

 

  

 

 

  

 

 

 

Tax at applicable rate 24.5% (2011: 26.5%; 2010: 28.0%)

  

   134    103    92  

Tax at applicable rate on share of results of joint ventures

  

   (137  (107  (96

Other

  

   (3  5    5  
        

 

 

  

 

 

  

 

 

 

Tax (credit)/expense

  

   (6  1    1  
        

 

 

  

 

 

  

 

 

 

9.     Equity dividends

        

        
Ordinary dividends declared in the year      2012    
pence
       2011    
pence
       2010    
pence
        2012     
£m
      2011    
£m
   2010 
£m
 

Ordinary shares

          

Final for prior financial year

   15.9p     15.0p     15.0p     191    180    180  

Interim for financial year

   6.0p     5.65p     5.4p     73    68    65  
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

  

 

 

 

Total

   21.9p     20.65p     20.4p     264    248    245  
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

  

 

 

 

The directors of Reed Elsevier PLC have proposed a final dividend of 17.0p (2011: 15.9p; 2010: 15.0p). The cost of funding the proposed final dividend is expected to be £202 million. No liability has been recognised at the statement of financial position date.

 

    

Ordinary dividends paid and proposed
relating to the financial year
                   2012     
pence
      2011    
pence
  2010
pence
 

Ordinary shares

          

Interim (paid)

  

   6.0p    5.65p    5.4p  

Final (proposed)

  

   17.0p    15.9p    15.0p  
        

 

 

  

 

 

  

 

 

 

Total

  

   23.0p    21.55p    20.4p  
        

 

 

  

 

 

  

 

 

 

10.   Earnings per ordinary share (“EPS”)

      

        
               2012 
               Weighted
average
number of
shares
(millions)
  Earnings
£m
  EPS
pence
 

Basic EPS

  

   1,200.6    552    46.0p  
        

 

 

  

 

 

  

 

 

 

Diluted EPS

  

   1,215.1    552    45.4p  
        

 

 

  

 

 

  

 

 

 
               2011 
               Weighted
average
number of
shares
(millions)
  Earnings
£m
  EPS
pence
 

Basic EPS

  

   1,202.0    389    32.4p  
        

 

 

  

 

 

  

 

 

 

Diluted EPS

  

   1,211.7    389    32.1p  
        

 

 

  

 

 

  

 

 

 

10.Earnings per ordinary share (“EPS”) – (continued)

       2013    
£m
      2012    
Restated
£m
      2011    
Restated
£m
 

UK corporation tax (expense)/credit

   (4  6    (1
  

 

 

  

 

 

  

 

 

 

A reconciliation of the notional tax charge based on the applicable rate of tax to the actual total tax expense is set out below.

  

       2013    
£m
      2012    
Restated

£m
      2011    
Restated

£m
 

Profit before tax

   576    532    375  
  

 

 

  

 

 

  

 

 

 

Tax at applicable rate 23.25% (2012: 24.5%; 2011: 26.5%)

   (134  (131  (99

Tax at applicable rate on share of results of joint ventures

   136    134    103  

Other

   (6  3    (5
  

 

 

  

 

 

  

 

 

 

Tax (expense)/credit

   (4  6    (1
  

 

 

  

 

 

  

 

 

 

 

   2010 
   Weighted
average
number of
shares
(millions)
   Earnings
£m
   EPS
pence
 

Basic EPS

   1,199.1     327     27.3p  
  

 

 

   

 

 

   

 

 

 

Diluted EPS

   1,205.1     327     27.1p  
  

 

 

   

 

 

   

 

 

 

8.     Equity dividends

        

          
Ordinary dividends paid in the year      2013    
pence
       2012    
pence
       2011    
pence
        2013     
£m
      2012    
£m
    2011 
£m
 

Ordinary shares

            

Final for prior financial year

   17.0p     15.9p     15.0p     200     191     180  

Interim for financial year

   6.65p     6.0p     5.65p     78     73     68  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

   23.65p     21.9p     20.65p     278     264     248  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The directors of Reed Elsevier PLC have proposed a final dividend of 17.95p (2012: 17.0p; 2011: 15.9p). The cost of funding the proposed final dividend is expected to be £208 million. No liability has been recognised at the statement of financial position date.

 

    

Ordinary dividends paid and proposed
relating to the financial year
                   2012     
pence
      2012   
pence
   2011
pence
 

Ordinary shares

            

Interim (paid)

  

   6.65p     6.0p     5.65p  

Final (proposed)

  

   17.95p     17.0p     15.9p  
        

 

 

   

 

 

   

 

 

 

Total

  

   24.60p     23.0p     21.55p  
        

 

 

   

 

 

   

 

 

 

9.     Earnings per ordinary share (“EPS”)

        

    
   2013 
   Weighted
average
number of
shares
(millions)
   Earnings
£m
   EPS
pence
 

Basic EPS

   1,172.2     572     48.8p  
  

 

 

   

 

 

   

 

 

 

Diluted EPS

   1,187.2     572     48.2p  
  

 

 

   

 

 

   

 

 

 
   2012 
   Weighted
average
number of
shares
(millions)
   Earnings
Restated
£m
   EPS
Restated
pence
 

Basic EPS

   1,200.6     538     44.8p  
  

 

 

   

 

 

   

 

 

 

Diluted EPS

   1,215.1     538     44.3p  
  

 

 

   

 

 

   

 

 

 

   2011 
   Weighted
average
number of
shares
(millions)
   Earnings
Restated
£m
   EPS
Restated
pence
 

Basic EPS

   1,202.0     374     31.1p  
  

 

 

   

 

 

   

 

 

 

Diluted EPS

   1,211.7     374     30.9p  
  

 

 

   

 

 

   

 

 

 

The diluted EPS figures are calculated after taking account of the effect of potential additional ordinary shares arising from share options and conditional shares.

The weighted average number of shares is after deducting shares held in treasury. Movements in the number of shares in issue net of treasury shares for the year ended December 31, 20122013 are shown below.

 

  Year Ended December 31,   Year Ended December 31, 
  Shares in
issue
(millions)
   Treasury
shares
(millions)
 2012
Shares in
issue net of
treasury
shares
(millions)
 2011
Shares in
issue net of
treasury
shares
(millions)
   2010
Shares in
issue net of
treasury
shares
(millions)
   Shares in
issue
(millions)
   Treasury
shares
(millions)
 2013
Shares in
issue net of
treasury
shares
(millions)
 2012
Shares in
issue net of
treasury
shares
(millions)
 2011
Shares in
issue net of
treasury
shares
(millions)
 

Number of ordinary shares

               

At January 1

   1,250.9     (48.3  1,202.6    1,200.4     1,197.7     1,257.6     (71.0  1,186.6    1,202.6    1,200.4  

Issue of ordinary shares

   6.7         6.7    1.6     2.0     9.4         9.4    6.7    1.6  

Repurchase of ordinary shares

        (23.3  (23.3                 (41.9  (41.9  (23.3    

Net release of shares by the employee benefit trust

        0.6    0.6    0.6     0.7          3.3    3.3    0.6    0.6  
  

 

   

 

  

 

  

 

   

 

   

 

   

 

  

 

  

 

  

 

 

At December 31

   1,257.6     (71.0  1,186.6    1,202.6     1200.4     1,267.0     (109.6  1,157.4    1,186.6    1,202.6  
  

 

   

 

  

 

  

 

   

 

   

 

   

 

  

 

  

 

  

 

 

Weighted average number of equivalent ordinary shares during the year

      1,200.6    1,202.0     1,199.1        1,172.2    1,200.6    1,202.0  
     

 

  

 

   

 

      

 

  

 

  

 

 

9.Earnings per ordinary share (“EPS”) – (continued)

The weighted average number of shares used in the diluted EPS calculations above is after deducting shares held in treasury and is derived as follows:

 

   2012
(millions)
  2011
(millions)
  2010
(millions)
 

Weighted average number of shares — Basic

   1,200.6    1,202.0    1,199.1  

Weighted average number of dilutive shares under option

   14.5    9.7    6.0  
  

 

 

  

 

 

  

 

 

 

Weighted average number of shares — Diluted

   1,215.1    1,211.7    1,205.1  
  

 

 

  

 

 

  

 

 

 

 

11.   Statement of cash flows

 

Reconciliation of profit before tax to cash used by operations

 

    
   2012
£m
  2011
£m
  2010
£m
 

Profit before tax

   546    390    328  

Effect of tax credit equalisation on distributed earnings

   14    13    13  

Net finance income

   (1  (1  (1

Share of results of joint ventures

   (561  (404  (342
  

 

 

  

 

 

  

 

 

 

Cash used by operations

   (2  (2  (2
  

 

 

  

 

 

  

 

 

 

11.Statement of cash flows – (continued)

   2013
(millions)
  2012
(millions)
  2011
(millions)
 

Weighted average number of shares — Basic

   1,172.2    1,200.6    1,202.0  

Weighted average number of dilutive shares under option

   15.0    14.5    9.7  
  

 

 

  

 

 

  

 

 

 

Weighted average number of shares — Diluted

   1,187.2    1,215.1    1,211.7  
  

 

 

  

 

 

  

 

 

 

 

10.   Statement of cash flows

 

Reconciliation of profit before tax to cash used by operations

 

    
   2013
£m
  2012
Restated
£m
  2011
Restated
£m
 

Profit before tax

   576    532    375  

Effect of tax credit equalisation on distributed earnings

   15    14    13  

Net finance income

   (10  (1  (1

Share of results of joint ventures

   (583  (547  (389
  

 

 

  

 

 

  

 

 

 

Cash used by operations

   (2  (2  (2
  

 

 

  

 

 

  

 

 

 

Reconciliation of net funding balances due from joint ventures

 

               2012
£m
  2011
£m
  2010
£m
 

At January 1

  

   632    274    521  

Cash flow

  

   317    358    (247
        

 

 

  

 

 

  

 

 

 

At December 31

  

   949    632    274  
        

 

 

  

 

 

  

 

 

 

12.   Investments in joint ventures

      

        
       2012
£m
  2011
£m
  2010
£m
 

Share of results of joint ventures

  

   561    404    342  

Share of joint ventures’:

          

Other comprehensive (expense)/income

  

   (146  (14  25  

Disposal/(acquisition) of non-controlling interests

  

   3    (23    

Increase/(decrease) in share based remuneration reserve

  

   16    14    (4

Equalisation adjustments

  

   (8  (18  (13

Dividends received from joint ventures

  

   (694  (600  (589

Increase in investment in joint ventures

  

           596  

Increase/(decrease) in net funding balances due from joint ventures

  

   317    358    (247
        

 

 

  

 

 

  

 

 

 

Net movement in the year

  

   49    121    110  

At January 1

  

   1,158    1,037    927  
        

 

 

  

 

 

  

 

 

 

At December 31

  

   1,207    1,158    1,037  
        

 

 

  

 

 

  

 

 

 

        During the year the company received dividends of £394 million from Elsevier Reed Finance BV and £300 million from Reed Elsevier Group plc.

 

        Summarised information showing total amounts in respect of joint ventures and Reed Elsevier PLC shareholders’ 52.9% share is set out below.

   

   

   Total joint ventures       Reed Elsevier PLC shareholders’ share      
   2012
£m
   2011
£m
   2010
£m
   2012
£m
  2011
£m
  2010
£m
 

Revenue

   6,116     6,002     6,055     3,235    3,175    3,203  

Net profit for the year

   1,074     767     648     561    404    342  
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

  

 

 

 
   2013
£m
  2012
£m
   2011
£m
 

At January 1

   949    632     274  

Cash flow

   (447  317     358  
  

 

 

  

 

 

   

 

 

 

At December 31

   502    949     632  
  

 

 

  

 

 

   

 

 

 

12.11.Investments in joint ventures

   2013
£m
  2012
Restated
£m
  2011
Restated
£m
 

Share of results of joint ventures

   583    547    389  

Share of joint ventures’:

    

Other comprehensive (loss)/income

   (13  (132  1  

Disposal/(acquisition) of non-controlling interests

       3    (23

Increase in share based remuneration reserve (net of tax)

   25    16    14  

Equalisation adjustments

   13    (8  (18

Dividends received from joint ventures

   (102  (694  (600

(Decrease)/increase in net funding balances due from joint ventures

   (447  317    358  
  

 

 

  

 

 

  

 

 

 

Net movement in the year

   59    49    121  

At January 1

   1,207    1,158    1,037  
  

 

 

  

 

 

  

 

 

 

At December 31

   1,266    1,207    1,158  
  

 

 

  

 

 

  

 

 

 

During the year the Company received dividends of £102 million (2012: £394 million; 2011: nil) from Elsevier Reed Finance BV and nil from Reed Elsevier Group plc (2012: £300 million; 2011: £600 million).

11.Investments in joint ventures– (continued)

 

Summarised information showing total amounts in respect of joint ventures and Reed Elsevier PLC shareholders’ 52.9% share is set out below.

   Total joint ventures   Reed Elsevier PLC shareholders’ share 
    2013
£m
   2012
Restated
£m
   2011
Restated
£m
   2013
£m
   2012
Restated
£m
   2011
Restated
£m
 

Revenue

   6,035     6,116     6,002     3,193     3,235     3,175  

Net profit for the year

   1,115     1,049     738     583     547     389  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Reed Elsevier PLC’s share of joint ventures’ net profit attributable to parent company shareholders for the year excludes the net profit that arose directly in Reed Elsevier PLC of £4 million (2012: £5 million (2011: £2 million loss; 2010:2011: £2 million loss).

Reed Elsevier PLC’s other comprehensive income includes a loss of £13 million (2012: £132 million loss; 2011: £1 million income) relating to joint ventures.

   Total joint ventures  Reed Elsevier PLC shareholders’ share 
    2012
£m
  2011
£m
  2010
£m
  2012
£m
  2011
£m
  2010
£m
 

Total assets

   11,014    11,503    11,158    5,826    6,085    5,903  

Total liabilities

   (8,700  (9,306  (9,188  (5,568  (5,559  (5,140
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net assets

   2,314    2,197    1,970    258    526    763  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Attributable to:

       

Joint ventures

   2,280    2,172    1,943    258    526    763  

Non-controlling interests

   34    25    27              
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 
   2,314    2,197    1,970    258    526    763  
  

 

 

  

 

 

  

 

 

    

Funding balances due from joint ventures

      949    632    274  
     

 

 

  

 

 

  

 

 

 

Total

      1,207    1,158    1,037  
     

 

 

  

 

 

  

 

 

 

   Total joint ventures  Reed Elsevier PLC shareholders’
share
 
    2013
£m
   2012
£m
  2011
£m
  2013
£m
  2012
£m
  2011
£m
 

Total assets

   10,495     11,014    11,503    5,552    5,826    6,085  

Total liabilities

   (8,072)     (8,700  (9,306  (4,788  (5,568  (5,559
  

 

 

   

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net assets

   2,423     2,314    2,197    764    258    526  
  

 

 

   

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Attributable to:

        

Joint ventures

   2,390     2,280    2,172    764    258    526  

Non-controlling interests

   33     34    25              
  

 

 

   

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 
   2,423     2,314    2,197    764    258    526  
  

 

 

   

 

 

  

 

 

    

Funding balances due from joint ventures

       502    949    632  
      

 

 

  

 

 

  

 

 

 

Total

       1,266    1,207    1,158  
      

 

 

  

 

 

  

 

 

 

The above amounts for Reed Elsevier PLC’s shareholders’ share of total assets and total liabilities exclude assets and liabilities held directly by Reed Elsevier PLC, andbut include the counterparty balances of amounts owed to and by other Reed Elsevier businesses. Included within Reed Elsevier PLC’s share of assets and liabilities are cash and cash equivalents of £70 million (2012: £339 million (2011:million; 2011: £384 million; 2010: £393 million) and borrowings of £1,736 million (2012: £2,059 million (2011:million; 2011: £2,265 million; 2010: £2,276 million) respectively.

 

13.12.Share capital

Called up share capital — issued and fully paid

   No. of
shares
       £m     

Authorised

    

Ordinary shares of 14 51/116p each

   1,257,597,977     181  

Unclassified shares of 14 51/116p each

   787,158,643     113  
    

 

 

 

Total

     294  
    

 

 

 

   2013   2012   2011 
   No. of shares   £m   No. of shares   £m   No. of shares   £m 

At January 1

   1,257,597,977     181     1,250,913,565     180     1,249,286,224     180  

Issue of ordinary shares

   9,438,719     1     6,684,412     1     1,627,341       
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At December 31

   1,267,036,696     182     1,257,597,977     181     1,250,913,565     180  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

All of the ordinary shares rank equally with respect to voting rights and rights to receive dividends.dividends, except for shares held in treasury by the parent company, which do not attract voting or dividend rights. There are no restrictions on the rights to transfer shares.

Called up share capital — issued and fully paid

  2012  2011  2010 
  No. of shares  £m  No. of shares  £m  No. of shares  £m 

At January 1

  1,250,913,565    180    1,249,286,224    180    1,247,275,833    180  

Issue of ordinary shares

  6,684,412    1    1,627,341        2,010,391      
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

At December 31

  1,257,597,977    181    1,250,913,565    180    1,249,286,224    180  
 

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

The issue of ordinary shares relates to the exercise of share options. Details of share option and conditional share schemes are set out in note 87 to the Reed Elsevier combined financial statements.

Details of shares held in treasury are provided in note 15.14.

14.13.Share premium

 

   2012
£m
  2011
£m
  2010
£m
 

At January 1

   1,176    1,168    1,159  

Issue of ordinary shares, net of expenses

   32    8    9  
  

 

 

  

 

 

  

 

 

 

At December 31

   1,208    1,176    1,168  
  

 

 

  

 

 

  

 

 

 

 

15.   Shares held in treasury

 

    
   2012
£m
  2011
£m
  2010
£m
 

At January 1

   308    312    317  

Repurchase of ordinary shares

   143          

Share of joint ventures’ settlement of share awards by the employee benefit trust

   (4  (4  (5
  

 

 

  

 

 

  

 

 

 

At December 31

   447    308    312  
  

 

 

  

 

 

  

 

 

 

 

At December 31, 2012, shares held in treasury related to 13,451,468 (2011: 14,051,025, 2010: 14,654,161) Reed Elsevier PLC ordinary shares held by the Reed Elsevier Group plc Employee Benefit Trust (“EBT”); and 57,484,915 (2011: 34,196,298, 2010: 34,196,298) Reed Elsevier PLC ordinary shares held by the parent company.

 

The EBT purchases Reed Elsevier PLC shares which, at the Trustees’ discretion, can be used in respect of the exercise of share options and to meet commitments under conditional shares awards. At December 31, 2012, Reed Elsevier PLC shares held by the EBT were £84 million (2011: £88 million; 2010: £92 million).

 

16.   Capital redemption reserve

 

    

    

      

   2012
£m
  2011
£m
  2010
£m
 

At January 1 and December 31

   4    4    4  
  

 

 

  

 

 

  

 

 

 

 

17.   Translation reserve

 

    
   2012
£m
  2011
£m
  2010
£m
 

At January 1

   159    142    92  

Share of joint ventures’ exchange differences on translation of foreign operations

   (72  17    50  
  

 

 

  

 

 

  

 

 

 

At December 31

   87    159    142  
  

 

 

  

 

 

  

 

 

 

 

18.   Other reserves

 

    
   2012
£m
  2011
£m
  2010
£m
 

At January 1

   (62  (154  (202

Profit attributable to ordinary shareholders

   552    389    327  

Share of joint ventures’:

    

Actuarial losses on defined benefit pension schemes

   (174  (60  (33

Fair value movements on available for sale investments

       (1    

Transfer to net profit on disposals of available for sale investments

   6          

Fair value movements on cash flow hedges

   37    (12  (31

Tax recognised directly in equity

   46    22    15  

Increase/(decrease) in share based remuneration reserve

   16    14    (4

Settlement of share awards

   (4  (4  (5

Transfer to net profit from cash flow hedge reserve

   11    20    24  

Disposal/(acquisition) of non-controlling interest

   3    (23    

Equalisation adjustments

   6    (5    

Equity dividends paid

   (264  (248  (245
  

 

 

  

 

 

  

 

 

 

At December 31

   173    (62  (154
  

 

 

  

 

 

  

 

 

 
   2013
£m
   2012
£m
   2011
£m
 

At January 1

   1,208     1,176     1,168  

Issue of ordinary shares, net of expenses

   49     32     8  
  

 

 

   

 

 

   

 

 

 

At December 31

   1,257     1,208     1,176  
  

 

 

   

 

 

   

 

 

 

14.Shares held in treasury

   2013
£m
  2012
£m
  2011
£m
 

At January 1

   447    308    312  

Repurchase of ordinary shares

   326    143      

Share of joint ventures’ settlement of share awards by the employee benefit trust

   (21  (4  (4
  

 

 

  

 

 

  

 

 

 

At December 31

   752    447    308  
  

 

 

  

 

 

  

 

 

 

At December 31, 2013, shares held in treasury related to 10,120,537 (2012: 13,451,468; 2011: 14,654,161) Reed Elsevier PLC ordinary shares held by the Reed Elsevier Group plc Employee Benefit Trust (“EBT”); and 99,446,834 (2012: 57,484,914; 2011: 34,196,298) Reed Elsevier PLC ordinary shares held by the parent company.

The EBT purchases Reed Elsevier PLC shares which, at the Trustees’ discretion, can be used in respect of the exercise of share options and to meet commitments under conditional shares awards. At December 31, 2013, Reed Elsevier PLC shares held by the EBT were £64 million (2012: £84 million; 2011: £88 million) at cost.

15.Capital redemption reserve

   2013
£m
   2012
£m
   2011
£m
 

At January 1 and December 31

   4     4     4  
  

 

 

   

 

 

   

 

 

 

16.Translation reserve

   2013
£m
  2012
£m
  2011
£m
 

At January 1

   87    159    142  

Share of joint ventures’ exchange differences on translation of foreign operations

   (47  (72  17  
  

 

 

  

 

 

  

 

 

 

At December 31

   40    87    159  
  

 

 

  

 

 

  

 

 

 

19.17.Other reserves

   2013
£m
  2012
Restated
£m
  2011
Restated
£m
 

At January 1

   173    (62  (154

Profit attributable to ordinary shareholders

   572    538    374  

Share of joint ventures’:

    

Actuarial gains/(losses) on defined benefit pension schemes

   21    (155  (37

Fair value movements on available for sale investments

           (1

Transfer to net profit on disposal of available for sale investments

       6      

Fair value movements on cash flow hedges

   34    37    (12

Tax recognised in other comprehensive income

   (20  41    14  

Increase in share based remuneration reserve (net of tax)

   25    16    14  

Settlement of share awards

   (21  (4  (4

Transfer to net profit from cash flow hedge reserve (net of tax)

   (1  11    20  

Disposal/(acquisition) of non-controlling interests

       3    (23

Equalisation adjustments

   28    6    (5

Equity dividends paid

   (278  (264  (248
  

 

 

  

 

 

  

 

 

 

At December 31

   533    173    (62
  

 

 

  

 

 

  

 

 

 

18.Contingent liabilities

There are contingent liabilities in respect of borrowings of joint ventures guaranteed by Reed Elsevier PLC as follows:

 

   2012
£m
   2011
£m
   2010
£m
 

Guaranteed jointly and severally with Reed Elsevier NV

   3,595     3,920     3,924  
  

 

 

   

 

 

   

 

 

 
    2013
£m
   2012
£m
   2011
£m
 

Guaranteed jointly and severally with Reed Elsevier NV

   3,063     3,595     3,920  
  

 

 

   

 

 

   

 

 

 

Financial instruments disclosures in respect of the borrowings covered by the above guarantees are given in note 1918 to the Reed Elsevier combined financial statements.

 

20.19.Approval of financial statements

The consolidated financial statements were approved by the Board of directors on February 27, 2013.26, 2014.

 

 

REED ELSEVIER NV

CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the membersBoard of the SupervisoryDirectors and Executive Boards and the shareholders of Reed Elsevier NV:

We have audited the accompanying consolidated statements of financial position of Reed Elsevier NV and its subsidiaries (the “Company”) as at December 31, 2013, 2012 2011 and 2010,2011, and the related consolidated income statements, and consolidated statements of comprehensive income, cash flows and changes in equity for each of the years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Reed Elsevier NV and its subsidiaries as at December 31, 2013, 2012 2011 and 2010,2011, and the results of their operations and their cash flows for each of the years then ended, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

As discussed in Accounting policies in the consolidated financial statements, the accompanying 2012 and 2011 financial statements have been retrospectively adjusted for the adoption of International Accounting Standards 19Employee Benefits (revised).

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company’s internal control over financial reporting as at December 31, 2012,2013, based on the criteria established inInternal Control — Integrated Framework (1992)issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 27, 201326, 2014 expressed an unqualified opinion on the Company’s internal control over financial reporting.

/s/ DELOITTE ACCOUNTANTS B.V.

Amsterdam, The Netherlands

February 27, 201326, 2014

REED ELSEVIER NV

CONSOLIDATED INCOME STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   2012
€m
 2011
€m
 2010
€m
   Note   2013
€m
 2012
Restated
€m
 2011
Restated
€m
 

Administrative expenses

   4     (2  (2  (2   4     (2  (2  (2

Share of results of joint ventures

   12     654    420    367     11     642    638    403  
    

 

  

 

  

 

     

 

  

 

  

 

 

Operating profit

     652    418    365       640    636    401  

Finance income

   7     8    20    14     6     19    8    20  
    

 

  

 

  

 

     

 

  

 

  

 

 

Profit before tax

     660    438    379       659    644    421  

Taxation

   8     (2  (1  (3

Tax expense

   7     (4  (2  (1
    

 

  

 

  

 

     

 

  

 

  

 

 

Profit attributable to shareholders

     658    437    376       655    642    420  
    

 

  

 

  

 

     

 

  

 

  

 

 

REED ELSEVIER NV

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  2012
€m
 2011
€m
   2010
€m
   2013
€m
 2012
Restated
€m
 2011
Restated
€m
 

Profit attributable to shareholders

   658    437     376     655    642    420  

Share of joint ventures’ other comprehensive (expense)/income for the year

   (137  20     71  

Share of joint ventures’ other comprehensive (loss)/income for the year

   (48  (121  37  
  

 

  

 

   

 

   

 

  

 

  

 

 

Total comprehensive income for the year

   521    457     447     607    521    457  
  

 

  

 

   

 

   

 

  

 

  

 

 

 

  Note   2012   2011   2010   Note   2013   2012
Restated
   2011
Restated
 

Earnings per share (“EPS”)

                

Basic earnings per share

   10    0.90    0.59    0.51     9    0.91    0.87    0.57  

Diluted earnings per share

   10    0.89    0.59    0.51     9    0.90    0.87    0.57  

REED ELSEVIER NV

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   2012
€m
 2011
€m
 2010
€m
   Note   2013
€m
 2012
€m
 2011
€m
 

Cash flows from operating activities

            

Cash used by operations

   11     (5  (3  (1   10     (3  (5  (3

Interest received

     6    20    14       19    6    20  

Tax paid

     (2  (5  (4     (1  (2  (5
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash (used in)/from operating activities

     (1  12    9  

Net cash from/(used in) operating activities

     15    (1  12  
    

 

  

 

  

 

     

 

  

 

  

 

 

Cash flows from investing activities

            

Dividends received from joint ventures

   12     754        1,093     11     186    754      

Increase in investment in joint ventures

   12             (719
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash from investing activities

     754        374       186    754      
    

 

  

 

  

 

     

 

  

 

  

 

 

Cash flows from financing activities

            

Equity dividends paid

   9     (319  (289  (281   8     (321  (319  (289

Repurchase of shares

     (141             (337  (141    

Proceeds on issue of ordinary shares

     18    2    2       88    18    2  

(Increase)/decrease in net funding balances due from joint ventures

   11     (313  275    (104

Decrease/(increase) in net funding balances due from joint ventures

   10     370    (313  275  
    

 

  

 

  

 

     

 

  

 

  

 

 

Net cash used in financing activities

     (755  (12  (383     (200  (755  (12
    

 

  

 

  

 

     

 

  

 

  

 

 

Net decrease in cash and cash equivalents

     (2        

Net increase/(decrease) in cash and cash equivalents

     1    (2    
    

 

  

 

  

 

     

 

  

 

  

 

 

Cash and cash equivalents at beginning of year

     3    3    3  
    

 

  

 

  

 

 

Cash and cash equivalents at end of year

     1    3    3  
    

 

  

 

  

 

 

REED ELSEVIER NV

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT DECEMBER 31, 20122013

 

  Note   2012
€m
 2011
€m
 2010
€m
   Note   2013
€m
 2012
€m
 2011
€m
 

Non-current assets

            

Investments in joint ventures

   12     1,455    1,359    1,198     11     1,488    1,455    1,359  

Current assets

            

Amounts due from joint ventures

     4    2    2       4    4    2  

Cash and cash equivalents

     1    3    3       2    1    3  
    

 

  

 

  

 

     

 

  

 

  

 

 
     5    5    5       6    5    5  
    

 

  

 

  

 

     

 

  

 

  

 

 

Total assets

     1,460    1,364    1203       1,494    1,460    1,364  
    

 

  

 

  

 

     

 

  

 

  

 

 

Current liabilities

            

Payables

   13     7    10    11     12     6    7    10  

Taxation

     51    51    55       54    51    51  
    

 

  

 

  

 

     

 

  

 

  

 

 

Total liabilities

     58    61    66       60    58    61  
    

 

  

 

  

 

     

 

  

 

  

 

 

Net assets

     1,402    1,303    1,137       1,434    1,402    1,303  
    

 

  

 

  

 

     

 

  

 

  

 

 

Capital and reserves

            

Share capital issued

   14     54    54    54     13     55    54    54  

Paid-in surplus

   15     2,189    2,171    2,169     14     2,276    2,189    2,171  

Shares held in treasury (including in joint ventures)

   16     (571  (432  (433   15     (881  (571  (432

Translation reserve

   17     (42  6    (51   16     (131  (42  6  

Other reserves

   18     (228  (496  (602   17     115    (228  (496
    

 

  

 

  

 

     

 

  

 

  

 

 

Total equity

     1,402    1,303    1,137       1,434    1,402    1,303  
    

 

  

 

  

 

     

 

  

 

  

 

 

REED ELSEVIER NV

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED DECEMBER 31, 20122013

 

  Note   Share
capital
€m
   Paid-in
surplus
€m
   Shares
held in
treasury
€m
   Translation
reserve
€m
   Other
reserves
€m
   Total
equity
€m
 

Balance at January 1, 2013

     54     2,189     (571   (42   (228   1,402  

Total comprehensive income for the year

                    (86   693     607  

Equity dividends paid

   8                         (321   (321

Issue of ordinary shares, net of expenses

     1     87                    88  

Repurchase of shares

               (337             (337

Share of joint ventures’ increase in share based remuneration reserve (net of tax)

                         29     29  

Share of joint ventures’ settlement of share awards by the employee benefit trust

               24          (24     

Equalisation adjustments

                         (34   (34

Exchange translation differences

               3     (3          
    

 

   

 

   

 

   

 

   

 

   

 

 

Balance at December 31, 2013

     55     2,276     (881   (131   115     1,434  
  Note   Share
capital
€m
   Paid-in
surplus
€m
   Shares
held in
treasury
€m
 Translation
reserve

€m
 Other
reserves
€m
 Total
equity
€m
     

 

   

 

   

 

   

 

   

 

   

 

 

Balance at January 1, 2012

     54     2,171     (432  6    (496  1,303       54     2,171     (432   6     (496   1,303  

Total comprehensive income for the year

                   (51  572    521                      (51   572     521  

Equity dividends paid

   9                       (319  (319   8                         (319   (319

Issue of ordinary shares, net of expenses

          18                 18            18                    18  

Repurchase of shares

               (141          (141               (141             (141

Share of joint ventures’ increase in share based remuneration reserve

                       19    19                           19     19  

Share of joint ventures’ settlement of share awards by the employee benefit trust

               5        (5                   5          (5     

Share of joint ventures’ disposal of non-controlling interest

                       4    4  

Share of joint ventures’ acquisition of non-controlling interest

                         4     4  

Equalisation adjustments

                       (3  (3                         (3   (3

Exchange translation difference

               (3  3          

Exchange translation differences

               (3   3            
    

 

   

 

   

 

  

 

  

 

  

 

     

 

   

 

   

 

   

 

   

 

   

 

 

Balance at December 31, 2012

     54     2,189     (571  (42  (228  1,402       54     2,189     (571   (42   (228   1,402  
    

 

   

 

   

 

  

 

  

 

  

 

     

 

   

 

   

 

   

 

   

 

   

 

 

Balance at January 1, 2011

     54     2,169     (433  (51  (602  1,137       54     2,169     (433   (51   (602   1,137  

Total comprehensive income for the year

                   54    403    457                      54     403     457  

Equity dividends paid

   9                       (289  (289   8                         (289   (289

Issue of ordinary shares, net of expenses

          2                 2            2                    2  

Share of joint ventures’ increase in share based remuneration reserve

                       16    16  

Share of joint ventures’ decrease in share based remuneration reserve

                         16     16  

Share of joint ventures’ settlement of share awards by the employee benefit trust

               4        (4                   4          (4     

Share of joint ventures’ acquisition of non-controlling interest

                       (25  (25                         (25   (25

Equalisation adjustments

                       5    5                           5     5  

Exchange translation difference

               (3  3          

Exchange translation differences

               (3   3            
    

 

   

 

   

 

  

 

  

 

  

 

     

 

   

 

   

 

   

 

   

 

   

 

 

Balance at December 31, 2011

     54     2,171     (432  6    (496  1,303       54     2,171     (432   6     (496   1,303  
    

 

   

 

   

 

  

 

  

 

  

 

     

 

   

 

   

 

   

 

   

 

   

 

 

Balance at January 1, 2010

     53     2,168     (434  (153  (664  970  

Total comprehensive income for the year

                   98    349    447  

Equity dividends paid

   9                       (281  (281

Issue of ordinary shares, net of expenses

     1     1                 2  

Share of joint ventures’ decrease in share based remuneration reserve

                       (4  (4

Share of joint ventures’ settlement of share awards by the employee benefit trust

               5        (5    

Equalisation adjustments

                       3    3  

Exchange translation differences

               (4  4          
    

 

   

 

   

 

  

 

  

 

  

 

 

Balance at December 31, 2010

     54     2,169     (433  (51  (602  1,137  
    

 

   

 

   

 

  

 

  

 

  

 

 

REED ELSEVIER NV

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

1.Basis of financial statements

On January 1, 1993 Reed Elsevier PLC and Reed Elsevier NV contributed their businesses to two companies, Reed Elsevier Group plc and Elsevier Reed Finance BV. Reed Elsevier Group plc, which owns all the publishing and information businesses, is incorporated in England and Elsevier Reed Finance BV, which owns the financing and treasury companies, is incorporated in the Netherlands. Reed Elsevier PLC and Reed Elsevier NV each hold a 50% interest in Reed Elsevier Group plc. Reed Elsevier PLC holds a 39% interest in Elsevier Reed Finance BV with Reed Elsevier NV holding a 61% interest. Reed Elsevier PLC additionally holds an indirect equity interest in Reed Elsevier NV, reflecting the arrangements entered into between Reed Elsevier PLC and Reed Elsevier NV at the time of the merger, which determined the equalisation ratio whereby one Reed Elsevier NV ordinary share is, in broad terms, intended to confer equivalent economic interests to 1.538 Reed Elsevier PLC ordinary shares.

As a consequence of the merger of the company’s businesses with those of Reed Elsevier PLC, the shareholders of Reed Elsevier NV and Reed Elsevier PLC can be regarded as having the interests of a single economic group, enjoying substantially equivalent ordinary dividend and capital rights in the earnings and net assets of the Reed Elsevier combined businesses.

Unless otherwise indicated, all amounts shown in the consolidated financial statements are stated in euros (“€”). Certain disclosures required to comply with Dutch statutory reporting requirements have been omitted.

The Reed Elsevier combined financial statements on pages F-3 to F-53F-55 form an integral part of the notes to Reed Elsevier NV’s consolidated financial statements.

 

2.Accounting policies

Basis of Preparation

These consolidated financial statements, which have been prepared under the historichistorical cost convention, report the consolidated statements of income, comprehensive income, cash flow, and financial position and changes in equity of Reed Elsevier NV (incorporated and domiciled in the Netherlands), and have been prepared in accordance with accounting policies that are in conformity with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and as adopted by the European Union.

Unless otherwise indicated, all amounts shown in the financial statements are in euros (“€”).

The basis of the merger of the businesses of Reed Elsevier PLC and Reed Elsevier NV is set out on page 11.12.

As a consequence of the merger of the company’s businesses with those of Reed Elsevier NV’sPLC, described on page 12, the shareholders of Reed Elsevier NV and Reed Elsevier PLC can be regarded as having the interests of a single economic group, enjoying substantially equivalent ordinary dividend and capital rights in the earnings and net assets of the Reed Elsevier Combined Businesses. The Combined Businesses are composed of Reed Elsevier Group plc and Elsevier Reed Finance BV and their respective subsidiaries and joint ventures, together with the two parent companies, Reed Elsevier NV and Reed Elsevier PLC. The Combined Businesses are jointly controlled by Reed Elsevier NV and Reed Elsevier PLC.

The Reed Elsevier NV consolidated financial statements are presented incorporating Reed Elsevier NV’s investments in the Reed Elsevier combined businessesCombined Businesses accounted for using the equity method, as adjusted for the effects of the equalisation arrangement between Reed Elsevier NV and Reed Elsevier PLC. The arrangement lays down the distribution of dividends and net assets in such a way that Reed Elsevier NV’sN.V’s share in the profit and net assets of the Reed Elsevier combined businessesCombined Businesses equals 50%, with all settlements accruing to shareholders from the equalisation arrangements taken directly to reserves.

Because the dividend paid to shareholders by Reed Elsevier NV is, other than in special circumstances, equivalent to the Reed Elsevier PLC dividend plus the UK tax credit received by certain Reed Elsevier PLC shareholders, Reed Elsevier NV normally distributes a higher proportion of the combined profit attributable than Reed Elsevier PLC. Reed Elsevier PLC’s share in this difference in dividend distributions is settled with Reed Elsevier NV and is credited directly to consolidated reserves under equalisation. Reed Elsevier NV can pay a nominal dividend on its R shares held by a subsidiary of Reed Elsevier PLC that is lower than the dividend on the ordinary shares. Equally, Reed Elsevier NV has the possibility to receive dividends directly from Dutch affiliates. Reed Elsevier PLC is compensated by direct dividend payments by Reed Elsevier Group plc. The settlements flowing from these arrangements are also taken directly to consolidated reserves under equalisation.

Combined financial statements

The accounting policies adopted in the preparation of the combined financial statements are set out on pages F-10 toF-17.

2.Accounting policies – (continued)

Basis of valuation of assets and liabilities

Reed Elsevier NV’s 50% economic interest in the net assets of the combined businesses has been shown on the consolidated statement of financial position as investments in joint ventures, net of the assets and liabilities reported as part of Reed Elsevier NV. Joint ventures are accounted for using the equity method.

Assets and liabilities are stated at historical cost, less provision, if appropriate, for any impairment in value.

2.Accounting policies – (continued)

Foreign exchange translation

Transactions in foreign currencies are recorded at the rate of exchange prevailing on the date of the transaction. At each statement of financial position date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rate prevailing on the statement of financial position date. Exchange differences arising are recorded in the income statement. The gains or losses relating to the retranslation of Reed Elsevier NV’s 50% interest in the net assets of the combined businesses are classified as equity and transferred to the translation reserve.

When foreign operations are disposed of, the related cumulative translation differences are recognised within the income statement in the period.

Taxation

TheTax expense comprises current and deferred tax. Current and deferred tax expense representsare charged or credited in the sum ofincome statement except to the extent that the tax payable on the current year taxable profits, adjustments in respect of prior year taxable profits and the movements on deferred tax that arearises from a transaction or event which is recognised, in the same or a different period, outside profit or loss (either in other comprehensive income, statement. Tax arisingdirectly in joint ventures is includedequity, or through a business combination) in which case the tax appears in the sharesame statement as the transaction that gave rise to it.

Current tax is the amount of results of joint ventures.

The taxcorporate income taxes payable or recoverable based on current yearthe profit for the period as adjusted for items that are not taxable profitsor not deductible, and is calculated using the applicable tax raterates and laws that has beenwere enacted or substantively enacted byat the date of the statement of financial position. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. Provisions are established where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax is recognised on temporary differences arising between the tax arising on differences between the carrying amountsbases of assets and liabilities and their carrying amounts in the statement of financial statementsposition. Deferred tax is calculated using tax rates and their correspondinglaws that have been enacted or substantively enacted at the end of the reporting period, and which are expected to apply when the related deferred tax bases used inasset is realised or the computation of taxable profit, anddeferred tax liability is accounted for using the balance sheet liability method. settled.

Deferred tax liabilities are generally recognised for all taxable temporary differences but not recognised for taxable temporary differences arising on investments in subsidiaries, associates and deferredjoint ventures where the reversal of the temporary difference can be controlled and it is probable that the difference will not reverse in the foreseeable future. Deferred tax liabilities are not recognised on temporary differences that arise from goodwill which is not deductible for tax purposes.

Deferred tax assets are recognised to the extent that, based on current forecasts, it is probable that taxable profits will be available against which the deductible temporary differences can be utilised.utilised, and reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are not recognised in respect of temporary differences that arise on initial recognition of assets and liabilities acquired other than in a business combination. Deferred tax is not recognised on temporary differences in respect of goodwill that is not deductible for tax purposes.

Deferred tax is calculated using tax rates that have been substantively enacted at the date of the statement of financial position. Full provision is made for deferred tax which would become payable on the distribution of retained profits from foreign subsidiaries, associates or joint ventures.

Movements in deferred tax are charged or credited in the income statement, except when they relate to items charged or credited directly to equity, in which case the deferred tax is also recognised in equity. Deferred tax credits in respect of share based remuneration are recognised in equity to the extent that expected tax deduction exceed the related expense.discounted.

Critical judgements and key sources of estimation uncertainty

Critical judgments in the preparation of the combined financial statements are set out on pages F-14 to F-16.F-15.

Standards and amendments effective for the year

As described on page F-16, the combined businesses adopted IAS19 Employee Benefits (revised) with effect from January 1, 2013. As required under the revised standard, comparative figures have been restated. For the year ended December 31, 2012, Reed Elsevier NV’s share of results of joint ventures is €16 million lower and basic earnings per share is €0.03 lower than previously reported. For the year ended December 31, 2011, Reed Elsevier NV’s share of results of joint ventures is €17 million lower and basic earnings per share is €0.02 lower than previously reported.

With effect from January 1, 2013, the combined businesses also adopted various other standards, interpretations and amendments to IFRS, none of which have had a significant impact on Reed Elsevier’s accounting policies or reporting.

2.Accounting policies – (continued)

Standards, amendments and interpretations not yet effective

Recently issued standards, amendments and interpretations and their impact on future accounting policies and reporting have been considered on pages F16F-16 to F17F-17 of the combined financial statements.

 

3.Basis of preparation

The consolidated financial statements of Reed Elsevier NV reflect the 50% economic interest that its shareholders have under the equalisation arrangements in the Reed Elsevier combined businesses, accounted for on an equity basis.

The Reed Elsevier combined financial statements are presented in pounds sterling, which is the functional currency of Reed Elsevier Group plc, a UK registered company which owns the publishing and information businesses of Reed Elsevier. The following analysis presents how the consolidated financial statements of Reed Elsevier NV, presented in euros, are derived from the Reed Elsevier combined financial statements.

 

Reed Elsevier NV consolidated profit attributable to shareholders

  2012   2011   2010 

Reed Elsevier combined businesses net profit attributable to parent company shareholders in pounds sterling

  £1,069m    £760m    £642m  

Reed Elsevier combined businesses net profit attributable to parent company shareholders translated into euros at year end exchange rates (2012: €1.23 to £1.00; 2011: €1.15 to £1.00; 2010: €1.17 to £1.00)

  1,315m    874m    751m  

Reed Elsevier NV’s 50% share of combined net profit attributable to shareholders

   €658m    437m    376m  
  

 

 

   

 

 

   

 

 

 

3.Reed Elsevier NV consolidated profit attributable to shareholders

2013Basis2012
Restated
2011
Restated

Reed Elsevier combined businesses net profit attributable to parent company shareholders in pounds sterling

£1,110m£1,044m£731m

Reed Elsevier combined businesses net profit attributable to parent company shareholders translated into euros at year end exchange rates (2013: €1.18 to £1.00; 2012: €1.23 to £1.00; 2011: €1.15 to £1.00)

1,310m1,284m840m

Reed Elsevier NV’s 50% share of preparation – (continued)combined net profit attributable to shareholders

655m642m420m

 

Reed Elsevier NV consolidated total equity

  2012   2011   2010   2013   2012   2011 

Reed Elsevier combined shareholders’ equity in pounds sterling

  £2,280m    £2,172m    £1,943m    £2,390m    £2,280m    £2,172m  

Reed Elsevier combined shareholders’ equity in pounds sterling translated into euros at year end exchange rates (2012: €1.23 to £1.00; 2011: €1.15 to £1.00; 2010: €1.17 to £1.00)

  2,804m    2,606m    2,273m  

Reed Elsevier combined shareholders’ equity in pounds sterling translated into euros at year end exchange rates (2013: €1.20 to £1.00; 2012: €1.23 to £1.00; 2011: €1.15 to £1.00)

  2,868m    2,804m    2,606m  

Reed Elsevier NV’s 50% share of combined equity

  1,402m    1,303m    1,137m    1,434m    1,402m    1,303m  
  

 

   

 

   

 

   

 

   

 

   

 

 

 

4.Administrative expenses

Administrative expenses include the gross remuneration for present and former directorsExecutive and Non-Executive Directors of Reed Elsevier NV in respect of services rendered to Reed Elsevier NV and the combined businesses. Fees for members of the Supervisory BoardNon-Executive Directors of Reed Elsevier NV of €0.3 million (2011:(2012: €0.3 million; 2010:2011: €0.3 million) are included in remuneration. Insofar as remuneration is related to services rendered to Reed Elsevier Group plc group and Elsevier Reed Finance BV group, it is borne by these groups. Reed Elsevier NV has no employees (2011:(2012: nil; 2010:2011: nil).

 

5.Auditor’s remuneration

Audit fees payable by Reed Elsevier NV were €142,000 (2011: €50,000; 2010: €48,000). Further information on the audit and non audit fees paid by the Reed Elsevier combined businesses to Deloitte Accountants B.V. and its associates is set out in note 5 to the combined financial statements.

6.Related party transactions

All transactions with joint ventures, which are related parties of Reed Elsevier NV, are reflected in these financial statements. Key management personnel are also related parties and comprise the members of the Executive BoardDirectors of Reed Elsevier NV. Transactions with key management personnel are set out in note 3432 to the combined financial statements.

 

7.6.Finance income

 

   2012
€m
   2011
€m
   2010
€m
 

Finance income from joint ventures

   8     20     14  
  

 

 

   

 

 

   

 

 

 
   2013
€m
   2012
€m
   2011
€m
 

Finance income from joint ventures

   19     8     20  
  

 

 

   

 

 

   

 

 

 

8.7.Taxation

A reconciliation of the notional tax charge based on the applicable rate of tax to the actual total tax expense is set out below.

 

  2012
€m
 2011
€m
 2010
€m
   2013
€m
 2012
Restated
€m
 2011
Restated
€m
 

Profit before tax

   660    438    379     659    644    438  
  

 

  

 

  

 

   

 

  

 

  

 

 

Tax at applicable rate 25.0% (2011: 25.0%; 2010: 25.5%)

   165    110    97  

Tax at applicable rate 25.0% (2012: 25.0%; 2011: 25.0%)

   (165  (161  (110

Tax at applicable rate on share of results of joint ventures

   (163  (105  (94   161    159    105  

Other

       (4               4  
  

 

  

 

  

 

   

 

  

 

  

 

 

Tax expense

   2    1    3     (4  (2  (1
  

 

  

 

  

 

   

 

  

 

  

 

 

 

9.8.Equity dividends

 

Dividends declared in the year  2012
   2011
   2010
   2012
€m
   2011
€m
   2010
€m
 

Ordinary shares

            

Final for prior financial year

  0.326    0.303    0.293     228     212     205  

Interim for financial year

  0.130    0.110    0.109     91     77     76  

R shares

                              
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  0.456    0.413    0.402     319     289     281  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

9.Equity dividends – (continued)

Dividends paid in the year  2013
   2012
   2011
   2013
€m
   2012
€m
   2011
€m
 

Ordinary shares

            

Final for prior financial year

  0.337    0.326    0.303     230     228     212  

Interim for financial year

  0.132    0.130    0.110     91     91     77  

R shares

                              
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  0.469    0.456    0.413     321     319     289  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The directors of Reed Elsevier NV have proposed a final dividend of €0.337 (2011: €0.326; 2010: €0.303)€0.374 (2012: €0.337; 2011: €0.326). The cost of funding the proposed final dividend is expected to be €232€252 million. No liability has been recognised at the statement of financial position date.

 

Dividends paid and proposed relating to the financial year  2012
   2011
   2010
   2013
   2012
   2011
 

Ordinary shares

            

Interim (paid)

   €0.130    0.110    0.109    0.132    0.130    0.110  

Final (proposed)

   €0.337    0.326    0.293    0.374    0.337    0.326  

R shares

                              
  

 

   

 

   

 

   

 

   

 

   

 

 

Total

   €0.467    0.436    0.402    0.506    0.467    0.436  
  

 

   

 

   

 

   

 

   

 

   

 

 

 

10.9.Earnings per share (“EPS”)

 

  2012   2013 
  Weighted
average
number of
shares
(millions)
   Earnings
€m
   EPS
   Weighted
average
number of
shares
(millions)
   Earnings
€m
   EPS
 

Basic EPS

   734.0     658    0.90     717.6     655    0.91  
  

 

   

 

   

 

   

 

   

 

   

 

 

Diluted EPS

   742.1     658    0.89     726.9     655    0.90  
  

 

   

 

   

 

   

 

   

 

   

 

 

 

  2011   2012 
  Weighted
average
number of
shares
(millions)
   Earnings
€m
   EPS
   Weighted
average
number of
shares
(millions)
   Earnings
Restated
€m
   EPS
Restated
 

Basic EPS

   735.3     437    0.59     734.0     642    0.87  
  

 

   

 

   

 

   

 

   

 

   

 

 

Diluted EPS

   740.8     437    0.59     742.1     642    0.87  
  

 

   

 

   

 

   

 

   

 

   

 

 

9.Earnings per share (“EPS”) – (continued)

 

  2010   2011 
  Weighted
average
number of
shares
(millions)
   Earnings
€m
   EPS
   Weighted
average
number of
shares
(millions)
   Earnings
Restated
€m
   EPS
Restated
 

Basic EPS

   734.5     376    0.51     735.3     420    0.57  
  

 

   

 

   

 

   

 

   

 

   

 

 

Diluted EPS

   737.8     376    0.51     740.8     420    0.57  
  

 

   

 

   

 

   

 

   

 

   

 

 

The diluted EPS figures are calculated after taking account of the effect of potential additional ordinary shares arising from share options and conditional shares.

10.Earnings per share (“EPS”) – (continued)

The weighted average number of shares reflects the equivalent ordinary shares amount taking into account R shares and is after deducting shares held in treasury. Movements in the number of ordinary shares or equivalents for the year ended December 31, 20122013 are shown below.

 

  Year Ended December 31,   Year Ended December 31, 
  Ordinary
shares in
issue
(millions)
   R shares
in issue
(millions)
   Treasury
shares
(millions)
 2012
Ordinary
share
equivalents
net of
treasury
shares
(millions)
 2011
Ordinary
shares
equivalents
net of
treasury
shares
(millions)
   2010
Ordinary
shares
equivalents
net of
treasury
shares
(millions)
   Ordinary
shares in
issue
(millions)
   R shares
in issue
(millions)
   Treasury
shares
(millions)
 2013
Ordinary
share
equivalents
net of
treasury
shares
(millions)
 2012
Ordinary
shares
equivalents
net of
treasury
shares
(millions)
 2011
Ordinary
shares
equivalents
net of
treasury
shares
(millions)
 

Number of ordinary shares or equivalents

                   

At January 1

   724.1     43.0     (31.3  735.8    735.2     734.5     726.0     43.0     (44.2  724.8    735.8    735.2  

Issue of ordinary shares

   1.9              1.9    0.2     0.2     8.1              8.1    1.9    0.2  

Repurchase of ordinary and R shares

             (13.3  (13.3                      (25.2  (25.2  (13.3    

Net release of shares by the employee benefit trust

             0.4    0.4    0.4     0.5               2.0    2.0    0.4    0.4  
  

 

   

 

   

 

  

 

  

 

   

 

   

 

   

 

   

 

  

 

  

 

  

 

 

At December 31

   726.0     43.0     (44.2  724.8    735.8     735.2     734.1     43.0     (67.4  709.7    724.8    735.8  
  

 

   

 

   

 

  

 

  

 

   

 

   

 

   

 

   

 

  

 

  

 

  

 

 

Weighted average number of equivalent ordinary shares during the year

        734.0    735.3     734.5          717.6    734.0    735.3  
       

 

  

 

   

 

        

 

  

 

  

 

 

The average number of equivalent ordinary shares takes into account the R shares in the company held by a subsidiary of Reed Elsevier PLC, which represents a 5.8% interest in the company’s share capital.

Treasury shares include 62,341156,394 R shares (2011: nil; 2010:(2012: 62,341; 2011: nil), equivalent to 623,4101,563,940 Reed Elsevier NV ordinary shares.

At December 31, 2012 4,240,8382013 4,146,785 R shares (2012: 4,240,838; 2011: 4,303,179) were held by a subsidiary of Reed Elsevier PLC. The R shares are convertible at the election of the holders into ten ordinary shares each and each R share carries an entitlement to cast ten votes. They have otherwise the same rights as the ordinary shares, except that Reed Elsevier NV may pay a lower dividend on the R shares.

The weighted average number of shares used in the calculation of diluted EPS is after deducting shares held in treasury and is derived as follows:

 

  2012
(millions)
   2011
(millions)
   2010
(millions)
   2013
(millions)
   2012
(millions)
   2011
(millions)
 

Weighted average number of shares — Basic

   734.0     735.3     734.5     717.6     734.0     735.3  

Weighted average number of dilutive shares under options

   8.1     5.5     3.3     9.3     8.1     5.5  
  

 

   

 

   

 

   

 

   

 

   

 

 

Weighted average number of shares — Diluted

   742.1     740.8     737.8     726.9     742.1     740.8  
  

 

   

 

   

 

   

 

   

 

   

 

 

11.10.Statement of cash flows

Reconciliation of profit before tax to cash used by operations

 

   2012
€m
  2011
€m
  2010
€m
 

Profit before tax

   660    438    379  

Finance income

   (8  (20  (14

Share of results of joint ventures

   (654  (420  (367

(Decrease)/increase in payables

   (3  (1  1  
  

 

 

  

 

 

  

 

 

 

Cash used by operations

   (5  (3  (1
  

 

 

  

 

 

  

 

 

 

11.Statement of cash flows – (continued)

   2013
€m
  2012
Restated
€m
  2011
Restated
€m
 

Profit before tax

   659    644    421  

Finance income

   (19  (8  (20

Share of results of joint ventures

   (642  (638  (403

Decrease in payables

   (1  (3  (1
  

 

 

  

 

 

  

 

 

 

Cash used by operations

   (3  (5  (3
  

 

 

  

 

 

  

 

 

 

Reconciliation of net funding balances due from joint ventures

 

  2012
€m
   2011
€m
 2010
€m
   2013
€m
 2012
€m
   2011
€m
 

At January 1

   1,084     1,359    1,255     1,397    1,084     1,359  

Cash flow

   313     (275  104     (370  313     (275
  

 

   

 

  

 

   

 

  

 

   

 

 

At December 31

   1,397     1,084    1,359     1,027    1,397     1,084  
  

 

   

 

  

 

   

 

  

 

   

 

 

 

12.11.Investments in joint ventures

 

  2012
€m
 2011
€m
 2010
€m
   2013
€m
 2012
Restated

€m
 2011
Restated

€m
 

Share of results of joint ventures

   654    420    367     642    638    420  

Share of joint ventures’:

        

Other comprehensive (expense)/income

   (137  20    71  

Other comprehensive (loss)/income

   (48  (121  20  

Disposal/(acquisition) of non-controlling interests

   4    (25           4    (25

Increase/(decrease) in share based remuneration reserve

   19    16    (4

Increase in share based remuneration reserve (net of tax)

   29    19    16  

Equalisation adjustments

   (3  5    3     (34  (3  5  

Dividends received from joint ventures

   (754      (1,093   (186  (754    

Increase in investment in joint ventures

           719  

Increase/(decrease) in net funding balances due from joint ventures

   313    (275  104  

(Decrease)/increase in net funding balances due from joint ventures

   (370  313    (275
  

 

  

 

  

 

   

 

  

 

  

 

 

Net movement in the year

   96    161    167     33    96    161  

At January 1

   1,359    1,198    1,031     1,455    1,359    1,198  
  

 

  

 

  

 

   

 

  

 

  

 

 

At December 31

   1,455    1,359    1,198     1,488    1,455    1,359  
  

 

  

 

  

 

   

 

  

 

  

 

 

During the year the companyCompany received dividends of €754€186 million from Elsevier Reed Finance BV.BV (2012: €394 million; 2011: nil) and nil from Reed Elsevier Group plc (2012: €300 million; 2011: nil).

Summarised information showing total amounts in respect of joint ventures and Reed Elsevier NV shareholders’ 50% share is set out below:

 

  Total joint ventures   Reed Elsevier NV shareholders’ share   Total joint ventures   Reed Elsevier NV shareholders’ share 
  2012
€m
   2011
€m
   2010
€m
   2012
€m
   2011
€m
   2010
€m
   2013
€m
   2012
Restated

€m
   2011
Restated

€m
   2013
€m
   2012
Restated
€m
   2011
Restated
€m
 

Revenue

   7,523     6,902     7,084     3,762     3,451     3,542     7,121     7,523     6,902     3,561     3,762     3,451  

Net profit for the year

   1,321     882     758     654     420     367     1,316     1,290     882     642     638     403  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

Reed Elsevier NV’s share of joint ventures’ net profit attributable to parent company shareholders for the year excludes the net profit that arose directly in Reed Elsevier NV of €13 million (2012: €4 million (2011:million; 2011: €17 million; 2010: €9 million).

   Total joint ventures  Reed Elsevier NV shareholders’ share 
   2012
€m
  2011
€m
  2010
€m
  2012
€m
  2011
€m
  2010
€m
 

Total assets

   13,547    13,804    13,055    6,773    6,897    6,523  

Total liabilities

   (10,701  (11,168  (10,750  (6,715  (6,622  (6,684
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net assets/(liabilities)

   2,846    2,636    2,305    58    275    (161
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Attributable to:

       

Joint ventures

   2,804    2,606    2,273    58    275    (161

Non-controlling interests

   42    30    32              
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 
   2,846    2,636    2,305    58    275    (161
  

 

 

  

 

 

  

 

 

    

Net funding balances due from joint ventures

      1,397    1,084    1,359  
     

 

 

  

 

 

  

 

 

 

Total

      1,455    1,359    1,198  
     

 

 

  

 

 

  

 

 

 

12.11.Investments in joint ventures – (continued)

 

Reed Elsevier NV’s other comprehensive income includes a loss of €48 million (2012: €21 million loss; 2011: €37 million income) relating to joint ventures.

   Total joint ventures  Reed Elsevier NV shareholders’ share 
   2013
€m
  2012
€m
  2011
€m
  2013
€m
  2012
€m
  2011
€m
 

Total assets

   12,594    13,547    13,804    6,295    6,773    6,897  

Total liabilities

   (9,686  (10,701  (11,168  (5,834  (6,715  (6,622
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net assets/(liabilities)

   2,908    2,846    2,636    461    58    275  
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Attributable to:

       

Joint ventures

   2,868    2,804    2,606    461    58    275  

Non-controlling interests

   40    42    30              
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 
   2,908    2,846    2,636    461    58    275  
  

 

 

  

 

 

  

 

 

    

Net funding balances due from joint ventures

      1,027    1,397    1,084  
     

 

 

  

 

 

  

 

 

 

Total

      1,488    1,455    1,359  
     

 

 

  

 

 

  

 

 

 

The above amounts for Reed Elsevier NV’s shareholders’ share of total assets and total liabilities exclude assets and liabilities held directly by Reed Elsevier NV, andbut include the counterparty balances of amounts owed to and by other Reed Elsevier businesses. Included within Reed Elsevier NV’s share of assets and liabilities are cash and cash equivalents of €77 million (2012: €393 million (2011:million; 2011: €433 million; 2010: €431 million) and borrowings of €1,963 million (2012: €2,386 million (2011:million; 2011: €2,561 million; 2010: €2,508 million) respectively.

 

13.12.Payables

Included within payables are employee convertible debenture loans of €5 million (2012: €7 million (2011:million; 2011: €8 million; 2010: €9 million) with a weighted average interest rate of 2.65% (2011:1.95% (2012: 2.56%; 2011: 3.13%; 2010: 3.30%). Depending on the conversion terms, the surrender of €200 par value debenture loans qualifies for 50 Reed Elsevier NV ordinary shares.

 

14.13.Share capital

Authorised

 

   No. of shares       €m     

Ordinary shares of €0.07 each

   1,800,000,000     126  

R shares of €0.70 each

   26,000,000     18  
    

 

 

 

Total

     144  
    

 

 

 

Issued and fully paid

 

  R shares
Number
   Ordinary
shares
Number
   R shares
€m
   Ordinary
shares

€m
       Total    
€m
 

At January 1, 2010

   4,303,179     723,692,901     3     50     53  

Issue of ordinary shares

        184,116          1     1  
  

 

   

 

   

 

   

 

   

 

   R shares
Number
   Ordinary
shares
Number
   R shares
€m
   Ordinary
shares
€m
       Total     
€m
 

At January 1, 2011

   4,303,179     723,877,017     3     51     54     4,303,179     723,877,017     3     51     54  

Issue of ordinary shares

        200,738                         200,738                 
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

At January 1, 2012

   4,303,179     724,077,755     3     51     54     4,303,179     724,077,755     3     51     54  

Issue of ordinary shares

        1,906,470                         1,906,470                 
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

At December 31, 2012

   4,303,179     725,984,225     3     51     54  

At January 1, 2013

   4,303,179     725,984,225     3     51     54  

Issue of ordinary shares

        8,165,731          1     1  
  

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

   

 

 

At December 31, 2013

   4,303,179     734,149,956     3     52     55  
  

 

   

 

   

 

   

 

   

 

 

13.Share capital – (continued)

The issue of shares relates to the exercise of share options. Details of share option and conditional share schemes are set out in note 87 to the Reed Elsevier combined financial statements.

Details of shares held in treasury are provided in note 16.15.

At December 31, 2012 4,240,8382013 4,146,785 R shares (2012: 4,240,838; 2011: 4,303,179) were held by a subsidiary of Reed Elsevier PLC. The R shares are convertible at the election of the holders into ten ordinary shares each and each R share carries an entitlement to cast ten votes. They have otherwise the same rights as the ordinary shares, except that Reed Elsevier NV may pay a lower dividend on the R shares.

 

15.14.Paid-in surplus

 

  2012
€m
   2011
€m
       2010    
€m
   2013
€m
   2012
€m
       2011    
€m
 

At January 1

   2,171     2,169     2,168     2,189     2,171     2,169  

Issue of ordinary shares

   18     2     1     87     18     2  
  

 

   

 

   

 

   

 

   

 

   

 

 

At December 31

   2,189     2,171     2,169     2,276     2,189     2,171  
  

 

   

 

   

 

   

 

   

 

   

 

 

Within paid-in surplus, an amount of €2,099 million (2012: €2,012 million (2011:million; 2011: €1,994 million; 2010: €1,992 million) is free of tax.

 

16.15.Shares held in treasury

 

   2012
€m
  2011
€m
  2010
€m
 

At January 1

   432    433    434  

Repurchase of ordinary and R shares

   141          

Share of joint ventures’ settlement of share awards by the employee benefit trust

   (5  (4  (5

Exchange translation differences

   3    3    4  
  

 

 

  

 

 

  

 

 

 

At December 31

   571    432    433  
  

 

 

  

 

 

  

 

 

 

16.Shares held in treasury – (continued)

   2013
€m
  2012
€m
  2011
€m
 

At January 1

   571    432    433  

Repurchase of ordinary and R shares

   337    141      

Share of joint ventures’ settlement of share awards by the employee benefit trust

   (24  (5  (4

Exchange translation differences

   (3  3    3  
  

 

 

  

 

 

  

 

 

 

At December 31

   881    571    432  
  

 

 

  

 

 

  

 

 

 

At December 31, 2012,2013, shares held in treasury related to 6,990,101 (2011: 7,380,906; 2010: 7,781,790)4,992,360 (2012: 6,990,101; 2011: 7,380,906) Reed Elsevier NV ordinary shares held by the Reed Elsevier Group plc Employee Benefit Trust (“EBT”); and 36,613,087 (2011: 23,952,791; 2010:60,895,193 (2012: 36,613,087; 2011: 23,952,791) Reed Elsevier NV ordinary shares and 62,341156,394 R shares (2011: nil; 2010:(2012: 62,341; 2011: nil) held by the parent company.

The EBT purchases Reed Elsevier NV shares which, at the trustees’ discretion, can be used in respect of the exercise of share options and to meet commitments under conditional share awards. At December 31, 2012,2013, Reed Elsevier NV shares held by the EBT were €56 million (2012: €84 million (2011:million; 2011: €85 million; 2010: €87 million). at cost.

 

17.16.Translation reserve

 

  2012
€m
 2011
€m
 2010
€m
   2013
€m
 2012
€m
 2011
€m
 

At January 1

   6    (51  (153   (42  6    (51

Share of joint ventures’ exchange differences on translation of foreign operations

   (51  54    98     (86  (51  54  

Exchange translation differences on capital and reserves

   3    3    4     (3  3    3  
  

 

  

 

  

 

   

 

  

 

  

 

 

At December 31

   (42  6    (51   (131  (42  6  
  

 

  

 

  

 

   

 

  

 

  

 

 

18.17.Other reserves

 

  2012
€m
 2011
€m
 2010
€m
   2013
€m
 2012
Restated
€m
 2011
Restated
€m
 

At January 1

   (496  (602  (664   (228  (496  (602

Profit attributable to shareholders

   658    437    376     655    642    420  

Share of joint ventures’:

        

Actuarial losses on defined benefit pension schemes

   (203  (65  (37

Actuarial gains/(losses) on defined benefit pension schemes

   24    (180  (42

Fair value movements on available for sale investments

       (1               (1

Transfer to net profit on disposal of available for sale investments

   7                 7      

Fair value movements on cash flow hedges

   43    (14  (34   38    43    (14

Tax recognised directly in equity

   54    24    17  

Increase/(decrease) in share based remuneration reserve

   19    16    (4

Tax recognised in other comprehensive income

   (23  47    18  

Increase in share based remuneration reserve (net of tax)

   29    19    16  

Settlement of share awards

   (5  (4  (5   (24  (5  (4

Transfer to net profit from cash flow hedge reserve

   13    22    27  

Transfer to net profit from cash flow hedge reserve (net of tax)

   (1  13    22  

Disposal/(acquisition) of non-controlling interests

   4    (25           4    (25

Equalisation adjustments

   (3  5    3     (34  (3  5  

Equity dividends paid

   (319  (289  (281   (321  (319  (289
  

 

  

 

  

 

   

 

  

 

  

 

 

At December 31

   (228  (496  (602   115    (228  (496
  

 

  

 

  

 

   

 

  

 

  

 

 

 

19.18.Contingent liabilities

There are contingent liabilities in respect of borrowings of joint ventures guaranteed by Reed Elsevier NV as follows:

 

   2012
€m
   2011
€m
   2010
€m
 

Guaranteed jointly and severally with Reed Elsevier PLC

   4,422     4,704     4,591  
  

 

 

   

 

 

   

 

 

 
   2013
€m
   2012
€m
   2011
€m
 

Guaranteed jointly and severally with Reed Elsevier PLC

   3,676     4,422     4,704  
  

 

 

   

 

 

   

 

 

 

Financial instruments disclosures in respect of the borrowings covered by the above guarantees are given in note 1918 to the Reed Elsevier combined financial statements.

 

20.19.Approval of financial statements

The consolidated financial statements were approved by the Combined Board of directors on February 27, 2013.26, 2014.

 

THIS PAGE INTENTIONALLY BLANK

 

 

 

GLOSSARY OF TERMS

 

Terms used in Annual Report on Form 20-F

US equivalent or brief description

 

Accruals

Accrued expenses

 

Adjusted operating cash flow

Cash generated from operations plus dividends from joint ventures less net capital expenditure on property, plant and equipment and internally developed intangible assets, and excluding payments in relation to exceptional restructuring and acquisition related costs

 

Adjusted operating margin

Adjusted operating profit expressed as a percentage of revenue. This is a key financial measure used by management to evaluate performance and allocate resources

 

Adjusted operating profit

Operating profit before amortisation of acquired intangible assets, exceptional restructuring and acquisition related costs, the share of profit on disposals in joint ventures, and grossed up to exclude the equity share of taxes in joint ventures. This is a key financial measure used by management to evaluate performance and allocate resources and is presented in accordance with IFRS8-Operating Segments

 

Allotted

Issued

 

Associate

An entity in which Reed Elsevier has a participating interest and, in the opinion of the directors, can exercise significant influence on its management

 

Bank borrowings

Payable to banks

 

Called up share capital

Issued share capital

 

Capital and reserves

Shareholders’ equity

 

Cash flow conversion

Adjusted operating cash flow expressed as a percentageThe proportion of adjusted operating profitprofits converted into cash

 

Combined businesses

Reed Elsevier PLC, Reed Elsevier NV, Reed Elsevier Group plc and Elsevier Reed Finance BV and their respective subsidiaries, associates and joint ventures

 

Current instalments of loans

Long term debt due within one year

 

Effective tax rate on adjusted operating profit

Tax rate excluding movements on deferred tax balances not expected to crystallise in the near term, more closely aligning with cash taxes payable, and includes the benefit of deductible tax amortisation on acquired goodwill and intangible assets

 

EPS

Earnings per ordinary share

 

Finance lease

Capital lease

 

Free cash flow

Operating cash flow excluding the effects of interest, tax and dividends

 

Invested capital

Average capital employed in the year expressed at the average exchange rates for the year. Capital employed represents the net assets of the business before borrowings and derivative financial instruments and current and deferred taxes, after adding back the cumulative amortisation and impairment of acquired intangible assets and goodwill and deducting from goodwill the gross up in respect of deferred tax liabilities recognised on acquisition of intangible assets

 

Investments

Non-current investments

 

Freehold

Ownership with absolute rights in perpetuity

 

Interest receivable

Interest income

 

Interest payable

Interest expense

 

Net borrowings

Gross borrowings, less related derivative financial instrument assets and cash and cash equivalents

 

Net cash acquired

Cash less debt acquired with a business

 

Operating costs

Cost of sales plus selling and distribution costs plus administration and other expenses

Prepayments

Prepaid expenses

Profit

Income

 

Profit attributable

Net income

 

Reed Elsevier

Reed Elsevier PLC, Reed Elsevier NV, Reed Elsevier Group plc and Elsevier Reed Finance BV and their respective subsidiaries, associates and joint ventures

 

Share based remuneration

Stock based compensation

Shareholders’ equity

Shareholders’ funds

 

Share premium account

Premiums paid in excess of par value of ordinary shares

 

Return on invested capital

Post tax adjusted operating profit expressed as a percentage of average capital employed. This is a key financial measure used by management

 

Revenue

Sales

 

Underlying growth

The year on year growth calculated excludingto exclude the effectsresults of all acquisitions and disposals made in the current year and the impact ofprior year and currency translation.translation effects. This is a key financial measure as it provides an assessment of year on year organic growth without distortion for part year contributions and the impact of changes in foreign exchange rates

ITEM 19: EXHIBITS

Exhibits filed as part of this annual report

 

  1.1  Articles of Association of Reed Elsevier PLC (incorporated by reference from Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-167058) filed with the SEC on May 25, 2010)
  1.2  Articles of Association of Reed Elsevier NV (incorporated by reference from Exhibit 1.24.2 to the 2009 Annual ReportRegistration Statement on Form 20-FS-8 (File No. 333-191419) filed with the SEC on March 18, 2010)September 27, 2013)
  1.3  Governing Agreement, (as amended on February 14, 2012)July 17, 2013) between Reed Elsevier PLC and Reed Elsevier NV
  1.4  RHBV Agreement, dated December 23, 1992 among Elsevier NV and Reed Holding B.V. (incorporated by reference from Exhibit 1.4 to the 2002 Annual Report on Form 20-F filed with the SEC on March 10, 2003)
  2.1  Deposit Agreement, dated as of October 27, 2003 among Reed Elsevier PLC, The Bank of New York and all holders from time to time of American Depositary Receipts (incorporated by reference from Exhibit(a)(1) to Amendment No. 1 to the Registration Statement on Form F-6 (File No. 333-109805) filed by Reed Elsevier PLC with the SEC on October 17, 2003)
  2.2  Deposit Agreement, dated as of October 27, 2003 among Reed Elsevier NV, The Bank of New York and all holders from time to time of American Depositary Receipts (incorporated by reference from Exhibit(a)(1) to Amendment No. 1 to the Registration Statement on Form F-6 (File No. 333-109805) filed by Reed Elsevier NV with the SEC on October 17, 2003)
  4.1  Reed Elsevier Group plc Share Option Scheme (incorporated by reference from Exhibit 4.3 to the 2003 Annual Report on Form 20-F filed with the SEC on March 15, 2004)
  4.2  

Reed Elsevier Group plc Long TermLong-Term Incentive Share Option Scheme (incorporated by reference from Exhibit 4.3

to the 2003 Annual Report on Form 20-F filed with the SEC on March 15, 2004)

  4.3Reed Elsevier Group plc Bonus Investment Plan (incorporated by reference from Exhibit 4.3 to the 2003 Annual Report on Form 20-F filed with the SEC on March 15, 2004)
  4.4Reed Elsevier Group plc Bonus Investment Plan (2002) (incorporated by reference from Exhibit 4.3 to the 2003 Annual Report on Form 20-F filed with the SEC on March 15, 2004)
  4.5Reed Elsevier Group plc Executive Share Option Schemes (No. 2) (incorporated by reference from Exhibit 4.3 to the 2003 Annual Report on Form 20-F filed with the SEC on March 15, 2004)
  4.6Reed Elsevier Group plc Executive UK and Overseas Share Option Schemes (incorporated by reference from Exhibit 10.9 to the 2000 Form F-3 Registration Statement) (File No. 333-12926)
  4.7  Reed Elsevier Group plc Retention Share Plan (as amended on March 13, 2006) (incorporated by reference from exhibit 4.9 on the 2006 Annual Report on Form 20-F filed with the SEC on March 22, 2007)
  4.8Reed Elsevier US Salary Investment Plan (incorporated by reference from Exhibit 4.10 to the Registration Statement on Form S-8 (File No. 333-13666) filed with the SEC on October 2, 2000)
  4.94.4  Reed Elsevier Group plc Long TermLong-Term Incentive Share Option Scheme (as restated for awards granted on or after April 19, 2006) (incorporated by reference from exhibit 4.11 to the 2006 Annual Report on Form 20-F filed with the SEC on March 22, 2007)
  4.104.5  Reed Elsevier Group plc Bonus Investment Plan 2010 (incorporated by reference from Exhibit 4.3 to the Registration Statement on Form S-8 (File No. 333-167058) filed with the SEC on May 25, 2010)
  4.114.6  Reed Elsevier Group plc Growth Plan (incorporated by reference from Exhibit 4.4 to the Registration Statement on Form S-8 (File No. 333-167058) filed with the SEC on May 25, 2010)
  4.124.7  Reed Elsevier Group plc LexisNexis Risk & Information Analytics Group Long Term Incentive Plan (incorporated by reference from Exhibit 4.5 to the Registration Statement on Form S-8 (File No. 333-167058) filed with the SEC on May 25, 2010)
  4.13Reed Elsevier Group plc Long TermLong-Term Incentive Plan 2010 (incorporated by reference from Exhibit 4.6 to the Registration Statement on Form S-8 filed (File No. 333-167058) with the SEC on May 25, 2010)
  4.144.8Reed Elsevier Group plc Long-Term Incentive Plan 2013 (incorporated by reference from Exhibit 10.2 to the Registration Statement on Form S-8 (File No. 333-191419) filed with the SEC on September 27, 2013)
  4.9Reed Elsevier Group plc Executive Share Option Scheme 2013 (incorporated by reference from Exhibit 10.1 to the Registration Statement on Form S-8 (File No. 333-191419) filed with the SEC on September 27, 2013)
  4.10  Service Agreement between Reed Elsevier Group plc and Erik Engstrom (dated March 14, 2011) (incorporated by reference from Exhibit 4.14 to the 2012 Annual Report on Form 20-F filed with the SEC on March 12, 2013)
  4.154.11  Service Agreement between Reed Elsevier Group plc and Duncan Palmer (dated August 15, 2012) (incorporated by reference from Exhibit 4.15 to the 2012 Annual Report on Form 20-F filed with the SEC on March 12, 2013)
  4.164.12  Letter between Reed Elsevier Group plc and Duncan Palmer (dated August 15, 2012) (incorporated by reference from Exhibit 4.16 to the 2012 Annual Report on Form 20-F filed with the SEC on March 12, 2013)
  8.0  List of significant subsidiaries, associates, joint ventures and business units
  12.1  Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002, by the Chief Executive Officer of Reed Elsevier PLC
  12.2  Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002, by the Chief Financial Officer of Reed Elsevier PLC

  12.3  Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002, by the Chief Executive Officer of Reed Elsevier NV
  12.4  Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002, by the Chief Financial Officer of Reed Elsevier NV
  13.1  Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by the Chief Executive Officer of Reed Elsevier PLC

  13.2  Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by the Chief Financial Officer of Reed Elsevier PLC
  13.3  Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by the Chief Executive Officer of Reed Elsevier NV
  13.4  Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by the Chief Financial Officer of Reed Elsevier NV
  15.1  Independent Registered Public Accounting Firm’s Consent — Reed Elsevier Combined Financial Statements
  15.2  Independent Registered Public Accounting Firm’s Consent — Reed Elsevier PLC Consolidated Financial Statements
  15.3  Independent Registered Public Accounting Firm’s Consent — Reed Elsevier NV Consolidated Financial Statements

The total amount of long term debt securities of Reed Elsevier authorised under any single instrument does not exceed 10% of the combined total assets of Reed Elsevier. The Registrants hereby agree to furnish to the Commission, upon its request, a copy of any instrument defining the rights of holders of long term debt of Reed Elsevier or any of the combined businesses for which consolidated or unconsolidated financial statements are required to be filed.

The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representation and warranties made by any of the registrants in there agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs at the date they were made or at any other time.

SIGNATURES

Pursuant to the requirements of Section 12Each of the Securities Exchange Act of 1934, each of the Registrants hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorised the undersigned to sign this annual report to be signed on its behalf by the undersigned, thereto duly authorised, on March 12, 2013.behalf.

 

REED ELSEVIER PLC

Registrant

 

REED ELSEVIER NV

Registrant

By: /s/ E ENGSTROM

 

E Engstrom

Chief Executive Officer

 

By: /s/ E ENGSTROM

 

E Engstrom

Chairman of the Executive Board &

Chief Executive Officer

By: /s/ D J PALMER

 

D J Palmer

Chief Financial Officer

 

By: /s/ D J PALMER

 

D J Palmer

Member, Executive Board &

Chief Financial Officer

Dated: March 12, 201311, 2014

 Dated: March 12, 201311, 2014

 

S-5